Processing 00000000.tx.1: Multicenter Phase III Trial to Evaluate CD34+ Selected Versus Unselected Autologous Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma By Robert Vescio, Gary Schiller, A. 

Phrase: "Multicenter Phase III Trial to"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   884   C0282461:Phase III Trial [Research Activity]
   875   C0206012:Trial, Multicenter [Research Activity]
   875   C1096776:multicenter trial [Research Activity]
   804   C0008976:Trial [Research Activity]
   804   C0205390:Phase [Temporal Concept]
   804   C0439070:III [Intellectual Product]
   804   C1705160:III [Qualitative Concept]

Phrase: "Evaluate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0220825:Evaluate [Functional Concept]

Phrase: "CD34+ Selected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1707391:Select [Activity]

Phrase: "Versus"

Phrase: "Unselected Autologous Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C0242602:peripheral blood progenitor cell transplantation [Therapeutic or Preventive Procedure]
   760   C0206153:Cell Transplantation [Therapeutic or Preventive Procedure]
   757   C0040736:Transplantation, Autologous [Therapeutic or Preventive Procedure]
   739   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   739   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   739   C0040733:transplantation [Functional Concept]
   716   C0189736:blood vessel transplantation [Therapeutic or Preventive Procedure]

Phrase: "By Robert Vescio,"

Phrase: "Gary Schiller,"

Phrase: "A."
Processing 00000000.tx.2: Keith Stewart, Oscar Ballester, Stephen Noga, Hope Rugo, Cesar Freytes, Edward Stadtmauer, Stefano Tarantolo, Firoozeh Sahebi, Pat Stiff, Jacinta Meharchard, Robert Schlossman, Randy Brown, Heather Tully, Mark Benyunes, Cindy Jacobs, Ronald Berenson, John DiPersio, Ken Anderson, and James Berenson From the West LA VAMC/University of California, Los Angeles, Los Angeles, CA; 

Phrase: "Keith Stewart,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1551641:Stewart [Population Group]

Phrase: "Oscar Ballester,"

Phrase: "Stephen Noga,"

Phrase: "Hope Rugo,"

Phrase: "Cesar Freytes,"

Phrase: "Edward Stadtmauer,"

Phrase: "Stefano Tarantolo,"

Phrase: "Firoozeh Sahebi,"

Phrase: "Pat Stiff,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0221170:Stiff [Sign or Symptom]

Phrase: "Jacinta Meharchard,"

Phrase: "Robert Schlossman,"

Phrase: "Randy Brown,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0678579:Brown [Natural Phenomenon or Process]

Phrase: "Heather Tully,"

Phrase: "Mark Benyunes,"

Phrase: "Cindy Jacobs,"

Phrase: "Ronald Berenson,"

Phrase: "John DiPersio,"

Phrase: "Ken Anderson,"

Phrase: "and"

Phrase: "James Berenson From the West LA VAMC/University of California,"

Phrase: "Los Angeles,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024015:Los Angeles [Geographic Area]

Phrase: "Los Angeles,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024015:Los Angeles [Geographic Area]

Phrase: "CA"

Phrase: ";"
Processing 00000000.tx.3: The Toronto Hospital, Toronto, Ontario, Canada; 

Phrase: "The Toronto Hospital,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0019994:Hospital, NOS [Health Care Related Organization,Manufactured Object]
   861   C1510665:Hospital [Qualitative Concept]
   777 E C1609061:Hospitals [Intellectual Product]

Phrase: "Toronto,"

Phrase: "Ontario,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0029040:Ontario [Geographic Area]

Phrase: "Canada"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0006823:Canada [Geographic Area]

Phrase: ";"
Processing 00000000.tx.4: the University of South Florida, Miami, FL; 

Phrase: "the University of South Florida,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0016253:Florida [Geographic Area]
   812   C0041740:University [Manufactured Object,Organization]
   812   C1710133:South [Spatial Concept]

Phrase: "Miami,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1551421:Miami [Population Group]

Phrase: "FL"

Phrase: ";"
Processing 00000000.tx.5: Johns Hopkins University, Baltimore, MD; 

Phrase: "Johns Hopkins University,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0041740:University [Manufactured Object,Organization]

Phrase: "Baltimore,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0004716:Baltimore [Geographic Area]

Phrase: "MD"

Phrase: ";"
Processing 00000000.tx.6: the University of California, San Francisco, San Francisco, CA; 

Phrase: "the University of California,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0006754:California [Geographic Area]
   827   C0041740:University [Manufactured Object,Organization]
   827   C3146274:California [Plant]

Phrase: "San Francisco,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0036152:San Francisco [Geographic Area]
   861   C1826357:San [Gene or Genome]

Phrase: "San Francisco,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0036152:San Francisco [Geographic Area]
   861   C1826357:San [Gene or Genome]

Phrase: "CA"

Phrase: ";"
Processing 00000000.tx.7: the University of Texas at San Antonio, San Antonio, TX; 

Phrase: "the University of Texas at San Antonio,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0039711:Texas [Geographic Area]
   748   C0041740:University [Manufactured Object,Organization]

Phrase: "San Antonio,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1826357:San [Gene or Genome]

Phrase: "TX"

Phrase: ";"
Processing 00000000.tx.8: the University of Pennsylvania, Philadelphia, PA; 

Phrase: "the University of Pennsylvania,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0030853:Pennsylvania [Geographic Area]
   827   C0041740:University [Manufactured Object,Organization]

Phrase: "Philadelphia,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0031525:Philadelphia [Geographic Area]

Phrase: "PA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3541314:PA [Idea or Concept]

Phrase: ";"
Processing 00000000.tx.9: the University of Nebraska, Omaha, NE; 

Phrase: "the University of Nebraska,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0027523:Nebraska [Geographic Area]
   827   C0041740:University [Manufactured Object,Organization]

Phrase: "Omaha,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1551450:Omaha [Population Group]

Phrase: "NE"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3538705:NE [Gene or Genome]

Phrase: ";"
Processing 00000000.tx.10: the Southern California Kaiser Permanente Medical Group, Los Angeles, CA; 

Phrase: "the Southern California Kaiser Permanente Medical Group,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   799   C0441833:Group [Idea or Concept]
   799   C0687744:group [Population Group]
   799   C1257890:Group [Population Group]
   799   C1552516:Group [Health Care Related Organization]
   799   C1705428:Group [Conceptual Entity]
   799   C1705429:Group [Population Group]

Phrase: "Los Angeles,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024015:Los Angeles [Geographic Area]

Phrase: "CA"

Phrase: ";"
Processing 00000000.tx.11: Loyola University, Chicago, IL; 

Phrase: "Loyola University,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0041740:University [Manufactured Object,Organization]

Phrase: "Chicago,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0008044:Chicago [Geographic Area]

Phrase: "IL"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0020898:IL [Geographic Area]
  1000   C0021764:IL [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0022271:IL [Geographic Area]

Phrase: ";"
Processing 00000000.tx.12: the Washington University School of Medicine, St Louis, MO; 

Phrase: "the Washington University School of Medicine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0036375:School [Manufactured Object,Organization]

Phrase: "St Louis,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3272372:ST [Intellectual Product]

Phrase: "MO"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3538743:MO [Idea or Concept]

Phrase: ";"
Processing 00000000.tx.13: the Dana Farber Cancer Institute, Boston, MA; 

Phrase: "the Dana Farber Cancer Institute,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1511716:Dana-Farber Cancer Institute [Health Care Related Organization]
   812   C0021622:institute [Organization]
   812   C1272753:Institute [Idea or Concept]

Phrase: "Boston,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0006037:Boston [Geographic Area]

Phrase: "MA"

Phrase: ";"
Processing 00000000.tx.14: and CellPro, Inc, Bothell, WA.  

Phrase: "and"

Phrase: "CellPro,"

Phrase: "Inc,"

Phrase: "Bothell,"

Phrase: "WA."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043038:WA [Geographic Area]
Processing 00000000.tx.15: ABSTRACT TOP ABSTRACT INTRODUCTION REFERENCES High-dose chemotherapy followed by autologous transplantation has been shown to improve response rates and survival in multiple myeloma and other malignancies. 

Phrase: "ABSTRACT TOP ABSTRACT INTRODUCTION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1293116:Introduction [Health Care Activity]
   812   C1875307:INTRODUCTION [Manufactured Object]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "High-dose chemotherapy"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C1328050:high-dose chemotherapy [Therapeutic or Preventive Procedure]
   901   C0444956:High dose [Quantitative Concept]
   827   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0013217:chemotherapy [Functional Concept]
   827   C0178602:Dose [Quantitative Concept]
   827   C0205250:High [Qualitative Concept]
   827   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0869039:Dose [Quantitative Concept]
   827   C1114758:Dose # [Clinical Attribute]
   827   C1299351:High [Qualitative Concept]
   827   C2700149:HIGH [Intellectual Product]

Phrase: "followed by autologous transplantation"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   833   C0040736:Transplantation, Autologous [Therapeutic or Preventive Procedure]
   833   C0332283:Followed by [Temporal Concept]
           followed
   770   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   770   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   770   C0040733:transplantation [Functional Concept]
   770   C0439859:Autologous [Qualitative Concept]
   737 E C1719822:Follow [Intellectual Product]

Phrase: "has"

Phrase: "been"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "improve"

Phrase: "response rates"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   966   C0237629:Response Rate [Temporal Concept]
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]
   827   C0871208:Rate [Activity]
   827   C1521828:Rate [Quantitative Concept]

Phrase: "and"

Phrase: "survival in multiple myeloma"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0038952:Survival [Activity]
   770   C0220921:survival [Functional Concept]

Phrase: "and"

Phrase: "other malignancies."
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0006826:MALIGNANCIES [Neoplastic Process]
   966 E C1306459:Malignancy [Finding]
   916 E C0205282:Malignant [Qualitative Concept]
   916 E C0334590:MALIGNANT [Neoplastic Process]
   916 E C1533592:MALIGNANT [Neoplastic Process]
Processing 00000000.tx.16: However, autografts frequently contain detectable tumor cells. 

Phrase: "However,"

Phrase: "autografts frequently"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0040736:autografts [Therapeutic or Preventive Procedure]
   861   C0559189:Autografts [Biomedical or Dental Material]

Phrase: "contain"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:contain [Functional Concept]
  1000   C2700400:Contain [Activity]

Phrase: "detectable tumor cells."
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   901   C0431085:Tumor cells [Cell]
   867 E C0597032:Tumor Cell [Cell]
   827   C0007634:Cells [Cell]
   827   C0027651:Tumor [Neoplastic Process]
   827   C1578706:Tumor [Intellectual Product]
   827   C3273930:Tumor [Finding]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.17: Enrichment for stem cells using anti-CD34 antibodies has been shown to reduce autograft tumor contamination in phase I/II studies. 

Phrase: "Enrichment for stem cells"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "anti-CD34 antibodies"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   913   C1624602:Anti-Antibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   896 E C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   793 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "has"

Phrase: "been"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "reduce"

Phrase: "autograft tumor contamination in phase I/II studies."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0259846:contamination [Human-caused Phenomenon or Process]
   744   C1881659:CONTAMINATION [Event]
   744   C2349974:Contamination [Idea or Concept]
Processing 00000000.tx.18: To more definitively assess the safety and efficacy of CD34 selection, a phase III study was completed in 131multiple myeloma patients randomized to receive an autologous transplant with either CD34-selected or unselected peripheral blood progenitor cells after myeloablative therapy. 

Phrase: "To more definitively"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1883351:To [Qualitative Concept]

Phrase: "assess"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1516048:Assess [Activity]

Phrase: "the safety"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0036043:Safety [Human-caused Phenomenon or Process]
  1000   C1705187:SAFETY [Research Activity]

Phrase: "and"

Phrase: "efficacy of CD34 selection,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1280519:Efficacy [Qualitative Concept]
   770   C1707887:EFFICACY [Research Activity]

Phrase: "a phase III study"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0282461:Phase 3 Study [Research Activity]
   827   C0205390:Phase [Temporal Concept]
   827   C0439070:III [Intellectual Product]
   827   C0557651:Study [Manufactured Object]
   827   C1705160:III [Qualitative Concept]
   827   C2603343:Study [Research Activity]

Phrase: "was"

Phrase: "completed in 131multiple myeloma patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0026764:Myeloma [Neoplastic Process]
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0205197:COMPLETED [Qualitative Concept]
   760   C3538749:Myeloma [Intellectual Product]

Phrase: "randomized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034656:randomized [Research Activity]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "receive"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Receive [Qualitative Concept]

Phrase: "an autologous transplant with either CD34-selected"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C0559189:Transplant, Autologous [Biomedical or Dental Material]
   748   C0040732:Transplant [Therapeutic or Preventive Procedure]
   748   C0332835:Transplant [Tissue]

Phrase: "or"

Phrase: "unselected peripheral blood progenitor cells after myeloablative therapy."
Meta Candidates (Total=17; Excluded=5; Pruned=0; Remaining=12)
   776   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   770   C0038250:Progenitor Cells [Cell]
   770   C0229664:peripheral blood [Body Substance]
           Blood
   767   C0302189:cells therapy [Therapeutic or Preventive Procedure]
   744   C0005767:Blood [Tissue]
   744   C0005768:blood [Body Substance]
   744   C0007634:Cells [Cell]
   744   C0205100:Peripheral [Spatial Concept]
   744   C0870134:Progenitor [Family Group]
   744   C3282337:Cells [Cell]
   729 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   722 E C2328697:Hemal cell [Cell]
   711 E C1269647:Cell [Cell]
   711 E C1704653:Cell [Medical Device]
   711 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.19: Tumor contamination in the autografts was assessed by a quantitative polymerase chain reaction detection assay using patient-specific, complementarity-determining region (CDR) Ig gene primers before and after CD34 selection. 

Phrase: "Tumor contamination in the autografts"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0259846:contamination [Human-caused Phenomenon or Process]
   760   C1881659:CONTAMINATION [Event]
   760   C2349974:Contamination [Idea or Concept]

Phrase: "was"

Phrase: "assessed by a quantitative polymerase chain reaction detection assay"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   790   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   742   C0005507:Assay [Laboratory Procedure]
   742   C0243073:assay [Qualitative Concept]
   742   C0337112:Chain [Manufactured Object]
   742   C0392762:Quantitative [Quantitative Concept]
   742   C0443286:Reaction [Functional Concept]
   742   C1114821:Reaction [Clinical Attribute]
   742   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   742   C1510438:Assay [Laboratory Procedure]
   742   C1511790:Detection [Therapeutic or Preventive Procedure]
   742   C1516048:Assessed [Activity]
   742   C1524075:Chain [Idea or Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "patient-specific, complementarity-determining region (CDR) Ig gene primers before"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   708   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "and after CD34 selection."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0036576:selection [Genetic Function]
   770   C1515981:And [Idea or Concept]
   770   C3538723:CD34 [Laboratory Procedure]
Processing 00000000.tx.20: A median 3.1log reduction in contaminating tumor cells was achieved in the CD34 selected product using the CEPRATE SC System (CellPro, Inc, Bothell, WA). 

Phrase: "A median 3.1log reduction in contaminating tumor cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   742   C0301630:Reduction [Natural Phenomenon or Process]
   742   C0392756:Reduction [Qualitative Concept]
   742   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "was"

Phrase: "achieved in the CD34"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C3538723:CD34 [Laboratory Procedure]

Phrase: "selected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1707391:Select [Activity]

Phrase: "product"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514468:product [Entity]
  1000   C1704444:Product [Quantitative Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the CEPRATE SC System"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   812   C0449913:System [Functional Concept]
   812   C1553451:System [Manufactured Object]
   812   C1704459:System [Medical Device]
   741 E C0205373:Systemic [Functional Concept]

Phrase: "(CellPro,"

Phrase: "Inc,"

Phrase: "Bothell,"

Phrase: "WA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043038:WA [Geographic Area]

Phrase: ")."
Processing 00000000.tx.21: Successful neutrophil engraftment was achieved in all patients by day 15and no significant between-arm difference for time to platelet engraftment occurred in patients who received an infused dose of at least 2.0106 CD34+ cells/kg. 

Phrase: "Successful neutrophil engraftment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C1882078:Neutrophil Engraftment [Finding]
   827   C0301944:Engraftment [Physiologic Function]

Phrase: "was"

Phrase: "achieved in all patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0030705:Patients [Patient or Disabled Group]

Phrase: "by day 15and"

Phrase: "no significant between-arm difference"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0237881:significant [Quantitative Concept]
   760   C0750502:Significant [Idea or Concept]
   760   C1546944:Significant [Qualitative Concept]

Phrase: "for time"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0040223:Time [Temporal Concept]
  1000   C3541383:Time [Temporal Concept]
   944 E C0442043:Temporal [Spatial Concept]
   944 E C2362314:Temporal [Temporal Concept]
   916 E C1632851:Times [Quantitative Concept]

Phrase: "to platelet engraftment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1882407:Platelet Engraftment [Finding]
   861   C0301944:Engraftment [Physiologic Function]

Phrase: "occurred in patients"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C1709305:Occurred [Activity]
   756 E C2745955:OCCUR [Temporal Concept]

Phrase: "who"

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "an infused dose of"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0178602:Dose [Quantitative Concept]
   770   C0869039:Dose [Quantitative Concept]
   770   C1114758:Dose # [Clinical Attribute]

Phrase: "at least 2.0106 CD34+ cells/kg."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C0022718:KG [Geographic Area]
   799   C0439209:kg [Quantitative Concept]
Processing 00000000.tx.22: In conclusion, this phase III trial demonstrates that CD34-selection of peripheral blood progenitor cells significantly reduces tumor cell contamination yet provides safe and rapid hematologic recovery for patients receiving myeloablative therapy.  

Phrase: "In conclusion,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707478:Conclusion [Idea or Concept]

Phrase: "this phase III trial"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0282461:Phase III Trial [Research Activity]
   827   C0008976:Trial [Research Activity]
   827   C0205390:Phase [Temporal Concept]
   827   C0439070:III [Intellectual Product]
   827   C1705160:III [Qualitative Concept]

Phrase: "demonstrates"

Phrase: "that CD34-selection of peripheral blood progenitor cells significantly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0036576:selection [Genetic Function]

Phrase: "reduces"

Phrase: "tumor cell contamination yet"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0259846:contamination [Human-caused Phenomenon or Process]
   812   C1881659:CONTAMINATION [Event]
   812   C2349974:Contamination [Idea or Concept]

Phrase: "provides"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0359589:provides [Food]
  1000   C1999230:Provide [Activity]

Phrase: "safe"

Phrase: "and"

Phrase: "rapid hematologic recovery for patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0237820:Recovery [Activity]
   760   C1555688:recovery [Idea or Concept]
   760   C2004454:Recovery [Organism Function]

Phrase: "receiving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514756:Receive [Qualitative Concept]

Phrase: "myeloablative therapy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039798:therapy [Functional Concept]
   861   C0087111:Therapy [Therapeutic or Preventive Procedure]
   861   C1363945:Therapy [Finding]
Processing 00000000.tx.23: 1999 by The American Society of Hematology.  

Phrase: "1999 by The American Society of Hematology."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   853   C1515949:American Society of Hematology [Professional Society]
   748   C0018943:Haematology NOS [Biomedical Occupation or Discipline]
   748   C0037455:society [Organization]
   748   C0200627:HEMATOLOGY [Laboratory Procedure]
   748   C0596070:American [Population Group]
Processing 00000000.tx.24: INTRODUCTION TOP ABSTRACT INTRODUCTION REFERENCES MULTIPLE MYELOMA is a fatal neoplasm in which malignant plasma cells derived from a single transformed cell (clone) accumulate in the bone marrow and produce an abundance of monoclonal Ig. 

Phrase: "INTRODUCTION TOP ABSTRACT INTRODUCTION"

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "MULTIPLE MYELOMA"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   861   C0439064:Multiple [Quantitative Concept]
   861   C3538749:Myeloma [Intellectual Product]

Phrase: "is"

Phrase: "a fatal neoplasm in which malignant plasma cells"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   776   C0026764:plasma cell neoplasm [Neoplastic Process]
   776   C1959632:Plasma Cell Neoplasm [Neoplastic Process]
   767   C0006826:Malignant neoplasm [Neoplastic Process]
   767   C1306459:Malignant neoplasm [Finding]
   744   C0027651:Neoplasm [Neoplastic Process]
   744   C2981607:NEOPLASM [Intellectual Product]

Phrase: "derived from a single transformed cell"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   753   C0007634:Cell [Cell]
   753   C0037179:Single [Population Group]
   753   C0087136:single [Finding]
   753   C0205171:Single [Quantitative Concept]
   753   C1269647:Cell [Cell]
   753   C1441547:Derived [Qualitative Concept]
   753   C1510411:Transformed [Pathologic Function]
   753   C1704653:Cell [Medical Device]
   753   C1948049:Cell [Spatial Concept]
   753   C3245521:derived [Idea or Concept]

Phrase: "(clone"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0009013:Clone [Cell]
  1000   C1522642:Clone [Tissue]
   928 E C1704387:Clonal [Qualitative Concept]
   900 E C0796368:clonality [Diagnostic Procedure]

Phrase: ")"

Phrase: "accumulate in the bone marrow"
Meta Candidates (Total=12; Excluded=4; Pruned=0; Remaining=8)
   806   C0005953:Bone Marrow [Tissue]
   770 E C1708973:Medullary Bone [Tissue]
   760   C0086590:Marrow [Food]
   760   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   760   C0376152:Marrow [Body Part, Organ, or Organ Component]
   760   C0391978:Bone [Tissue]
   760   C1266908:Bone [Body Part, Organ, or Organ Component]
   760   C1266909:Bone [Body System]
   760   C1546708:Marrow [Intellectual Product]
   704 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   704 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   704 E C1550278:Medullary [Body Part, Organ, or Organ Component]

Phrase: "and"

Phrase: "produce"

Phrase: "an abundance of monoclonal Ig."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C2346714:Abundance [Qualitative Concept]
Processing 00000000.tx.25: Although conventional therapy with oral melphalan and prednisone has achieved remissions in approximately 40% of patients, the disease remains incurable, with a median overall survival of 30to 36months.1-3 Attempts to improve overall survival have led to the evaluation of more aggressive, multiagent, conventional-dose chemotherapy regimens such as M2, VCMP, VBAP, and ABCM. 

Phrase: "Although"

Phrase: "conventional therapy with oral melphalan"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C2945704:Conventional Therapy [Therapeutic or Preventive Procedure]
   760   C0039798:therapy [Functional Concept]
   760   C0087111:Therapy [Therapeutic or Preventive Procedure]
   760   C0439858:Conventional [Qualitative Concept]
   760   C1363945:Therapy [Finding]

Phrase: "and"

Phrase: "prednisone"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0032952:Prednisone [Hormone,Pharmacologic Substance,Steroid]
   944 E C0728770:Meticorten [Pharmacologic Substance,Steroid]
   944 E C0740144:Deltasone [Pharmacologic Substance,Steroid]
   944 E C0740145:Deltra [Hormone,Pharmacologic Substance,Steroid]
   944 E C0740149:Lisacort [Hormone,Pharmacologic Substance,Steroid]

Phrase: "has"

Phrase: "achieved remissions in approximately 40% of patients,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   778   C1277626:Patient in remission [Finding]
           patients remissions
   748   C0544452:remissions [Finding]
   748   C0687702:remissions [Neoplastic Process]

Phrase: "the disease"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0012634:Disease [Disease or Syndrome]
   944 E C1836721:MALS [Finding]
   944 E C3538764:MALS [Gene or Genome]
   944 E C3540595:MAL [Gene or Genome]

Phrase: "remains"

Phrase: "incurable,"

Phrase: "with a median overall survival"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0038952:Survival [Activity]
   827   C0220921:survival [Functional Concept]
   827   C0282416:Overall [Intellectual Product]
   827   C1561607:Overall [Qualitative Concept]

Phrase: "of 30to 36months.1-3"

Phrase: "Attempts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1516084:Attempt [Event]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "improve"

Phrase: "overall survival"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0038952:Survival [Activity]
   861   C0220921:survival [Functional Concept]
   861   C0282416:Overall [Intellectual Product]
   861   C1561607:Overall [Qualitative Concept]

Phrase: "have"

Phrase: "led to the evaluation"
Meta Candidates (Total=8; Excluded=5; Pruned=0; Remaining=3)
   770   C0220825:Evaluation [Functional Concept]
   770   C1261322:Evaluation [Health Care Activity]
   770   C1708698:LED [Manufactured Object]
   737 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   737 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   737 E C1522538:Lead [Functional Concept]
   737 E C2348269:Lead [Element, Ion, or Isotope]
   737 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "of more aggressive, multiagent, conventional-dose chemotherapy regimens"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   818   C0392920:chemotherapy regimens [Therapeutic or Preventive Procedure]
   813   C2348331:Dose Regimen [Therapeutic or Preventive Procedure]
   795   C2945654:regimens [Intellectual Product]
   762 E C0040808:Regimen [Therapeutic or Preventive Procedure]

Phrase: "such as M2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0457242:m2 [Quantitative Concept]

Phrase: "VCMP,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0078398:VCMP [Therapeutic or Preventive Procedure]

Phrase: "VBAP,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0078139:VBAP [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "ABCM."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0165053:ABCM [Therapeutic or Preventive Procedure]
  1000   C0279181:ABCM [Therapeutic or Preventive Procedure]
Processing 00000000.tx.26: Unfortunately, despite improved response rates, a meta-analysis of several prospective randomized trials showed no significant improvement in the survival of patients treated with these multidrug regimens compared with standard doses of melphalan and prednisone.4 Because the dose intensity of standard chemotherapy is often limited by hematologic toxicity, higher doses of chemotherapy followed by autologous bone marrow transplantation have been attempted to improve upon myeloma cell kill.5-8 High-dose melphalan followed by autologous bone marrow transplantation was shown to improve response rates, disease-free survival, and overall survival in a randomized study when compared with standard chemotherapy.9,10 However, the majority of myeloma patients treated with autologous bone marrow transplantation develop progressive disease within 3years. 

Phrase: "Unfortunately,"

Phrase: "despite improved response rates,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   867   C0237629:Response Rate [Temporal Concept]
   827   C0871261:Response [Organism Attribute]
   827   C1704632:Response [Finding]
   827   C1706817:Response [Intellectual Product]
   827   C2911692:Response [Mental Process]
   793   C0871208:Rate [Activity]
   793   C1521828:Rate [Quantitative Concept]

Phrase: "a meta-analysis of several prospective randomized trials"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0282458:Meta-Analysis [Intellectual Product]
   770   C0920317:Meta-Analysis [Research Activity]
   744   C0002778:Analysis [Laboratory Procedure]
   744   C0936012:Analysis [Research Activity]
   744   C1042496:Meta [Eukaryote]
   744   C1524024:analysis [Functional Concept]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "no significant improvement in the survival of patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C2986411:Improvement [Conceptual Entity]

Phrase: "treated with these multidrug regimens"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   806   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   760   C1522326:Treated [Functional Concept]
   760   C2945654:regimens [Intellectual Product]
   726 E C0040808:Regimen [Therapeutic or Preventive Procedure]
   726 E C1292734:TREAT [Functional Concept]

Phrase: "compared with standard doses of melphalan"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   753   C0025241:Melphalan [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   753   C0178602:Doses [Quantitative Concept]
   753   C1442989:Standard [Qualitative Concept]
   753   C1707455:Compared [Activity]
   753   C2828392:Standard [Intellectual Product]
   719 E C0869039:Dose [Quantitative Concept]
   719 E C1114758:Dose # [Clinical Attribute]
   719 E C1428722:DOS [Gene or Genome]

Phrase: "and"

Phrase: "prednisone.4"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   861   C0032952:Prednisone [Hormone,Pharmacologic Substance,Steroid]
   805 E C0728770:Meticorten [Pharmacologic Substance,Steroid]
   805 E C0740144:Deltasone [Pharmacologic Substance,Steroid]
   805 E C0740145:Deltra [Hormone,Pharmacologic Substance,Steroid]
   805 E C0740149:Lisacort [Hormone,Pharmacologic Substance,Steroid]

Phrase: "Because"

Phrase: "the dose intensity of standard chemotherapy"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0178602:Dose [Quantitative Concept]
   753   C0522510:Intensity [Qualitative Concept]
   753   C0869039:Dose [Quantitative Concept]
   753   C1114758:Dose # [Clinical Attribute]

Phrase: "is"

Phrase: "often"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332183:Often [Temporal Concept]

Phrase: "limited by hematologic toxicity,"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   770   C0018943:Hematologic [Biomedical Occupation or Discipline]
   770   C0040539:toxicity [Qualitative Concept]
   770   C0205488:Haematologic [Functional Concept]
   770   C0439801:Limited [Functional Concept]
   770   C0600688:Toxicity [Injury or Poisoning]
   770   C3542948:Limited [Intellectual Product]
   737 E C1549649:Limit [Idea or Concept]
   737 E C2349209:Limit [Conceptual Entity]

Phrase: "higher doses of chemotherapy"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   859   C1328050:high-dose chemotherapy [Therapeutic or Preventive Procedure]
   799   C0444956:High dose [Quantitative Concept]
   770   C0178602:Doses [Quantitative Concept]
   737 E C0869039:Dose [Quantitative Concept]
   737 E C1114758:Dose # [Clinical Attribute]
   737 E C1428722:DOS [Gene or Genome]

Phrase: "followed by autologous bone marrow transplantation"
Meta Candidates (Total=23; Excluded=2; Pruned=0; Remaining=21)
   882   C0194037:autologous bone marrow transplantation [Therapeutic or Preventive Procedure]
           Autologous Marrow Transplantation
   833   C0005961:Bone Marrow Transplantation [Therapeutic or Preventive Procedure]
           Marrow Transplantation
   833   C2986504:Autologous Bone Marrow [Body Substance]
   790   C0005953:Bone Marrow [Tissue]
   790   C0332283:Followed by [Temporal Concept]
           followed
   783   C0005976:Bone Transplantation [Therapeutic or Preventive Procedure]
   783   C0040736:Transplantation, Autologous [Therapeutic or Preventive Procedure]
   756 E C1708973:Medullary Bone [Tissue]
   753   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   753   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   753   C0040733:transplantation [Functional Concept]
   753   C0086590:Marrow [Food]
   753   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   753   C0376152:Marrow [Body Part, Organ, or Organ Component]
   753   C0391978:Bone [Tissue]
   753   C0439859:Autologous [Qualitative Concept]
   753   C1266908:Bone [Body Part, Organ, or Organ Component]
   753   C1266909:Bone [Body System]
   753   C1546708:Marrow [Intellectual Product]
   719 E C1719822:Follow [Intellectual Product]

Phrase: "have"

Phrase: "been"

Phrase: "attempted"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1516084:Attempt [Event]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "improve upon myeloma cell kill.5-8 High-dose melphalan"
Meta Candidates (Total=19; Excluded=0; Pruned=0; Remaining=19)
   760   C0333843:Myeloma cell [Cell]
   760   C0444956:High dose [Quantitative Concept]
   760   C0599733:cell kill [Cell Function]
   739   C0007634:Cell [Cell]
   739   C0025241:Melphalan [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   739   C0026764:Myeloma [Neoplastic Process]
   739   C0162388:kill [Social Behavior]
   739   C0178602:Dose [Quantitative Concept]
   739   C0205250:High [Qualitative Concept]
   739   C0681205:Kill [Idea or Concept]
   739   C0869039:Dose [Quantitative Concept]
   739   C1114758:Dose # [Clinical Attribute]
   739   C1269647:Cell [Cell]
   739   C1299351:High [Qualitative Concept]
   739   C1550555:kill [Functional Concept]
   739   C1704653:Cell [Medical Device]
   739   C1948049:Cell [Spatial Concept]
   739   C2700149:HIGH [Intellectual Product]
   739   C3538749:Myeloma [Intellectual Product]

Phrase: "followed by autologous bone marrow transplantation"
Meta Candidates (Total=23; Excluded=2; Pruned=0; Remaining=21)
   882   C0194037:autologous bone marrow transplantation [Therapeutic or Preventive Procedure]
           Autologous Marrow Transplantation
   833   C0005961:Bone Marrow Transplantation [Therapeutic or Preventive Procedure]
           Marrow Transplantation
   833   C2986504:Autologous Bone Marrow [Body Substance]
   790   C0005953:Bone Marrow [Tissue]
   790   C0332283:Followed by [Temporal Concept]
           followed
   783   C0005976:Bone Transplantation [Therapeutic or Preventive Procedure]
   783   C0040736:Transplantation, Autologous [Therapeutic or Preventive Procedure]
   756 E C1708973:Medullary Bone [Tissue]
   753   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   753   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   753   C0040733:transplantation [Functional Concept]
   753   C0086590:Marrow [Food]
   753   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   753   C0376152:Marrow [Body Part, Organ, or Organ Component]
   753   C0391978:Bone [Tissue]
   753   C0439859:Autologous [Qualitative Concept]
   753   C1266908:Bone [Body Part, Organ, or Organ Component]
   753   C1266909:Bone [Body System]
   753   C1546708:Marrow [Intellectual Product]
   719 E C1719822:Follow [Intellectual Product]

Phrase: "was"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "improve"

Phrase: "response rates,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   966   C0237629:Response Rate [Temporal Concept]
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]
   827   C0871208:Rate [Activity]
   827   C1521828:Rate [Quantitative Concept]

Phrase: "disease-free survival,"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
  1000   C0242793:Disease-Free Survival [Quantitative Concept]
   827   C0012634:Disease [Disease or Syndrome]
   827   C0038952:Survival [Activity]
   827   C0220921:survival [Functional Concept]
   827   C0332296:free [Functional Concept]
   827   C1880497:Free [Qualitative Concept]
   827   C1996904:Free [Qualitative Concept]
   771 E C1836721:MALS [Finding]
   771 E C3538764:MALS [Gene or Genome]
   771 E C3540595:MAL [Gene or Genome]

Phrase: "and"

Phrase: "overall survival in a randomized study"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0038952:Survival [Activity]
   753   C0220921:survival [Functional Concept]
   753   C0282416:Overall [Intellectual Product]
   753   C1561607:Overall [Qualitative Concept]

Phrase: "when"

Phrase: "compared with standard chemotherapy.9,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   760   C0013217:chemotherapy [Functional Concept]
   760   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
   760   C1442989:Standard [Qualitative Concept]
   760   C1707455:Compared [Activity]
   760   C2828392:Standard [Intellectual Product]

Phrase: "10 However,"

Phrase: "the majority of myeloma patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0680220:majority [Social Behavior]

Phrase: "treated with autologous bone marrow transplantation"
Meta Candidates (Total=24; Excluded=2; Pruned=0; Remaining=22)
   882   C0194037:autologous bone marrow transplantation [Therapeutic or Preventive Procedure]
           Autologous Marrow Transplantation
   833   C0005961:Bone Marrow Transplantation [Therapeutic or Preventive Procedure]
           Marrow Transplantation
   833   C2986504:Autologous Bone Marrow [Body Substance]
   790   C0005953:Bone Marrow [Tissue]
   790   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   783   C0005976:Bone Transplantation [Therapeutic or Preventive Procedure]
   783   C0040736:Transplantation, Autologous [Therapeutic or Preventive Procedure]
   756 E C1708973:Medullary Bone [Tissue]
   753   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   753   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   753   C0040733:transplantation [Functional Concept]
   753   C0086590:Marrow [Food]
   753   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   753   C0376152:Marrow [Body Part, Organ, or Organ Component]
   753   C0391978:Bone [Tissue]
   753   C0439859:Autologous [Qualitative Concept]
   753   C1266908:Bone [Body Part, Organ, or Organ Component]
   753   C1266909:Bone [Body System]
   753   C1522326:Treated [Functional Concept]
   753   C1546708:Marrow [Intellectual Product]
   719 E C1292734:TREAT [Functional Concept]

Phrase: "develop"

Phrase: "progressive disease within 3years."
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   833   C0677932:progressive disease [Neoplastic Process]
   833   C1335499:Progressive Disease [Finding]
   833   C3539781:Progressive Disease [Disease or Syndrome]
   770   C0012634:Disease [Disease or Syndrome]
   770   C0205329:Progressive [Functional Concept]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.27: The use of peripheral blood progenitor cells (PBPCs) as the source of hematopoietic stem cells has been evaluated as an alternative approach to improve upon the efficacy of autologous transplantation in patients with multiple myeloma.11-13 Several studies have demonstrated that PBPCs can be used for autologous transplantation and that restoration of hematopoiesis occurred more rapidly when compared with bone marrow stem cells.12,14-16 Furthermore, PBPCs can be harvested without the use of general anesthesia. 

Phrase: "The use of peripheral blood progenitor cells (PBPCs)"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   778   C1524063:Use of [Functional Concept]
   748   C0042153:use [Functional Concept]
   748   C0457083:Use [Functional Concept]
   748   C1947944:Use [Intellectual Product]

Phrase: "as the source"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0449416:Source [Finding]
  1000   C1705919:Source [Idea or Concept]

Phrase: "of hematopoietic stem cells"
Meta Candidates (Total=13; Excluded=4; Pruned=0; Remaining=9)
  1000   C0018956:Hematopoietic stem cells [Cell]
   901   C0038250:Stem cells [Cell]
   896   C2323499:Hematopoietic cell [Cell]
   827   C0007634:Cells [Cell]
   827   C0018957:Haematopoietic [Body System]
   827   C0229601:Hematopoietic [Functional Concept]
   827   C0242767:Stem [Plant]
   827   C1186763:Stem [Body Part, Organ, or Organ Component]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
   755 E C0018951:Haematopoiesis [Organ or Tissue Function]

Phrase: "has"

Phrase: "been"

Phrase: "evaluated as an alternative approach to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0220825:Evaluated [Functional Concept]
   753   C0449445:Approach [Spatial Concept]
   753   C1523987:Alternative [Conceptual Entity]

Phrase: "improve upon the efficacy of autologous transplantation"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   778   C0040736:Transplantation, Autologous [Therapeutic or Preventive Procedure]
   748   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   748   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   748   C0040733:transplantation [Functional Concept]
   748   C0439859:Autologous [Qualitative Concept]
   748   C1280519:Efficacy [Qualitative Concept]
   748   C1707887:EFFICACY [Research Activity]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with multiple myeloma.11-13 Several studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   799   C0947630:studies [Laboratory Procedure]
   766 E C0557651:Study [Manufactured Object]
   766 E C2603343:Study [Research Activity]

Phrase: "have"

Phrase: "demonstrated"

Phrase: "that PBPCs"
Meta Candidates (Total=23; Excluded=12; Pruned=0; Remaining=11)
   906   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   861   C0038250:Progenitor Cells [Cell]
   861   C0229664:peripheral blood [Body Substance]
           Blood
   830 E C2328697:Hemal cell [Cell]
   819 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   812   C0005767:Blood [Tissue]
   812   C0005768:blood [Body Substance]
   812   C0007634:Cells [Cell]
   812   C0205100:Peripheral [Spatial Concept]
   812   C0870134:Progenitor [Family Group]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]
   741 E C0333275:Bloody [Qualitative Concept]
   729 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   729 E C0392895:Bloods [Population Group]
   729 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   729 E C1511228:VESSEL, BLOOD [Tissue]
   712 E C1558950:VASCULAR [Finding]
   712 E C1801960:Vascular [Qualitative Concept]

Phrase: "can"

Phrase: "be"

Phrase: "used for autologous transplantation"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   833   C0040736:Transplantation, Autologous [Therapeutic or Preventive Procedure]
   770   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   770   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   770   C0040733:transplantation [Functional Concept]
   770   C0439859:Autologous [Qualitative Concept]
   770   C1273517:used [Finding]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1947944:Use [Intellectual Product]

Phrase: "and"

Phrase: "that restoration of hematopoiesis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0449982:Restoration [Intellectual Product]

Phrase: "occurred"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1709305:Occurred [Activity]
   966 E C2745955:OCCUR [Temporal Concept]

Phrase: "more rapidly"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205172:More [Functional Concept]
   861   C1637379:Rapidly [Qualitative Concept]

Phrase: "when"

Phrase: "compared with bone marrow stem cells.12,"
Meta Candidates (Total=22; Excluded=5; Pruned=0; Remaining=17)
   853   C1511246:Bone Marrow Stem Cells [Cell]
   804   C0005955:Bone Marrow Cells [Cell]
   778   C0005953:Bone Marrow [Tissue]
   778   C0038250:Stem cells [Cell]
   774   C0222677:Bone cells [Cell]
   757 E C0029432:Bone cell [Cell]
   748   C0007634:Cells [Cell]
   748   C0086590:Marrow [Food]
   748   C0242767:Stem [Plant]
   748   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   748   C0376152:Marrow [Body Part, Organ, or Organ Component]
   748   C0391978:Bone [Tissue]
   748   C1186763:Stem [Body Part, Organ, or Organ Component]
   748   C1266908:Bone [Body Part, Organ, or Organ Component]
   748   C1266909:Bone [Body System]
   748   C1546708:Marrow [Intellectual Product]
   748   C1707455:Compared [Activity]
   748   C3282337:Cells [Cell]
   746 E C1708973:Medullary Bone [Tissue]
   714 E C1269647:Cell [Cell]
   714 E C1704653:Cell [Medical Device]
   714 E C1948049:Cell [Spatial Concept]

Phrase: "14-16 Furthermore,"

Phrase: "PBPCs"
Meta Candidates (Total=23; Excluded=12; Pruned=0; Remaining=11)
   906   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   861   C0038250:Progenitor Cells [Cell]
   861   C0229664:peripheral blood [Body Substance]
           Blood
   830 E C2328697:Hemal cell [Cell]
   819 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   812   C0005767:Blood [Tissue]
   812   C0005768:blood [Body Substance]
   812   C0007634:Cells [Cell]
   812   C0205100:Peripheral [Spatial Concept]
   812   C0870134:Progenitor [Family Group]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]
   741 E C0333275:Bloody [Qualitative Concept]
   729 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   729 E C0392895:Bloods [Population Group]
   729 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   729 E C1511228:VESSEL, BLOOD [Tissue]
   712 E C1558950:VASCULAR [Finding]
   712 E C1801960:Vascular [Qualitative Concept]

Phrase: "can"

Phrase: "be"

Phrase: "harvested without the use of general anesthesia."
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   778   C0002915:General Anesthesia [Therapeutic or Preventive Procedure]
   778   C1524063:Use of [Functional Concept]
   778   C2930406:General Anesthesia [Physiologic Function]
   748   C0002903:Anesthesia [Therapeutic or Preventive Procedure]
   748   C0002930:Anaesthesia [Biomedical Occupation or Discipline]
   748   C0042153:use [Functional Concept]
   748   C0205246:General [Spatial Concept]
   748   C0457083:Use [Functional Concept]
   748   C1553889:General [Idea or Concept]
   748   C1947944:Use [Intellectual Product]
   721 E C0017302:General anaesthetic [Pharmacologic Substance]
   721 E C3536928:General Anesthetic [Pharmacologic Substance]
   714   C1512335:Harvest [Health Care Activity]
Processing 00000000.tx.28: As a result, PBPCs have become the preferred source for autografts in support of myeloablative therapy. 

Phrase: "As a result,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1274040:Result [Functional Concept]
  1000   C1546471:Result [Idea or Concept]
  1000   C2825142:Result [Finding]

Phrase: "PBPCs"
Meta Candidates (Total=23; Excluded=12; Pruned=0; Remaining=11)
   906   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   861   C0038250:Progenitor Cells [Cell]
   861   C0229664:peripheral blood [Body Substance]
           Blood
   830 E C2328697:Hemal cell [Cell]
   819 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   812   C0005767:Blood [Tissue]
   812   C0005768:blood [Body Substance]
   812   C0007634:Cells [Cell]
   812   C0205100:Peripheral [Spatial Concept]
   812   C0870134:Progenitor [Family Group]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]
   741 E C0333275:Bloody [Qualitative Concept]
   729 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   729 E C0392895:Bloods [Population Group]
   729 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   729 E C1511228:VESSEL, BLOOD [Tissue]
   712 E C1558950:VASCULAR [Finding]
   712 E C1801960:Vascular [Qualitative Concept]

Phrase: "have"

Phrase: "become"

Phrase: "the preferred source for autografts"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0449416:Source [Finding]
   760   C1705919:Source [Idea or Concept]

Phrase: "in support"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0183683:Support [Medical Device]
  1000   C1521721:Support [Conceptual Entity]

Phrase: "of myeloablative therapy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039798:therapy [Functional Concept]
   861   C0087111:Therapy [Therapeutic or Preventive Procedure]
   861   C1363945:Therapy [Finding]
Processing 00000000.tx.29: Malignant cells have been detected in bone marrow harvests of patients with multiple myeloma17,18 as well as in the peripheral blood and in the leukapheresis products.18-21 A recent prospective study of 33patients found an inverse correlation between the monoclonal plasma cell concentration in leukapheresis or peripheral blood samples and disease-free survival.18 In this study, the presence of 0.2106 malignant plasma cells/L was a significant predictor of early relapse. 

Phrase: "Malignant cells"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
  1000   C0334227:Malignant cells [Cell]
  1000   C2698007:Malignant Cells, NOS [Laboratory Procedure]
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "have"

Phrase: "been"

Phrase: "detected in bone marrow"
Meta Candidates (Total=14; Excluded=4; Pruned=0; Remaining=10)
   833   C0005953:Bone Marrow [Tissue]
   791 E C1708973:Medullary Bone [Tissue]
   770   C0086590:Marrow [Food]
   770   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   770   C0376152:Marrow [Body Part, Organ, or Organ Component]
   770   C0391978:Bone [Tissue]
   770   C0442726:Detected [Finding]
   770   C1266908:Bone [Body Part, Organ, or Organ Component]
   770   C1266909:Bone [Body System]
   770   C1511790:Detected [Therapeutic or Preventive Procedure]
   770   C1546708:Marrow [Intellectual Product]
   715 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   715 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   715 E C1550278:Medullary [Body Part, Organ, or Organ Component]

Phrase: "harvests of patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C1512335:Harvest [Health Care Activity]

Phrase: "with multiple myeloma17,"

Phrase: "18"

Phrase: "as well as in the peripheral blood"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   778   C0229664:peripheral blood [Body Substance]
           Blood
   748   C0005767:Blood [Tissue]
   748   C0005768:blood [Body Substance]
   748   C0205100:Peripheral [Spatial Concept]
   748   C0205170:Well [Qualitative Concept]
   748   C3146287:Well [Manufactured Object]
   737 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]

Phrase: "and in the leukapheresis products.18-21"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   748   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]
   748   C1514468:Products [Entity]
   748   C1515981:And [Idea or Concept]
   714 E C1704444:Product [Quantitative Concept]

Phrase: "A recent prospective study of 33patients"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0033522:prospective study [Research Activity]
   790   C1709709:Prospective Study [Research Activity]
   753   C0023981:prospective [Research Activity]
   753   C0557651:Study [Manufactured Object]
   753   C2603343:Study [Research Activity]

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "an inverse correlation between the monoclonal plasma cell concentration"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C1707520:Correlation [Qualitative Concept]

Phrase: "in leukapheresis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]

Phrase: "or"

Phrase: "peripheral blood samples"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0178913:blood samples [Body Substance]
   793   C0370003:Sample [Substance]
   793   C2347026:Sample [Conceptual Entity]
   734   C0229664:peripheral blood [Body Substance]

Phrase: "and"

Phrase: "disease-free survival.18 In this study,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   814   C0242793:Disease-Free Survival [Quantitative Concept]
   748   C0012634:Disease [Disease or Syndrome]
   748   C0038952:Survival [Activity]
   748   C0220921:survival [Functional Concept]
   748   C0332296:free [Functional Concept]
   748   C0557651:Study [Manufactured Object]
   748   C1880497:Free [Qualitative Concept]
   748   C1996904:Free [Qualitative Concept]
   748   C2603343:Study [Research Activity]

Phrase: "the presence of 0.2106 malignant plasma cells/L"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   784   C0427850:Presence of cells [Laboratory or Test Result]
   742   C0392148:Presence [Therapeutic or Preventive Procedure]

Phrase: "was"

Phrase: "a significant predictor of early relapse."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C2698872:Predictor [Idea or Concept]
Processing 00000000.tx.30: Because circulating tumor cell numbers may simply reflect overall tumor burden, this finding does not directly demonstrate that the reinfusion of circulating myeloma cells contributed to disease recurrence. 

Phrase: "Because"

Phrase: "circulating tumor cell numbers"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0007584:Numbers, Cell [Laboratory Procedure]
   812   C0237753:*Number [Quantitative Concept]
   812   C0449788:Number [Quantitative Concept]
   756   C0027625:Circulating Tumor Cell [Cell]

Phrase: "may"

Phrase: "simply"

Phrase: "reflect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0558058:reflect [Mental Process]

Phrase: "overall tumor burden,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C1449699:Tumor Burden [Diagnostic Procedure]
   827   C2828008:Burden [Idea or Concept]

Phrase: "this finding"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0037088:Finding [Sign or Symptom]
  1000   C0243095:Finding [Finding]
  1000   C2825141:Finding [Finding]

Phrase: "does"

Phrase: "not directly"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1518422:Not [Functional Concept]
   861   C1947931:Directly [Qualitative Concept]

Phrase: "demonstrate"

Phrase: "that"

Phrase: "the reinfusion of circulating myeloma cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0854643:Reinfusion [Therapeutic or Preventive Procedure]

Phrase: "contributed to disease recurrence."
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   833   C0679254:disease recurrence [Finding]
   783 E C0277556:Recurrent disease [Disease or Syndrome]
   770   C0012634:Disease [Disease or Syndrome]
   770   C0034897:Recurrence [Phenomenon or Process]
   770   C1458156:recurrence [Neoplastic Process]
   770   C2825055:Recurrence [Pathologic Function]
   737   C1880177:Contribute [Activity]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.31: However, studies using gene marking techniques and clonogenic tumor cell assays in other malignancies suggest that tumor cells infused in an autologous graft can contribute to relapse and affect overall outcome.22,23 Initial studies in patients with multiple myeloma evaluated ex vivo purging of bone marrow harvests by incubation with cyclophosphamide derivatives or monoclonal B-cell antibodies.24-26 These purging procedures substantially reduced autograft tumor burden yet were associated with significant delays in engraftment. 

Phrase: "However,"

Phrase: "studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0947630:studies [Laboratory Procedure]
   966 E C0557651:Study [Manufactured Object]
   966 E C2603343:Study [Research Activity]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "gene marking techniques"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0025664:techniques [Intellectual Product]
   827   C0449851:Techniques [Functional Concept]

Phrase: "and"

Phrase: "clonogenic tumor cell assays in other malignancies"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   822   C0041372:Clonogenic Cell Assay, Tumor [Laboratory Procedure]
   804   C0009385:Clonogenic Cell Assays [Laboratory Procedure]
   714   C0005507:Assay [Laboratory Procedure]
   714   C0243073:assay [Qualitative Concept]
   714   C1510438:Assay [Laboratory Procedure]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that tumor cells"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
  1000   C0431085:Tumor cells [Cell]
   966 E C0597032:Tumor Cell [Cell]
   861   C0007634:Cells [Cell]
   861   C0027651:Tumor [Neoplastic Process]
   861   C1578706:Tumor [Intellectual Product]
   861   C3273930:Tumor [Finding]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "infused in an autologous graft"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C0559189:Autologous graft [Biomedical or Dental Material]
   760   C0181074:{Graft} [Biomedical or Dental Material]
   760   C0332835:Graft [Tissue]
   760   C0439859:Autologous [Qualitative Concept]
   760   C1961139:Graft, NOS [Therapeutic or Preventive Procedure]

Phrase: "can"

Phrase: "contribute"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1880177:Contribute [Activity]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "relapse"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0035020:Relapse [Phenomenon or Process]
  1000   C0205336:relapse [Temporal Concept]
  1000   C0277556:Relapse [Disease or Syndrome]

Phrase: "and"

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "overall outcome.22,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0282416:Overall [Intellectual Product]
   827   C1274040:Outcome [Functional Concept]
   827   C1561607:Overall [Qualitative Concept]

Phrase: "23 Initial studies in patients"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   760   C0205265:Initial [Temporal Concept]
   760   C0947630:studies [Laboratory Procedure]
   760   C1279901:Initial [Qualitative Concept]
   760   C1555582:Initial [Idea or Concept]
   760   C1705685:INITIAL [Functional Concept]
   726 E C0557651:Study [Manufactured Object]
   726 E C2603343:Study [Research Activity]

Phrase: "with multiple myeloma"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   861   C0439064:Multiple [Quantitative Concept]
   861   C3538749:Myeloma [Intellectual Product]

Phrase: "evaluated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0220825:Evaluated [Functional Concept]

Phrase: "ex vivo purging of bone marrow"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   820   C0085079:Bone Marrow Purging [Therapeutic or Preventive Procedure]
           Marrow purging
   753   C0855227:purging [Disease or Syndrome]
   719 E C0722910:Purge [Lipid,Pharmacologic Substance]

Phrase: "harvests by incubation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1512335:Harvest [Health Care Activity]

Phrase: "with cyclophosphamide derivatives"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0243072:derivatives [Chemical Viewed Structurally]
   827 E C1527240:Derivative [Functional Concept]

Phrase: "or"

Phrase: "monoclonal B-cell antibodies.24-26"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   858   C0003250:Monoclonal Antibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   844   C0301850:B cell antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0004561:B-cell [Cell]
   799   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   799   C0007634:Cell [Cell]
   799   C0746619:monoclonal [Finding]
   799   C1269647:Cell [Cell]
   799   C1704653:Cell [Medical Device]
   799   C1948049:Cell [Spatial Concept]
   766 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "These purging procedures substantially"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   827   C0025664:procedures [Intellectual Product]
   827   C0184661:Procedures [Diagnostic Procedure,Therapeutic or Preventive Procedure]
   827   C2700391:procedures [Activity]
   793 E C1948041:Procedure [Therapeutic or Preventive Procedure]
   793 E C3274430:PROCEDURE [Health Care Activity]
   793 E C3538935:Procedure [Idea or Concept]
   793 E C3539779:Procedure [Intellectual Product]

Phrase: "reduced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392756:Reduced [Qualitative Concept]

Phrase: "autograft tumor"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0027651:Tumor [Neoplastic Process]
   861   C1578706:Tumor [Intellectual Product]
   861   C3273930:Tumor [Finding]

Phrase: "burden"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2828008:Burden [Idea or Concept]

Phrase: "yet"

Phrase: "were"

Phrase: "associated with significant delays"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0237881:significant [Quantitative Concept]
   770   C0750502:Significant [Idea or Concept]
   770   C1546944:Significant [Qualitative Concept]
   737   C0205421:Delay [Temporal Concept]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]

Phrase: "in engraftment."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0301944:Engraftment [Physiologic Function]
Processing 00000000.tx.32: Because the malignant clone in myeloma does not express CD34,27 an alternative approach for purging the autograft uses the positive selection of stem cells using anti-CD34 antibodies. 

Phrase: "Because"

Phrase: "the malignant clone in myeloma"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0009013:Clone [Cell]
   760   C1522642:Clone [Tissue]

Phrase: "does"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "express"

Phrase: "CD34,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3538723:CD34 [Laboratory Procedure]

Phrase: "27"

Phrase: "an alternative approach for purging"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0449445:Approach [Spatial Concept]

Phrase: "the autograft"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0040736:autograft [Therapeutic or Preventive Procedure]
   944 E C0559189:Autotransplant [Biomedical or Dental Material]

Phrase: "uses"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0042153:use [Functional Concept]
  1000   C0457083:Use [Functional Concept]
  1000   C1947944:Use [Intellectual Product]

Phrase: "the positive selection of stem cells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C2347644:Positive Selection [Laboratory Procedure]
   753   C0036576:selection [Genetic Function]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "anti-CD34 antibodies."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   913   C1624602:Anti-Antibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   896 E C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   793 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
Processing 00000000.tx.33: This method of purging has the advantage of more widespread applicability among tumor types not expressing CD34 and eliminates the need to expose the autograft to potentially harmful agents. 

Phrase: "This method of purging"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0025663:Method [Intellectual Product]
   770   C0449851:Method [Functional Concept]
   770   C0871511:METHOD [Intellectual Product]

Phrase: "has"

Phrase: "the advantage of more widespread applicability"

Phrase: "among tumor types"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0332307:Types [Qualitative Concept]
   827 E C1547052:*Type [Quantitative Concept]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "expressing"

Phrase: "CD34"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3538723:CD34 [Laboratory Procedure]

Phrase: "and"

Phrase: "eliminates"

Phrase: "the need to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0027552:Need [Qualitative Concept]
   861   C0686904:need [Functional Concept]

Phrase: "expose"

Phrase: "the autograft to potentially harmful agents."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   771   C0450442:Agent [Chemical Viewed Functionally]
   771   C1254351:Agent [Pharmacologic Substance]
   771   C1521826:Agent [Intellectual Product]
Processing 00000000.tx.34: Autologous transplantation using CD34-selected products can provide effective hematopoietic support for patients receiving myeloablative therapy.15,28,29 In a phase I/II study of 37myeloma patients, neutrophil engraftment (absolute neutrophil count [ANC] >500/L) and platelet (>20,000/L) engraftment were rapid (median of 12days for both) provided that a cell dose of at least 2106 CD34+ cells/kg was reinfused. 

Phrase: "Autologous transplantation"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0040736:Transplantation, Autologous [Therapeutic or Preventive Procedure]
   861   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   861   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   861   C0040733:transplantation [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "CD34-selected products"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C1514468:Products [Entity]
   793 E C1704444:Product [Quantitative Concept]

Phrase: "can"

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "effective hematopoietic support for patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0183683:Support [Medical Device]
   760   C1521721:Support [Conceptual Entity]

Phrase: "receiving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514756:Receive [Qualitative Concept]

Phrase: "myeloablative therapy.15,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0039798:therapy [Functional Concept]
   827   C0087111:Therapy [Therapeutic or Preventive Procedure]
   827   C1363945:Therapy [Finding]

Phrase: "28,"

Phrase: "29 In a phase I/II study of 37myeloma patients,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   777   C0282460:Phase II Study [Research Activity]
   777   C0920321:Phase I Study [Research Activity]
   739   C0021966:I- [Inorganic Chemical]
   739   C0030705:Patients [Patient or Disabled Group]
   739   C0205390:Phase [Temporal Concept]
   739   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   739   C0557651:Study [Manufactured Object]
   739   C2603343:Study [Research Activity]

Phrase: "neutrophil engraftment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1882078:Neutrophil Engraftment [Finding]
   861   C0301944:Engraftment [Physiologic Function]

Phrase: "(absolute neutrophil count [ANC]"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C0948762:Absolute neutrophil count [Laboratory Procedure]
   901   C0200633:Neutrophil count [Laboratory Procedure]
   827   C0027950:Neutrophile [Cell]
   827   C0205344:Absolute [Qualitative Concept]
   827   C0750480:Count [Activity]
   827   C1705566:Count [Quantitative Concept]
   755 E C0746885:neutrophilic [Cell Function]
   727 E C0151683:Neutrophilia [Finding]

Phrase: ">500/L)"

Phrase: "and"

Phrase: "platelet"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0005821:Platelet [Cell]
   916 E C1963076:Platelets [Finding]

Phrase: "("

Phrase: ">20,000/L) engraftment"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0301944:Engraftment [Physiologic Function]

Phrase: "were"

Phrase: "rapid"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439831:Rapid [Qualitative Concept]

Phrase: "(median of 12days"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0549183:Median [Spatial Concept]
   790   C0876920:Median [Quantitative Concept]
   790   C2347635:Median [Quantitative Concept]
   790   C2348144:Median [Quantitative Concept]
   790   C2939193:Median [Spatial Concept]

Phrase: "for both"

Phrase: ")"

Phrase: "provided that"

Phrase: "a cell dose of"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0178602:Dose [Quantitative Concept]
   770   C0869039:Dose [Quantitative Concept]
   770   C1114758:Dose # [Clinical Attribute]

Phrase: "at least 2106 CD34+ cells/kg"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0022718:KG [Geographic Area]
   804   C0439209:kg [Quantitative Concept]

Phrase: "was"

Phrase: "reinfused."
Processing 00000000.tx.35: Tumor cell contamination was measured before and after CD34 selection using a sensitive polymerase chain reaction (PCR) assay based on the unique Ig heavy-chain variable region (VDJ) sequence expressed by the myeloma cell clone. 

Phrase: "Tumor cell contamination"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0259846:contamination [Human-caused Phenomenon or Process]
   827   C1881659:CONTAMINATION [Event]
   827   C2349974:Contamination [Idea or Concept]
   734   C0431085:Tumor cell [Cell]
   734   C0597032:Tumor Cell [Cell]

Phrase: "was"

Phrase: "measured before"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   833   C0444706:Measured [Qualitative Concept]
   833   C3541902:MEASURED [Diagnostic Procedure]
   799 E C0079809:Measure [Quantitative Concept]
   799 E C0242485:Measure [Functional Concept]

Phrase: "and after CD34 selection"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0036576:selection [Genetic Function]
   770   C1515981:And [Idea or Concept]
   770   C3538723:CD34 [Laboratory Procedure]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a sensitive polymerase chain reaction (PCR) assay"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   884   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   804   C0005507:Assay [Laboratory Procedure]
   804   C0243073:assay [Qualitative Concept]
   804   C0337112:Chain [Manufactured Object]
   804   C0443286:Reaction [Functional Concept]
   804   C1114821:Reaction [Clinical Attribute]
   804   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   804   C1510438:Assay [Laboratory Procedure]
   804   C1524075:Chain [Idea or Concept]

Phrase: "based on the unique Ig heavy-chain variable region"
Meta Candidates (Total=19; Excluded=3; Pruned=0; Remaining=16)
   790   C0021034:IG HEAVY CHAIN [Amino Acid, Peptide, or Protein,Immunologic Factor]
   784   C0877857:Variable Region, Ig [Amino Acid, Peptide, or Protein,Immunologic Factor]
   764   C1420192:heavy chain [Gene or Genome]
   742   C0017446:Region [Geographic Area]
   742   C0021027:Ig [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   742   C0205147:Region [Spatial Concept]
   742   C0305052:IG [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   742   C0337112:Chain [Manufactured Object]
   742   C0360506:IG [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   742   C0439539:Heavy [Qualitative Concept]
   742   C0439828:Variable [Qualitative Concept]
   742   C1524075:Chain [Idea or Concept]
   742   C1527178:Based [Functional Concept]
   742   C1705938:Based [Idea or Concept]
   742   C1710548:Unique [Qualitative Concept]
   742   C3541296:IG [Idea or Concept]
   708 E C0002055:base [Inorganic Chemical]
   708 E C0178499:Base [Chemical Viewed Functionally]
   708 E C1880279:Base [Biomedical or Dental Material]

Phrase: "(VDJ"

Phrase: ")"

Phrase: "sequence"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C0004793:Sequence [Nucleotide Sequence]
  1000   C0162326:Sequence [Nucleotide Sequence]
  1000   C0162327:Sequence [Nucleotide Sequence]
  1000   C1519249:Sequence [Functional Concept]
   928 E C1548958:Sequential [Idea or Concept]
   928 E C1705294:Sequential [Qualitative Concept]

Phrase: "expressed by the myeloma cell clone."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   790   C0009013:Cell Clone [Cell]
           Clone
   790   C0333843:Myeloma cell [Cell]
   753   C0007634:Cell [Cell]
   753   C0026764:Myeloma [Neoplastic Process]
   753   C1269647:Cell [Cell]
   753   C1522642:Clone [Tissue]
   753   C1704653:Cell [Medical Device]
   753   C1948049:Cell [Spatial Concept]
   753   C3538749:Myeloma [Intellectual Product]
Processing 00000000.tx.36: Tumor cells were detected in 70% of the unmanipulated PBPC products. 

Phrase: "Tumor cells"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
  1000   C0431085:Tumor cells [Cell]
   966 E C0597032:Tumor Cell [Cell]
   861   C0007634:Cells [Cell]
   861   C0027651:Tumor [Neoplastic Process]
   861   C1578706:Tumor [Intellectual Product]
   861   C3273930:Tumor [Finding]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "detected in 70% of the unmanipulated PBPC products."
Meta Candidates (Total=22; Excluded=7; Pruned=0; Remaining=15)
   756   C0038250:Progenitor Cells [Cell]
   756   C0229664:peripheral blood [Body Substance]
           Blood
   755   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   754   C0456388:Blood products [Pharmacologic Substance]
   738   C0005767:Blood [Tissue]
   738   C0005768:blood [Body Substance]
   738   C0007634:Cells [Cell]
   738   C0205100:Peripheral [Spatial Concept]
   738   C0442726:Detected [Finding]
   738   C0870134:Progenitor [Family Group]
   738   C1511790:Detected [Therapeutic or Preventive Procedure]
   738   C1514468:Products [Entity]
   738   C3282337:Cells [Cell]
   737 E C1547007:Blood product [Idea or Concept]
   714 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   709 E C2328697:Hemal cell [Cell]
   704 E C1269647:Cell [Cell]
   704 E C1704444:Product [Quantitative Concept]
   704 E C1704653:Cell [Medical Device]
   704 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.37: The CD34 selection using the CEPRATE SC Stem Cell Concentration System (CellPro, Inc, Bothell, WA) reduced the tumor cell contamination between 2.7and 4.5logs.15 A phase III, randomized study was conducted to more definitively evaluate the tumor-purging capabilities of the CEPRATE SC System. 

Phrase: "The CD34 selection"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0036576:selection [Genetic Function]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the CEPRATE SC Stem Cell Concentration System"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   795   C0449913:System [Functional Concept]
   795   C1553451:System [Manufactured Object]
   795   C1704459:System [Medical Device]
   724 E C0205373:Systemic [Functional Concept]

Phrase: "(CellPro,"

Phrase: "Inc,"

Phrase: "Bothell,"

Phrase: "WA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043038:WA [Geographic Area]

Phrase: ")"

Phrase: "reduced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392756:Reduced [Qualitative Concept]

Phrase: "the tumor cell contamination between 2.7and 4.5logs.15"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   739   C0259846:contamination [Human-caused Phenomenon or Process]
   739   C1881659:CONTAMINATION [Event]
   739   C2349974:Contamination [Idea or Concept]

Phrase: "A phase III,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439070:III [Intellectual Product]
   861   C1705160:III [Qualitative Concept]

Phrase: "randomized study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "was"

Phrase: "conducted"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0004927:Conduct [Individual Behavior]

Phrase: "to more definitively"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1883351:To [Qualitative Concept]

Phrase: "evaluate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0220825:Evaluate [Functional Concept]

Phrase: "the tumor-purging capabilities of the CEPRATE SC System."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   706   C2698977:Capability [Qualitative Concept]
Processing 00000000.tx.38: Tumor cell contamination of the autografts was quantified using a PCR-based tumor detection assay.15,17 To determine the safety of CD34 selection using the CEPRATE SC System, hematologic recovery and toxicity after autologous transplantation with either CD34 selected or unselected PBPCs were compared.  

Phrase: "Tumor cell contamination of the autografts"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0259846:contamination [Human-caused Phenomenon or Process]
   753   C1881659:CONTAMINATION [Event]
   753   C2349974:Contamination [Idea or Concept]

Phrase: "was"

Phrase: "quantified"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a PCR-based tumor detection assay.15,"
Meta Candidates (Total=18; Excluded=3; Pruned=0; Remaining=15)
   835   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   793   C0005507:Assay [Laboratory Procedure]
   793   C0027651:Tumor [Neoplastic Process]
   793   C0243073:assay [Qualitative Concept]
   793   C0337112:Chain [Manufactured Object]
   793   C0443286:Reaction [Functional Concept]
   793   C1114821:Reaction [Clinical Attribute]
   793   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   793   C1510438:Assay [Laboratory Procedure]
   793   C1511790:Detection [Therapeutic or Preventive Procedure]
   793   C1524075:Chain [Idea or Concept]
   793   C1527178:Based [Functional Concept]
   793   C1578706:Tumor [Intellectual Product]
   793   C1705938:Based [Idea or Concept]
   793   C3273930:Tumor [Finding]
   760 E C0002055:base [Inorganic Chemical]
   760 E C0178499:Base [Chemical Viewed Functionally]
   760 E C1880279:Base [Biomedical or Dental Material]

Phrase: "17 To"

Phrase: "determine"

Phrase: "the safety of CD34 selection"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0036043:Safety [Human-caused Phenomenon or Process]
   760   C1705187:SAFETY [Research Activity]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the CEPRATE SC System,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   812   C0449913:System [Functional Concept]
   812   C1553451:System [Manufactured Object]
   812   C1704459:System [Medical Device]
   741 E C0205373:Systemic [Functional Concept]

Phrase: "hematologic recovery"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0237820:Recovery [Activity]
   861   C1555688:recovery [Idea or Concept]
   861   C2004454:Recovery [Organism Function]

Phrase: "and"

Phrase: "toxicity after autologous transplantation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0040539:toxicity [Qualitative Concept]
   770   C0600688:Toxicity [Injury or Poisoning]

Phrase: "with either CD34"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538723:CD34 [Laboratory Procedure]

Phrase: "selected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1707391:Select [Activity]

Phrase: "or"

Phrase: "unselected PBPCs"
Meta Candidates (Total=23; Excluded=12; Pruned=0; Remaining=11)
   872   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   840   C0038250:Progenitor Cells [Cell]
   840   C0229664:peripheral blood [Body Substance]
           Blood
   808 E C2328697:Hemal cell [Cell]
   804   C0005767:Blood [Tissue]
   804   C0005768:blood [Body Substance]
   804   C0007634:Cells [Cell]
   804   C0205100:Peripheral [Spatial Concept]
   804   C0870134:Progenitor [Family Group]
   804   C3282337:Cells [Cell]
   798 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   771 E C1269647:Cell [Cell]
   771 E C1704653:Cell [Medical Device]
   771 E C1948049:Cell [Spatial Concept]
   733 E C0333275:Bloody [Qualitative Concept]
   721 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   721 E C0392895:Bloods [Population Group]
   721 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   721 E C1511228:VESSEL, BLOOD [Tissue]
   704 E C1558950:VASCULAR [Finding]
   704 E C1801960:Vascular [Qualitative Concept]

Phrase: "were"

Phrase: "compared."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compared [Activity]
Processing 00000000.tx.39: MATERIALS AND METHODS Study design.  

Phrase: "MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS Study design."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   901   C0035171:Study Design [Research Activity]
   901   C2983265:Study Design [Intellectual Product]
           DESIGN
   901   C2986888:Study Design [Research Activity]
   827   C0557651:Study [Manufactured Object]
   827   C1707689:Design [Activity]
   827   C2603343:Study [Research Activity]
Processing 00000000.tx.40: From January 1995to June 1996,134patients with multiple myeloma between the ages of 18and 70years were enrolled in a phase III open-label, randomized trial at 15sites in North America, including the University of California, Los Angeles (UCLA), The Toronto Hospital, the Dana Farber Cancer Institute (DFCI), Washington University, the University of South Florida, Johns Hopkins University, the University of California, San Francisco (UCSF), the University of Texas at San Antonio, the University of Pennsylvania, the Southern California Kaiser Permanente Medical Group, the University of Nebraska, Baylor University, the University of Arizona, and the University of California, San Diego (UCSD). 

Phrase: "From January 1995to June 1996,"

Phrase: "134patients with multiple myeloma"

Phrase: "between the ages"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001779:Age [Organism Attribute]

Phrase: "of 18and 70years"

Phrase: "were"

Phrase: "enrolled in a phase III open-label, randomized trial"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   784   C0282461:Phase III Trial [Research Activity]
   764   C1709323:OPEN LABEL [Research Activity]
   762   C1710475:Trial Phase [Classification]
   762   C1879951:Trial Phase [Intellectual Product]
   742   C0008976:Trial [Research Activity]
   742   C0034656:randomized [Research Activity]
   742   C0175566:Open [Spatial Concept]
   742   C0181496:Label [Manufactured Object]
   742   C0205390:Phase [Temporal Concept]
   742   C0439070:III [Intellectual Product]
   742   C1705160:III [Qualitative Concept]
   742   C2827499:Label [Governmental or Regulatory Activity]

Phrase: "at 15sites"

Phrase: "in North America,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0028405:North America [Geographic Area]
   928 E C0425358:NORTH AMERICAN [Finding]
   928 E C2700615:North American [Population Group]
   861   C0002454:America [Geographic Area]
   861   C1709269:North [Spatial Concept]
   789 E C0596070:American [Population Group]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "the University of California,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0006754:California [Geographic Area]
   827   C0041740:University [Manufactured Object,Organization]
   827   C3146274:California [Plant]

Phrase: "Los Angeles (UCLA),"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024015:Los Angeles [Geographic Area]

Phrase: "The Toronto Hospital,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0019994:Hospital, NOS [Health Care Related Organization,Manufactured Object]
   861   C1510665:Hospital [Qualitative Concept]
   777 E C1609061:Hospitals [Intellectual Product]

Phrase: "the Dana Farber Cancer Institute (DFCI),"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1511716:Dana-Farber Cancer Institute [Health Care Related Organization]
   812   C0021622:institute [Organization]
   812   C1272753:Institute [Idea or Concept]

Phrase: "Washington University,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0041740:University [Manufactured Object,Organization]
   861   C0043038:Washington [Geographic Area]

Phrase: "the University of South Florida,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0016253:Florida [Geographic Area]
   812   C0041740:University [Manufactured Object,Organization]
   812   C1710133:South [Spatial Concept]

Phrase: "Johns Hopkins University,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0041740:University [Manufactured Object,Organization]

Phrase: "the University of California,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0006754:California [Geographic Area]
   827   C0041740:University [Manufactured Object,Organization]
   827   C3146274:California [Plant]

Phrase: "San Francisco (UCSF),"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0036152:San Francisco [Geographic Area]
   861   C1826357:San [Gene or Genome]

Phrase: "the University of Texas at San Antonio,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0039711:Texas [Geographic Area]
   748   C0041740:University [Manufactured Object,Organization]

Phrase: "the University of Pennsylvania,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0030853:Pennsylvania [Geographic Area]
   827   C0041740:University [Manufactured Object,Organization]

Phrase: "the Southern California Kaiser Permanente Medical Group,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   799   C0441833:Group [Idea or Concept]
   799   C0687744:group [Population Group]
   799   C1257890:Group [Population Group]
   799   C1552516:Group [Health Care Related Organization]
   799   C1705428:Group [Conceptual Entity]
   799   C1705429:Group [Population Group]

Phrase: "the University of Nebraska,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0027523:Nebraska [Geographic Area]
   827   C0041740:University [Manufactured Object,Organization]

Phrase: "Baylor University,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0041740:University [Manufactured Object,Organization]

Phrase: "the University of Arizona,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0003787:Arizona [Geographic Area]
   827   C0041740:University [Manufactured Object,Organization]

Phrase: "and"

Phrase: "the University of California,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0006754:California [Geographic Area]
   827   C0041740:University [Manufactured Object,Organization]
   827   C3146274:California [Plant]

Phrase: "San Diego (UCSD)."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1826357:San [Gene or Genome]
Processing 00000000.tx.41: Data were analyzed as of January 1998.

Phrase: "Data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "were"

Phrase: "analyzed as of January 1998."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0936012:Analyzed [Research Activity]
Processing 00000000.tx.42: The study design was approved by the Institutional Review Boards of all participating institutions and by the Food and Drug Administration under an investigational device exemption (IDE). 

Phrase: "The study design"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0035171:Study Design [Research Activity]
  1000   C2983265:Study Design [Intellectual Product]
           DESIGN
  1000   C2986888:Study Design [Research Activity]
   861   C0557651:Study [Manufactured Object]
   861   C1707689:Design [Activity]
   861   C2603343:Study [Research Activity]

Phrase: "was"

Phrase: "approved by the Institutional Review Boards of all participating institutions"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   782   C0086911:Institutional Review Boards [Professional or Occupational Group]
   739   C0205540:Approved [Qualitative Concept]
   739   C0282443:Review [Intellectual Product]
   739   C0679823:Participating [Functional Concept]
   739   C0972401:board [Medical Device]
   739   C1552617:Review [Idea or Concept]
   739   C1948070:Board [Organization]

Phrase: "and by the Food and Drug Administration"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   853   C0041714:Food and Drug Administration [Health Care Related Organization]
           drug administration food
   778   C0150270:Drug administration [Health Care Activity]
   778   C3469597:Drug administration [Health Care Activity]
   748   C0001554:Administration [Occupational Activity]
   748   C0013227:Drug [Pharmacologic Substance]
   748   C0016452:Food [Food]
   748   C1254351:Drug [Pharmacologic Substance]
   748   C1515981:And [Idea or Concept]
   748   C1533734:Administration [Therapeutic or Preventive Procedure]

Phrase: "under an investigational device exemption (IDE)."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C2826366:Investigational Device Exemption [Idea or Concept]
   827   C2348482:Exemption [Conceptual Entity]
   734   C2346570:Investigational Device [Medical Device]
Processing 00000000.tx.43: All patients gave written informed consent to participate. 

Phrase: "All patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "gave"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1947971:Give [Functional Concept]

Phrase: "written informed consent to"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   861   C0021430:Informed Consent [Regulation or Law]
   812   C1511481:Consent [Functional Concept]
   812   C1522154:Informed [Qualitative Concept]
   812   C1554192:consent [Idea or Concept]
   779 E C0537670:Inform [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   779 E C0700287:inform [Health Care Activity]
   779 E C1552002:inform [Idea or Concept]

Phrase: "participate."
Processing 00000000.tx.44: All patients had a diagnosis of multiple myeloma and were staged based on the criteria developed by Durie and Salmon.30 Patients were eligible for enrollment if they had evidence of one of the following features at diagnosis or any time thereafter: (1) intermediate to high M-component production rates (IgG 5 g/dL or IgA 3 g/dL or urine M-component 4 g/24 h); 

Phrase: "All patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "had"

Phrase: "a diagnosis of multiple myeloma"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0011900:Diagnosis [Finding]
   760   C1704338:diagnosis [Qualitative Concept]
   760   C1704656:DIAGNOSIS [Research Activity]

Phrase: "and"

Phrase: "were"

Phrase: "staged"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0205390:Stage [Temporal Concept]
   966   C1300072:Stage [Clinical Attribute]
   966   C1306673:Stage [Qualitative Concept]

Phrase: "based on the criteria"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   770   C0243161:criteria [Intellectual Product]
   770   C1527178:Based [Functional Concept]
   770   C1705938:Based [Idea or Concept]
   737 E C0002055:base [Inorganic Chemical]
   737 E C0178499:Base [Chemical Viewed Functionally]
   737 E C1880279:Base [Biomedical or Dental Material]

Phrase: "developed by Durie"

Phrase: "and"

Phrase: "Salmon.30 Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "eligible for enrollment"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1548635:eligible [Idea or Concept]

Phrase: "if"

Phrase: "they"

Phrase: "had"

Phrase: "evidence of one of the following features"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   778   C0332120:Evidence of [Functional Concept]
           Evidence

Phrase: "at diagnosis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0011900:Diagnosis [Finding]
  1000   C1704338:diagnosis [Qualitative Concept]
  1000   C1704656:DIAGNOSIS [Research Activity]

Phrase: "or"

Phrase: "any time thereafter"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0040223:Time [Temporal Concept]
   827   C3541383:Time [Temporal Concept]
   771 E C0442043:Temporal [Spatial Concept]
   771 E C2362314:Temporal [Temporal Concept]
   743 E C1632851:Times [Quantitative Concept]

Phrase: ":"

Phrase: "(1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ")"

Phrase: "intermediate to high M-component production rates"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0205103:Intermediate [Spatial Concept]
   748   C1550465:intermediate [Idea or Concept]
   748   C2827755:INTERMEDIATE [Laboratory or Test Result]

Phrase: "(IgG 5 g/dL"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439267:g/dL [Quantitative Concept]
   812   C3642216:/dL [Quantitative Concept]

Phrase: "or"

Phrase: "IgA 3 g/dL"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439267:g/dL [Quantitative Concept]
   812   C3642216:/dL [Quantitative Concept]

Phrase: "or"

Phrase: "urine M-component 4 g/24 h"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   845   C0439417:g/24.h [Quantitative Concept]
   829   C0560020:g h [Quantitative Concept]
   795   C0033727:H+ [Element, Ion, or Isotope]
   795   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   795   C0441932:H+ [Classification]
   795   C0564385:/h [Quantitative Concept]

Phrase: ")"

Phrase: ";"
Processing 00000000.tx.45: (2) more than one osteolytic bone lesion, or radiographic evidence of diffuse osteoporosis; 

Phrase: "(2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: ")"

Phrase: "more than one osteolytic bone lesion,"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   833   C0302846:OSTEOLYTIC BONE LESION [Disease or Syndrome]
   790   C0238792:Bone Lesion [Disease or Syndrome]
   783   C0302313:Osteolytic lesion [Finding]
   753   C0205172:More [Functional Concept]
   753   C0205447:One [Quantitative Concept]
   753   C0221198:Lesion [Finding]
   753   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   753   C0391978:Bone [Tissue]
   753   C1266908:Bone [Body Part, Organ, or Organ Component]
   753   C1266909:Bone [Body System]
   753   C1518633:Osteolytic [Qualitative Concept]
   753   C1546698:Lesion [Intellectual Product]

Phrase: "or"

Phrase: "radiographic evidence of diffuse osteoporosis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C0332120:Evidence of [Functional Concept]
           Evidence
   760   C0444708:Radiographic [Natural Phenomenon or Process]

Phrase: ";"
Processing 00000000.tx.46: (3) -2 microglobulin 3 mg/L; 

Phrase: "(3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ") -"

Phrase: "2 microglobulin 3 mg/L"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   840   C0439268:mg/L [Quantitative Concept]

Phrase: ";"
Processing 00000000.tx.47: and (4) nonsecretory myeloma if bone marrow plasmacytosis was greater than 30%. 

Phrase: "and ("

Phrase: "4"

Phrase: ")"

Phrase: "nonsecretory myeloma"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0456845:Non-secretory myeloma [Neoplastic Process]
   861   C0026764:Myeloma [Neoplastic Process]
   861   C3538749:Myeloma [Intellectual Product]

Phrase: "if"

Phrase: "bone marrow plasmacytosis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0238803:BONE MARROW PLASMACYTOSIS [Finding]
   827   C0085663:Plasmacytosis [Disease or Syndrome]
   734   C0005953:Bone Marrow [Tissue]

Phrase: "was"

Phrase: "greater than 30%."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   882   C0439093:Greater Than [Quantitative Concept]
   790   C0443228:greater [Quantitative Concept]
   790   C1704243:Greater [Quantitative Concept]
   756 E C0549177:Great [Quantitative Concept]
Processing 00000000.tx.48: Patients were required to have stable or responsive disease after a minimum of three cycles of chemotherapy. 

Phrase: "Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "required"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514873:Required [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "have"

Phrase: "stable"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205360:Stable [Qualitative Concept]
  1000   C1547311:Stable [Intellectual Product]

Phrase: "or"

Phrase: "responsive disease after a minimum of three cycles of chemotherapy."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C0012634:Disease [Disease or Syndrome]
Processing 00000000.tx.49: Patients who had received more than 3months of alkylator-based therapy and/or 6months of any other prior chemotherapy or disease progression at anytime were ineligible for study entry. 

Phrase: "Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "had"

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "more than 3months of alkylator-based therapy"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   748   C0002073:Alkylator [Hazardous or Poisonous Substance,Pharmacologic Substance]
   748   C0039798:therapy [Functional Concept]
   748   C0087111:Therapy [Therapeutic or Preventive Procedure]
   748   C0205172:More [Functional Concept]
   748   C1363945:Therapy [Finding]
   748   C1527178:Based [Functional Concept]
   748   C1705938:Based [Idea or Concept]
   714 E C0002055:base [Inorganic Chemical]
   714 E C0178499:Base [Chemical Viewed Functionally]
   714 E C1880279:Base [Biomedical or Dental Material]

Phrase: "and/or"

Phrase: "6months of any"

Phrase: "other prior chemotherapy"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1514457:Prior Chemotherapy [Clinical Attribute]
   861   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   861   C0013217:chemotherapy [Functional Concept]
   861   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]

Phrase: "or"

Phrase: "disease progression at anytime"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0242656:Disease Progression [Pathologic Function]
           progression
   833   C1947900:Disease progression NOS [Finding]
   770   C0449258:Progression [Functional Concept]

Phrase: "were"

Phrase: "ineligible for study entry."
Processing 00000000.tx.50: Patients who had a creatinine level 2 mg/dL, Karnofsky performance status less than 70%, or other significant heart, lung, or gastrointestinal dysfunction were ineligible. 

Phrase: "Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "had"

Phrase: "a creatinine level 2 mg/dL,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   840   C0439269:mg dl [Quantitative Concept]
   804   C3642216:/dL [Quantitative Concept]

Phrase: "Karnofsky performance status less than 70%,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C0206065:Karnofsky Performance Status [Diagnostic Procedure]
           Karnofsky
   820   C2346647:Performance Status 70 [Finding]
   790   C1518965:Performance Status [Clinical Attribute]
   753   C0449438:Status [Qualitative Concept]
   753   C0597198:Performance [Individual Behavior]
   753   C1882330:Performance [Activity]

Phrase: "or"

Phrase: "other significant heart,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0018787:Heart [Body Part, Organ, or Organ Component]
   861   C1281570:Heart [Body Part, Organ, or Organ Component]

Phrase: "lung,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0024109:Lung [Body Part, Organ, or Organ Component]
  1000   C0819757:LUNG [Tissue]
  1000   C1278908:Lung [Body Part, Organ, or Organ Component]
   944 E C2707265:Pulmonary [Clinical Attribute]
   944 E C2709248:Pulmonary [Qualitative Concept]
   907 E C0032285:Pneumonia [Disease or Syndrome]

Phrase: "or"

Phrase: "gastrointestinal dysfunction"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0679407:gastrointestinal dysfunction [Disease or Syndrome]
   861   C0031847:dysfunction [Functional Concept]
   861   C0277785:Dysfunction, NOS [Qualitative Concept]
   805 E C0231174:Malfunction [Functional Concept]
   805 E C1881681:MALFUNCTION [Phenomenon or Process]

Phrase: "were"

Phrase: "ineligible."
Processing 00000000.tx.51: Randomization was stratified by patient age (<55 or 55 years) and site. 

Phrase: "Randomization"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034656:Randomization [Research Activity]

Phrase: "was"

Phrase: "stratified by patient age (<55"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0001779:Age [Organism Attribute]
   760   C0030705:*^patient [Patient or Disabled Group]
   760   C0205363:Stratified [Qualitative Concept]
   760   C0450382:55 [Intellectual Product]

Phrase: "or"

Phrase: "55 years"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439234:years [Temporal Concept]
   827 E C0439508:/year [Temporal Concept]

Phrase: ")"

Phrase: "and"

Phrase: "site."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205145:Site [Spatial Concept]
  1000   C1515974:Site [Body Location or Region]
  1000   C2825164:Site [Spatial Concept]
Processing 00000000.tx.52: Study schema.  

Phrase: "Study schema."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0871287:schema [Intellectual Product]
Processing 00000000.tx.53: Figure 1 shows a schema of the study. 

Phrase: "Figure 1"

Phrase: "shows"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "a schema of the study."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0871287:schema [Intellectual Product]
Processing 00000000.tx.54: Collection of autologous PBPCs occurred within 3weeks of the patient's evaluation for eligibility. 

Phrase: "Collection of autologous PBPCs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1516698:Collection [Functional Concept]
   748   C1704814:Collection [Idea or Concept]

Phrase: "occurred within 3weeks of the patient's evaluation"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   778   C0679830:patient evaluation [Health Care Activity]
   748   C0030705:*^patient [Patient or Disabled Group]
   748   C0220825:Evaluation [Functional Concept]
   748   C1261322:Evaluation [Health Care Activity]
   748   C1709305:Occurred [Activity]
   714 E C2745955:OCCUR [Temporal Concept]

Phrase: "for eligibility."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0013893:Eligibility [Health Care Activity]
   928 E C1548635:eligible [Idea or Concept]
Processing 00000000.tx.55: The mobilization regimen consisted of cyclophosphamide (2.5g/m2) administered intravenously on the first day of mobilization, prednisone (2mg/kg/d) administered orally on the first 4days, and granulocyte colony-stimulating factor (G-CSF; 10g/kg/d) administered subcutaneously beginning on the second day and continuing until the last day of leukapheresis. 

Phrase: "The mobilization regimen"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0040808:Regimen [Therapeutic or Preventive Procedure]
   861   C2945654:regimen [Intellectual Product]

Phrase: "consisted of cyclophosphamide"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   756   C0332529:CONSIST [Qualitative Concept]
   734 E C0699319:Cytoxan [Organophosphorus Compound,Pharmacologic Substance]
   734 E C0699320:Endoxan [Organophosphorus Compound,Pharmacologic Substance]

Phrase: "(2.5g/m2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0457242:m2 [Quantitative Concept]

Phrase: ")"

Phrase: "administered"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521801:Administered [Functional Concept]
   966 E C1621583:Administer [Functional Concept]

Phrase: "intravenously on the first day of mobilization,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   748   C0185112:Mobilisation [Therapeutic or Preventive Procedure]
   748   C0205435:First [Quantitative Concept]
   748   C0300926:mobilization [Functional Concept]
   748   C0332173:/day [Temporal Concept]
   748   C0439228:day [Temporal Concept]
   748   C0439505:/day [Temporal Concept]
   748   C1279901:First [Qualitative Concept]

Phrase: "prednisone"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0032952:Prednisone [Hormone,Pharmacologic Substance,Steroid]
   944 E C0728770:Meticorten [Pharmacologic Substance,Steroid]
   944 E C0740144:Deltasone [Pharmacologic Substance,Steroid]
   944 E C0740145:Deltra [Hormone,Pharmacologic Substance,Steroid]
   944 E C0740149:Lisacort [Hormone,Pharmacologic Substance,Steroid]

Phrase: "(2mg/kg/"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0022718:KG [Geographic Area]
   861   C0439209:kg [Quantitative Concept]

Phrase: "d)"

Phrase: "administered"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521801:Administered [Functional Concept]
   966 E C1621583:Administer [Functional Concept]

Phrase: "orally on the first 4days,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0205435:First [Quantitative Concept]
   760   C0442027:Orally [Spatial Concept]
   760   C1279901:First [Qualitative Concept]

Phrase: "and"

Phrase: "granulocyte colony-stimulating factor"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0079459:Granulocyte Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   923   C0009392:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   923   C0079460:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   812   C0018183:granulocyte [Cell]
   812   C0439158:colony [Quantitative Concept]
   812   C1521761:Factor [Functional Concept]
   812   C1947989:Colony [Cell]
   812   C1948023:Stimulating [Natural Phenomenon or Process]
   812   C2827422:Factor [Conceptual Entity]

Phrase: "(G-CSF"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0079459:G CSF [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0439267:g% [Quantitative Concept]
   861   C3540512:CSF [Therapeutic or Preventive Procedure]

Phrase: "; 10g/kg/"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0022718:KG [Geographic Area]
   861   C0439209:kg [Quantitative Concept]

Phrase: "d)"

Phrase: "administered"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521801:Administered [Functional Concept]
   966 E C1621583:Administer [Functional Concept]

Phrase: "subcutaneously"

Phrase: "beginning on the second day"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   760   C0205436:Second [Quantitative Concept]
   760   C0332173:/day [Temporal Concept]
   760   C0439228:day [Temporal Concept]
   760   C0439505:/day [Temporal Concept]
   760   C0439659:Beginning [Temporal Concept]
   760   C0457385:Second [Temporal Concept]
   760   C0565930:/second [Quantitative Concept]
   760   C1561503:second [Idea or Concept]
   760   C1705190:Second [Qualitative Concept]

Phrase: "and"

Phrase: "continuing until the last day of leukapheresis."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0549178:Continuing [Idea or Concept]
Processing 00000000.tx.56: View larger version (15K): [in this window] [in a new window]  Fig 1. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(15K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Fig 1."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]
Processing 00000000.tx.57: Schema of study design. 

Phrase: "Schema of study design."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0871287:schema [Intellectual Product]
Processing 00000000.tx.58: Eligible patients were registered and PBPCs were mobilized. 

Phrase: "Eligible patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "registered"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514821:Registered [Health Care Activity]
  1000   C1578536:Registered [Finding]

Phrase: "and"

Phrase: "PBPCs"
Meta Candidates (Total=23; Excluded=12; Pruned=0; Remaining=11)
   906   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   861   C0038250:Progenitor Cells [Cell]
   861   C0229664:peripheral blood [Body Substance]
           Blood
   830 E C2328697:Hemal cell [Cell]
   819 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   812   C0005767:Blood [Tissue]
   812   C0005768:blood [Body Substance]
   812   C0007634:Cells [Cell]
   812   C0205100:Peripheral [Spatial Concept]
   812   C0870134:Progenitor [Family Group]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]
   741 E C0333275:Bloody [Qualitative Concept]
   729 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   729 E C0392895:Bloods [Population Group]
   729 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   729 E C1511228:VESSEL, BLOOD [Tissue]
   712 E C1558950:VASCULAR [Finding]
   712 E C1801960:Vascular [Qualitative Concept]

Phrase: "were"

Phrase: "mobilized."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0185112:mobilized [Therapeutic or Preventive Procedure]
  1000   C0578718:mobilized [Finding]
Processing 00000000.tx.59: Before initiating leukapheresis, patients were randomized to one of the two treatment arms. 

Phrase: "Before"

Phrase: "initiating leukapheresis,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]

Phrase: "patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "randomized to one of the two treatment arms."
Meta Candidates (Total=15; Excluded=0; Pruned=0; Remaining=15)
   770   C1522541:Treatment Arm [Research Activity]
   744   C0034656:randomized [Research Activity]
   744   C0039798:treatment [Functional Concept]
   744   C0087111:Treatment [Therapeutic or Preventive Procedure]
   744   C0205447:One [Quantitative Concept]
   744   C0205448:Two [Quantitative Concept]
   744   C0206655:ARMS [Neoplastic Process]
   744   C0446516:Arm [Body Location or Region]
   744   C1269078:Arm [Body Part, Organ, or Organ Component]
   744   C1269612:Arm [Body Location or Region]
   744   C1522326:Treatment [Functional Concept]
   744   C1533734:Treatment [Therapeutic or Preventive Procedure]
   744   C1705169:Treatment [Conceptual Entity]
   744   C2681631:ARMS [Gene or Genome]
   744   C3538994:TREATMENT [Research Activity]
Processing 00000000.tx.60: All patients received high-dose chemotherapy followed by an infusion of either CD34-selected or unselected PBPCs, with GM-CSF administered posttransplant. 

Phrase: "All patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "high-dose chemotherapy"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C1328050:high-dose chemotherapy [Therapeutic or Preventive Procedure]
   901   C0444956:High dose [Quantitative Concept]
   827   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0013217:chemotherapy [Functional Concept]
   827   C0178602:Dose [Quantitative Concept]
   827   C0205250:High [Qualitative Concept]
   827   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0869039:Dose [Quantitative Concept]
   827   C1114758:Dose # [Clinical Attribute]
   827   C1299351:High [Qualitative Concept]
   827   C2700149:HIGH [Intellectual Product]

Phrase: "followed by an infusion of either CD34-selected"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   770   C0332283:Followed by [Temporal Concept]
           followed
   744   C0574032:Infusion [Therapeutic or Preventive Procedure]
   744   C1827465:Infusion [Functional Concept]
   744   C3538723:CD34 [Laboratory Procedure]
   711   C1707391:Select [Activity]
   711 E C1719822:Follow [Intellectual Product]

Phrase: "or"

Phrase: "unselected PBPCs,"
Meta Candidates (Total=23; Excluded=12; Pruned=0; Remaining=11)
   872   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   840   C0038250:Progenitor Cells [Cell]
   840   C0229664:peripheral blood [Body Substance]
           Blood
   808 E C2328697:Hemal cell [Cell]
   804   C0005767:Blood [Tissue]
   804   C0005768:blood [Body Substance]
   804   C0007634:Cells [Cell]
   804   C0205100:Peripheral [Spatial Concept]
   804   C0870134:Progenitor [Family Group]
   804   C3282337:Cells [Cell]
   798 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   771 E C1269647:Cell [Cell]
   771 E C1704653:Cell [Medical Device]
   771 E C1948049:Cell [Spatial Concept]
   733 E C0333275:Bloody [Qualitative Concept]
   721 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   721 E C0392895:Bloods [Population Group]
   721 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   721 E C1511228:VESSEL, BLOOD [Tissue]
   704 E C1558950:VASCULAR [Finding]
   704 E C1801960:Vascular [Qualitative Concept]

Phrase: "with GM-CSF"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
  1000   C0079460:Granulocyte-Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Colony-Stimulating Factor
  1000   C0376563:Colony-Stimulating Factor, Granulocyte-Macrophage [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
  1000   C1149401:granulocyte macrophage colony-stimulating factor [Molecular Function]
  1000   C1332791:GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR [Gene or Genome]
   937   C0079784:Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   937   C1524095:macrophage colony-stimulating factor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   933   C0079459:Granulocyte Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   884   C0009392:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   804   C0018183:granulocyte [Cell]
   804   C0024432:macrophage [Cell]
   804   C0439158:colony [Quantitative Concept]
   804   C1521761:Factor [Functional Concept]
   804   C1947989:Colony [Cell]
   804   C1948023:Stimulating [Natural Phenomenon or Process]
   804   C2827422:Factor [Conceptual Entity]

Phrase: "administered"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521801:Administered [Functional Concept]
   966 E C1621583:Administer [Functional Concept]

Phrase: "posttransplant."
Processing 00000000.tx.61: The primary study period was completed at 6months posttransplant with follow-up currently at 1year posttransplant. 

Phrase: "The primary study period"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0439531:/period [Temporal Concept]
   827   C1948053:Period [Temporal Concept]
   755 E C0332182:Periodic [Temporal Concept]
   755 E C1706381:PERIODIC [Intellectual Product]
   727 E C0031084:Periodicities [Temporal Concept]

Phrase: "was"

Phrase: "completed at 6months"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0205197:COMPLETED [Qualitative Concept]

Phrase: "posttransplant with follow-up currently"

Phrase: "at 1year"

Phrase: "posttransplant."
Processing 00000000.tx.62: Additional follow-up is planned on a yearly basis. 

Phrase: "Additional follow-up"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C0589120:Follow-up [Finding]
   901   C1522577:follow-up [Health Care Activity]
   901   C1704685:FOLLOW-UP [Intellectual Product]
   901   C3274571:FOLLOW-UP [Health Care Activity]
   827   C0332283:follow [Temporal Concept]
   827   C1719822:Follow [Intellectual Product]

Phrase: "is"

Phrase: "planned on a yearly basis."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   760   C0332181:Yearly [Temporal Concept]
   760   C0439508:Yearly [Temporal Concept]
   760   C1301732:Planned [Functional Concept]
   760   C1527178:Basis [Functional Concept]
   760   C1874451:Basis [Pharmacologic Substance]
   726 E C0270724:PLAN [Disease or Syndrome]
Processing 00000000.tx.63: Before leukapheresis, patients were randomized to receive CD34 selected (the selected arm) or unselected PBPC (the unselected arm). 

Phrase: "Before leukapheresis,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]

Phrase: "patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "randomized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034656:randomized [Research Activity]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "receive"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Receive [Qualitative Concept]

Phrase: "CD34"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3538723:CD34 [Laboratory Procedure]

Phrase: "selected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1707391:Select [Activity]

Phrase: "("

Phrase: "the selected arm)"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "or"

Phrase: "unselected PBPC"
Meta Candidates (Total=23; Excluded=12; Pruned=0; Remaining=11)
   872   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   840   C0038250:Progenitor Cells [Cell]
   840   C0229664:peripheral blood [Body Substance]
           Blood
   808 E C2328697:Hemal cell [Cell]
   804   C0005767:Blood [Tissue]
   804   C0005768:blood [Body Substance]
   804   C0007634:Cells [Cell]
   804   C0205100:Peripheral [Spatial Concept]
   804   C0870134:Progenitor [Family Group]
   804   C3282337:Cells [Cell]
   798 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   771 E C1269647:Cell [Cell]
   771 E C1704653:Cell [Medical Device]
   771 E C1948049:Cell [Spatial Concept]
   733 E C0333275:Bloody [Qualitative Concept]
   721 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   721 E C0392895:Bloods [Population Group]
   721 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   721 E C1511228:VESSEL, BLOOD [Tissue]
   704 E C1558950:VASCULAR [Finding]
   704 E C1801960:Vascular [Qualitative Concept]

Phrase: "("

Phrase: "the unselected arm"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: ")."
Processing 00000000.tx.64: After the PBPC collection was completed, patients received a myeloablative high-dose chemotherapy regimen consisting of busulfan and cyclophosphamide. 

Phrase: "After the PBPC collection"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   804   C1516698:Collection [Functional Concept]
   804   C1704814:Collection [Idea or Concept]
   733 E C1516695:Collected [Idea or Concept]
   705   C0005773:Peripheral blood cell [Cell]

Phrase: "was"

Phrase: "completed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205197:COMPLETED [Qualitative Concept]

Phrase: ","

Phrase: "patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "a myeloablative high-dose chemotherapy regimen"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   853   C2348331:Dose Regimen [Therapeutic or Preventive Procedure]
   840   C0392920:Chemotherapy Regimen [Therapeutic or Preventive Procedure]
   804   C0040808:Regimen [Therapeutic or Preventive Procedure]
   804   C2945654:regimen [Intellectual Product]
   717   C1328050:high-dose chemotherapy [Therapeutic or Preventive Procedure]
   708   C1513784:Myeloablative Chemotherapy [Therapeutic or Preventive Procedure]

Phrase: "consisting of busulfan"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0006463:Busulfan [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance]
   756   C0332529:CONSIST [Qualitative Concept]
   734 E C0700015:Myleran [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "cyclophosphamide."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0010583:Cyclophosphamide [Organophosphorus Compound,Pharmacologic Substance]
   944 E C0699319:Cytoxan [Organophosphorus Compound,Pharmacologic Substance]
   944 E C0699320:Endoxan [Organophosphorus Compound,Pharmacologic Substance]
Processing 00000000.tx.65: A total dosage of 14mg/kg of busulfan (0.875mg/kg administered orally 4times daily for 4days on days 7 to 4) and 120mg/kg of cyclophosphamide (60mg/kg administered intravenously daily for 2days on days 3 and 2) was administered to all patients as in the previous phase I/II study.15 Patients received the thawed CD34 selected or unselected products 2days after the last infusion of cyclophosphamide. 

Phrase: "A total dosage of 14mg/kg of busulfan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0178602:Dosage [Quantitative Concept]

Phrase: "(0.875mg/kg"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0022718:KG [Geographic Area]
   827   C0439209:kg [Quantitative Concept]

Phrase: "administered"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521801:Administered [Functional Concept]
   966 E C1621583:Administer [Functional Concept]

Phrase: "orally 4times daily for 4days"

Phrase: "on days 7"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0439228:days [Temporal Concept]
   827 E C0332173:/day [Temporal Concept]
   827 E C0439505:/day [Temporal Concept]

Phrase: "to 4"

Phrase: ")"

Phrase: "and"

Phrase: "120mg/kg of cyclophosphamide"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0022718:KG [Geographic Area]
   770   C0439209:kg [Quantitative Concept]

Phrase: "(60mg/kg"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0022718:KG [Geographic Area]
   861   C0439209:kg [Quantitative Concept]

Phrase: "administered"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521801:Administered [Functional Concept]
   966 E C1621583:Administer [Functional Concept]

Phrase: "intravenously daily for 2days"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0332173:Daily [Temporal Concept]

Phrase: "on days 3"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0439228:days [Temporal Concept]
   827 E C0332173:/day [Temporal Concept]
   827 E C0439505:/day [Temporal Concept]

Phrase: "and"

Phrase: "2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: ")"

Phrase: "was"

Phrase: "administered to all patients"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C1521801:Administered [Functional Concept]
   737 E C1621583:Administer [Functional Concept]

Phrase: "as in the previous phase I/II study.15 Patients"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   777   C0282460:Phase II Study [Research Activity]
   777   C0920321:Phase I Study [Research Activity]
   739   C0021966:I- [Inorganic Chemical]
   739   C0030705:Patients [Patient or Disabled Group]
   739   C0205156:Previous [Temporal Concept]
   739   C0205390:Phase [Temporal Concept]
   739   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   739   C0557651:Study [Manufactured Object]
   739   C1552607:previous [Temporal Concept]
   739   C2603343:Study [Research Activity]

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "the thawed CD34"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538723:CD34 [Laboratory Procedure]

Phrase: "selected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1707391:Select [Activity]

Phrase: "or"

Phrase: "unselected products 2days after the last infusion of cyclophosphamide."
Processing 00000000.tx.66: To speed hematologic recovery, granulocyte-macrophage colony-stimulating factor (GM-CSF) at 250g/m2 (maximum of 500g) was administered daily until the patient's ANC was at least 1,000/L for 2consecutive days. 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "speed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678536:Speed [Quantitative Concept]

Phrase: "hematologic recovery,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0237820:Recovery [Activity]
   861   C1555688:recovery [Idea or Concept]
   861   C2004454:Recovery [Organism Function]

Phrase: "granulocyte-macrophage colony-stimulating factor (GM-CSF) at 250g/m2"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
   869   C0079460:Granulocyte-Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
           Colony-Stimulating Factor
   869   C0376563:Colony-Stimulating Factor, Granulocyte-Macrophage [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   869   C1149401:granulocyte macrophage colony-stimulating factor [Molecular Function]
   869   C1332791:GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR [Gene or Genome]
   833   C0079784:Macrophage Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   833   C1524095:macrophage colony-stimulating factor [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   822   C0079459:Granulocyte Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Immunologic Factor]
   800   C0009392:Colony-Stimulating Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   744   C0018183:granulocyte [Cell]
   744   C0024432:macrophage [Cell]
   744   C0439158:colony [Quantitative Concept]
   744   C1521761:Factor [Functional Concept]
   744   C1947989:Colony [Cell]
   744   C1948023:Stimulating [Natural Phenomenon or Process]
   744   C2827422:Factor [Conceptual Entity]

Phrase: "(maximum of 500g"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0806909:Maximum [Quantitative Concept]
   790   C1552615:maximum [Quantitative Concept]
   790   C2826546:MAXIMUM [Quantitative Concept]
   718 E C0205289:Maximal [Qualitative Concept]

Phrase: ")"

Phrase: "was"

Phrase: "administered"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521801:Administered [Functional Concept]
   966 E C1621583:Administer [Functional Concept]

Phrase: "daily until the patient's ANC"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   814   C0948762:Absolute neutrophil count [Laboratory Procedure]
   778   C0200633:Neutrophil count [Laboratory Procedure]
   748   C0027950:Neutrophile [Cell]
   748   C0030705:*^patient [Patient or Disabled Group]
   748   C0205344:Absolute [Qualitative Concept]
   748   C0332173:Daily [Temporal Concept]
   748   C0750480:Count [Activity]
   748   C1705566:Count [Quantitative Concept]

Phrase: "was at least 1,000/L"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0043194:WAS [Disease or Syndrome]
   753   C0258432:WAS [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   753   C1421478:WAS [Gene or Genome]

Phrase: "for 2consecutive days."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0439228:days [Temporal Concept]
   827 E C0332173:/day [Temporal Concept]
   827 E C0439505:/day [Temporal Concept]
Processing 00000000.tx.67: Each site used its own standardized supportive care protocols for patients on both arms of the study. 

Phrase: "Each site"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205145:Site [Spatial Concept]
  1000   C1515974:Site [Body Location or Region]
  1000   C2825164:Site [Spatial Concept]

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "its own standardized supportive care protocols for patients"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   770   C0250336:care protocols [Therapeutic or Preventive Procedure]
   744   C0442711:Protocols [Intellectual Product]
   711 E C1507394:Protocol [Intellectual Product]
   711 E C1522729:Protocol [Intellectual Product]
   711 E C2348563:Protocol [Intellectual Product]

Phrase: "on both arms"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0206655:ARMS [Neoplastic Process]
  1000   C0446516:Arm [Body Location or Region]
  1000   C1269078:Arm [Body Part, Organ, or Organ Component]
  1000   C1269612:Arm [Body Location or Region]
  1000   C2681631:ARMS [Gene or Genome]
   944 E C0445456:Brachial [Spatial Concept]

Phrase: "of the study."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]
Processing 00000000.tx.68: According to the protocol, the first 58patients (28selected arm and 30unselected arm) began leukapheresis no sooner than day 15of PBPC mobilization and had to have a white blood cell (WBC) count 1,000/L on two occasions more than 24hours apart and a platelet count 30,000/L. 

Phrase: "According to the protocol,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0442711:Protocol [Intellectual Product]
  1000   C1507394:Protocol [Intellectual Product]
  1000   C1522729:Protocol [Intellectual Product]
  1000   C2348563:Protocol [Intellectual Product]

Phrase: "the first 58patients"

Phrase: "(28selected arm"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "and"

Phrase: "30unselected arm)"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "began"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0439659:Begin [Temporal Concept]

Phrase: "leukapheresis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]

Phrase: "no sooner than day 15of PBPC mobilization"
Meta Candidates (Total=23; Excluded=5; Pruned=0; Remaining=18)
   761   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   760   C0038250:Progenitor Cells [Cell]
   760   C0229664:peripheral blood [Body Substance]
           Blood
   739   C0005767:Blood [Tissue]
   739   C0005768:blood [Body Substance]
   739   C0007634:Cells [Cell]
   739   C0185112:Mobilisation [Therapeutic or Preventive Procedure]
   739   C0205100:Peripheral [Spatial Concept]
   739   C0300926:mobilization [Functional Concept]
   739   C0332173:/day [Temporal Concept]
   739   C0439228:day [Temporal Concept]
   739   C0439505:/day [Temporal Concept]
   739   C0870134:Progenitor [Family Group]
   739   C1298908:no [Idea or Concept]
   739   C1549444:No [Idea or Concept]
   739   C3282337:Cells [Cell]
   718 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   713 E C2328697:Hemal cell [Cell]
   706 E C1269647:Cell [Cell]
   706 E C1704653:Cell [Medical Device]
   706 E C1948049:Cell [Spatial Concept]

Phrase: "and"

Phrase: "had"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "have"

Phrase: "a white blood cell (WBC) count 1,000/L on two"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   757   C0022827:cell l [Cell]

Phrase: "occasions"

Phrase: "more than 24hours apart"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0205172:More [Functional Concept]

Phrase: "and"

Phrase: "a platelet count 30,000/L."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   856   C0456525:platelets/L [Quantitative Concept]
Processing 00000000.tx.69: The day 15start date was chosen for scheduling convenience and was based on successful stem cell collection in the phase II protocol using this schema. 

Phrase: "The day 15start date"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0011008:Date [Temporal Concept]
   827   C2348077:Date [Food]

Phrase: "was"

Phrase: "chosen for scheduling convenience"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0205539:scheduling [Qualitative Concept]
   770   C1446911:Scheduling [Health Care Activity]
   770   C1707391:Chosen [Activity]
   737 E C0086960:Schedule [Intellectual Product]

Phrase: "and"

Phrase: "was"

Phrase: "based on successful stem cell collection"
Meta Candidates (Total=15; Excluded=3; Pruned=0; Remaining=12)
   790   C0038250:Stem cell [Cell]
   753   C0007634:Cell [Cell]
   753   C0242767:Stem [Plant]
   753   C1186763:Stem [Body Part, Organ, or Organ Component]
   753   C1269647:Cell [Cell]
   753   C1272703:Successful [Qualitative Concept]
   753   C1516698:Collection [Functional Concept]
   753   C1527178:Based [Functional Concept]
   753   C1704653:Cell [Medical Device]
   753   C1704814:Collection [Idea or Concept]
   753   C1705938:Based [Idea or Concept]
   753   C1948049:Cell [Spatial Concept]
   719 E C0002055:base [Inorganic Chemical]
   719 E C0178499:Base [Chemical Viewed Functionally]
   719 E C1880279:Base [Biomedical or Dental Material]

Phrase: "in the phase II protocol"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0282460:Phase II Protocol [Research Activity]
   827   C0442711:Protocol [Intellectual Product]
   827   C1507394:Protocol [Intellectual Product]
   827   C1522729:Protocol [Intellectual Product]
   827   C2348563:Protocol [Intellectual Product]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "this schema."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0871287:schema [Intellectual Product]
Processing 00000000.tx.70: Because of concerns that the peak of circulating CD34+ cells was being missed before day 15,possibly because these patients were less heavily pretreated, the remaining 76patients (39selected arm, 34unselected arm, and 3patients not randomized) began leukapheresis as soon as the hematologic parameters outlined above were met. 

Phrase: "Because of"

Phrase: "concerns"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2699424:Concern [Idea or Concept]

Phrase: "that"

Phrase: "the peak of circulating CD34+ cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0444505:Peak [Quantitative Concept]

Phrase: "was"

Phrase: "being"

Phrase: "missed before day 15,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   770   C0332173:/day [Temporal Concept]
   770   C0439228:day [Temporal Concept]
   770   C0439505:/day [Temporal Concept]
   770   C1705492:Missed [Qualitative Concept]
   737 E C2349206:Miss [Conceptual Entity]

Phrase: "possibly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2362652:Possibly [Qualitative Concept]

Phrase: "because"

Phrase: "these patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "less heavily"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439092:less [Intellectual Product]
   861   C0547044:Less [Qualitative Concept]

Phrase: "pretreated"

Phrase: ","

Phrase: "the remaining 76patients"

Phrase: "(39selected arm,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "34unselected arm,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "and"

Phrase: "3patients"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "randomized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034656:randomized [Research Activity]

Phrase: ")"

Phrase: "began"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0439659:Begin [Temporal Concept]

Phrase: "leukapheresis as soon"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]

Phrase: "as the hematologic parameters"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0449381:Parameters [Finding]
   827 E C0549193:Parameter [Spatial Concept]
   827 E C1704769:Parameter [Conceptual Entity]
   827 E C2350001:Parameter [Quantitative Concept]

Phrase: "outlined above"

Phrase: "were"

Phrase: "met."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1550543:Meet [Idea or Concept]
Processing 00000000.tx.71: Leukapheresis was performed daily until at least 5.0108 total nucleated cells/kg were obtained (minimum of 2days). 

Phrase: "Leukapheresis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]

Phrase: "was"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "daily"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332173:Daily [Temporal Concept]

Phrase: "until at least 5.0108 total nucleated cells/kg"
Meta Candidates (Total=13; Excluded=3; Pruned=0; Remaining=10)
   764   C1180059:Nucleated cells [Cell]
   762   C1441375:Cells.total [Cell]
   742   C0007634:Cells [Cell]
   742   C0022718:KG [Geographic Area]
   742   C0439175:% total [Quantitative Concept]
   742   C0439209:kg [Quantitative Concept]
   742   C0439810:Total [Qualitative Concept]
   742   C1720302:Until [Intellectual Product]
   742   C1979936:Nucleated [Qualitative Concept]
   742   C3282337:Cells [Cell]
   708 E C1269647:Cell [Cell]
   708 E C1704653:Cell [Medical Device]
   708 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "obtained"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C1301820:Obtained [Functional Concept]
   966 E C1706701:Obtain [Activity]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0205217:Increased [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442805:Increase [Functional Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "(minimum of 2days"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   790   C1524031:Minimum [Qualitative Concept]
   790   C1552614:minimum [Idea or Concept]
   790   C2826545:MINIMUM [Quantitative Concept]
   718 E C0547040:Minimal [Qualitative Concept]
   718 E C2945599:Minimal [Qualitative Concept]

Phrase: ")."
Processing 00000000.tx.72: For patients randomized to receive a CD34 selected autograft, there was an additional stopping criterion of at least 4.0106 nucleated cells/kg in the selected product after processing on the CEPRATE SC System. 

Phrase: "For patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "randomized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034656:randomized [Research Activity]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "receive"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Receive [Qualitative Concept]

Phrase: "a CD34"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3538723:CD34 [Laboratory Procedure]

Phrase: "selected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1707391:Select [Activity]

Phrase: "autograft,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0040736:autograft [Therapeutic or Preventive Procedure]
   944 E C0559189:Autotransplant [Biomedical or Dental Material]

Phrase: "there"

Phrase: "was"

Phrase: "an additional stopping criterion of"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0243161:Criterion [Intellectual Product]

Phrase: "at least 4.0106 nucleated cells/kg"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C0022718:KG [Geographic Area]
   799   C0439209:kg [Quantitative Concept]

Phrase: "in the selected product"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1514468:product [Entity]
   861   C1704444:Product [Quantitative Concept]

Phrase: "after processing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1709694:Processing [Activity]

Phrase: "on the CEPRATE SC System."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   812   C0449913:System [Functional Concept]
   812   C1553451:System [Manufactured Object]
   812   C1704459:System [Medical Device]
   741 E C0205373:Systemic [Functional Concept]
Processing 00000000.tx.73: This criterion was based on the assumption that the selected product would contain at least 50% CD34+ cells; 

Phrase: "This criterion"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0243161:Criterion [Intellectual Product]

Phrase: "was"

Phrase: "based on the assumption"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   770   C1527178:Based [Functional Concept]
   770   C1705938:Based [Idea or Concept]
   737 E C0002055:base [Inorganic Chemical]
   737 E C0178499:Base [Chemical Viewed Functionally]
   737 E C1880279:Base [Biomedical or Dental Material]

Phrase: "that"

Phrase: "the selected product"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1514468:product [Entity]
   861   C1704444:Product [Quantitative Concept]

Phrase: "would"

Phrase: "contain at least 50% CD34+ cells"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   790   C0882849:cd34 cells [Cell]
   753   C0007634:Cells [Cell]
   753   C0332256:contain [Functional Concept]
   753   C2700400:Contain [Activity]
   753   C3282337:Cells [Cell]
   753   C3538723:CD34 [Laboratory Procedure]
   719 E C1269647:Cell [Cell]
   719 E C1704653:Cell [Medical Device]
   719 E C1948049:Cell [Spatial Concept]

Phrase: ";"
Processing 00000000.tx.74: thus, patients would receive an infused CD34+ cell dose of at least 2106 cells/kg. 

Phrase: "thus,"

Phrase: "patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "would"

Phrase: "receive"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Receive [Qualitative Concept]

Phrase: "an infused CD34+ cell dose of"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0178602:Dose [Quantitative Concept]
   753   C0869039:Dose [Quantitative Concept]
   753   C1114758:Dose # [Clinical Attribute]

Phrase: "at least 2106 cells/kg."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0022718:KG [Geographic Area]
   812   C0439209:kg [Quantitative Concept]
Processing 00000000.tx.75: Study endpoints.  

Phrase: "Study endpoints."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0557651:Study [Manufactured Object]
   861   C2349179:endpoints [Qualitative Concept]
   861   C2603343:Study [Research Activity]
   827 E C2826544:ENDPOINT [Quantitative Concept]
Processing 00000000.tx.76: There were two primary study endpoints. 

Phrase: "There"

Phrase: "were"

Phrase: "two primary study endpoints."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   858   C2986535:Primary Endpoint [Indicator, Reagent, or Diagnostic Aid]
   812   C0557651:Study [Manufactured Object]
   812   C2349179:endpoints [Qualitative Concept]
   812   C2603343:Study [Research Activity]
   779 E C2826544:ENDPOINT [Quantitative Concept]
Processing 00000000.tx.77: The primary efficacy endpoint was a reduction of tumor cell contamination in the PBPC product after processing with the CEPRATE SC System. 

Phrase: "The primary efficacy endpoint"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   913   C2986535:Primary Endpoint [Indicator, Reagent, or Diagnostic Aid]
   827   C2349179:End Point [Qualitative Concept]
   827   C2826544:ENDPOINT [Quantitative Concept]

Phrase: "was"

Phrase: "a reduction of tumor cell contamination"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0301630:Reduction [Natural Phenomenon or Process]
   753   C0392756:Reduction [Qualitative Concept]
   753   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "in the PBPC product"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   875   C0456388:Blood product [Pharmacologic Substance]
   875   C1547007:Blood product [Idea or Concept]
   804   C1514468:product [Entity]
   804   C1704444:Product [Quantitative Concept]
   705   C0005773:Peripheral blood cell [Cell]

Phrase: "after processing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1709694:Processing [Activity]

Phrase: "with the CEPRATE SC System."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   812   C0449913:System [Functional Concept]
   812   C1553451:System [Manufactured Object]
   812   C1704459:System [Medical Device]
   741 E C0205373:Systemic [Functional Concept]
Processing 00000000.tx.78: Success was defined as greater than a 2log reduction in the number of contaminating tumor cells. 

Phrase: "Success"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0597535:Success [Social Behavior]
   928 E C1272703:Successful [Qualitative Concept]

Phrase: "was"

Phrase: "defined as greater"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   790   C0443228:greater [Quantitative Concept]
   790   C1704243:Greater [Quantitative Concept]
   790   C1704788:Defined [Conceptual Entity]
   790   C3539106:Defined [Intellectual Product]
   756 E C0549177:Great [Quantitative Concept]

Phrase: "than a 2log reduction"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0301630:Reduction [Natural Phenomenon or Process]
   861   C0392756:Reduction [Qualitative Concept]
   861   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "in the number"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0237753:*Number [Quantitative Concept]
  1000   C0449788:Number [Quantitative Concept]

Phrase: "of contaminating tumor cells."
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   901   C0431085:Tumor cells [Cell]
   867 E C0597032:Tumor Cell [Cell]
   827   C0007634:Cells [Cell]
   827   C0027651:Tumor [Neoplastic Process]
   827   C1578706:Tumor [Intellectual Product]
   827   C3273930:Tumor [Finding]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.79: The primary safety endpoint was successful neutrophil engraftment (the first day of two consecutive ANCs 500/L after the nadir) on or before day 14after stem cell infusion. 

Phrase: "The primary safety endpoint"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   913   C2986535:Primary Endpoint [Indicator, Reagent, or Diagnostic Aid]
   827   C2349179:End Point [Qualitative Concept]
   827   C2826544:ENDPOINT [Quantitative Concept]

Phrase: "was"

Phrase: "successful neutrophil engraftment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C1882078:Neutrophil Engraftment [Finding]
   827   C0301944:Engraftment [Physiologic Function]

Phrase: "("

Phrase: "the first day of two consecutive ANCs 500/L"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   742   C0332173:/day [Temporal Concept]
   742   C0439228:day [Temporal Concept]
   742   C0439505:/day [Temporal Concept]

Phrase: "after the nadir"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1708760:Nadir [Qualitative Concept]

Phrase: ")"

Phrase: "on"

Phrase: "or before day 14after stem cell infusion."
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   778   C0038250:Stem cell [Cell]
   748   C0007634:Cell [Cell]
   748   C0242767:Stem [Plant]
   748   C0332173:/day [Temporal Concept]
   748   C0439228:day [Temporal Concept]
   748   C0439505:/day [Temporal Concept]
   748   C0574032:Infusion [Therapeutic or Preventive Procedure]
   748   C1186763:Stem [Body Part, Organ, or Organ Component]
   748   C1269647:Cell [Cell]
   748   C1704653:Cell [Medical Device]
   748   C1827465:Infusion [Functional Concept]
   748   C1948049:Cell [Spatial Concept]
Processing 00000000.tx.80: There were other secondary endpoints, including the following: number of tumor cells infused; 

Phrase: "There"

Phrase: "were"

Phrase: "other secondary endpoints,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C2349179:endpoints [Qualitative Concept]
   827 E C2826544:ENDPOINT [Quantitative Concept]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "the following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: ":"

Phrase: "number of tumor cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   802   C0007584:Cell Number [Laboratory Procedure]
   770   C0237753:*Number [Quantitative Concept]
   770   C0449788:Number [Quantitative Concept]

Phrase: "infused"

Phrase: ";"
Processing 00000000.tx.81: infusion-related toxicities; 

Phrase: "infusion-related toxicities"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   827   C0600688:toxicities [Injury or Poisoning]
   793 E C0040539:toxicity [Qualitative Concept]
   743 E C1407029:Toxic [Qualitative Concept]
   727 E C0032346:Poison [Hazardous or Poisonous Substance]
   727 E C1548769:Poison [Intellectual Product]
   727 E C1550590:poison [Idea or Concept]

Phrase: ";"
Processing 00000000.tx.82: time to neutrophil engraftment; 

Phrase: "time to neutrophil engraftment"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C0040223:Time [Temporal Concept]
   770   C3541383:Time [Temporal Concept]
   715 E C0442043:Temporal [Spatial Concept]
   715 E C2362314:Temporal [Temporal Concept]

Phrase: ";"
Processing 00000000.tx.83: time to platelet engraftment (7consecutive days of platelet transfusion independence) and platelet recovery (platelet count 20103/L and platelet transfusion independence for at least 7days); 

Phrase: "time to platelet engraftment"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C0040223:Time [Temporal Concept]
   770   C3541383:Time [Temporal Concept]
   715 E C0442043:Temporal [Spatial Concept]
   715 E C2362314:Temporal [Temporal Concept]

Phrase: "(7consecutive days of platelet transfusion independence"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   753   C0439228:days [Temporal Concept]
   719 E C0332173:/day [Temporal Concept]
   719 E C0439505:/day [Temporal Concept]

Phrase: ")"

Phrase: "and"

Phrase: "platelet recovery"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0237820:Recovery [Activity]
   861   C1555688:recovery [Idea or Concept]
   861   C2004454:Recovery [Organism Function]

Phrase: "(platelet count 20103/L"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0456525:platelets/L [Quantitative Concept]

Phrase: "and"

Phrase: "platelet transfusion independence for"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0085862:Independence [Idea or Concept]

Phrase: "at least 7days"

Phrase: ")"

Phrase: ";"
Processing 00000000.tx.84: the number of patients with bleeding episodes, infections, and adverse events; 

Phrase: "the number of patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   909   C2360800:Number of patients [Finding]
   802   C1830427:Patient number [Intellectual Product]
   770   C0237753:*Number [Quantitative Concept]
   770   C0449788:Number [Quantitative Concept]

Phrase: "with bleeding episodes,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1970394:Bleeding episodes [Finding]
   861   C0332189:Episodes [Temporal Concept]

Phrase: "infections,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0009450:Infections [Disease or Syndrome]
   916 E C0439663:Infected [Functional Concept]
   884 E C0030657:infectivity [Qualitative Concept]

Phrase: "and"

Phrase: "adverse events"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0877248:adverse events [Finding]
  1000   C1705413:Adverse Events [Idea or Concept]
   861   C0441471:Events [Event]
   861   C3541888:Events [Classification]

Phrase: ";"
Processing 00000000.tx.85: days of hospitalization; 

Phrase: "days of hospitalization"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   790   C0439228:days [Temporal Concept]
   756 E C0332173:/day [Temporal Concept]
   756 E C0439505:/day [Temporal Concept]

Phrase: ";"
Processing 00000000.tx.86: number of red blood cell (RBC) or platelet transfusions; 

Phrase: "number of red blood cell (RBC)"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   844   C0005771:Blood Cell Number [Laboratory Procedure]
   797   C0007584:Cell Number [Laboratory Procedure]
   760   C0237753:*Number [Quantitative Concept]
   760   C0449788:Number [Quantitative Concept]

Phrase: "or"

Phrase: "platelet transfusions"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C0086818:Transfusions, Platelet [Therapeutic or Preventive Procedure]
   861   C0005841:Transfusions [Therapeutic or Preventive Procedure]
   861   C0199960:transfusions [Functional Concept]
   861   C1879316:Transfusions [Therapeutic or Preventive Procedure]
   827 E C0455012:Transfusion [Therapeutic or Preventive Procedure]
   777 E C1549003:Transfused [Idea or Concept]

Phrase: ";"
Processing 00000000.tx.87: and long-term engraftment and immune reconstitution posttransplant. 

Phrase: "and"

Phrase: "long-term engraftment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0301944:Engraftment [Physiologic Function]
   734   C0443252:Long-term [Temporal Concept]

Phrase: "and"

Phrase: "immune reconstitution"

Phrase: "posttransplant."
Processing 00000000.tx.88: The rate of progression-free survival was another secondary endpoint. 

Phrase: "The rate of progression-free survival"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   783   C0038954:Survival Rate [Quantitative Concept]
   753   C0871208:Rate [Activity]
   753   C1521828:Rate [Quantitative Concept]

Phrase: "was"

Phrase: "another secondary endpoint."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C2349179:End Point [Qualitative Concept]
   861   C2826544:ENDPOINT [Quantitative Concept]
Processing 00000000.tx.89: Although the data are immature, progression-free and overall survival at 1year posttransplant is presented. 

Phrase: "Although"

Phrase: "the data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "are"

Phrase: "immature, progression-free"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0332296:free [Functional Concept]
   827   C1880497:Free [Qualitative Concept]
   827   C1996904:Free [Qualitative Concept]

Phrase: "and"

Phrase: "overall survival at 1year"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0038952:Survival [Activity]
   770   C0220921:survival [Functional Concept]
   770   C0282416:Overall [Intellectual Product]
   770   C1561607:Overall [Qualitative Concept]

Phrase: "posttransplant"

Phrase: "is"

Phrase: "presented."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0449450:Presented [Idea or Concept]
   966 E C0150312:Present [Quantitative Concept]
Processing 00000000.tx.90: Leukapheresis, processing, and cryopreservation.  

Phrase: "Leukapheresis,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]

Phrase: "processing"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C1709694:Processing [Activity]
   966 E C1184743:Process [Body Part, Organ, or Organ Component]
   966 E C1522240:Process [Phenomenon or Process]

Phrase: ","

Phrase: "and"

Phrase: "cryopreservation."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0010405:Cryopreservation [Laboratory Procedure]
Processing 00000000.tx.91: Autologous PBPCs were procured by continuous flow leukapheresis using a Cobe Spectra (Cobe, Lakewood, CO). 

Phrase: "Autologous PBPCs"
Meta Candidates (Total=23; Excluded=12; Pruned=0; Remaining=11)
   872   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   840   C0038250:Progenitor Cells [Cell]
   840   C0229664:peripheral blood [Body Substance]
           Blood
   808 E C2328697:Hemal cell [Cell]
   804   C0005767:Blood [Tissue]
   804   C0005768:blood [Body Substance]
   804   C0007634:Cells [Cell]
   804   C0205100:Peripheral [Spatial Concept]
   804   C0870134:Progenitor [Family Group]
   804   C3282337:Cells [Cell]
   798 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   771 E C1269647:Cell [Cell]
   771 E C1704653:Cell [Medical Device]
   771 E C1948049:Cell [Spatial Concept]
   733 E C0333275:Bloody [Qualitative Concept]
   721 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   721 E C0392895:Bloods [Population Group]
   721 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   721 E C1511228:VESSEL, BLOOD [Tissue]
   704 E C1558950:VASCULAR [Finding]
   704 E C1801960:Vascular [Qualitative Concept]

Phrase: "were"

Phrase: "procured by continuous flow leukapheresis"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]
   760   C0549178:Continuous [Idea or Concept]
   760   C0806140:Flow [Natural Phenomenon or Process]
   726   C3274540:Procure [Immunologic Factor,Pharmacologic Substance]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a Cobe Spectra"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1883073:Spectrum [Quantitative Concept]
   827   C2827424:Spectrum [Conceptual Entity]

Phrase: "(Cobe,"

Phrase: "Lakewood,"

Phrase: "CO"

Phrase: ")."
Processing 00000000.tx.92: Blood volume processed per run was 10L.

Phrase: "Blood volume"
Meta Candidates (Total=15; Excluded=7; Pruned=0; Remaining=8)
  1000   C0005850:Blood Volume [Organism Attribute]
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   861   C0449468:*Volume [Quantitative Concept]
   861   C1690016:% volume [Qualitative Concept]
   861   C1705102:Volume [Intellectual Product]
   861   C2700258:Volume [Laboratory Procedure]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: "processed per run"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   790   C0035953:run [Daily or Recreational Activity]
   790   C0600140:run [Finding]
   790   C1522240:Processed [Phenomenon or Process]
   790   C1704688:Run [Functional Concept]
   790   C2346414:Run [Finding]
   756 E C1184743:Process [Body Part, Organ, or Organ Component]

Phrase: "was"

Phrase: "10L."
Processing 00000000.tx.93: Patients randomized to receive unselected PBPCs each had individual leukapheresis products cryopreserved in 10% dimethyl sulfoxide (DMSO) by control-rated freezing and stored in the vapor phase of liquid nitrogen. 

Phrase: "Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "randomized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034656:randomized [Research Activity]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "receive"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Receive [Qualitative Concept]

Phrase: "unselected PBPCs"
Meta Candidates (Total=23; Excluded=12; Pruned=0; Remaining=11)
   872   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   840   C0038250:Progenitor Cells [Cell]
   840   C0229664:peripheral blood [Body Substance]
           Blood
   808 E C2328697:Hemal cell [Cell]
   804   C0005767:Blood [Tissue]
   804   C0005768:blood [Body Substance]
   804   C0007634:Cells [Cell]
   804   C0205100:Peripheral [Spatial Concept]
   804   C0870134:Progenitor [Family Group]
   804   C3282337:Cells [Cell]
   798 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   771 E C1269647:Cell [Cell]
   771 E C1704653:Cell [Medical Device]
   771 E C1948049:Cell [Spatial Concept]
   733 E C0333275:Bloody [Qualitative Concept]
   721 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   721 E C0392895:Bloods [Population Group]
   721 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   721 E C1511228:VESSEL, BLOOD [Tissue]
   704 E C1558950:VASCULAR [Finding]
   704 E C1801960:Vascular [Qualitative Concept]

Phrase: "each"

Phrase: "had"

Phrase: "individual leukapheresis products"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]
   827   C1514468:Products [Entity]
   793 E C1704444:Product [Quantitative Concept]

Phrase: "cryopreserved in 10% dimethyl sulfoxide (DMSO)"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C0012403:Dimethyl Sulfoxide [Organic Chemical,Pharmacologic Substance]
   760   C0010405:Cryopreserved [Laboratory Procedure]
   760   C0038770:sulfoxide [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
   760   C0038771:sulfoxide [Organic Chemical]
   760   C0851343:Sulfoxide [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance]

Phrase: "by control-rated freezing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0016701:Freezing [Natural Phenomenon or Process]

Phrase: "and"

Phrase: "stored in the vapor phase of liquid nitrogen."
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   770   C0260055:Liquid nitrogen [Element, Ion, or Isotope]
   770   C1550121:Liquid nitrogen [Intellectual Product]
   744   C0028158:Nitrogen [Element, Ion, or Isotope]
   744   C0205390:Phase [Temporal Concept]
   744   C0302908:Liquid [Substance]
   744   C0597635:Vapor [Chemical Viewed Structurally]
   744   C1304698:Liquid [Finding]
   744   C1546699:Liquid NOS [Intellectual Product]
   744   C1550581:nitrogen [Human-caused Phenomenon or Process]
   744   C1561501:Liquid NOS [Substance]
   711   C1698986:Store [Functional Concept]
Processing 00000000.tx.94: Patients randomized to receive CD34-selected PBPCs had each individual leukapheresis products selected using the CEPRATE SC System, as previously described15 following the manufacturer's protocol. 

Phrase: "Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "randomized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034656:randomized [Research Activity]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "receive"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Receive [Qualitative Concept]

Phrase: "CD34-selected PBPCs"
Meta Candidates (Total=22; Excluded=10; Pruned=0; Remaining=12)
   895   C0882849:cd34 cells [Cell]
   850   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   827   C0038250:Progenitor Cells [Cell]
   827   C0229664:peripheral blood [Body Substance]
           Blood
   799   C0005767:Blood [Tissue]
   799   C0005768:blood [Body Substance]
   799   C0007634:Cells [Cell]
   799   C0205100:Peripheral [Spatial Concept]
   799   C0870134:Progenitor [Family Group]
   799   C3282337:Cells [Cell]
   795 E C2328697:Hemal cell [Cell]
   785 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   766 E C1269647:Cell [Cell]
   766 E C1704653:Cell [Medical Device]
   766 E C1948049:Cell [Spatial Concept]
   727 E C0333275:Bloody [Qualitative Concept]
   716 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   716 E C0392895:Bloods [Population Group]
   716 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   716 E C1511228:VESSEL, BLOOD [Tissue]

Phrase: "had"

Phrase: "each individual leukapheresis products"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]
   827   C1514468:Products [Entity]
   793 E C1704444:Product [Quantitative Concept]

Phrase: "selected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1707391:Select [Activity]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the CEPRATE SC System,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   812   C0449913:System [Functional Concept]
   812   C1553451:System [Manufactured Object]
   812   C1704459:System [Medical Device]
   741 E C0205373:Systemic [Functional Concept]

Phrase: "as"

Phrase: "previously described15"

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "the manufacturer's protocol."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0442711:Protocol [Intellectual Product]
   861   C1507394:Protocol [Intellectual Product]
   861   C1522729:Protocol [Intellectual Product]
   861   C2348563:Protocol [Intellectual Product]
Processing 00000000.tx.95: The CD34-selected PBPCs were then cryopreserved in 7.5% DMSO by control-rated freezing and stored in the vapor phase of liquid nitrogen. 

Phrase: "The CD34-selected PBPCs"
Meta Candidates (Total=22; Excluded=10; Pruned=0; Remaining=12)
   895   C0882849:cd34 cells [Cell]
   850   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   827   C0038250:Progenitor Cells [Cell]
   827   C0229664:peripheral blood [Body Substance]
           Blood
   799   C0005767:Blood [Tissue]
   799   C0005768:blood [Body Substance]
   799   C0007634:Cells [Cell]
   799   C0205100:Peripheral [Spatial Concept]
   799   C0870134:Progenitor [Family Group]
   799   C3282337:Cells [Cell]
   795 E C2328697:Hemal cell [Cell]
   785 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   766 E C1269647:Cell [Cell]
   766 E C1704653:Cell [Medical Device]
   766 E C1948049:Cell [Spatial Concept]
   727 E C0333275:Bloody [Qualitative Concept]
   716 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   716 E C0392895:Bloods [Population Group]
   716 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   716 E C1511228:VESSEL, BLOOD [Tissue]

Phrase: "were"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "cryopreserved in 7.5% DMSO"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0012403:Dimethyl Sulfoxide [Organic Chemical,Pharmacologic Substance]
   753   C0010405:Cryopreserved [Laboratory Procedure]
   753   C0038770:sulfoxide [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
   753   C0038771:sulfoxide [Organic Chemical]
   753   C0851343:Sulfoxide [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance]

Phrase: "by control-rated freezing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0016701:Freezing [Natural Phenomenon or Process]

Phrase: "and"

Phrase: "stored in the vapor phase of liquid nitrogen."
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   770   C0260055:Liquid nitrogen [Element, Ion, or Isotope]
   770   C1550121:Liquid nitrogen [Intellectual Product]
   744   C0028158:Nitrogen [Element, Ion, or Isotope]
   744   C0205390:Phase [Temporal Concept]
   744   C0302908:Liquid [Substance]
   744   C0597635:Vapor [Chemical Viewed Structurally]
   744   C1304698:Liquid [Finding]
   744   C1546699:Liquid NOS [Intellectual Product]
   744   C1550581:nitrogen [Human-caused Phenomenon or Process]
   744   C1561501:Liquid NOS [Substance]
   711   C1698986:Store [Functional Concept]
Processing 00000000.tx.96: For all patients receiving CD34-selected PBPCs, the CD34-depleted fraction was cryopreserved for backup in the event of graft failure. 

Phrase: "For all patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "receiving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514756:Receive [Qualitative Concept]

Phrase: "CD34-selected PBPCs,"
Meta Candidates (Total=22; Excluded=10; Pruned=0; Remaining=12)
   895   C0882849:cd34 cells [Cell]
   850   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   827   C0038250:Progenitor Cells [Cell]
   827   C0229664:peripheral blood [Body Substance]
           Blood
   799   C0005767:Blood [Tissue]
   799   C0005768:blood [Body Substance]
   799   C0007634:Cells [Cell]
   799   C0205100:Peripheral [Spatial Concept]
   799   C0870134:Progenitor [Family Group]
   799   C3282337:Cells [Cell]
   795 E C2328697:Hemal cell [Cell]
   785 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   766 E C1269647:Cell [Cell]
   766 E C1704653:Cell [Medical Device]
   766 E C1948049:Cell [Spatial Concept]
   727 E C0333275:Bloody [Qualitative Concept]
   716 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   716 E C0392895:Bloods [Population Group]
   716 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   716 E C1511228:VESSEL, BLOOD [Tissue]

Phrase: "the CD34-depleted fraction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1264633:Fraction [Quantitative Concept]
   827   C1554103:Fraction [Idea or Concept]

Phrase: "was"

Phrase: "cryopreserved for backup"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0010405:Cryopreserved [Laboratory Procedure]

Phrase: "in the event"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0441471:Event [Event]

Phrase: "of graft failure."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1262018:Graft failure [Pathologic Function]
   861   C0231174:Failure [Functional Concept]
   861   C0680095:failure [Individual Behavior]
Processing 00000000.tx.97: Flow cytometry and colony-forming unit (CFU) analysis.  

Phrase: "Flow cytometry"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016263:Flow Cytometry [Laboratory Procedure]
   861   C0806140:Flow [Natural Phenomenon or Process]
   861   C0814048:Cytometry [Laboratory Procedure]

Phrase: "and"

Phrase: "colony-forming unit (CFU) analysis."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0002778:Analysis [Laboratory Procedure]
   812   C0936012:Analysis [Research Activity]
   812   C1524024:analysis [Functional Concept]
   756   C0553561:Colony-forming unit [Quantitative Concept]
Processing 00000000.tx.98: Samples were analyzed by Cytometry Associates, Inc (Brentwood, TN) using fluorochrome-conjugated monoclonal antibodies and a flow cytometer. 

Phrase: "Samples"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0370003:Sample [Substance]
   966   C2347026:Sample [Conceptual Entity]

Phrase: "were"

Phrase: "analyzed by Cytometry"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0814048:Cytometry [Laboratory Procedure]
   790   C0936012:Analyzed [Research Activity]

Phrase: "Associates"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0750490:Associate [Idea or Concept]
  1000   C1706221:Associate [Professional or Occupational Group]

Phrase: ","

Phrase: "Inc (Brentwood,"

Phrase: "TN)"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "fluorochrome-conjugated monoclonal antibodies"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0003250:Monoclonal Antibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   812   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   812   C0746619:monoclonal [Finding]
   779 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "and"

Phrase: "a flow cytometer."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0180279:Flow Cytometer [Medical Device]
   861   C0806140:Flow [Natural Phenomenon or Process]
Processing 00000000.tx.99: Briefly, samples from the leukapheresis product, CD34-selected product, and the CD34-depleted product were incubated with anti-CD14 monoclonal antibody conjugated with fluorescein isothiocyanate (CD14-FITC) and with either anti-CD34 monoclonal antibody (CD34-PE) or an isotypic control (MsIgG-PE) conjugated with phycoerythrin. 

Phrase: "Briefly,"

Phrase: "samples from the leukapheresis product,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   726   C0370003:Sample [Substance]
   726   C2347026:Sample [Conceptual Entity]

Phrase: "CD34-selected product,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1514468:product [Entity]
   827   C1704444:Product [Quantitative Concept]

Phrase: "and"

Phrase: "the CD34-depleted product"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1514468:product [Entity]
   827   C1704444:Product [Quantitative Concept]

Phrase: "were"

Phrase: "incubated with anti-CD14 monoclonal antibody"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   790   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   783   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   753   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   753   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   753   C0746619:monoclonal [Finding]
   753   C1367477:CD14 [Gene or Genome]
   753   C1439852:Incubated [Laboratory Procedure]
   753   C3538991:CD14 [Laboratory Procedure]

Phrase: "conjugated with fluorescein isothiocyanate"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   770   C0060520:Fluorescein [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
   770   C0124209:Isothiocyanate [Organic Chemical]
   770   C0206359:isothiocyanate [Organic Chemical]
   770   C0522529:Conjugated [Spatial Concept]
   737 E C0301869:Conjugate [Immunologic Factor]

Phrase: "(CD14-FITC)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0085216:FITC [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "and with either anti-CD34 monoclonal antibody"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   778   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   774   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   748   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   748   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   748   C0746619:monoclonal [Finding]
   748   C1515981:And [Idea or Concept]
   748   C3538723:CD34 [Laboratory Procedure]

Phrase: "(CD34-PE)"

Phrase: "or"

Phrase: "an isotypic control"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: "(MsIgG-PE)"

Phrase: "conjugated with phycoerythrin."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0031789:Phycoerythrin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   790   C0522529:Conjugated [Spatial Concept]
   756 E C0301869:Conjugate [Immunologic Factor]
Processing 00000000.tx.100: In addition, the cells were stained with 7-Actinomycin D (7-AAD) to assess viability. 

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "the cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "stained with 7-Actinomycin"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0001259:Actinomycin [Amino Acid, Peptide, or Protein,Antibiotic]
   770   C2986582:Stained [Qualitative Concept]
   770   C3536807:Actinomycin [Pharmacologic Substance]
   737 E C0038128:Stain [Indicator, Reagent, or Diagnostic Aid]

Phrase: "D (D)"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205173:Double [Functional Concept]
  1000   C1705764:Double [Activity]
  1000   C1705765:Double [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "assess"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1516048:Assess [Activity]

Phrase: "viability."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443348:viability [Qualitative Concept]
Processing 00000000.tx.101: After acquisition of data from the flow cytometer, the CD34+ cells were identified based on Boolean gating of light scatter, viability, and absence of CD14 expression. 

Phrase: "After acquisition"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1706701:Acquisition [Activity]

Phrase: "of data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "from the flow cytometer,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0180279:Flow Cytometer [Medical Device]
   861   C0806140:Flow [Natural Phenomenon or Process]

Phrase: "the CD34+ cells"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0882849:cd34 cells [Cell]
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "identified"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]

Phrase: "based on Boolean gating of light scatter,"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   748   C0023693:Light [Natural Phenomenon or Process]
   748   C0439742:scatter [Spatial Concept]
   748   C1306462:Light [Functional Concept]
   748   C1527178:Based [Functional Concept]
   748   C1552663:Boolean [Idea or Concept]
   748   C1705938:Based [Idea or Concept]
   748   C1881376:Light [Qualitative Concept]
   714 E C0002055:base [Inorganic Chemical]
   714 E C0178499:Base [Chemical Viewed Functionally]
   714 E C1880279:Base [Biomedical or Dental Material]

Phrase: "viability,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443348:viability [Qualitative Concept]

Phrase: "and"

Phrase: "absence of CD14 expression."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0332197:absence [Quantitative Concept]
   770   C1689985:Absence [Anatomical Abnormality]
Processing 00000000.tx.102: The percentage of positive CD34+ cells was calculated by dividing the number of CD34+ events, derived from the above gating strategy, by the total nucleated cells acquired and multiplying this result by 100. 

Phrase: "The percentage of positive CD34+ cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0439165:Percentage [Quantitative Concept]
   753   C1549488:Percentage [Idea or Concept]
   753   C1561533:Percentage [Idea or Concept]

Phrase: "was"

Phrase: "calculated by dividing"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0332849:dividing [Functional Concept]
   790   C0444686:Calculated [Functional Concept]
   790   C1441506:Calculated [Activity]
   790   C1443182:Calculated [Laboratory Procedure]

Phrase: "the number of CD34+ events,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0237753:*Number [Quantitative Concept]
   760   C0449788:Number [Quantitative Concept]

Phrase: "derived from the above gating strategy,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0679199:strategy [Mental Process]
   753   C1441547:Derived [Qualitative Concept]
   753   C3245521:derived [Idea or Concept]

Phrase: "by the total nucleated cells"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   901   C1180059:Nucleated cells [Cell]
   827   C0007634:Cells [Cell]
   827   C1979936:Nucleated [Qualitative Concept]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "acquired"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0439661:Acquired [Temporal Concept]
  1000   C3245488:acquired [Intellectual Product]
   966 E C1706701:Acquire [Activity]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0205217:Increased [Quantitative Concept]
   907 E C0442805:Increase [Functional Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]

Phrase: "and"

Phrase: "multiplying"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1719797:Multiply [Functional Concept]
   966   C2911648:Multiply [Quantitative Concept]

Phrase: "this result by 100."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C1274040:Result [Functional Concept]
   770   C1546471:Result [Idea or Concept]
   770   C2825142:Result [Finding]
Processing 00000000.tx.103: The culture and enumeration of CFU (including granulocyte-macrophage, granulocyte-erythroid-monocyte-macrophage, and burst-forming unit-erythroid colonies) were performed by each site using standard media and procedures.29 Myeloma Ig gene identification.  

Phrase: "The culture"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0010453:Culture [Idea or Concept]
  1000   C0220814:culture [Functional Concept]
  1000   C0430400:Culture [Laboratory Procedure]
  1000   C2242979:Culture [Laboratory Procedure]

Phrase: "and"

Phrase: "enumeration of CFU"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1707927:Enumeration [Qualitative Concept]

Phrase: "("

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "granulocyte-macrophage,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0018183:granulocyte [Cell]
   861   C0024432:macrophage [Cell]

Phrase: "granulocyte-erythroid-monocyte-macrophage,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0024432:macrophage [Cell]

Phrase: "and"

Phrase: "burst-forming unit-erythroid colonies"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   804   C0439158:colonies [Quantitative Concept]
   771   C1257771:Burst-forming unit erythroid [Cell]
   771 E C1947989:Colony [Cell]

Phrase: ")"

Phrase: "were"

Phrase: "performed by each site"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   833   C1550369:Performed By [Qualitative Concept]
   770   C0205145:Site [Spatial Concept]
   770   C0884358:Performed [Functional Concept]
   770   C1515974:Site [Body Location or Region]
   770   C2825164:Site [Spatial Concept]
   737 E C2947996:Perform [Pharmacologic Substance]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "standard media"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0009458:Media [Intellectual Product]
   861   C0162867:Media [Tissue]
   861   C1254021:Media [Tissue]
   827 E C0439536:Medium [Quantitative Concept]
   827 E C1705217:Medium [Substance]
   827 E C3244283:medium [Intellectual Product]

Phrase: "and"

Phrase: "procedures.29 Myeloma Ig gene identification."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C0020792:Identification [Mental Process]
   799   C0205396:Identification [Qualitative Concept]
Processing 00000000.tx.104: The Ig heavy chain variable region (VH) or light chain (light chain only secreting tumors) variable region (VL) sequence expressed by the myeloma clone was determined using a bone marrow aspirate obtained from each patient at study entry, not at diagnosis. 

Phrase: "The Ig heavy chain variable region"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   911   C0877857:Variable Region, Ig [Amino Acid, Peptide, or Protein,Immunologic Factor]
   884   C0021034:IG HEAVY CHAIN [Amino Acid, Peptide, or Protein,Immunologic Factor]
   840   C1420192:heavy chain [Gene or Genome]
   804   C0017446:Region [Geographic Area]
   804   C0205147:Region [Spatial Concept]
   804   C0337112:Chain [Manufactured Object]
   804   C0439539:Heavy [Qualitative Concept]
   804   C0439828:Variable [Qualitative Concept]
   804   C1524075:Chain [Idea or Concept]
   733 E C0205276:Regional [Spatial Concept]
   733 E C1947913:Regional [Spatial Concept]

Phrase: "(VH)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1420224:VH [Gene or Genome]

Phrase: "or"

Phrase: "light chain"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0023693:Light [Natural Phenomenon or Process]
   861   C0337112:Chain [Manufactured Object]
   861   C1306462:Light [Functional Concept]
   861   C1524075:Chain [Idea or Concept]
   861   C1881376:Light [Qualitative Concept]

Phrase: "(light chain only secreting tumors"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   804   C0027651:Tumors [Neoplastic Process]
   771 E C1578706:Tumor [Intellectual Product]
   771 E C3273930:Tumor [Finding]

Phrase: ")"

Phrase: "variable region"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   861   C0017446:Region [Geographic Area]
   861   C0205147:Region [Spatial Concept]
   861   C0439828:Variable [Qualitative Concept]
   789 E C0205276:Regional [Spatial Concept]
   789 E C1947913:Regional [Spatial Concept]

Phrase: "(VL) sequence"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   861   C0004793:Sequence [Nucleotide Sequence]
   861   C0162326:Sequence [Nucleotide Sequence]
   861   C0162327:Sequence [Nucleotide Sequence]
   861   C1519249:Sequence [Functional Concept]
   789 E C1548958:Sequential [Idea or Concept]
   789 E C1705294:Sequential [Qualitative Concept]

Phrase: "expressed by the myeloma clone"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0009013:Clone [Cell]
   760   C0026764:Myeloma [Neoplastic Process]
   760   C1522642:Clone [Tissue]
   760   C3538749:Myeloma [Intellectual Product]

Phrase: "was"

Phrase: "determined"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a bone marrow aspirate"
Meta Candidates (Total=15; Excluded=5; Pruned=0; Remaining=10)
  1000   C0857285:bone marrow aspirate [Body Substance]
   901   C0005953:Bone Marrow [Tissue]
   827   C0086590:Marrow [Food]
   827   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   827   C0370199:Aspirate [Body Substance]
   827   C0376152:Marrow [Body Part, Organ, or Organ Component]
   827   C0391978:Bone [Tissue]
   827   C1266908:Bone [Body Part, Organ, or Organ Component]
   827   C1266909:Bone [Body System]
   827   C1546708:Marrow [Intellectual Product]
   771 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   771 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   771 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   755 E C0443157:Bony [Functional Concept]
   743 E C0330477:Marrows [Plant]

Phrase: "obtained from each patient"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0030705:*^patient [Patient or Disabled Group]
   770   C1301820:Obtained [Functional Concept]
   737 E C1706701:Obtain [Activity]

Phrase: "at study entry,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1705654:Entry [Intellectual Product]

Phrase: "not at diagnosis."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0011900:Diagnosis [Finding]
   790   C1518422:Not [Functional Concept]
   790   C1704338:diagnosis [Qualitative Concept]
   790   C1704656:DIAGNOSIS [Research Activity]
Processing 00000000.tx.105: When present, the predominant, appropriately sized PCR product was excised from an agarose gel impregnated with ethidium bromide, cloned, and sequenced by methods previously described.15,17 A minimum of three identical clones of five was required to assign an Ig sequence to the myeloma cell. 

Phrase: "When"

Phrase: "present,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0150312:Present [Quantitative Concept]
  1000   C0449450:Present [Idea or Concept]

Phrase: "the predominant, appropriately sized PCR product"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   795   C1514468:product [Entity]
   795   C1704444:Product [Quantitative Concept]

Phrase: "was"

Phrase: "excised from an agarose gel"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C1706746:Agarose Gel [Research Device]
   760   C0017243:Gel [Biomedical or Dental Material]
   760   C0036681:Agarose [Carbohydrate]
   760   C1382104:Gel [Substance]

Phrase: "impregnated with ethidium bromide,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C0019873:Ethidium Bromide [Organic Chemical,Pharmacologic Substance]
   770   C0006222:Bromide [Inorganic Chemical]
   770   C0015008:Ethidium [Organic Chemical,Pharmacologic Substance]

Phrase: "cloned"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0009013:cloned [Cell]
   966 E C1522642:Clone [Tissue]

Phrase: ","

Phrase: "and"

Phrase: "sequenced by methods previously"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   770   C0025663:Methods [Intellectual Product]
   770   C0025664:methods [Intellectual Product]
   770   C0449851:Methods [Functional Concept]
   737   C0004793:Sequence [Nucleotide Sequence]
   737   C0162326:Sequence [Nucleotide Sequence]
   737   C0162327:Sequence [Nucleotide Sequence]
   737 E C0871511:METHOD [Intellectual Product]
   737   C1519249:Sequence [Functional Concept]

Phrase: "described.15,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1552738:described [Idea or Concept]

Phrase: "17"

Phrase: "A minimum of three identical clones of five"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C1524031:Minimum [Qualitative Concept]
   744   C1552614:minimum [Idea or Concept]
   744   C2826545:MINIMUM [Quantitative Concept]

Phrase: "was"

Phrase: "required"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514873:Required [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "assign"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1516050:Assign [Functional Concept]

Phrase: "an Ig sequence to the myeloma cell."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0004793:Sequence [Nucleotide Sequence]
   748   C0162326:Sequence [Nucleotide Sequence]
   748   C0162327:Sequence [Nucleotide Sequence]
   748   C1519249:Sequence [Functional Concept]
Processing 00000000.tx.106: Assessment and quantification of tumor contamination.  

Phrase: "Assessment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1261322:Assessment [Health Care Activity]
  1000   C1516048:Assessment [Activity]

Phrase: "and"

Phrase: "quantification of tumor contamination."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1709793:Quantification [Quantitative Concept]
Processing 00000000.tx.107: Tumor contamination was determined using a PCR assay as previously described in the phase I/II study.15,17 Briefly, DNA was extracted from bone marrow and peripheral blood mononuclear cells, unselected leukapheresis products, and CD34-selected and CD34-depleted PBPCs products using standard techniques and quantitated using a fluorometer (Hoeffer Scientific, San Francisco, CA). 

Phrase: "Tumor contamination"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0259846:contamination [Human-caused Phenomenon or Process]
   861   C1881659:CONTAMINATION [Event]
   861   C2349974:Contamination [Idea or Concept]

Phrase: "was"

Phrase: "determined"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a PCR assay"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   923   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   812   C0005507:Assay [Laboratory Procedure]
   812   C0243073:assay [Qualitative Concept]
   812   C0337112:Chain [Manufactured Object]
   812   C0443286:Reaction [Functional Concept]
   812   C1114821:Reaction [Clinical Attribute]
   812   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   812   C1510438:Assay [Laboratory Procedure]
   812   C1524075:Chain [Idea or Concept]

Phrase: "as"

Phrase: "previously"

Phrase: "described in the phase I/II study.15,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   793   C0282460:Phase II Study [Research Activity]
   793   C0920321:Phase I Study [Research Activity]
   744   C0021966:I- [Inorganic Chemical]
   744   C0205390:Phase [Temporal Concept]
   744   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   744   C0557651:Study [Manufactured Object]
   744   C1552738:described [Idea or Concept]
   744   C2603343:Study [Research Activity]

Phrase: "17 Briefly,"

Phrase: "DNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "was"

Phrase: "extracted from bone marrow"
Meta Candidates (Total=15; Excluded=5; Pruned=0; Remaining=10)
   833   C0005953:Bone Marrow [Tissue]
   791 E C1708973:Medullary Bone [Tissue]
   770   C0086590:Marrow [Food]
   770   C0185115:Extracted [Therapeutic or Preventive Procedure]
   770   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   770   C0376152:Marrow [Body Part, Organ, or Organ Component]
   770   C0391978:Bone [Tissue]
   770   C1266908:Bone [Body Part, Organ, or Organ Component]
   770   C1266909:Bone [Body System]
   770   C1546708:Marrow [Intellectual Product]
   770   C3541890:EXTRACTED [Finding]
   737 E C2828366:Extract [Substance]
   715 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   715 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   715 E C1550278:Medullary [Body Part, Organ, or Organ Component]

Phrase: "and"

Phrase: "peripheral blood mononuclear cells,"
Meta Candidates (Total=24; Excluded=12; Pruned=0; Remaining=12)
  1000   C1321301:Peripheral Blood Mononuclear Cells [Cell]
   906   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   861   C0229664:peripheral blood [Body Substance]
           Blood
   861   C0806987:Mononuclear cells [Cell]
   830 E C2328697:Hemal cell [Cell]
   819 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   812   C0005767:Blood [Tissue]
   812   C0005768:blood [Body Substance]
   812   C0007634:Cells [Cell]
   812   C0205100:Peripheral [Spatial Concept]
   812   C1513475:Mononuclear [Clinical Attribute]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]
   741 E C0333275:Bloody [Qualitative Concept]
   729 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   729 E C0392895:Bloods [Population Group]
   729 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   729 E C1511228:VESSEL, BLOOD [Tissue]
   712 E C1558950:VASCULAR [Finding]
   712 E C1801960:Vascular [Qualitative Concept]

Phrase: "unselected leukapheresis products,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]
   827   C1514468:Products [Entity]
   793 E C1704444:Product [Quantitative Concept]

Phrase: "and"

Phrase: "CD34-selected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1707391:Select [Activity]

Phrase: "and"

Phrase: "CD34-depleted PBPCs products"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   845   C0456388:Blood products [Pharmacologic Substance]
   829 E C1547007:Blood product [Idea or Concept]
   795   C1514468:Products [Entity]
   762 E C1704444:Product [Quantitative Concept]
   710   C0882849:cd34 cells [Cell]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "standard techniques"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0025664:techniques [Intellectual Product]
   861   C0449851:Techniques [Functional Concept]

Phrase: "and"

Phrase: "quantitated"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a fluorometer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0180919:FLUOROMETER [Medical Device]

Phrase: "(Hoeffer Scientific, San Francisco,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0036152:San Francisco [Geographic Area]
   812   C1826357:San [Gene or Genome]

Phrase: "CA)."
Processing 00000000.tx.108: The VH and VL myeloma gene sequences were compared (DNAsis; Hitachi, San Bruno, CA) with known germline gene segments.31,32 Patient-specific oligonucleotides (Operon, Alameda, CA) were designed complementary to the most unique sequences in the sense (CDR1 or CDR2) and antisense orientation (CDR3). 

Phrase: "The VH"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1420224:VH [Gene or Genome]

Phrase: "and"

Phrase: "VL myeloma gene sequences"
Meta Candidates (Total=7; Excluded=5; Pruned=0; Remaining=2)
   812   C0017337:Gene [Gene or Genome]
   812   C0162326:Sequences [Nucleotide Sequence]
   779 E C0004793:Sequence [Nucleotide Sequence]
   779 E C0162327:Sequence [Nucleotide Sequence]
   779 E C1519249:Sequence [Functional Concept]
   729 E C1548958:Sequential [Idea or Concept]
   729 E C1705294:Sequential [Qualitative Concept]

Phrase: "were"

Phrase: "compared"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compared [Activity]

Phrase: "(DNAsis"

Phrase: "; Hitachi,"

Phrase: "San Bruno,"

Phrase: "CA) with known germline gene segments.31,"

Phrase: "32 Patient-specific oligonucleotides"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0028953:Oligonucleotides [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "(Operon,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0029073:Operon [Gene or Genome]

Phrase: "Alameda,"

Phrase: "CA)"

Phrase: "were"

Phrase: "designed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1707689:Design [Activity]
   966   C2983265:DESIGN [Intellectual Product]

Phrase: "complementary to the most unique sequences"

Phrase: "in the sense"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0036658:sense [Organ or Tissue Function]

Phrase: "(CDR1"

Phrase: "or"

Phrase: "CDR2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1413296:CDR2 [Gene or Genome]

Phrase: ")"

Phrase: "and"

Phrase: "antisense orientation"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1879714:Antisense Orientation [Functional Concept]
   861   C0029266:Orientation [Mental Process]
   861   C1704322:orientation [Spatial Concept]
   861   C1704972:Orientation [Spatial Concept]
   861   C3539923:Orientation [Intellectual Product]

Phrase: "(CDR3"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1865782:CDR3 [Gene or Genome]

Phrase: ")."
Processing 00000000.tx.109: PCR conditions were optimized using the PCR Optimizer Kit (Invitrogen, San Diego, CA) on bone marrow DNA diluted 100-fold with 0.6g of placental DNA. 

Phrase: "PCR conditions"
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   779   C0012634:condition [Disease or Syndrome]
   779   C0348080:Condition [Qualitative Concept]
   779   C1705253:Condition [Conceptual Entity]
   756   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   729 E C0009647:Conditioned [Mental Process]
   729 E C1701901:Conditional [Qualitative Concept]
   729 E C1963686:Conditional [Functional Concept]
   706 E C1519605:Conditionality [Conceptual Entity]

Phrase: "were"

Phrase: "optimized"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the PCR Optimizer Kit (Invitrogen,"

Phrase: "San Diego,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1826357:San [Gene or Genome]

Phrase: "CA) on bone marrow DNA"

Phrase: "diluted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1720119:Dilute [Functional Concept]
   966   C1948037:Dilute [Functional Concept]

Phrase: "100-fold with 0.6g of placental DNA."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0332462:Fold [Spatial Concept]
   744   C1880834:FOLD [Phenomenon or Process]
Processing 00000000.tx.110: Sixty cycles of amplification were performed with Taq polymerase and Taq antibody. 

Phrase: "Sixty cycles of amplification"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   737   C1511572:Cycle [Temporal Concept]

Phrase: "were"

Phrase: "performed with Taq polymerase"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   833   C0075813:Taq Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   770   C0884358:Performed [Functional Concept]
   770   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   737 E C2947996:Perform [Pharmacologic Substance]

Phrase: "and"

Phrase: "Taq antibody."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   861   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
Processing 00000000.tx.111: To quantify the tumor cell contamination, multiple PCR reactions were performed with sample DNA serially diluted in 0.5log increments with placental DNA. 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "quantify"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1709793:Quantify [Quantitative Concept]

Phrase: "the tumor cell contamination,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0259846:contamination [Human-caused Phenomenon or Process]
   827   C1881659:CONTAMINATION [Event]
   827   C2349974:Contamination [Idea or Concept]
   734   C0431085:Tumor cell [Cell]
   734   C0597032:Tumor Cell [Cell]

Phrase: "multiple PCR reactions"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   888   C0032520:Reactions, Polymerase Chain [Laboratory Procedure,Molecular Biology Research Technique]
           Polymerase Chain Reaction

Phrase: "were"

Phrase: "performed with sample DNA serially"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   760   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   760   C0370003:Sample [Substance]
   760   C0884358:Performed [Functional Concept]
   760   C2347026:Sample [Conceptual Entity]
   726 E C2947996:Perform [Pharmacologic Substance]

Phrase: "diluted in 0.5log increments"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   726   C1705117:Increment [Quantitative Concept]
   726   C1720119:Dilute [Functional Concept]
   726   C1948037:Dilute [Functional Concept]

Phrase: "with placental DNA."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.112: Five reactions were performed at each serial dilution until PCR products were no longer detectable. 

Phrase: "Five reactions"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0443286:Reaction [Functional Concept]
   827   C1114821:Reaction [Clinical Attribute]

Phrase: "were"

Phrase: "performed at each serial dilution"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   760   C0031082:serial [Intellectual Product,Manufactured Object]
   760   C0079240:Dilution [Laboratory Procedure]
   760   C0884358:Performed [Functional Concept]
   760   C1948037:Dilution [Functional Concept]
   726 E C2947996:Perform [Pharmacologic Substance]

Phrase: "until PCR products"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   812   C1514468:Products [Entity]
   779 E C1704444:Product [Quantitative Concept]
   756   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]

Phrase: "were"

Phrase: "no longer detectable."
Processing 00000000.tx.113: Tumor contamination was calculated by a Poisson distribution analysis of positive and negative reactions at each serial dilution.15,17,33 Amplification of tubes containing a diluted bone marrow specimen (positive), placental DNA (negative), and water only (negative) using the patient-specific primers served as controls for each assay. 

Phrase: "Tumor contamination"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0259846:contamination [Human-caused Phenomenon or Process]
   861   C1881659:CONTAMINATION [Event]
   861   C2349974:Contamination [Idea or Concept]

Phrase: "was"

Phrase: "calculated by a Poisson distribution analysis of positive"
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   770   C0032347:Poisson Distribution [Quantitative Concept]
   744   C0002778:Analysis [Laboratory Procedure]
   744   C0439178:% Positive [Quantitative Concept]
   744   C0444686:Calculated [Functional Concept]
   744   C0520511:distribution [Idea or Concept]
   744   C0936012:Analysis [Research Activity]
   744   C1441506:Calculated [Activity]
   744   C1443182:Calculated [Laboratory Procedure]
   744   C1446409:Positive [Qualitative Concept]
   744   C1514241:Positive [Finding]
   744   C1524024:analysis [Functional Concept]
   744   C1704711:Distribution [Functional Concept]
   744   C2825490:Positive [Qualitative Concept]

Phrase: "and"

Phrase: "negative reactions at each serial dilution.15,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   714   C0443286:Reaction [Functional Concept]
   714   C1114821:Reaction [Clinical Attribute]

Phrase: "17,"

Phrase: "33 Amplification of tubes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C1517480:Amplification [Molecular Biology Research Technique]
   770   C1521871:Amplification [Phenomenon or Process]
   770   C1705759:Amplification [Cell or Molecular Dysfunction]

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "a diluted bone marrow specimen"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   923   C0438737:Bone marrow specimen [Body Substance]
   812   C0370003:Specimen [Substance]
   812   C2347026:Specimen [Conceptual Entity]

Phrase: "(positive"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0439178:% Positive [Quantitative Concept]
  1000   C1446409:Positive [Qualitative Concept]
  1000   C1514241:Positive [Finding]
  1000   C2825490:Positive [Qualitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "placental DNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "(negative"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0205160:Negative [Qualitative Concept]
  1000   C1513916:Negative [Finding]
  1000   C2825415:Negative [Conceptual Entity]
  1000   C2825491:Negative [Qualitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "water only"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0043047:Water [Inorganic Chemical,Pharmacologic Substance]
   861   C0599638:WATER [Substance]
   861   C1550678:Water [Inorganic Chemical]
   789 E C0443350:Watery [Qualitative Concept]

Phrase: "(negative"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0205160:Negative [Qualitative Concept]
  1000   C1513916:Negative [Finding]
  1000   C2825415:Negative [Conceptual Entity]
  1000   C2825491:Negative [Qualitative Concept]

Phrase: ")"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the patient-specific primers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "served as controls"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   756   C0243148:control [Qualitative Concept]
   756   C1550141:Control [Substance]
   756   C1882979:Control [Conceptual Entity]
   756   C2587213:Control [Functional Concept]
   756   C3274648:Control [Qualitative Concept]

Phrase: "for each assay."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0005507:Assay [Laboratory Procedure]
  1000   C0243073:assay [Qualitative Concept]
  1000   C1510438:Assay [Laboratory Procedure]
Processing 00000000.tx.114: To reduce assay-to-assay variability, the leukapheresis product and CD34-selected product collected from the same patient were amplified simultaneously in the same PCR machine. 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "reduce"

Phrase: "assay-to-assay variability,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C2827666:Variability [Conceptual Entity]
   741 E C0439828:Variable [Qualitative Concept]

Phrase: "the leukapheresis product"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]
   861   C1514468:product [Entity]
   861   C1704444:Product [Quantitative Concept]

Phrase: "and"

Phrase: "CD34-selected product"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1514468:product [Entity]
   827   C1704444:Product [Quantitative Concept]

Phrase: "collected from the same patient"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0030705:*^patient [Patient or Disabled Group]
   760   C0445247:Same [Qualitative Concept]
   760   C1516695:Collected [Idea or Concept]
   760   C1516698:Collected [Functional Concept]

Phrase: "were"

Phrase: "amplified"

Phrase: "simultaneously in the same PCR machine."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   800   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   744   C0336779:Machine [Manufactured Object]
   744   C0337112:Chain [Manufactured Object]
   744   C0443286:Reaction [Functional Concept]
   744   C0445247:Same [Qualitative Concept]
   744   C0521115:simultaneously [Temporal Concept]
   744   C1114821:Reaction [Clinical Attribute]
   744   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   744   C1524075:Chain [Idea or Concept]
Processing 00000000.tx.115: All PCR products were electrophoresed through ethidium bromide-impregnated agarose gels, photographed, and scored in triplicate by technicians blinded to sample identification. 

Phrase: "All PCR products"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   812   C1514468:Products [Entity]
   779 E C1704444:Product [Quantitative Concept]
   756   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]

Phrase: "were"

Phrase: "electrophoresed through ethidium bromide-impregnated agarose gels,"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   778   C0019873:Ethidium Bromide [Organic Chemical,Pharmacologic Substance]
   762   C1706746:Agarose Gel [Research Device]
   748   C0006222:Bromide [Inorganic Chemical]
   748   C0015008:Ethidium [Organic Chemical,Pharmacologic Substance]
   748   C0017243:Gels [Biomedical or Dental Material]
   748   C0036681:Agarose [Carbohydrate]
   714   C0013855:electrophorese [Laboratory Procedure]
   714 E C1382104:Gel [Substance]

Phrase: "photographed,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0441468:photograph [Manufactured Object]

Phrase: "and"

Phrase: "scored in triplicate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0205174:Triplicate [Quantitative Concept]
   790   C0449820:scored [Quantitative Concept]

Phrase: "by technicians"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1556020:Technician [Professional or Occupational Group]

Phrase: "blinded"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0150108:Blinded [Research Activity]
   966 E C0456909:Blind [Disease or Syndrome]
   966 E C0525065:blind [Patient or Disabled Group]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "sample"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0370003:Sample [Substance]
  1000   C2347026:Sample [Conceptual Entity]

Phrase: "identification."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0020792:Identification [Mental Process]
  1000   C0205396:Identification [Qualitative Concept]
Processing 00000000.tx.116: The validation of the PCR tumor detection assay and statistical derivation of the tumor cell contamination has been reported previously in the phase I/II study.15,17 Immune reconstitution.  

Phrase: "The validation of the PCR tumor detection assay"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C1519941:Validation [Research Activity]

Phrase: "and"

Phrase: "statistical derivation of the tumor cell contamination"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0805874:derivation [Idea or Concept]
   748   C1441547:Derivation [Qualitative Concept]
   748   C1524082:Derivation [Therapeutic or Preventive Procedure]

Phrase: "has"

Phrase: "been"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "previously in the phase I/II study.15,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   793   C0282460:Phase II Study [Research Activity]
   793   C0920321:Phase I Study [Research Activity]
   744   C0021966:I- [Inorganic Chemical]
   744   C0205390:Phase [Temporal Concept]
   744   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   744   C0557651:Study [Manufactured Object]
   744   C2603343:Study [Research Activity]

Phrase: "17 Immune reconstitution."
Processing 00000000.tx.117: The process of enriching for stem cells by CD34 selection passively removes lymphocytes from the PBPC collection and may potentially impact immune reconstitution. 

Phrase: "The process of enriching"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1184743:Process [Body Part, Organ, or Organ Component]
   770   C1522240:Process [Phenomenon or Process]

Phrase: "for stem cells"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
  1000   C0038250:Stem cells [Cell]
   861   C0007634:Cells [Cell]
   861   C0242767:Stem [Plant]
   861   C1186763:Stem [Body Part, Organ, or Organ Component]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "by CD34 selection passively"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0036576:selection [Genetic Function]

Phrase: "removes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0849355:remove [Qualitative Concept]
  1000   C1883720:Remove [Activity]
  1000   C3244314:remove [Functional Concept]

Phrase: "lymphocytes from the PBPC collection"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   776   C1518997:Peripheral Blood Lymphocyte [Cell]
   750   C0024264:Blood lymphocyte [Cell]
           Lymphocytes

Phrase: "and"

Phrase: "may"

Phrase: "potentially impact immune reconstitution."
Processing 00000000.tx.118: To determine whether immune function was more significantly impaired in those patients who received a CD34-selected autograft, lymphocyte immunophenotyping and quantitative Ig levels were performed at the premobilization, day-100, 6-month, and 1-year posttransplant visits. 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "determine"

Phrase: "whether"

Phrase: "immune function"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1817756:Immune Function [Organ or Tissue Function]
   861   C0031843:function [Physiologic Function]
   861   C0439662:Immune [Functional Concept]
   861   C0542341:Function [Functional Concept]
   861   C0700205:FUNCTION [Classification]
   861   C1705273:Function [Intellectual Product]
   789 E C0205245:Functional [Functional Concept]
   789 E C2700217:Functional [Conceptual Entity]

Phrase: "was"

Phrase: "more significantly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205172:More [Functional Concept]

Phrase: "impaired in those patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0221099:Impaired [Functional Concept]
   770   C0684336:Impaired [Pathologic Function]

Phrase: "who"

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "a CD34-selected autograft,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0040736:autograft [Therapeutic or Preventive Procedure]
   771 E C0559189:Autotransplant [Biomedical or Dental Material]

Phrase: "lymphocyte immunophenotyping"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0079718:Lymphocyte Immunophenotyping [Laboratory Procedure]
   861   C0079611:Immunophenotyping [Laboratory Procedure]

Phrase: "and"

Phrase: "quantitative Ig levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   827   C0441889:Levels [Qualitative Concept]
   793 E C0456079:Level [Classification]
   793 E C1547707:Level [Geographic Area]
   793 E C2946261:Level [Pharmacologic Substance]

Phrase: "were"

Phrase: "performed at the premobilization,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0884358:Performed [Functional Concept]
   737 E C2947996:Perform [Pharmacologic Substance]

Phrase: "day-100,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0332173:/day [Temporal Concept]
   861   C0439228:day [Temporal Concept]
   861   C0439505:/day [Temporal Concept]

Phrase: "6-month,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439231:month [Temporal Concept]
   861   C0439507:/month [Temporal Concept]

Phrase: "and"

Phrase: "1-year posttransplant visits."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   812   C0545082:Visits [Behavior]
   779 E C1512346:visit [Health Care Activity]
   779 E C2826704:VISIT [Intellectual Product]
Processing 00000000.tx.119: Statistical methods.  

Phrase: "Statistical methods."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   983   C1710191:Statistical Method [Research Activity]
   861   C0025663:Methods [Intellectual Product]
   861   C0025664:methods [Intellectual Product]
   861   C0449851:Methods [Functional Concept]
   827 E C0871511:METHOD [Intellectual Product]
Processing 00000000.tx.120: An intent-to-treat primary analysis of engraftment (safety) and tumor purging (efficacy) was performed that included all eligible and randomized patients. 

Phrase: "An intent-to-"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0162425:intent [Mental Process]
   861   C1283828:intent [Qualitative Concept]
   861   C1550453:intent [Idea or Concept]

Phrase: "treat"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1292734:TREAT [Functional Concept]
  1000   C1522326:Treat [Functional Concept]

Phrase: "primary analysis of engraftment"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0002778:Analysis [Laboratory Procedure]
   770   C0936012:Analysis [Research Activity]
   770   C1524024:analysis [Functional Concept]

Phrase: "(safety"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0036043:Safety [Human-caused Phenomenon or Process]
  1000   C1705187:SAFETY [Research Activity]

Phrase: ")"

Phrase: "and"

Phrase: "tumor purging"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C2348825:Tumor Purging [Therapeutic or Preventive Procedure]
   861   C0855227:purging [Disease or Syndrome]
   827 E C0722910:Purge [Lipid,Pharmacologic Substance]

Phrase: "(efficacy"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1280519:Efficacy [Qualitative Concept]
  1000   C1707887:EFFICACY [Research Activity]

Phrase: ")"

Phrase: "was"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "that"

Phrase: "included"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0332257:included [Functional Concept]
  1000   C3538986:INCLUDED [Gene or Genome]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "all eligible"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1548635:eligible [Idea or Concept]

Phrase: "and"

Phrase: "randomized patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]
Processing 00000000.tx.121: Patients who did not engraft their neutrophils (ANC 500) on or by day 14after transplant and randomized patients not infused were considered engraftment failures. 

Phrase: "Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "engraft"

Phrase: "their neutrophils"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0027950:Neutrophils [Cell]
   916 E C0746885:neutrophilic [Cell Function]
   893 E C0151683:Neutrophilia [Finding]

Phrase: "(ANC 500"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   923   C0948762:Absolute neutrophil count [Laboratory Procedure]
   923   C1709222:Neutrophil Count 500 [Laboratory or Test Result]
   861   C0200633:Neutrophil count [Laboratory Procedure]
   812   C0027950:Neutrophile [Cell]
   812   C0205344:Absolute [Qualitative Concept]
   812   C0750480:Count [Activity]
   812   C1705566:Count [Quantitative Concept]
   741 E C0746885:neutrophilic [Cell Function]
   712 E C0151683:Neutrophilia [Finding]

Phrase: ")"

Phrase: "on"

Phrase: "or by day 14after transplant"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0040732:Transplant [Therapeutic or Preventive Procedure]
   760   C0332173:/day [Temporal Concept]
   760   C0332835:Transplant [Tissue]
   760   C0439228:day [Temporal Concept]
   760   C0439505:/day [Temporal Concept]

Phrase: "and"

Phrase: "randomized patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "infused"

Phrase: "were"

Phrase: "considered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considered [Idea or Concept]

Phrase: "engraftment failures."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0231174:failures [Functional Concept]
   861   C0680095:failures [Individual Behavior]
Processing 00000000.tx.122: Comparisons between the treatment arms in terms of the demographic, baseline, efficacy, and safety data were performed using the two-sample t-test or Wilcoxon rank sum test for continuous data and Fisher's Exact Test (FET) for categorical data. 

Phrase: "Comparisons between the treatment arms"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   726   C1707455:Comparison [Activity]

Phrase: "in terms of the demographic, baseline,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0168634:baseline [Biomedical or Dental Material]
   861   C1442488:Baseline [Quantitative Concept]

Phrase: "efficacy,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1280519:Efficacy [Qualitative Concept]
  1000   C1707887:EFFICACY [Research Activity]

Phrase: "and"

Phrase: "safety data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1511726:Data [Idea or Concept]
   861   C3245479:data [Medical Device]

Phrase: "were"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the two-sample t-test"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0022885:Test [Laboratory Procedure]
   812   C0039593:Test [Functional Concept]
   812   C0392366:test [Intellectual Product]

Phrase: "or"

Phrase: "Wilcoxon rank sum test for continuous data"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   814   C0242928:Test, Rank-Sum [Quantitative Concept]
   804   C0242931:Wilcoxon Rank Test [Quantitative Concept]
   774   C0871608:Wilcoxon Test [Intellectual Product]
   748   C0022885:Test [Laboratory Procedure]
   748   C0039593:Test [Functional Concept]
   748   C0392366:test [Intellectual Product]
   748   C0699794:Rank [Intellectual Product]
   748   C1515051:Sum [Quantitative Concept]

Phrase: "and"

Phrase: "Fisher's Exact Test"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C1708064:Fisher's Exact Test [Intellectual Product]
           Fisher's Test
   827   C0022885:Test [Laboratory Procedure]
   827   C0039593:Test [Functional Concept]
   827   C0325045:Fisher [Mammal]
   827   C0392366:test [Intellectual Product]
   827   C2828393:Exact [Qualitative Concept]

Phrase: "(FET) for categorical data."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0643582:fet [Steroid]
Processing 00000000.tx.123: Time to engraftment, survival time, and progression-free survival time were calculated from the date of transplant and summarized using Kaplan-Meier curves.34 The treatment arms were compared using the Cox proportional hazards model. 

Phrase: "Time to engraftment,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   790   C0040223:Time [Temporal Concept]
   790   C3541383:Time [Temporal Concept]
   734 E C0442043:Temporal [Spatial Concept]
   734 E C2362314:Temporal [Temporal Concept]
   706 E C1632851:Times [Quantitative Concept]

Phrase: "survival time,"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
  1000   C2919552:Survival time [Clinical Attribute]
   861   C0038952:Survival [Activity]
   861   C0040223:Time [Temporal Concept]
   861   C0220921:survival [Functional Concept]
   861   C3541383:Time [Temporal Concept]
   805 E C0442043:Temporal [Spatial Concept]
   805 E C2362314:Temporal [Temporal Concept]
   777 E C1632851:Times [Quantitative Concept]

Phrase: "and"

Phrase: "progression-free survival time"
Meta Candidates (Total=15; Excluded=3; Pruned=0; Remaining=12)
   923   C0242792:Progression-Free Survival [Quantitative Concept]
   875   C0683585:free time [Daily or Recreational Activity]
   861   C2919552:Survival time [Clinical Attribute]
   812   C0038952:Survival [Activity]
   812   C0040223:Time [Temporal Concept]
   812   C0220921:survival [Functional Concept]
   812   C0242656:progression [Pathologic Function]
   812   C0332296:free [Functional Concept]
   812   C0449258:Progression [Functional Concept]
   812   C1880497:Free [Qualitative Concept]
   812   C1996904:Free [Qualitative Concept]
   812   C3541383:Time [Temporal Concept]
   756 E C0442043:Temporal [Spatial Concept]
   756 E C2362314:Temporal [Temporal Concept]
   729 E C1632851:Times [Quantitative Concept]

Phrase: "were"

Phrase: "calculated from the date of transplant"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   783   C3262320:Date transplant [Clinical Attribute]
   783   C3262321:Date transplant [Temporal Concept]
   753   C0011008:Date [Temporal Concept]
   753   C0040732:Transplant [Therapeutic or Preventive Procedure]
   753   C0332835:Transplant [Tissue]
   753   C0444686:Calculated [Functional Concept]
   753   C1441506:Calculated [Activity]
   753   C1443182:Calculated [Laboratory Procedure]
   753   C2348077:Date [Food]

Phrase: "and"

Phrase: "summarized"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "Kaplan-Meier curves.34"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   779   C0205134:Curve [Spatial Concept]

Phrase: "The treatment arms"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
  1000   C1522541:Treatment Arm [Research Activity]
   861   C0206655:ARMS [Neoplastic Process]
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   861   C2681631:ARMS [Gene or Genome]
   805 E C0445456:Brachial [Spatial Concept]

Phrase: "were"

Phrase: "compared"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compared [Activity]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the Cox proportional hazards model."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   923   C0033489:Proportional Hazards Model [Intellectual Product,Quantitative Concept]
   861   C0018623:Model, Hazards [Intellectual Product,Quantitative Concept]
   812   C0205351:Proportional [Qualitative Concept]
   812   C0598697:Hazards [Qualitative Concept]
   812   C3161035:Model [Intellectual Product]
   741 E C1709707:Proportion [Quantitative Concept]
Processing 00000000.tx.124: Multiple regression with stepwise variable selection was used in the analyses of factors influencing time to engraftment.  

Phrase: "Multiple regression with stepwise variable selection"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0681923:multiple regression [Qualitative Concept]
   753   C0439064:Multiple [Quantitative Concept]
   753   C0684320:Regression [Pathologic Function]
   753   C0684321:Regression [Mental Process]

Phrase: "was"

Phrase: "used in the analyses of factors"
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
   767   C0085801:Factor Analyses [Quantitative Concept]
   767   C1524063:Use of [Functional Concept]
   753   C1273517:used [Finding]
   719   C0002778:Analysis [Laboratory Procedure]
   719 E C0042153:use [Functional Concept]
   719 E C0457083:Use [Functional Concept]
   719   C0936012:Analysis [Research Activity]
   719   C1521761:Factor [Functional Concept]
   719   C1524024:analysis [Functional Concept]
   719 E C1947944:Use [Intellectual Product]
   719   C2827422:Factor [Conceptual Entity]

Phrase: "influencing"

Phrase: "time to engraftment."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   790   C0040223:Time [Temporal Concept]
   790   C3541383:Time [Temporal Concept]
   734 E C0442043:Temporal [Spatial Concept]
   734 E C2362314:Temporal [Temporal Concept]
   706 E C1632851:Times [Quantitative Concept]
Processing 00000000.tx.125: RESULTS Patient demographics.  

Phrase: "RESULTS Patient demographics."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0011292:Demographics [Idea or Concept]
   827   C0011298:Demographics [Occupation or Discipline]
   827   C1704791:Demographics [Idea or Concept]
Processing 00000000.tx.126: Between January 1995and June 1996,134patients were enrolled at 15sites throughout North America. 

Phrase: "Between January 1995and June 1996,"

Phrase: "134patients"

Phrase: "were"

Phrase: "enrolled at 15sites"

Phrase: "throughout North America."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0028405:North America [Geographic Area]
   928 E C0425358:NORTH AMERICAN [Finding]
   928 E C2700615:North American [Population Group]
   861   C0002454:America [Geographic Area]
   861   C1709269:North [Spatial Concept]
   789 E C0596070:American [Population Group]
Processing 00000000.tx.127: Three patients were not randomized; 

Phrase: "Three patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "randomized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034656:randomized [Research Activity]

Phrase: ";"
Processing 00000000.tx.128: one patient elected to receive an allogeneic transplant, another patient died before randomization, and the third developed disease progression before randomization. 

Phrase: "one patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "elected"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "receive"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Receive [Qualitative Concept]

Phrase: "an allogeneic transplant,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0040732:Transplant [Therapeutic or Preventive Procedure]
   861   C0332835:Transplant [Tissue]

Phrase: "another patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:*^patient [Patient or Disabled Group]

Phrase: "died before randomization,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   790   C0011065:Died [Organism Function]
   790   C0034656:Randomization [Research Activity]
   790   C1546956:Died [Finding]
   718 E C0231800:Expired [Organ or Tissue Function]
   718 E C1704631:Expire [Idea or Concept]

Phrase: "and"

Phrase: "the third developed disease progression before randomization."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   778   C0242656:Disease Progression [Pathologic Function]
           progression
   778   C1947900:Disease progression NOS [Finding]
   748   C0449258:Progression [Functional Concept]
Processing 00000000.tx.129: There were 131patients randomized in the intent-to-treat population, and 130patients underwent transplantation. 

Phrase: "There"

Phrase: "were"

Phrase: "131patients"

Phrase: "randomized in the intent-to-"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0034656:randomized [Research Activity]
   760   C0162425:intent [Mental Process]
   760   C1283828:intent [Qualitative Concept]
   760   C1550453:intent [Idea or Concept]

Phrase: "treat"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1292734:TREAT [Functional Concept]
  1000   C1522326:Treat [Functional Concept]

Phrase: "population,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032659:Population [Quantitative Concept]
  1000   C1257890:Population [Population Group]

Phrase: "and"

Phrase: "130patients"

Phrase: "underwent"

Phrase: "transplantation."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0029216:Transplantation [Therapeutic or Preventive Procedure]
  1000   C0040732:Transplantation [Therapeutic or Preventive Procedure]
  1000   C0040733:transplantation [Functional Concept]
Processing 00000000.tx.130: One patient had inadequate mobilization of stem cells and did not proceed to transplant; 

Phrase: "One patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "had"

Phrase: "inadequate mobilization of stem cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0524864:Stem Cell Mobilization [Therapeutic or Preventive Procedure]
   760   C0185112:Mobilisation [Therapeutic or Preventive Procedure]
   760   C0300926:mobilization [Functional Concept]

Phrase: "and"

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "proceed to transplant"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0040732:Transplant [Therapeutic or Preventive Procedure]
   790   C0332835:Transplant [Tissue]

Phrase: ";"
Processing 00000000.tx.131: this patient had been randomized on the trial and is included in the primary analyses. 

Phrase: "this patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:*^patient [Patient or Disabled Group]

Phrase: "had"

Phrase: "been"

Phrase: "randomized on the trial"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0008976:Trial [Research Activity]
   770   C0034656:randomized [Research Activity]

Phrase: "and"

Phrase: "is"

Phrase: "included in the primary analyses."
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   760   C0205225:Primary [Qualitative Concept]
   760   C0332257:included [Functional Concept]
   760   C0439631:Primary [Therapeutic or Preventive Procedure]
   760   C3538986:INCLUDED [Gene or Genome]
   726   C0002778:Analysis [Laboratory Procedure]
   726   C0936012:Analysis [Research Activity]
   726   C1524024:analysis [Functional Concept]
   726 E C1552866:include [Idea or Concept]
   726 E C2700399:Include [Activity]
Processing 00000000.tx.132: The treatment arms were similar at the time of the premobilization visit with respect to performance and disease status, -2 microglobulin levels, and the number of previous cycles of chemotherapy. 

Phrase: "The treatment arms"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
  1000   C1522541:Treatment Arm [Research Activity]
   861   C0206655:ARMS [Neoplastic Process]
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   861   C2681631:ARMS [Gene or Genome]
   805 E C0445456:Brachial [Spatial Concept]

Phrase: "were"

Phrase: "similar at the time of the premobilization visit"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C2348205:Similar [Qualitative Concept]

Phrase: "with respect to performance"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597198:Performance [Individual Behavior]
  1000   C1882330:Performance [Activity]

Phrase: "and"

Phrase: "disease status, -"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0012634:Disease [Disease or Syndrome]
   861   C0449438:Status [Qualitative Concept]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "2 microglobulin levels,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   913   C0456948:2 levels [Intellectual Product]
   827   C0441889:Levels [Qualitative Concept]
   793 E C0456079:Level [Classification]
   793 E C1547707:Level [Geographic Area]
   793 E C2946261:Level [Pharmacologic Substance]

Phrase: "and"

Phrase: "the number of previous cycles of chemotherapy."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0237753:*Number [Quantitative Concept]
   748   C0449788:Number [Quantitative Concept]
Processing 00000000.tx.133: There was a significantly higher proportion of females in the selected arm (45% v 27%, P=.030; Table 1). 

Phrase: "There"

Phrase: "was"

Phrase: "a significantly higher proportion of females"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1709707:Proportion [Quantitative Concept]

Phrase: "in the selected arm (45% v 27%,"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   804   C0446516:Arm [Body Location or Region]
   804   C1269078:Arm [Body Part, Organ, or Organ Component]
   804   C1269612:Arm [Body Location or Region]
   771   C1707391:Select [Activity]
   748 E C0445456:Brachial [Spatial Concept]
   721 E C0206655:ARMS [Neoplastic Process]
   721 E C2681631:ARMS [Gene or Genome]

Phrase: "P=.030"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: "; Table 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.134: The only other baseline characteristics that differed significantly between the treatment arms were a lower median CD4/CD8 ratio, platelet, and WBC counts (1.3v 1.7,P=.032; 110v 152103/L, P=.002; 15.9v 26.2103/L, P=.042,respectively) for patients in the selected arm at the time of randomization (Table 1 and see Table 6).  

Phrase: "The only"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205171:Only [Quantitative Concept]
  1000   C1720467:Only [Intellectual Product]

Phrase: "other baseline characteristics"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1521970:Characteristics [Qualitative Concept]

Phrase: "that"

Phrase: "differed"

Phrase: "significantly between the treatment arms"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
   806   C1522541:Treatment Arm [Research Activity]
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C0206655:ARMS [Neoplastic Process]
   760   C0446516:Arm [Body Location or Region]
   760   C1269078:Arm [Body Part, Organ, or Organ Component]
   760   C1269612:Arm [Body Location or Region]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C2681631:ARMS [Gene or Genome]
   760   C3538994:TREATMENT [Research Activity]
   704 E C0445456:Brachial [Spatial Concept]

Phrase: "were"

Phrase: "a lower median CD4/CD8 ratio,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   884   C0085115:CD4-CD8 Ratio [Laboratory Procedure]
   804   C0456603:Ratio [Quantitative Concept]
   804   C1547037:Ratio [Intellectual Product]

Phrase: "platelet,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0005821:Platelet [Cell]
   916 E C1963076:Platelets [Finding]

Phrase: "and"

Phrase: "WBC counts"
Meta Candidates (Total=29; Excluded=11; Pruned=0; Remaining=18)
   966   C0023508:Blood Cell Count, White [Laboratory Procedure]
   966   C0427512:white blood cell count [Laboratory or Test Result]
   923   C0005771:Counts, Blood Cell [Laboratory Procedure]
   923   C0023516:White blood cell [Cell]
           White Cell
   890 E C0009555:Blood Cell Count [Laboratory Procedure]
   861   C0005773:Blood cell [Cell]
   861   C0007584:Counts, Cell [Laboratory Procedure]
   833 E C2328697:Hemal cell [Cell]
   812   C0005767:Blood [Tissue]
   812   C0005768:blood [Body Substance]
   812   C0007457:White [Population Group]
   812   C0007634:Cell [Cell]
   812   C0043157:White [Population Group]
   812   C0220938:White [Qualitative Concept]
   812   C0229664:Blood [Body Substance]
   812   C0439157:counts [Quantitative Concept]
   812   C1269647:Cell [Cell]
   812   C1704653:Cell [Medical Device]
   812   C1948049:Cell [Spatial Concept]
   779 E C0750480:Count [Activity]
   779 E C1705566:Count [Quantitative Concept]
   741 E C0333275:Bloody [Qualitative Concept]
   729 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   729 E C0392895:Bloods [Population Group]
   729 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   729 E C1511228:VESSEL, BLOOD [Tissue]
   712 E C1558950:VASCULAR [Finding]
   712 E C1801960:Vascular [Qualitative Concept]

Phrase: "(1.3v 1.7,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   902   C3541329:1-7 [Gene or Genome]
   812   C2827734:1+ [Quantitative Concept]
   812   C2981698:1+ [Classification]

Phrase: "P=.032"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: "; 110v 152103/L,"

Phrase: "P=.002"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: "; 15.9v 26.2103/L,"

Phrase: "P=.042,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: "respectively"

Phrase: ")"

Phrase: "for patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "in the selected arm"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "at the time"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0040223:Time [Temporal Concept]
  1000   C3541383:Time [Temporal Concept]
   944 E C0442043:Temporal [Spatial Concept]
   944 E C2362314:Temporal [Temporal Concept]
   916 E C1632851:Times [Quantitative Concept]

Phrase: "of randomization"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034656:Randomization [Research Activity]

Phrase: "(Table 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: "and"

Phrase: "see"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042789:see [Organism Function]
  1000   C1947903:See [Activity]

Phrase: "Table 6"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.135: View this table: [in this window] [in a new window]  Table 1. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 1."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.136: Demographic Characteristics and Hematology Measurements at Randomization Stem cell collection and enrichment.  

Phrase: "Demographic Characteristics"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0683970:demographic characteristics [Group Attribute]
   861   C1521970:Characteristics [Qualitative Concept]

Phrase: "and"

Phrase: "Hematology Measurements at Randomization Stem cell collection"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0242485:measurements [Functional Concept]

Phrase: "and"

Phrase: "enrichment."
Processing 00000000.tx.137: A median of two leukaphereses were required for both treatment arms to reach the target of 5108 nucleated cells/kg. 

Phrase: "A median of two leukaphereses"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0549183:Median [Spatial Concept]
   760   C0876920:Median [Quantitative Concept]
   760   C2347635:Median [Quantitative Concept]
   760   C2348144:Median [Quantitative Concept]
   760   C2939193:Median [Spatial Concept]

Phrase: "were"

Phrase: "required for both treatment arms to"
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   790   C1522541:Treatment Arm [Research Activity]
   753   C0039798:treatment [Functional Concept]
   753   C0087111:Treatment [Therapeutic or Preventive Procedure]
   753   C0206655:ARMS [Neoplastic Process]
   753   C0446516:Arm [Body Location or Region]
   753   C1269078:Arm [Body Part, Organ, or Organ Component]
   753   C1269612:Arm [Body Location or Region]
   753   C1514873:Required [Functional Concept]
   753   C1522326:Treatment [Functional Concept]
   753   C1533734:Treatment [Therapeutic or Preventive Procedure]
   753   C1705169:Treatment [Conceptual Entity]
   753   C2681631:ARMS [Gene or Genome]
   753   C3538994:TREATMENT [Research Activity]

Phrase: "reach"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2584321:Reach [Organism Function]

Phrase: "the target of 5108 nucleated cells/kg."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   774   C0221284:Target cells [Cell]
   774   C3272919:Target Cells [Laboratory Procedure]
   748   C1521840:Target [Functional Concept]
   748   C2986546:TARGET [Diagnostic Procedure]
Processing 00000000.tx.138: However, 18of the 67patients in the selected arm required an additional leukapheresis to meet the second criterion of 4106 nucleated cells/kg in the selected product. 

Phrase: "However,"

Phrase: "18of"

Phrase: "the 67patients in the selected arm"

Phrase: "required"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514873:Required [Functional Concept]

Phrase: "an additional leukapheresis to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]

Phrase: "meet"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1550543:Meet [Idea or Concept]

Phrase: "the second criterion of 4106 nucleated cells/kg"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0243161:Criterion [Intellectual Product]

Phrase: "in the selected product."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1514468:product [Entity]
   861   C1704444:Product [Quantitative Concept]
Processing 00000000.tx.139: Consequently, the mean number of leukaphereses required for patients in the selected arm was 3.0(range, 2to 8) versus 2.3for patients in the unselected arm (range, 2to 6; P=.002). 

Phrase: "Consequently,"

Phrase: "the mean number of leukaphereses"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0237753:*Number [Quantitative Concept]
   760   C0444504:Mean [Quantitative Concept]
   760   C0449788:Number [Quantitative Concept]
   760   C2347634:Mean [Quantitative Concept]
   760   C2348143:Mean [Quantitative Concept]

Phrase: "required for patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C1514873:Required [Functional Concept]

Phrase: "in the selected arm"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "was"

Phrase: "3.0"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0439086:<3 [Quantitative Concept]
   861   C2827736:3+ [Quantitative Concept]
   861   C2981702:3+ [Classification]

Phrase: "(range,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1514721:Range [Quantitative Concept]
  1000   C2348147:Range [Quantitative Concept]
  1000   C3542016:Range [Intellectual Product]

Phrase: "2to 8"

Phrase: ")"

Phrase: "versus"

Phrase: "2.3for patients in the unselected arm (range,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0030705:Patients [Patient or Disabled Group]

Phrase: "2to 6"

Phrase: "; P=.002"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.140: The median number of CD34+ cells in the leukapheresis product before processing was 10.13and 8.67106/kg for the selected and the unselected arms, respectively (P=.253). 

Phrase: "The median number of CD34+ cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   767   C0007584:Cell Number [Laboratory Procedure]
   753   C0237753:*Number [Quantitative Concept]
   753   C0449788:Number [Quantitative Concept]

Phrase: "in the leukapheresis product"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]
   861   C1514468:product [Entity]
   861   C1704444:Product [Quantitative Concept]

Phrase: "before processing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1709694:Processing [Activity]

Phrase: "was"

Phrase: "10.13and 8.67106/kg for the selected"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0022718:KG [Geographic Area]
   744   C0439209:kg [Quantitative Concept]

Phrase: "and"

Phrase: "the unselected arms,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   861   C0206655:ARMS [Neoplastic Process]
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   861   C2681631:ARMS [Gene or Genome]
   805 E C0445456:Brachial [Spatial Concept]

Phrase: "respectively"

Phrase: "(P=.253"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.141: After enrichment, the median number of CD34+ cells was 5.40106/kg in the selected arm for a median CD34+ cell yield of 52%. 

Phrase: "After enrichment,"

Phrase: "the median number of CD34+ cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   767   C0007584:Cell Number [Laboratory Procedure]
   753   C0237753:*Number [Quantitative Concept]
   753   C0449788:Number [Quantitative Concept]

Phrase: "was"

Phrase: "5.40106/kg in the selected arm"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0022718:KG [Geographic Area]
   748   C0439209:kg [Quantitative Concept]

Phrase: "for a median CD34+ cell yield"

Phrase: "of 52%."
Processing 00000000.tx.142: The median purity of CD34+ cells was 0.9% before CD34 selection and 66.4% after selection. 

Phrase: "The median purity of CD34+ cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1882508:Purity [Quantitative Concept]

Phrase: "was"

Phrase: "0.9% before CD34 selection"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0036576:selection [Genetic Function]
   760   C3538723:CD34 [Laboratory Procedure]

Phrase: "and"

Phrase: "66.4% after selection."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0036576:selection [Genetic Function]
Processing 00000000.tx.143: As expected, the patients in the selected arm had significantly fewer nucleated cells/kg (P<0.001) and CD34+ cells/kg (P=.012) infused than did the patients in the unselected arm (Table 2). 

Phrase: "As"

Phrase: "expected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1517001:Expected [Idea or Concept]

Phrase: ","

Phrase: "the patients in the selected arm"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0030705:Patients [Patient or Disabled Group]

Phrase: "had"

Phrase: "significantly fewer nucleated cells/kg (P<0.001"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   812   C1180059:Nucleated cells [Cell]
   793   C0007634:Cells [Cell]
   793   C0022718:KG [Geographic Area]
   793   C0439209:kg [Quantitative Concept]
   793   C1979936:Nucleated [Qualitative Concept]
   793   C3282337:Cells [Cell]
   760 E C1269647:Cell [Cell]
   760 E C1704653:Cell [Medical Device]
   760 E C1948049:Cell [Spatial Concept]

Phrase: ")"

Phrase: "and"

Phrase: "CD34+ cells/kg (P=.012"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   840   C0882849:cd34 cells [Cell]
   804   C0007634:Cells [Cell]
   804   C0022718:KG [Geographic Area]
   804   C0439209:kg [Quantitative Concept]
   804   C3282337:Cells [Cell]
   804   C3538723:CD34 [Laboratory Procedure]
   771 E C1269647:Cell [Cell]
   771 E C1704653:Cell [Medical Device]
   771 E C1948049:Cell [Spatial Concept]

Phrase: ")"

Phrase: "infused than"

Phrase: "did"

Phrase: "the patients in the unselected arm (Table 2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0030705:Patients [Patient or Disabled Group]

Phrase: ")."
Processing 00000000.tx.144: The median number of CD34 cells in the cryopreserved backup stem cell product (CD34-depleted product) was 2.78106 CD34+ cells/kg.  

Phrase: "The median number of CD34 cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   767   C0007584:Cell Number [Laboratory Procedure]
   753   C0237753:*Number [Quantitative Concept]
   753   C0449788:Number [Quantitative Concept]

Phrase: "in the cryopreserved backup stem cell product"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   884   C1706452:Stem cell product [Immunologic Factor]
   804   C1514468:product [Entity]
   804   C1704444:Product [Quantitative Concept]
   708   C1511548:Cryopreserved Cell [Cell]

Phrase: "(CD34-depleted product"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1514468:product [Entity]
   827   C1704444:Product [Quantitative Concept]

Phrase: ")"

Phrase: "was"

Phrase: "2.78106 CD34+ cells/kg."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0022718:KG [Geographic Area]
   804   C0439209:kg [Quantitative Concept]
Processing 00000000.tx.145: View this table: [in this window] [in a new window]  Table 2. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.146: Processing of PBPCs: Total of All Leukaphereses There were no significant differences between the treatment arms in terms of CFU/kg either before or after CD34 selection (P=.287). 

Phrase: "Processing of PBPCs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   767   C0230625:cell processing [Cell Component]
   753   C1709694:Processing [Activity]

Phrase: ":"

Phrase: "Total of All Leukaphereses There"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0439175:% total [Quantitative Concept]
   760   C0439810:Total [Qualitative Concept]

Phrase: "were"

Phrase: "no significant differences between the treatment arms"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   714   C1705241:*Difference [Quantitative Concept]
   714   C1705242:Difference [Qualitative Concept]

Phrase: "in terms of CFU/kg either before"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
   861   C0553561:Colony-forming unit [Quantitative Concept]
   827   C1300561:unit/kg [Quantitative Concept]
   799   C0022718:KG [Geographic Area]
   799   C0205431:Forming [Functional Concept]
   799   C0439148:Unit [Quantitative Concept]
   799   C0439158:colony [Quantitative Concept]
   799   C0439209:kg [Quantitative Concept]
   799   C1519795:Unit [Quantitative Concept]
   799   C1522492:Forming [Functional Concept]
   799   C1704753:Unit [Manufactured Object]
   799   C1880519:Unit [Quantitative Concept]
   799   C1947989:Colony [Cell]
   766 E C0348078:Form [Qualitative Concept]
   766 E C0376315:Form [Manufactured Object]

Phrase: "or after CD34 selection"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0036576:selection [Genetic Function]
   770   C3538723:CD34 [Laboratory Procedure]

Phrase: "(P=.287"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.147: The median number of CFU per kilogram infused was 53.5104/kg in the selected arm and 102.4104/kg in the unselected arm. 

Phrase: "The median number of CFU"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   774   C0449801:number unit [Quantitative Concept]
   774   C0449961:number unit [Quantitative Concept]
   748   C0237753:*Number [Quantitative Concept]
   748   C0449788:Number [Quantitative Concept]

Phrase: "per kilogram"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439209:Kilogram [Quantitative Concept]

Phrase: "infused"

Phrase: "was"

Phrase: "53.5104/kg in the selected arm"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0022718:KG [Geographic Area]
   748   C0439209:kg [Quantitative Concept]

Phrase: "and"

Phrase: "102.4104/kg in the unselected arm."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0022718:KG [Geographic Area]
   748   C0439209:kg [Quantitative Concept]
Processing 00000000.tx.148: Tumor purging efficacy of the CEPRATE SC System.  

Phrase: "Tumor purging efficacy of the CEPRATE SC System."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C1280519:Efficacy [Qualitative Concept]
   742   C1707887:EFFICACY [Research Activity]
Processing 00000000.tx.149: Bone marrow samples were obtained from every patient at the time of study registration. 

Phrase: "Bone marrow samples"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   983   C0438737:Bone marrow sample [Body Substance]
   793   C0370003:Sample [Substance]
   793   C2347026:Sample [Conceptual Entity]
   734   C0005953:Bone Marrow [Tissue]

Phrase: "were"

Phrase: "obtained from every patient"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0030705:*^patient [Patient or Disabled Group]
   770   C1301820:Obtained [Functional Concept]
   737 E C1706701:Obtain [Activity]

Phrase: "at the time"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0040223:Time [Temporal Concept]
  1000   C3541383:Time [Temporal Concept]
   944 E C0442043:Temporal [Spatial Concept]
   944 E C2362314:Temporal [Temporal Concept]
   916 E C1632851:Times [Quantitative Concept]

Phrase: "of study registration."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1514821:Registration [Health Care Activity]
   861   C1553384:registration [Idea or Concept]
   861   C2697663:Registration [Machine Activity]
Processing 00000000.tx.150: A minimum of 3months of prior chemotherapy was required, potentially affecting the ability to identify the clonal Ig sequences. 

Phrase: "A minimum of 3months of prior chemotherapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C1524031:Minimum [Qualitative Concept]
   748   C1552614:minimum [Idea or Concept]
   748   C2826545:MINIMUM [Quantitative Concept]

Phrase: "was"

Phrase: "required"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514873:Required [Functional Concept]

Phrase: ","

Phrase: "potentially"

Phrase: "affecting"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0392760:Affecting [Functional Concept]
  1000   C1314939:Affecting [Functional Concept]
   966 E C0001721:Affect [Mental Process]

Phrase: "the ability to"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0085732:Ability [Organism Attribute]
   789 E C1299581:Able [Finding]

Phrase: "identify"

Phrase: "the clonal Ig sequences."
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   827   C0162326:Sequences [Nucleotide Sequence]
   793 E C0004793:Sequence [Nucleotide Sequence]
   793 E C0162327:Sequence [Nucleotide Sequence]
   793 E C1519249:Sequence [Functional Concept]
   743 E C1548958:Sequential [Idea or Concept]
   743 E C1705294:Sequential [Qualitative Concept]
Processing 00000000.tx.151: A clonal Ig sequence was able to be identified and used in the analysis for 47patients: 28(42%) in the selected arm and 19(30%) in the unselected arm. 

Phrase: "A clonal Ig sequence"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   827   C0004793:Sequence [Nucleotide Sequence]
   827   C0162326:Sequence [Nucleotide Sequence]
   827   C0162327:Sequence [Nucleotide Sequence]
   827   C1519249:Sequence [Functional Concept]
   755 E C1548958:Sequential [Idea or Concept]
   755 E C1705294:Sequential [Qualitative Concept]

Phrase: "was"

Phrase: "able to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0085732:Able [Organism Attribute]
   861   C1299581:Able [Finding]

Phrase: "be"

Phrase: "identified"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]

Phrase: "and"

Phrase: "used in the analysis"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   770   C0002778:Analysis [Laboratory Procedure]
   770   C0936012:Analysis [Research Activity]
   770   C1273517:used [Finding]
   770   C1524024:analysis [Functional Concept]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1947944:Use [Intellectual Product]

Phrase: "for 47patients"

Phrase: ":"

Phrase: "28"

Phrase: "(42%"

Phrase: ")"

Phrase: "in the selected arm"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "and"

Phrase: "19"

Phrase: "(30%"

Phrase: ")"

Phrase: "in the unselected arm."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]
Processing 00000000.tx.152: A clonal Ig sequence was not identified for 81patients (36in the selected arm and 45in the unselected arm) for the following reasons: normal SPEP and UPEP at study entry (22), ineffective (19) or polyclonal (24) Ig gene amplification, and inadequate (12) or unavailable (4) BM specimens. 

Phrase: "A clonal Ig sequence"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   827   C0004793:Sequence [Nucleotide Sequence]
   827   C0162326:Sequence [Nucleotide Sequence]
   827   C0162327:Sequence [Nucleotide Sequence]
   827   C1519249:Sequence [Functional Concept]
   755 E C1548958:Sequential [Idea or Concept]
   755 E C1705294:Sequential [Qualitative Concept]

Phrase: "was"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "identified for 81patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0205396:Identified [Qualitative Concept]
   790   C1550043:Identified [Finding]
   790   C1551388:Identified [Functional Concept]

Phrase: "(36in"

Phrase: "the selected arm"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "and"

Phrase: "45in"

Phrase: "the unselected arm) for the following reasons"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0446516:Arm [Body Location or Region]
   748   C1269078:Arm [Body Part, Organ, or Organ Component]
   748   C1269612:Arm [Body Location or Region]

Phrase: ":"

Phrase: "normal SPEP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0201720:spep [Laboratory Procedure]

Phrase: "and"

Phrase: "UPEP at study entry"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0201721:UPEP [Laboratory Procedure]

Phrase: "(22"

Phrase: ")"

Phrase: ","

Phrase: "ineffective"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3242229:ineffective [Idea or Concept]

Phrase: "(19"

Phrase: ")"

Phrase: "or"

Phrase: "polyclonal"

Phrase: "(24"

Phrase: ")"

Phrase: "Ig gene amplification,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   901   C0017256:Gene Amplification [Genetic Function]
   901   C0017350:Ig Gene [Gene or Genome]
   901   C1705759:Gene Amplification [Cell or Molecular Dysfunction]
           Amplification
   827   C0017337:Gene [Gene or Genome]
   827   C1517480:Amplification [Molecular Biology Research Technique]
   827   C1521871:Amplification [Phenomenon or Process]

Phrase: "and"

Phrase: "inadequate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205412:Inadequate [Qualitative Concept]

Phrase: "(12"

Phrase: ")"

Phrase: "or"

Phrase: "unavailable"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0686905:Unavailable [Functional Concept]

Phrase: "(4"

Phrase: ")"

Phrase: "BM specimens."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0370003:specimens [Substance]
   827 E C2347026:Specimen [Conceptual Entity]
Processing 00000000.tx.153: In addition, there were 3patients that had clonal Ig gene sequences identified who were not included in the analyses: for 2patients, PCR conditions could not be adjusted to specifically amplify only the myeloma Ig gene product, and 1patient did not have samples obtained from leukapheresis products. 

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "there"

Phrase: "were"

Phrase: "3patients"

Phrase: "that"

Phrase: "had"

Phrase: "clonal Ig gene sequences"
Meta Candidates (Total=8; Excluded=5; Pruned=0; Remaining=3)
   861   C0017350:Ig Gene [Gene or Genome]
   812   C0017337:Gene [Gene or Genome]
   812   C0162326:Sequences [Nucleotide Sequence]
   779 E C0004793:Sequence [Nucleotide Sequence]
   779 E C0162327:Sequence [Nucleotide Sequence]
   779 E C1519249:Sequence [Functional Concept]
   729 E C1548958:Sequential [Idea or Concept]
   729 E C1705294:Sequential [Qualitative Concept]

Phrase: "identified"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]

Phrase: "who"

Phrase: "were"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "included in the analyses"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   770   C0332257:included [Functional Concept]
   770   C3538986:INCLUDED [Gene or Genome]
   737   C0002778:Analysis [Laboratory Procedure]
   737   C0936012:Analysis [Research Activity]
   737   C1524024:analysis [Functional Concept]
   737 E C1552866:include [Idea or Concept]
   737 E C2700399:Include [Activity]

Phrase: ":"

Phrase: "for 2patients,"

Phrase: "PCR conditions"
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   779   C0012634:condition [Disease or Syndrome]
   779   C0348080:Condition [Qualitative Concept]
   779   C1705253:Condition [Conceptual Entity]
   756   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   729 E C0009647:Conditioned [Mental Process]
   729 E C1701901:Conditional [Qualitative Concept]
   729 E C1963686:Conditional [Functional Concept]
   706 E C1519605:Conditionality [Conceptual Entity]

Phrase: "could"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "be"

Phrase: "adjusted"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0456081:Adjusted [Functional Concept]

Phrase: "to specifically"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1883351:To [Qualitative Concept]

Phrase: "amplify"

Phrase: "only"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205171:Only [Quantitative Concept]
  1000   C1720467:Only [Intellectual Product]

Phrase: "the myeloma Ig gene product,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0017350:Ig Gene [Gene or Genome]
   861   C0033684:gene product [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C1704222:Gene Product [Amino Acid, Peptide, or Protein,Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0017337:Gene [Gene or Genome]
   812   C1514468:product [Entity]
   812   C1704444:Product [Quantitative Concept]

Phrase: "and"

Phrase: "1patient"

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "have"

Phrase: "samples"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0370003:Sample [Substance]
   966   C2347026:Sample [Conceptual Entity]

Phrase: "obtained from leukapheresis products."
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   770   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]
   770   C1301820:Obtained [Functional Concept]
   770   C1514468:Products [Entity]
   737 E C1704444:Product [Quantitative Concept]
   737 E C1706701:Obtain [Activity]
Processing 00000000.tx.154: There were no detectable tumor cells in the initial leukapheresis PBPC product of 4patients in each treatment arm (14% in the selected arm and 21% in the unselected arm; see Table 4). 

Phrase: "There"

Phrase: "were"

Phrase: "no detectable tumor cells in the initial leukapheresis PBPC product"
Meta Candidates (Total=17; Excluded=5; Pruned=0; Remaining=12)
   750   C0431085:Tumor cells [Cell]
   749   C0005773:Blood Cells [Cell]
           Peripheral blood cell
   749   C0038250:Progenitor Cells [Cell]
   735   C0007634:Cells [Cell]
   735   C0027651:Tumor [Neoplastic Process]
   735   C1578706:Tumor [Intellectual Product]
   735   C3273930:Tumor [Finding]
   735   C3282337:Cells [Cell]
   732   C0017471:initial cell [Cell]
   717 E C0597032:Tumor Cell [Cell]
   707   C0027668:Tumor, Blood Vessel [Neoplastic Process]
   707   C0282607:Blood vessel tumor [Neoplastic Process]
   704 E C2328697:Hemal cell [Cell]
   702 E C1269647:Cell [Cell]
   702 E C1704653:Cell [Medical Device]
   702 E C1948049:Cell [Spatial Concept]

Phrase: "of 4patients"

Phrase: "in each treatment arm (14%"
Meta Candidates (Total=13; Excluded=3; Pruned=0; Remaining=10)
   901   C1522541:Treatment Arm [Research Activity]
   827   C0039798:treatment [Functional Concept]
   827   C0087111:Treatment [Therapeutic or Preventive Procedure]
   827   C0446516:Arm [Body Location or Region]
   827   C1269078:Arm [Body Part, Organ, or Organ Component]
   827   C1269612:Arm [Body Location or Region]
   827   C1522326:Treatment [Functional Concept]
   827   C1533734:Treatment [Therapeutic or Preventive Procedure]
   827   C1705169:Treatment [Conceptual Entity]
   827   C3538994:TREATMENT [Research Activity]
   771 E C0445456:Brachial [Spatial Concept]
   743 E C0206655:ARMS [Neoplastic Process]
   743 E C2681631:ARMS [Gene or Genome]

Phrase: "in the selected arm"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "and"

Phrase: "21% in the unselected arm"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   760   C0446516:Arm [Body Location or Region]
   760   C1269078:Arm [Body Part, Organ, or Organ Component]
   760   C1269612:Arm [Body Location or Region]
   704 E C0445456:Brachial [Spatial Concept]

Phrase: ";"

Phrase: "see"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042789:see [Organism Function]
  1000   C1947903:See [Activity]

Phrase: "Table 4"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.155: A median of 2.6106 and 2.3106 tumor cells was detected in the initial leukapheresis product of patients in the selected and unselected arms, respectively (Table 3). 

Phrase: "A median of 2.6106"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0549183:Median [Spatial Concept]
   760   C0876920:Median [Quantitative Concept]
   760   C2347635:Median [Quantitative Concept]
   760   C2348144:Median [Quantitative Concept]
   760   C2939193:Median [Spatial Concept]

Phrase: "and"

Phrase: "2.3106 tumor cells"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   861   C0431085:Tumor cells [Cell]
   827 E C0597032:Tumor Cell [Cell]
   812   C0007634:Cells [Cell]
   812   C0027651:Tumor [Neoplastic Process]
   812   C1578706:Tumor [Intellectual Product]
   812   C3273930:Tumor [Finding]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]

Phrase: "was"

Phrase: "detected in the initial leukapheresis product of patients"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   744   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]
   744   C0030705:Patients [Patient or Disabled Group]
   744   C0205265:Initial [Temporal Concept]
   744   C0442726:Detected [Finding]
   744   C1279901:Initial [Qualitative Concept]
   744   C1511790:Detected [Therapeutic or Preventive Procedure]
   744   C1514468:product [Entity]
   744   C1555582:Initial [Idea or Concept]
   744   C1704444:Product [Quantitative Concept]
   744   C1705685:INITIAL [Functional Concept]

Phrase: "in the selected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1707391:Select [Activity]

Phrase: "and"

Phrase: "unselected arms,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   861   C0206655:ARMS [Neoplastic Process]
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   861   C2681631:ARMS [Gene or Genome]
   805 E C0445456:Brachial [Spatial Concept]

Phrase: "respectively"

Phrase: "(Table 3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.156: The primary efficacy endpoint of the study was a greater than 2log reduction in tumor cell contamination after CD34 selection using the CEPRATE SC System. 

Phrase: "The primary efficacy endpoint of the study"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   774   C2986535:Primary Endpoint [Indicator, Reagent, or Diagnostic Aid]
   748   C2349179:End Point [Qualitative Concept]
   748   C2826544:ENDPOINT [Quantitative Concept]

Phrase: "was"

Phrase: "a greater than 2log reduction"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   806   C0439093:Greater Than [Quantitative Concept]
   760   C0443228:greater [Quantitative Concept]
   760   C1704243:Greater [Quantitative Concept]
   726 E C0549177:Great [Quantitative Concept]

Phrase: "in tumor cell contamination"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0259846:contamination [Human-caused Phenomenon or Process]
   827   C1881659:CONTAMINATION [Event]
   827   C2349974:Contamination [Idea or Concept]
   734   C0431085:Tumor cell [Cell]
   734   C0597032:Tumor Cell [Cell]

Phrase: "after CD34 selection"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0036576:selection [Genetic Function]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the CEPRATE SC System."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   812   C0449913:System [Functional Concept]
   812   C1553451:System [Manufactured Object]
   812   C1704459:System [Medical Device]
   741 E C0205373:Systemic [Functional Concept]
Processing 00000000.tx.157: This was evaluated in 24patients in the selected arm for whom a clonal Ig sequence could be identified and who had detectable tumor cells in the PBPC product before CD34 selection (Fig 2). 

Phrase: "This"

Phrase: "was"

Phrase: "evaluated in 24patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0220825:Evaluated [Functional Concept]

Phrase: "in the selected arm"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "for whom"

Phrase: "a clonal Ig sequence"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   827   C0004793:Sequence [Nucleotide Sequence]
   827   C0162326:Sequence [Nucleotide Sequence]
   827   C0162327:Sequence [Nucleotide Sequence]
   827   C1519249:Sequence [Functional Concept]
   755 E C1548958:Sequential [Idea or Concept]
   755 E C1705294:Sequential [Qualitative Concept]

Phrase: "could"

Phrase: "be"

Phrase: "identified"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]

Phrase: "and"

Phrase: "who"

Phrase: "had"

Phrase: "detectable tumor cells in the PBPC product"
Meta Candidates (Total=16; Excluded=5; Pruned=0; Remaining=11)
   761   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   760   C0431085:Tumor cells [Cell]
   757   C0038250:Progenitor Cells [Cell]
   739   C0007634:Cells [Cell]
   739   C0027651:Tumor [Neoplastic Process]
   739   C1578706:Tumor [Intellectual Product]
   739   C3273930:Tumor [Finding]
   739   C3282337:Cells [Cell]
   726 E C0597032:Tumor Cell [Cell]
   716   C0027668:Tumor, Blood Vessel [Neoplastic Process]
   716   C0282607:Blood vessel tumor [Neoplastic Process]
   713 E C2328697:Hemal cell [Cell]
   706 E C1269647:Cell [Cell]
   706 E C1704653:Cell [Medical Device]
   706 E C1948049:Cell [Spatial Concept]

Phrase: "before CD34 selection"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0036576:selection [Genetic Function]

Phrase: "(Fig 2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.158: Of the 24patients with detectable tumor cells in this PBPC product, 11(46%) had no detectable tumor cells in the CD34-selected product. 

Phrase: "Of the 24patients"

Phrase: "with detectable tumor cells"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   901   C0431085:Tumor cells [Cell]
   867 E C0597032:Tumor Cell [Cell]
   827   C0007634:Cells [Cell]
   827   C0027651:Tumor [Neoplastic Process]
   827   C1578706:Tumor [Intellectual Product]
   827   C3273930:Tumor [Finding]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "in this PBPC product,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   875   C0456388:Blood product [Pharmacologic Substance]
   875   C1547007:Blood product [Idea or Concept]
   804   C1514468:product [Entity]
   804   C1704444:Product [Quantitative Concept]
   705   C0005773:Peripheral blood cell [Cell]

Phrase: "11"

Phrase: "(46%"

Phrase: ")"

Phrase: "had"

Phrase: "no detectable tumor cells in the CD34-selected product."
Meta Candidates (Total=11; Excluded=4; Pruned=0; Remaining=7)
   764   C0431085:Tumor cells [Cell]
   762   C0882849:Cells.CD34 [Cell]
   742   C0007634:Cells [Cell]
   742   C0027651:Tumor [Neoplastic Process]
   742   C1578706:Tumor [Intellectual Product]
   742   C3273930:Tumor [Finding]
   742   C3282337:Cells [Cell]
   731 E C0597032:Tumor Cell [Cell]
   708 E C1269647:Cell [Cell]
   708 E C1704653:Cell [Medical Device]
   708 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.159: To estimate the log depletion of tumor cells for these patients, the minimal detection limit was used for the percentage of tumor cells, after CD34 selection in the calculations. 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "estimate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750572:Estimate [Quantitative Concept]

Phrase: "the log depletion of tumor cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0333668:Depletion [Functional Concept]

Phrase: "for these patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "the minimal detection limit"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   901   C2718050:Detection Limit [Quantitative Concept]
   827   C0439801:limit [Functional Concept]
   827   C1549649:Limit [Idea or Concept]
   827   C2349209:Limit [Conceptual Entity]
   755 E C3542948:Limited [Intellectual Product]

Phrase: "was"

Phrase: "used for the percentage of tumor cells,"
Meta Candidates (Total=18; Excluded=7; Pruned=0; Remaining=11)
   778   C0431085:Tumor cells [Cell]
   757   C1524063:Use of [Functional Concept]
   748   C0007634:Cells [Cell]
   748   C0027651:Tumor [Neoplastic Process]
   748   C0439165:Percentage [Quantitative Concept]
   748   C1273517:used [Finding]
   748   C1549488:Percentage [Idea or Concept]
   748   C1561533:Percentage [Idea or Concept]
   748   C1578706:Tumor [Intellectual Product]
   748   C3273930:Tumor [Finding]
   748   C3282337:Cells [Cell]
   745 E C0597032:Tumor Cell [Cell]
   714 E C0042153:use [Functional Concept]
   714 E C0457083:Use [Functional Concept]
   714 E C1269647:Cell [Cell]
   714 E C1704653:Cell [Medical Device]
   714 E C1947944:Use [Intellectual Product]
   714 E C1948049:Cell [Spatial Concept]

Phrase: "after"

Phrase: "CD34 selection in the calculations."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0036576:selection [Genetic Function]
Processing 00000000.tx.160: Thus, the mean and median log depletion of tumor cells may be underestimated. 

Phrase: "Thus,"

Phrase: "the mean"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0444504:Mean [Quantitative Concept]
  1000   C2347634:Mean [Quantitative Concept]
  1000   C2348143:Mean [Quantitative Concept]

Phrase: "and"

Phrase: "median log depletion of tumor cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0333668:Depletion [Functional Concept]

Phrase: "may"

Phrase: "be"

Phrase: "underestimated."
Processing 00000000.tx.161: A median 3.10log (mean, 3.29log) depletion of tumor cells was achieved by the CEPRATE SC System in the selected arm (range, 1.56to 6.02logs). 

Phrase: "A median 3.10log"

Phrase: "(mean,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0444504:Mean [Quantitative Concept]
  1000   C2347634:Mean [Quantitative Concept]
  1000   C2348143:Mean [Quantitative Concept]

Phrase: "3.29log"

Phrase: ")"

Phrase: "depletion of tumor cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0333668:Depletion [Functional Concept]

Phrase: "was"

Phrase: "achieved by the CEPRATE SC System"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   778   C0038250:Stem cell [Cell]
   748   C0007634:Cell [Cell]
   748   C0242767:Stem [Plant]
   748   C0449913:System [Functional Concept]
   748   C1186763:Stem [Body Part, Organ, or Organ Component]
   748   C1269647:Cell [Cell]
   748   C1553451:System [Manufactured Object]
   748   C1704459:System [Medical Device]
   748   C1704653:Cell [Medical Device]
   748   C1948049:Cell [Spatial Concept]

Phrase: "in the selected arm (range,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1514721:Range [Quantitative Concept]
   827   C2348147:Range [Quantitative Concept]
   827   C3542016:Range [Intellectual Product]

Phrase: "1.56to 6.02logs"

Phrase: ")."
Processing 00000000.tx.162: Moreover, the number of tumor cells infused was significantly lower in the selected arm (median, 0; range, 0to 1.2106) compared with the unselected arm (median, 2.3106; range, 0to 930106; Table 3). 

Phrase: "Moreover,"

Phrase: "the number of tumor cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   781   C0007584:Cell Number [Laboratory Procedure]
   760   C0237753:*Number [Quantitative Concept]
   760   C0449788:Number [Quantitative Concept]

Phrase: "infused"

Phrase: "was"

Phrase: "significantly lower in the selected arm (median,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0441994:Lower [Spatial Concept]
   748   C1548802:Lower [Body Location or Region]
   748   C2003888:Lower [Activity]

Phrase: "0"

Phrase: "; range,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1514721:Range [Quantitative Concept]
  1000   C2348147:Range [Quantitative Concept]
  1000   C3542016:Range [Intellectual Product]

Phrase: "0to 1.2106"

Phrase: ")"

Phrase: "compared with the unselected arm (median,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   753   C0446516:Arm [Body Location or Region]
   753   C0549183:Median [Spatial Concept]
   753   C0876920:Median [Quantitative Concept]
   753   C1269078:Arm [Body Part, Organ, or Organ Component]
   753   C1269612:Arm [Body Location or Region]
   753   C1707455:Compared [Activity]
   753   C2347635:Median [Quantitative Concept]
   753   C2348144:Median [Quantitative Concept]
   753   C2939193:Median [Spatial Concept]

Phrase: "2.3106"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0740116:+2 [Quantitative Concept]
   861   C2827735:2+ [Quantitative Concept]
   861   C2981700:2+ [Classification]

Phrase: "; range,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1514721:Range [Quantitative Concept]
  1000   C2348147:Range [Quantitative Concept]
  1000   C3542016:Range [Intellectual Product]

Phrase: "0to 930106"

Phrase: "; Table 3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.163: Overall, the number of patients who received an autograft with no detectable tumor cells was also significantly greater in the selected arm (54% v 21%, P=.036; Table 4).  

Phrase: "Overall,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0282416:Overall [Intellectual Product]
  1000   C1561607:Overall [Qualitative Concept]

Phrase: "the number of patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   909   C2360800:Number of patients [Finding]
   802   C1830427:Patient number [Intellectual Product]
   770   C0237753:*Number [Quantitative Concept]
   770   C0449788:Number [Quantitative Concept]

Phrase: "who"

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "an autograft with no detectable tumor cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0040736:autograft [Therapeutic or Preventive Procedure]

Phrase: "was"

Phrase: "also significantly greater in the selected arm (54% v 21%,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   739   C0443228:greater [Quantitative Concept]
   739   C1704243:Greater [Quantitative Concept]
   706 E C0549177:Great [Quantitative Concept]

Phrase: "P=.036"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: "; Table 4"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.164: View this table: [in this window] [in a new window]  Table 3. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 3."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.165: Reduction in Number of Tumor Cells View larger version (30K): [in this window] [in a new window]  Fig 2. 

Phrase: "Reduction in Number of Tumor Cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0301630:Reduction [Natural Phenomenon or Process]
   753   C0392756:Reduction [Qualitative Concept]
   753   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(30K"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1413114:30K [Gene or Genome]

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Fig 2."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]
Processing 00000000.tx.166: Depletion of tumor cells from first leukapheresis. 

Phrase: "Depletion of tumor cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0333668:Depletion [Functional Concept]

Phrase: "from first leukapheresis."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]
Processing 00000000.tx.167: Tumor contamination was determined in the PBPC product before and after CD34 selection. 

Phrase: "Tumor contamination"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0259846:contamination [Human-caused Phenomenon or Process]
   861   C1881659:CONTAMINATION [Event]
   861   C2349974:Contamination [Idea or Concept]

Phrase: "was"

Phrase: "determined in the PBPC product"
Meta Candidates (Total=20; Excluded=5; Pruned=0; Remaining=15)
   776   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   770   C0038250:Progenitor Cells [Cell]
   770   C0229664:peripheral blood [Body Substance]
           Blood
   767   C0456388:Blood product [Pharmacologic Substance]
   767   C1547007:Blood product [Idea or Concept]
   744   C0005767:Blood [Tissue]
   744   C0005768:blood [Body Substance]
   744   C0007634:Cells [Cell]
   744   C0205100:Peripheral [Spatial Concept]
   744   C0870134:Progenitor [Family Group]
   744   C1514468:product [Entity]
   744   C1704444:Product [Quantitative Concept]
   744   C3282337:Cells [Cell]
   729 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   722 E C2328697:Hemal cell [Cell]
   711 E C1269647:Cell [Cell]
   711 E C1704653:Cell [Medical Device]
   711 E C1948049:Cell [Spatial Concept]

Phrase: "before"

Phrase: "and after CD34 selection."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0036576:selection [Genetic Function]
   770   C1515981:And [Idea or Concept]
   770   C3538723:CD34 [Laboratory Procedure]
Processing 00000000.tx.168: The number of tumor cells was calculated as the product of the total number of nucleated cells and the percentage of tumor cells detected. 

Phrase: "The number of tumor cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   781   C0007584:Cell Number [Laboratory Procedure]
   760   C0237753:*Number [Quantitative Concept]
   760   C0449788:Number [Quantitative Concept]

Phrase: "was"

Phrase: "calculated as the product of the total number of nucleated cells"
Meta Candidates (Total=18; Excluded=3; Pruned=0; Remaining=15)
   756   C1180059:Nucleated cells [Cell]
   754   C1441375:Cells.total [Cell]
   738   C0007634:Cells [Cell]
   738   C0237753:*Number [Quantitative Concept]
   738   C0439175:% total [Quantitative Concept]
   738   C0439810:Total [Qualitative Concept]
   738   C0444686:Calculated [Functional Concept]
   738   C0449788:Number [Quantitative Concept]
   738   C1441506:Calculated [Activity]
   738   C1443182:Calculated [Laboratory Procedure]
   738   C1514468:product [Entity]
   738   C1704444:Product [Quantitative Concept]
   738   C1979936:Nucleated [Qualitative Concept]
   738   C3282337:Cells [Cell]
   737   C0007584:Cell Number [Laboratory Procedure]
   704 E C1269647:Cell [Cell]
   704 E C1704653:Cell [Medical Device]
   704 E C1948049:Cell [Spatial Concept]

Phrase: "and"

Phrase: "the percentage of tumor cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0439165:Percentage [Quantitative Concept]
   760   C1549488:Percentage [Idea or Concept]
   760   C1561533:Percentage [Idea or Concept]

Phrase: "detected."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0442726:Detected [Finding]
  1000   C1511790:Detected [Therapeutic or Preventive Procedure]
Processing 00000000.tx.169: The figure represents the log number of tumor cells detected in the 24of 28patients (86%) in the CD34-selected arm with detectable tumor cells in the first leukapheresis. 

Phrase: "The figure"

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "the log number of tumor cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   767   C0007584:Cell Number [Laboratory Procedure]
   753   C0237753:*Number [Quantitative Concept]
   753   C0449788:Number [Quantitative Concept]

Phrase: "detected in the 24of 28patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0442726:Detected [Finding]
   760   C1511790:Detected [Therapeutic or Preventive Procedure]

Phrase: "(86%"

Phrase: ")"

Phrase: "in the CD34-selected arm"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   827   C0446516:Arm [Body Location or Region]
   827   C1269078:Arm [Body Part, Organ, or Organ Component]
   827   C1269612:Arm [Body Location or Region]
   771 E C0445456:Brachial [Spatial Concept]
   743 E C0206655:ARMS [Neoplastic Process]
   743 E C2681631:ARMS [Gene or Genome]

Phrase: "with detectable tumor cells"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   901   C0431085:Tumor cells [Cell]
   867 E C0597032:Tumor Cell [Cell]
   827   C0007634:Cells [Cell]
   827   C0027651:Tumor [Neoplastic Process]
   827   C1578706:Tumor [Intellectual Product]
   827   C3273930:Tumor [Finding]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "in the first leukapheresis."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]
Processing 00000000.tx.170: For those products purged below the detection level of the assay, the line intersects 0on the x-axis (no detectable tumor cells). 

Phrase: "For those products"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1514468:Products [Entity]
   966 E C1704444:Product [Quantitative Concept]

Phrase: "purged below the detection level of the assay,"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   744   C0005507:Assay [Laboratory Procedure]
   744   C0243073:assay [Qualitative Concept]
   744   C0441889:Level [Qualitative Concept]
   744   C0456079:Level [Classification]
   744   C1510438:Assay [Laboratory Procedure]
   744   C1511790:Detection [Therapeutic or Preventive Procedure]
   744   C1547707:Level [Geographic Area]
   744   C1548399:purged [Idea or Concept]
   744   C2946261:Level [Pharmacologic Substance]
   711 E C0722910:Purge [Lipid,Pharmacologic Substance]

Phrase: "the line"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205132:Line [Spatial Concept]
  1000   C1550648:Line [Substance]
  1000   C1552960:Line [Quantitative Concept]

Phrase: "intersects"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1555443:intersect [Idea or Concept]

Phrase: "0on"

Phrase: "the x-axis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0004457:Axis [Body Part, Organ, or Organ Component]
   861   C0999597:Axis [Mammal]
   861   C1522496:Axis [Spatial Concept]

Phrase: "("

Phrase: "no detectable tumor cells"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   901   C0431085:Tumor cells [Cell]
   867 E C0597032:Tumor Cell [Cell]
   827   C0007634:Cells [Cell]
   827   C0027651:Tumor [Neoplastic Process]
   827   C1578706:Tumor [Intellectual Product]
   827   C3273930:Tumor [Finding]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: ")."
Processing 00000000.tx.171: Only 2of the 24patients had their autografts purged of tumor cells by less than 2logs (dashed lines).  

Phrase: "Only 2of"

Phrase: "the 24patients"

Phrase: "had"

Phrase: "their autografts"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0040736:autografts [Therapeutic or Preventive Procedure]
  1000   C0559189:Autografts [Biomedical or Dental Material]

Phrase: "purged of tumor cells"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
   833   C0431085:Tumor cells [Cell]
   799 E C0597032:Tumor Cell [Cell]
   770   C0007634:Cells [Cell]
   770   C0027651:Tumor [Neoplastic Process]
   770   C1548399:purged [Idea or Concept]
   770   C1578706:Tumor [Intellectual Product]
   770   C3273930:Tumor [Finding]
   770   C3282337:Cells [Cell]
   737 E C0722910:Purge [Lipid,Pharmacologic Substance]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]

Phrase: "by less"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439092:less [Intellectual Product]
  1000   C0547044:Less [Qualitative Concept]

Phrase: "than 2logs"

Phrase: "(dashed lines"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0205132:lines [Spatial Concept]
   827 E C1550648:Line [Substance]
   827 E C1552960:Line [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.172: View this table: [in this window] [in a new window]  Table 4. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 4."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.173: Number of Patients With No Detectable Tumor Cells From First Leukapheresis Hematologic recovery and toxicity.  

Phrase: "Number of Patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C2360800:Number of patients [Finding]
   841   C1830427:Patient number [Intellectual Product]
   790   C0237753:*Number [Quantitative Concept]
   790   C0449788:Number [Quantitative Concept]

Phrase: "With No Detectable Tumor Cells"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   901   C0431085:Tumor cells [Cell]
   867 E C0597032:Tumor Cell [Cell]
   827   C0007634:Cells [Cell]
   827   C0027651:Tumor [Neoplastic Process]
   827   C1578706:Tumor [Intellectual Product]
   827   C3273930:Tumor [Finding]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "From First Leukapheresis Hematologic recovery"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0237820:Recovery [Activity]
   812   C1555688:recovery [Idea or Concept]
   812   C2004454:Recovery [Organism Function]

Phrase: "and"

Phrase: "toxicity."
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0040539:toxicity [Qualitative Concept]
  1000   C0600688:Toxicity [Injury or Poisoning]
   928 E C1407029:Toxic [Qualitative Concept]
   907 E C0032346:Poison [Hazardous or Poisonous Substance]
   907 E C1548769:Poison [Intellectual Product]
   907 E C1550590:poison [Idea or Concept]
Processing 00000000.tx.174: Successful neutrophil engraftment (ANC 500/L) by day 14was achieved by 63of 67patients (94%) in the selected arm and all 64patients in the unselected arm. 

Phrase: "Successful neutrophil engraftment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C1882078:Neutrophil Engraftment [Finding]
   827   C0301944:Engraftment [Physiologic Function]

Phrase: "(ANC 500/L) by day 14was"

Phrase: "achieved by 63of 67patients"

Phrase: "(94%"

Phrase: ")"

Phrase: "in the selected arm"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "and"

Phrase: "all 64patients in the unselected arm."
Processing 00000000.tx.175: Three of the 4patients in the selected arm who did not achieve neutrophil engraftment by day 14engrafted on day 15.

Phrase: "Three of the 4patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0205449:Three [Quantitative Concept]

Phrase: "in the selected arm"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "who"

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "achieve"

Phrase: "neutrophil engraftment by day 14engrafted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C1882078:Neutrophil Engraftment [Finding]
   760   C0301944:Engraftment [Physiologic Function]

Phrase: "on day 15."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0332173:/day [Temporal Concept]
   861   C0439228:day [Temporal Concept]
   861   C0439505:/day [Temporal Concept]
Processing 00000000.tx.176: The fourth patient was not transplanted because of an inadequate stem cell collection but was included in the intent-to-treat analysis as an engraftment failure. 

Phrase: "The fourth patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "was"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "transplanted because of an inadequate stem cell collection"
Meta Candidates (Total=15; Excluded=0; Pruned=0; Remaining=15)
   776   C1504389:Stem cell transplant [Therapeutic or Preventive Procedure]
   770   C0038250:Stem cell [Cell]
   750   C0206152:Transplant, Cell [Cell]
   744   C0007634:Cell [Cell]
   744   C0040732:transplanted [Therapeutic or Preventive Procedure]
   744   C0205412:Inadequate [Qualitative Concept]
   744   C0242767:Stem [Plant]
   744   C0332835:transplanted [Tissue]
   744   C0700106:Transplanted [Functional Concept]
   744   C1186763:Stem [Body Part, Organ, or Organ Component]
   744   C1269647:Cell [Cell]
   744   C1516698:Collection [Functional Concept]
   744   C1704653:Cell [Medical Device]
   744   C1704814:Collection [Idea or Concept]
   744   C1948049:Cell [Spatial Concept]

Phrase: "but"

Phrase: "was"

Phrase: "included in the intent-to-"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   760   C0162425:intent [Mental Process]
   760   C0332257:included [Functional Concept]
   760   C1283828:intent [Qualitative Concept]
   760   C1550453:intent [Idea or Concept]
   760   C3538986:INCLUDED [Gene or Genome]
   726 E C1552866:include [Idea or Concept]
   726 E C2700399:Include [Activity]

Phrase: "treat"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1292734:TREAT [Functional Concept]
  1000   C1522326:Treat [Functional Concept]

Phrase: "analysis as an engraftment failure."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0002778:Analysis [Laboratory Procedure]
   760   C0936012:Analysis [Research Activity]
   760   C1524024:analysis [Functional Concept]
Processing 00000000.tx.177: The median time to neutrophil engraftment was 12days for both arms (Table 5).  

Phrase: "The median time to neutrophil engraftment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0040223:Time [Temporal Concept]
   753   C3541383:Time [Temporal Concept]

Phrase: "was"

Phrase: "12days for both arms (Table 5"

Phrase: ")."
Processing 00000000.tx.178: View this table: [in this window] [in a new window]  Table 5. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 5."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.179: Results of Secondary Safety Endpoints Secondary safety endpoints assessed the times to platelet engraftment and recovery as well as RBC and platelet transfusions. 

Phrase: "Results of Secondary Safety Endpoints Secondary safety endpoints"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   711   C1274040:Result [Functional Concept]
   711   C1546471:Result [Idea or Concept]
   711   C2825142:Result [Finding]

Phrase: "assessed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1516048:Assessed [Activity]

Phrase: "the times to platelet engraftment"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   760   C0040223:times [Temporal Concept]
   760   C1632851:Times [Quantitative Concept]
   726 E C3541383:Time [Temporal Concept]

Phrase: "and"

Phrase: "recovery"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237820:Recovery [Activity]
  1000   C1555688:recovery [Idea or Concept]
  1000   C2004454:Recovery [Organism Function]

Phrase: "as well as"

Phrase: "RBC"
Meta Candidates (Total=20; Excluded=8; Pruned=0; Remaining=12)
  1000   C0014792:Red blood cell [Cell]
           Red Cell
   901   C0005773:Blood cell [Cell]
   873 E C2328697:Hemal cell [Cell]
   827   C0005767:Blood [Tissue]
   827   C0005768:blood [Body Substance]
   827   C0007634:Cell [Cell]
   827   C0229664:Blood [Body Substance]
   827   C0332575:Red [Finding]
   827   C1260956:Red [Qualitative Concept]
   827   C1269647:Cell [Cell]
   827   C1704653:Cell [Medical Device]
   827   C1948049:Cell [Spatial Concept]
   755 E C0333275:Bloody [Qualitative Concept]
   743 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   743 E C0392895:Bloods [Population Group]
   743 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   743 E C1511228:VESSEL, BLOOD [Tissue]
   727 E C1558950:VASCULAR [Finding]
   727 E C1801960:Vascular [Qualitative Concept]

Phrase: "and"

Phrase: "platelet transfusions."
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C0086818:Transfusions, Platelet [Therapeutic or Preventive Procedure]
   861   C0005841:Transfusions [Therapeutic or Preventive Procedure]
   861   C0199960:transfusions [Functional Concept]
   861   C1879316:Transfusions [Therapeutic or Preventive Procedure]
   827 E C0455012:Transfusion [Therapeutic or Preventive Procedure]
   777 E C1549003:Transfused [Idea or Concept]
Processing 00000000.tx.180: Although all patients achieved platelet engraftment, the times to platelet engraftment and recovery were statistically significantly longer in the selected arm (median of 11days for both platelet engraftment and recovery) than in the unselected arm (median of 9and 10days for platelet engraftment and recovery, respectively; P=.003and P=.004; Table 5). 

Phrase: "Although"

Phrase: "all patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "achieved"

Phrase: "platelet engraftment,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1882407:Platelet Engraftment [Finding]
   861   C0301944:Engraftment [Physiologic Function]

Phrase: "the times to platelet engraftment"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   760   C0040223:times [Temporal Concept]
   760   C1632851:Times [Quantitative Concept]
   726 E C3541383:Time [Temporal Concept]

Phrase: "and"

Phrase: "recovery"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237820:Recovery [Activity]
  1000   C1555688:recovery [Idea or Concept]
  1000   C2004454:Recovery [Organism Function]

Phrase: "were"

Phrase: "statistically significantly longer in the selected arm (median of 11days"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   741   C0575519:Long arm [Finding]
   716 E C0426866:Arm length [Finding]
   706   C0205166:Long [Qualitative Concept]
   706   C1706317:Long [Qualitative Concept]

Phrase: "for both platelet engraftment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1882407:Platelet Engraftment [Finding]
   861   C0301944:Engraftment [Physiologic Function]

Phrase: "and"

Phrase: "recovery"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237820:Recovery [Activity]
  1000   C1555688:recovery [Idea or Concept]
  1000   C2004454:Recovery [Organism Function]

Phrase: ")"

Phrase: "than"

Phrase: "in the unselected arm (median"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0549183:Median [Spatial Concept]
   827   C0876920:Median [Quantitative Concept]
   827   C2347635:Median [Quantitative Concept]
   827   C2348144:Median [Quantitative Concept]
   827   C2939193:Median [Spatial Concept]

Phrase: "of 9and 10days"

Phrase: "for platelet engraftment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1882407:Platelet Engraftment [Finding]
   861   C0301944:Engraftment [Physiologic Function]

Phrase: "and"

Phrase: "recovery,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237820:Recovery [Activity]
  1000   C1555688:recovery [Idea or Concept]
  1000   C2004454:Recovery [Organism Function]

Phrase: "respectively"

Phrase: "; P=.003and P=.004"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   812   C2603361:P' [Clinical Attribute]

Phrase: "; Table 5"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.181: In addition, the number of platelet transfusion events per patient was significantly greater in the selected arm (median, 3; range, 0to 26) than in the unselected arm (median, 2; range, 0to 24; P=.011; Table 5). 

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "the number of platelet transfusion events"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   783   C0032181:Platelet Number [Laboratory Procedure]
   753   C0237753:*Number [Quantitative Concept]
   753   C0449788:Number [Quantitative Concept]

Phrase: "per patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:*^patient [Patient or Disabled Group]

Phrase: "was"

Phrase: "significantly greater in the selected arm (median,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   748   C0443228:greater [Quantitative Concept]
   748   C1704243:Greater [Quantitative Concept]
   714 E C0549177:Great [Quantitative Concept]

Phrase: "3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "; range,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1514721:Range [Quantitative Concept]
  1000   C2348147:Range [Quantitative Concept]
  1000   C3542016:Range [Intellectual Product]

Phrase: "0to 26"

Phrase: ")"

Phrase: "than"

Phrase: "in the unselected arm (median,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0549183:Median [Spatial Concept]
   827   C0876920:Median [Quantitative Concept]
   827   C2347635:Median [Quantitative Concept]
   827   C2348144:Median [Quantitative Concept]
   827   C2939193:Median [Spatial Concept]

Phrase: "2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "; range,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1514721:Range [Quantitative Concept]
  1000   C2348147:Range [Quantitative Concept]
  1000   C3542016:Range [Intellectual Product]

Phrase: "0to 24"

Phrase: "; P=.011"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: "; Table 5"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.182: The median number of RBC transfusions was comparable for both arms (median, 4U; P=.21; Table 5). 

Phrase: "The median number of RBC transfusions"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   793   C0005771:Blood Cell Number [Laboratory Procedure]
   767   C0007584:Cell Number [Laboratory Procedure]
   744   C0237753:*Number [Quantitative Concept]
   744   C0449788:Number [Quantitative Concept]

Phrase: "was"

Phrase: "comparable for both arms (median,"

Phrase: "4U"

Phrase: "; P=.21"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: "; Table 5"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.183: Multiple regression analysis of factors potentially influencing the time to platelet engraftment and recovery showed that the number of CD34+ cells per kilogram in the infused product and the platelet count at the time of randomization had significant (P.01) effects on both platelet engraftment and recovery. 

Phrase: "Multiple regression analysis of factors potentially"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0034980:Regression Analysis [Intellectual Product]
   783   C0085801:analysis factors [Quantitative Concept]
   753   C0002778:Analysis [Laboratory Procedure]
   753   C0936012:Analysis [Research Activity]
   753   C1524024:analysis [Functional Concept]

Phrase: "influencing"

Phrase: "the time to platelet engraftment"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   760   C0040223:Time [Temporal Concept]
   760   C3541383:Time [Temporal Concept]
   704 E C0442043:Temporal [Spatial Concept]
   704 E C2362314:Temporal [Temporal Concept]

Phrase: "and"

Phrase: "recovery"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237820:Recovery [Activity]
  1000   C1555688:recovery [Idea or Concept]
  1000   C2004454:Recovery [Organism Function]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that"

Phrase: "the number of CD34+ cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   781   C0007584:Cell Number [Laboratory Procedure]
   760   C0237753:*Number [Quantitative Concept]
   760   C0449788:Number [Quantitative Concept]

Phrase: "per kilogram"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439209:Kilogram [Quantitative Concept]

Phrase: "in the infused product"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1514468:product [Entity]
   861   C1704444:Product [Quantitative Concept]

Phrase: "and"

Phrase: "the platelet count at the time of randomization"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0032181:Platelet Count [Laboratory Procedure]
   770   C1287267:Platelet count [Laboratory or Test Result]
   744   C0005821:Platelet [Cell]
   744   C0750480:Count [Activity]
   744   C1705566:Count [Quantitative Concept]

Phrase: "had"

Phrase: "significant"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237881:significant [Quantitative Concept]
  1000   C0750502:Significant [Idea or Concept]
  1000   C1546944:Significant [Qualitative Concept]

Phrase: "(P.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: ")"

Phrase: "effects on both platelet engraftment"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C1280500:effects [Qualitative Concept]
   726 E C2348382:Effect [Qualitative Concept]

Phrase: "and"

Phrase: "recovery."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237820:Recovery [Activity]
  1000   C1555688:recovery [Idea or Concept]
  1000   C2004454:Recovery [Organism Function]
Processing 00000000.tx.184: Additionally, the WBC count at the premobilization visit had a significant (P=.048) effect on time to platelet engraftment. 

Phrase: "Additionally,"

Phrase: "the WBC count at the premobilization visit"
Meta Candidates (Total=22; Excluded=1; Pruned=0; Remaining=21)
   818   C0023508:Blood Cell Count, White [Laboratory Procedure]
   818   C0427512:white blood cell count [Laboratory or Test Result]
   790   C0005771:Blood Cell Count [Laboratory Procedure]
   790   C0009555:Blood Cell Count [Laboratory Procedure]
   790   C0023516:White blood cell [Cell]
           White Cell
   764   C0005773:Blood cell [Cell]
   764   C0007584:Cell Count [Laboratory Procedure]
   762   C0007634:THE CELL [Cell]
           Cell
   742   C0005767:Blood [Tissue]
   742   C0005768:blood [Body Substance]
   742   C0007457:White [Population Group]
   742   C0043157:White [Population Group]
   742   C0220938:White [Qualitative Concept]
   742   C0229664:Blood [Body Substance]
   742   C0750480:Count [Activity]
   742   C1269647:Cell [Cell]
   742   C1704653:Cell [Medical Device]
   742   C1705566:Count [Quantitative Concept]
   742   C1948049:Cell [Spatial Concept]
   736 E C2328697:Hemal cell [Cell]

Phrase: "had"

Phrase: "a significant"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237881:significant [Quantitative Concept]
  1000   C0750502:Significant [Idea or Concept]
  1000   C1546944:Significant [Qualitative Concept]

Phrase: "(P=.048"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: ")"

Phrase: "effect on time"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1280500:Effect [Qualitative Concept]
   790   C2348382:Effect [Qualitative Concept]

Phrase: "to platelet engraftment."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1882407:Platelet Engraftment [Finding]
   861   C0301944:Engraftment [Physiologic Function]
Processing 00000000.tx.185: Both platelet count and WBC count at randomization were significantly lower in the selected arm compared with the unselected arm. 

Phrase: "Both platelet count"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0032181:Platelet Count [Laboratory Procedure]
  1000   C1287267:Platelet count [Laboratory or Test Result]
   861   C0005821:Platelet [Cell]
   861   C0750480:Count [Activity]
   861   C1705566:Count [Quantitative Concept]
   777 E C1963076:Platelets [Finding]

Phrase: "and"

Phrase: "WBC count at randomization"
Meta Candidates (Total=21; Excluded=1; Pruned=0; Remaining=20)
   882   C0023508:Blood Cell Count, White [Laboratory Procedure]
   882   C0427512:white blood cell count [Laboratory or Test Result]
   833   C0005771:Blood Cell Count [Laboratory Procedure]
   833   C0009555:Blood Cell Count [Laboratory Procedure]
   833   C0023516:White blood cell [Cell]
           White Cell
   790   C0005773:Blood cell [Cell]
   790   C0007584:Cell Count [Laboratory Procedure]
   762 E C2328697:Hemal cell [Cell]
   753   C0005767:Blood [Tissue]
   753   C0005768:blood [Body Substance]
   753   C0007457:White [Population Group]
   753   C0007634:Cell [Cell]
   753   C0043157:White [Population Group]
   753   C0220938:White [Qualitative Concept]
   753   C0229664:Blood [Body Substance]
   753   C0750480:Count [Activity]
   753   C1269647:Cell [Cell]
   753   C1704653:Cell [Medical Device]
   753   C1705566:Count [Quantitative Concept]
   753   C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "significantly lower in the selected arm"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0441994:Lower [Spatial Concept]
   753   C1548802:Lower [Body Location or Region]
   753   C2003888:Lower [Activity]

Phrase: "compared with the unselected arm."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   760   C0446516:Arm [Body Location or Region]
   760   C1269078:Arm [Body Part, Organ, or Organ Component]
   760   C1269612:Arm [Body Location or Region]
   760   C1707455:Compared [Activity]
   704 E C0445456:Brachial [Spatial Concept]
Processing 00000000.tx.186: When the 108patients (55in the selected arm and 53in the unselected arm) who received a dose of at least 2.0106 CD34+ cells/kg (target dose suggested by protocol and based on the phase I/II study15) were compared, there were no significant differences between the arms in time to platelet engraftment (Fig 3), time to platelet recovery, or number of platelet transfusion events. 

Phrase: "When"

Phrase: "the 108patients"

Phrase: "(55in"

Phrase: "the selected arm"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "and"

Phrase: "53in"

Phrase: "the unselected arm)"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "who"

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "a dose of"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0178602:Dose [Quantitative Concept]
   790   C0869039:Dose [Quantitative Concept]
   790   C1114758:Dose # [Clinical Attribute]

Phrase: "at least 2.0106 CD34+ cells/kg (target dose"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   793   C0178602:Dose [Quantitative Concept]
   793   C0869039:Dose [Quantitative Concept]
   793   C1114758:Dose # [Clinical Attribute]

Phrase: "suggested by protocol"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0442711:Protocol [Intellectual Product]
   790   C1507394:Protocol [Intellectual Product]
   790   C1522729:Protocol [Intellectual Product]
   790   C2348563:Protocol [Intellectual Product]
   756   C1705535:Suggest [Idea or Concept]

Phrase: "and"

Phrase: "based on the phase I/II study15"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   748   C0021966:I- [Inorganic Chemical]
   748   C0205390:Phase [Temporal Concept]
   748   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   748   C1527178:Based [Functional Concept]
   748   C1705938:Based [Idea or Concept]
   714 E C0002055:base [Inorganic Chemical]
   714 E C0178499:Base [Chemical Viewed Functionally]
   714 E C1880279:Base [Biomedical or Dental Material]

Phrase: ")"

Phrase: "were"

Phrase: "compared"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compared [Activity]

Phrase: ","

Phrase: "there"

Phrase: "were"

Phrase: "no significant differences between the arms"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   719   C1705241:*Difference [Quantitative Concept]
   719   C1705242:Difference [Qualitative Concept]

Phrase: "in time"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0040223:Time [Temporal Concept]
  1000   C3541383:Time [Temporal Concept]
   944 E C0442043:Temporal [Spatial Concept]
   944 E C2362314:Temporal [Temporal Concept]
   916 E C1632851:Times [Quantitative Concept]

Phrase: "to platelet engraftment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1882407:Platelet Engraftment [Finding]
   861   C0301944:Engraftment [Physiologic Function]

Phrase: "(Fig 3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")"

Phrase: ","

Phrase: "time to platelet recovery,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C0040223:Time [Temporal Concept]
   770   C3541383:Time [Temporal Concept]
   715 E C0442043:Temporal [Spatial Concept]
   715 E C2362314:Temporal [Temporal Concept]

Phrase: "or"

Phrase: "number of platelet transfusion events."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   797   C0032181:Platelet Number [Laboratory Procedure]
   760   C0237753:*Number [Quantitative Concept]
   760   C0449788:Number [Quantitative Concept]
Processing 00000000.tx.187: View larger version (21K): [in this window] [in a new window]  Fig 3. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(21K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Fig 3."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]
Processing 00000000.tx.188: Kaplan-Meier probability of achieving platelet engraftment for the patients who received at least 2106 CD34+ cells/kg in the infused product. 

Phrase: "Kaplan-Meier probability of achieving platelet engraftment"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0033204:Probability [Quantitative Concept]

Phrase: "for the patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "received at least 2106 CD34+ cells/kg"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   778   C0882849:cd34 cells [Cell]
   748   C0007634:Cells [Cell]
   748   C0022718:KG [Geographic Area]
   748   C0439209:kg [Quantitative Concept]
   748   C1514756:Received [Qualitative Concept]
   748   C3282337:Cells [Cell]
   748   C3538723:CD34 [Laboratory Procedure]
   714 E C1269647:Cell [Cell]
   714 E C1704653:Cell [Medical Device]
   714 E C1948049:Cell [Spatial Concept]

Phrase: "in the infused product."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1514468:product [Entity]
   861   C1704444:Product [Quantitative Concept]
Processing 00000000.tx.189: Of the 130patients infused, the number of CD34+ cells per kilogram was not assessed in 5patients and were less than 2106 CD34+ cells/kg for 17patients. 

Phrase: "Of the 130patients"

Phrase: "infused"

Phrase: ","

Phrase: "the number of CD34+ cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   781   C0007584:Cell Number [Laboratory Procedure]
   760   C0237753:*Number [Quantitative Concept]
   760   C0449788:Number [Quantitative Concept]

Phrase: "per kilogram"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439209:Kilogram [Quantitative Concept]

Phrase: "was"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "assessed in 5patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1516048:Assessed [Activity]

Phrase: "and"

Phrase: "were"

Phrase: "less than 2106 CD34+ cells/kg"
Meta Candidates (Total=12; Excluded=3; Pruned=0; Remaining=9)
   790   C0439092:Less Than [Intellectual Product]
           less
   790   C0882849:cd34 cells [Cell]
   753   C0007634:Cells [Cell]
   753   C0022718:KG [Geographic Area]
   753   C0439209:kg [Quantitative Concept]
   753   C0547044:Less [Qualitative Concept]
   753   C3282337:Cells [Cell]
   753   C3538723:CD34 [Laboratory Procedure]
   719 E C1269647:Cell [Cell]
   719 E C1704653:Cell [Medical Device]
   719 E C1948049:Cell [Spatial Concept]

Phrase: "for 17patients."
Processing 00000000.tx.190: For the remaining 108patients with at least 2106 CD34+ cells/kg infused, probabilities of the time to achieve platelet engraftment (transfusion independence) were the same for the unselected arm (n =53) and the selected arm (n =55). 

Phrase: "For the remaining 108patients"

Phrase: "with"

Phrase: "at least 2106 CD34+ cells/kg"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0022718:KG [Geographic Area]
   804   C0439209:kg [Quantitative Concept]

Phrase: "infused"

Phrase: ","

Phrase: "probabilities of the time to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0033204:Probabilities [Quantitative Concept]

Phrase: "achieve"

Phrase: "platelet engraftment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1882407:Platelet Engraftment [Finding]
   861   C0301944:Engraftment [Physiologic Function]

Phrase: "(transfusion independence"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0085862:Independence [Idea or Concept]
   789 E C1299583:Independent [Finding]
   761 E C0599749:independency [Mental Process]

Phrase: ")"

Phrase: "were"

Phrase: "the same for the unselected arm (n =53"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0445247:Same [Qualitative Concept]

Phrase: ")"

Phrase: "and"

Phrase: "the selected arm (n =55"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   812   C0446516:Arm [Body Location or Region]
   812   C0450382:55 [Intellectual Product]
   812   C1269078:Arm [Body Part, Organ, or Organ Component]
   812   C1269612:Arm [Body Location or Region]
   779   C1707391:Select [Activity]
   756 E C0445456:Brachial [Spatial Concept]
   729 E C0206655:ARMS [Neoplastic Process]
   729 E C2681631:ARMS [Gene or Genome]

Phrase: ")."
Processing 00000000.tx.191: Similar results occurred for the probabilities of the time to achieve platelet recovery. 

Phrase: "Similar results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1274040:Result [Functional Concept]
   827   C1546471:Result [Idea or Concept]
   827   C2825142:Result [Finding]

Phrase: "occurred for the probabilities of the time to"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   744   C0033204:Probabilities [Quantitative Concept]
   744   C0040223:Time [Temporal Concept]
   744   C1709305:Occurred [Activity]
   744   C3541383:Time [Temporal Concept]
   711 E C2745955:OCCUR [Temporal Concept]

Phrase: "achieve"

Phrase: "platelet recovery."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0237820:Recovery [Activity]
   861   C1555688:recovery [Idea or Concept]
   861   C2004454:Recovery [Organism Function]
Processing 00000000.tx.192: Adverse events.  

Phrase: "Adverse events."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0877248:adverse events [Finding]
  1000   C1705413:Adverse Events [Idea or Concept]
   861   C0441471:Events [Event]
   861   C3541888:Events [Classification]
Processing 00000000.tx.193: The percentage of patients with at least one episode of hypertension during the 24-hour posttransplant period was significantly higher in the unselected arm (53%) than in the selected arm (33%; P=.023). 

Phrase: "The percentage of patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0439165:Percentage [Quantitative Concept]
   770   C1549488:Percentage [Idea or Concept]
   770   C1561533:Percentage [Idea or Concept]

Phrase: "with"

Phrase: "at least one episode"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0332189:Episode [Temporal Concept]

Phrase: "of hypertension"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0020538:Hypertension [Disease or Syndrome]
  1000   C1963138:Hypertension [Finding]

Phrase: "during the 24-hour posttransplant period"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   812   C0439531:/period [Temporal Concept]
   812   C1948053:Period [Temporal Concept]
   741 E C0332182:Periodic [Temporal Concept]
   741 E C1706381:PERIODIC [Intellectual Product]
   712 E C0031084:Periodicities [Temporal Concept]

Phrase: "was"

Phrase: "significantly higher in the unselected arm (53%"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   714   C0205250:High [Qualitative Concept]
   714   C1299351:High [Qualitative Concept]
   714   C2700149:HIGH [Intellectual Product]

Phrase: ")"

Phrase: "than"

Phrase: "in the selected arm (33%"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   827   C0446516:Arm [Body Location or Region]
   827   C1269078:Arm [Body Part, Organ, or Organ Component]
   827   C1269612:Arm [Body Location or Region]
   793   C1707391:Select [Activity]
   771 E C0445456:Brachial [Spatial Concept]
   743 E C0206655:ARMS [Neoplastic Process]
   743 E C2681631:ARMS [Gene or Genome]

Phrase: "; P=.023"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.194: The percentage of patients with at least one episode of bradycardia during the 24-hour posttransplant period was higher in the unselected arm (9%) compared with the selected arm (2%; P=.060). 

Phrase: "The percentage of patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0439165:Percentage [Quantitative Concept]
   770   C1549488:Percentage [Idea or Concept]
   770   C1561533:Percentage [Idea or Concept]

Phrase: "with"

Phrase: "at least one episode"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0332189:Episode [Temporal Concept]

Phrase: "of bradycardia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0428977:Bradycardia [Pathologic Function]

Phrase: "during the 24-hour posttransplant period"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   812   C0439531:/period [Temporal Concept]
   812   C1948053:Period [Temporal Concept]
   741 E C0332182:Periodic [Temporal Concept]
   741 E C1706381:PERIODIC [Intellectual Product]
   712 E C0031084:Periodicities [Temporal Concept]

Phrase: "was"

Phrase: "higher in the unselected arm (9%"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   719   C0205250:High [Qualitative Concept]
   719   C1299351:High [Qualitative Concept]
   719   C2700149:HIGH [Intellectual Product]

Phrase: ")"

Phrase: "compared with the selected arm (2%"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0446516:Arm [Body Location or Region]
   753   C1269078:Arm [Body Part, Organ, or Organ Component]
   753   C1269612:Arm [Body Location or Region]
   753   C1707455:Compared [Activity]
   719   C1707391:Select [Activity]

Phrase: "; P=.060"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.195: Other than these two specific events, the incidence of adverse events was similar between the arms. 

Phrase: "Other than these two specific events,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0441471:Events [Event]
   827   C3541888:Events [Classification]

Phrase: "the incidence of adverse events"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0021149:Incidence [Quantitative Concept]
   760   C0220856:incidence [Functional Concept]

Phrase: "was"

Phrase: "similar between the arms."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C2348205:Similar [Qualitative Concept]
Processing 00000000.tx.196: No significant differences were detected between the treatment arms for days of posttransplant hospitalization, percentage of patients rehospitalized, days of rehospitalization, the percentage of patients with at least one bleeding event, or number of bleeding events (Table 5). 

Phrase: "No significant differences"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C1705241:*Difference [Quantitative Concept]
   827   C1705242:Difference [Qualitative Concept]
   777 E C0443199:Differential [Qualitative Concept]

Phrase: "were"

Phrase: "detected between the treatment arms"
Meta Candidates (Total=15; Excluded=1; Pruned=0; Remaining=14)
   806   C1522541:Treatment Arm [Research Activity]
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C0206655:ARMS [Neoplastic Process]
   760   C0442726:Detected [Finding]
   760   C0446516:Arm [Body Location or Region]
   760   C1269078:Arm [Body Part, Organ, or Organ Component]
   760   C1269612:Arm [Body Location or Region]
   760   C1511790:Detected [Therapeutic or Preventive Procedure]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C2681631:ARMS [Gene or Genome]
   760   C3538994:TREATMENT [Research Activity]
   704 E C0445456:Brachial [Spatial Concept]

Phrase: "for days"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0439228:days [Temporal Concept]
   966 E C0332173:/day [Temporal Concept]
   966 E C0439505:/day [Temporal Concept]

Phrase: "of posttransplant hospitalization,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0019993:Hospitalization [Health Care Activity]

Phrase: "percentage of patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0439165:Percentage [Quantitative Concept]
   790   C1549488:Percentage [Idea or Concept]
   790   C1561533:Percentage [Idea or Concept]

Phrase: "rehospitalized"

Phrase: ","

Phrase: "days of rehospitalization,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   790   C0439228:days [Temporal Concept]
   756 E C0332173:/day [Temporal Concept]
   756 E C0439505:/day [Temporal Concept]

Phrase: "the percentage of patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0439165:Percentage [Quantitative Concept]
   770   C1549488:Percentage [Idea or Concept]
   770   C1561533:Percentage [Idea or Concept]

Phrase: "with"

Phrase: "at least one bleeding event,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0441471:Event [Event]

Phrase: "or"

Phrase: "number of bleeding events"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0237753:*Number [Quantitative Concept]
   770   C0449788:Number [Quantitative Concept]

Phrase: "(Table 5"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.197: One patient in the CD34-selected arm received the backup CD34-depleted product on day 119posttransplant due to a failure to achieve platelet recovery, although the patient was platelet transfusion independent. 

Phrase: "One patient in the CD34-selected arm"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0030705:*^patient [Patient or Disabled Group]

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "the backup CD34-depleted product on day 119posttransplant"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1514468:product [Entity]
   744   C1704444:Product [Quantitative Concept]

Phrase: "due to a failure to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0231174:Failure [Functional Concept]
   861   C0680095:failure [Individual Behavior]

Phrase: "achieve"

Phrase: "platelet recovery,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0237820:Recovery [Activity]
   861   C1555688:recovery [Idea or Concept]
   861   C2004454:Recovery [Organism Function]

Phrase: "although"

Phrase: "the patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:*^patient [Patient or Disabled Group]

Phrase: "was"

Phrase: "platelet transfusion"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0086818:Platelet Transfusion [Therapeutic or Preventive Procedure]
   861   C0005841:Transfusion [Therapeutic or Preventive Procedure]
   861   C0199960:Transfusion [Functional Concept]
   861   C0455012:Transfusion [Therapeutic or Preventive Procedure]
   861   C1879316:Transfusion [Therapeutic or Preventive Procedure]
   789 E C1549003:Transfused [Idea or Concept]

Phrase: "independent."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0085862:Independent [Idea or Concept]
  1000   C1299583:Independent [Finding]
Processing 00000000.tx.198: In retrospect, this patient was ineligible for the study due to progressive disease before mobilization and received an autograft containing only 1.7106 CD34+ cells/kg. 

Phrase: "In retrospect,"

Phrase: "this patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:*^patient [Patient or Disabled Group]

Phrase: "was"

Phrase: "ineligible for the study"

Phrase: "due to progressive disease"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
  1000   C0677932:progressive disease [Neoplastic Process]
  1000   C1335499:Progressive Disease [Finding]
  1000   C3539781:Progressive Disease [Disease or Syndrome]
   861   C0012634:Disease [Disease or Syndrome]
   861   C0205329:Progressive [Functional Concept]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "before mobilization"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0185112:Mobilisation [Therapeutic or Preventive Procedure]
  1000   C0300926:mobilization [Functional Concept]

Phrase: "and"

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "an autograft"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0040736:autograft [Therapeutic or Preventive Procedure]
   944 E C0559189:Autotransplant [Biomedical or Dental Material]

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "only 1.7106 CD34+ cells/kg."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C0022718:KG [Geographic Area]
   799   C0439209:kg [Quantitative Concept]
Processing 00000000.tx.199: The platelet count remained less than 20103/L after receipt of the CD34-depleted product. 

Phrase: "The platelet count"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0032181:Platelet Count [Laboratory Procedure]
  1000   C1287267:Platelet count [Laboratory or Test Result]
   861   C0005821:Platelet [Cell]
   861   C0750480:Count [Activity]
   861   C1705566:Count [Quantitative Concept]
   777 E C1963076:Platelets [Finding]

Phrase: "remained"

Phrase: "less than 20103/L"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C0439092:Less Than [Intellectual Product]
           less
   770   C0547044:Less [Qualitative Concept]

Phrase: "after"

Phrase: "receipt of the CD34-depleted product."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0333668:Depleted [Functional Concept]
   753   C1514468:product [Entity]
   753   C1704444:Product [Quantitative Concept]
   753   C3538723:CD34 [Laboratory Procedure]
Processing 00000000.tx.200: Immune reconstitution/infections/hospital days.  

Phrase: "Immune reconstitution/infections/hospital days."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   823   C0587438:hospital day [Health Care Related Organization,Manufactured Object]
   804   C0439228:days [Temporal Concept]
   771 E C0332173:/day [Temporal Concept]
   771 E C0439505:/day [Temporal Concept]
Processing 00000000.tx.201: Patients randomized to the selected arm had a significantly lower baseline CD4/CD8 ratio and this difference persisted posttransplant at the day-100, 6-month, and 1-year time points (Table 6). 

Phrase: "Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "randomized to the selected arm"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   760   C0034656:randomized [Research Activity]
   760   C0446516:Arm [Body Location or Region]
   760   C1269078:Arm [Body Part, Organ, or Organ Component]
   760   C1269612:Arm [Body Location or Region]
   726   C1707391:Select [Activity]
   704 E C0445456:Brachial [Spatial Concept]

Phrase: "had"

Phrase: "a significantly lower baseline CD4/CD8 ratio"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0085115:CD4-CD8 Ratio [Laboratory Procedure]
   799   C0456603:Ratio [Quantitative Concept]
   799   C1547037:Ratio [Intellectual Product]

Phrase: "and"

Phrase: "this difference"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1705241:*Difference [Quantitative Concept]
  1000   C1705242:Difference [Qualitative Concept]
   928 E C0443199:Differential [Qualitative Concept]

Phrase: "persisted"

Phrase: "posttransplant at the day-100,"

Phrase: "6-month,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439231:month [Temporal Concept]
   861   C0439507:/month [Temporal Concept]

Phrase: "and"

Phrase: "1-year time points"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   827   C2348792:Time Point [Temporal Concept]
   812   C0040223:Time [Temporal Concept]
   812   C3541383:Time [Temporal Concept]
   779   C1552961:Point [Quantitative Concept]
   779   C2347617:point [Quantitative Concept]
   756 E C0442043:Temporal [Spatial Concept]
   756 E C2362314:Temporal [Temporal Concept]
   729 E C1632851:Times [Quantitative Concept]

Phrase: "(Table 6"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.202: Although the CD4 lymphocyte count was not significantly different at baseline, it was significantly lower in the selected arm at the day-100 and 6-month visits (211v 298cells/L, P=.003; and 261v 314cells/L, P=.018,respectively). 

Phrase: "Although"

Phrase: "the CD4 lymphocyte count"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0243009:CD4 Lymphocyte Count [Laboratory Procedure]
           CD4 Count
   913   C1561565:CD4 count [Finding]
   901   C0200635:Lymphocyte Count [Laboratory Procedure]
   827   C0750480:Count [Activity]
   827   C1705566:Count [Quantitative Concept]
   734   C0039215:CD4 lymphocyte [Cell]

Phrase: "was"

Phrase: "not significantly different at baseline,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1705242:Different [Qualitative Concept]

Phrase: "it"

Phrase: "was"

Phrase: "significantly lower in the selected arm"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0441994:Lower [Spatial Concept]
   753   C1548802:Lower [Body Location or Region]
   753   C2003888:Lower [Activity]

Phrase: "at the day-100"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0332173:/day [Temporal Concept]
   861   C0439228:day [Temporal Concept]
   861   C0439505:/day [Temporal Concept]

Phrase: "and"

Phrase: "6-month visits"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0545082:Visits [Behavior]
   793 E C1512346:visit [Health Care Activity]
   793 E C2826704:VISIT [Intellectual Product]

Phrase: "(211v 298cells/L,"

Phrase: "P=.003"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: ";"

Phrase: "and"

Phrase: "261v 314cells/L,"

Phrase: "P=.018,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: "respectively"

Phrase: ")."
Processing 00000000.tx.203: By the 1-year visit there was no significant difference in the median CD4+ lymphocyte count between the arms. 

Phrase: "By the 1-year visit there"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0545082:Visit [Behavior]
   812   C1512346:visit [Health Care Activity]
   812   C2826704:VISIT [Intellectual Product]

Phrase: "was"

Phrase: "no significant difference in the median CD4+ lymphocyte count"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C1705241:*Difference [Quantitative Concept]
   742   C1705242:Difference [Qualitative Concept]

Phrase: "between the arms."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0206655:ARMS [Neoplastic Process]
  1000   C0446516:Arm [Body Location or Region]
  1000   C1269078:Arm [Body Part, Organ, or Organ Component]
  1000   C1269612:Arm [Body Location or Region]
  1000   C2681631:ARMS [Gene or Genome]
   944 E C0445456:Brachial [Spatial Concept]
Processing 00000000.tx.204: The median CD3+, CD8+, CD56+, and CD19+ lymphocyte counts were not significantly different between the arms at more than one of the evaluation time points. 

Phrase: "The median CD3+,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3542405:CD3 [Laboratory Procedure]

Phrase: "CD8+,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C3538720:CD8 [Laboratory Procedure]
  1000   C3540595:CD8 [Gene or Genome]

Phrase: "CD56+,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3539926:CD56 [Laboratory Procedure]

Phrase: "and"

Phrase: "CD19+ lymphocyte counts"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   901   C0200635:Lymphocyte Counts [Laboratory Procedure]
   827   C0439157:counts [Quantitative Concept]
   793 E C0750480:Count [Activity]
   793 E C1705566:Count [Quantitative Concept]
   734   C1267886:CD19+ Lymphocyte [Cell]

Phrase: "were"

Phrase: "not significantly different between the arms"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1705242:Different [Qualitative Concept]

Phrase: "at more"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205172:More [Functional Concept]

Phrase: "than one"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205447:One [Quantitative Concept]

Phrase: "of the evaluation time points."
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   867   C2348792:Time Point [Temporal Concept]
   827   C0040223:Time [Temporal Concept]
   827   C3541383:Time [Temporal Concept]
   793   C1552961:Point [Quantitative Concept]
   793   C2347617:point [Quantitative Concept]
   771 E C0442043:Temporal [Spatial Concept]
   771 E C2362314:Temporal [Temporal Concept]
   743 E C1632851:Times [Quantitative Concept]
Processing 00000000.tx.205: There was no significant difference between the selected arm and the unselected arm with respect to IgA, IgM, or IgG levels by the day-100, 6-month, or 1-year visits.  

Phrase: "There"

Phrase: "was"

Phrase: "no significant difference between the selected arm"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1705241:*Difference [Quantitative Concept]
   748   C1705242:Difference [Qualitative Concept]

Phrase: "and"

Phrase: "the unselected arm with respect to IgA,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0446516:Arm [Body Location or Region]
   748   C1269078:Arm [Body Part, Organ, or Organ Component]
   748   C1269612:Arm [Body Location or Region]

Phrase: "IgM,"

Phrase: "or"

Phrase: "IgG levels by the day-100,"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   753   C0441889:Levels [Qualitative Concept]
   719 E C0456079:Level [Classification]
   719 E C1547707:Level [Geographic Area]
   719 E C2946261:Level [Pharmacologic Substance]

Phrase: "6-month,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439231:month [Temporal Concept]
   861   C0439507:/month [Temporal Concept]

Phrase: "or"

Phrase: "1-year visits."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0545082:Visits [Behavior]
   793 E C1512346:visit [Health Care Activity]
   793 E C2826704:VISIT [Intellectual Product]
Processing 00000000.tx.206: View this table: [in this window] [in a new window]  Table 6. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 6."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.207: Differences in Lymphocyte Populations Between the Arms There were no significant differences between the treatment arms in the number of patients with infections or the type of infections during the transplant (day 0to 100) or posttransplant (after day 100) periods and neither were there differences in days of hospitalization (Table 5). 

Phrase: "Differences in Lymphocyte Populations"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   737   C1705241:*Difference [Quantitative Concept]
   737   C1705242:Difference [Qualitative Concept]

Phrase: "Between the Arms There"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   861   C0206655:ARMS [Neoplastic Process]
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   861   C2681631:ARMS [Gene or Genome]
   805 E C0445456:Brachial [Spatial Concept]

Phrase: "were"

Phrase: "no significant differences between the treatment arms"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   714   C1705241:*Difference [Quantitative Concept]
   714   C1705242:Difference [Qualitative Concept]

Phrase: "in the number"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0237753:*Number [Quantitative Concept]
  1000   C0449788:Number [Quantitative Concept]

Phrase: "of patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with infections"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0009450:Infections [Disease or Syndrome]
   916 E C0439663:Infected [Functional Concept]
   884 E C0030657:infectivity [Qualitative Concept]

Phrase: "or"

Phrase: "the type of infections"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   802   C0457463:infection type [Classification]
   770   C0332307:Type [Qualitative Concept]
   770   C1547052:*Type [Quantitative Concept]

Phrase: "during the transplant"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0040732:Transplant [Therapeutic or Preventive Procedure]
  1000   C0332835:Transplant [Tissue]

Phrase: "(day 0to 100"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0332173:/day [Temporal Concept]
   827   C0439228:day [Temporal Concept]
   827   C0439505:/day [Temporal Concept]

Phrase: ")"

Phrase: "or"

Phrase: "posttransplant"

Phrase: "("

Phrase: "after day 100"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0332173:/day [Temporal Concept]
   861   C0439228:day [Temporal Concept]
   861   C0439505:/day [Temporal Concept]

Phrase: ")"

Phrase: "periods"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   966   C0439531:/period [Temporal Concept]
   966   C1948053:Period [Temporal Concept]
   916 E C0332182:Periodic [Temporal Concept]
   916 E C1706381:PERIODIC [Intellectual Product]
   893 E C0031084:Periodicities [Temporal Concept]

Phrase: "and"

Phrase: "neither"

Phrase: "were"

Phrase: "there differences in days of hospitalization"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   719   C1705241:*Difference [Quantitative Concept]
   719   C1705242:Difference [Qualitative Concept]

Phrase: "(Table 5"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.208: Clinical response, progression-free survival, and overall survival.  

Phrase: "Clinical response,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "progression-free survival,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C0242792:Progression-Free Survival [Quantitative Concept]
   827   C0038952:Survival [Activity]
   827   C0220921:survival [Functional Concept]
   827   C0242656:progression [Pathologic Function]
   827   C0332296:free [Functional Concept]
   827   C0449258:Progression [Functional Concept]
   827   C1880497:Free [Qualitative Concept]
   827   C1996904:Free [Qualitative Concept]

Phrase: "and"

Phrase: "overall survival."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0038952:Survival [Activity]
   861   C0220921:survival [Functional Concept]
   861   C0282416:Overall [Intellectual Product]
   861   C1561607:Overall [Qualitative Concept]
Processing 00000000.tx.209: Disease status and survival were assessed at the day-100, 6-month, and 1-year follow-up visits. 

Phrase: "Disease status"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0012634:Disease [Disease or Syndrome]
   861   C0449438:Status [Qualitative Concept]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "and"

Phrase: "survival"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0038952:Survival [Activity]
  1000   C0220921:survival [Functional Concept]

Phrase: "were"

Phrase: "assessed at the day-100,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0332173:/day [Temporal Concept]
   760   C0439228:day [Temporal Concept]
   760   C0439505:/day [Temporal Concept]
   760   C1516048:Assessed [Activity]

Phrase: "6-month,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439231:month [Temporal Concept]
   861   C0439507:/month [Temporal Concept]

Phrase: "and"

Phrase: "1-year follow-up visits."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   884   C0589121:follow up visits [Health Care Activity]
   804   C0545082:Visits [Behavior]
   771 E C1512346:visit [Health Care Activity]
   771 E C2826704:VISIT [Intellectual Product]
Processing 00000000.tx.210: The percentage of patients in complete remission (CR), defined by a lack of detectable monoclonal protein on serum and urine immunoelectrophoresis and less than 5% plasma cells within the bone marrow, was 28% at 1year. 

Phrase: "The percentage of patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0439165:Percentage [Quantitative Concept]
   770   C1549488:Percentage [Idea or Concept]
   770   C1561533:Percentage [Idea or Concept]

Phrase: "in complete remission (CR),"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0677874:Complete Remission [Finding]
   861   C0205197:Complete [Qualitative Concept]
   861   C0544452:Remission [Finding]
   861   C0687702:remission [Neoplastic Process]
   861   C0725685:COMPLEAT [Food]
   789 E C0439812:Completeness [Qualitative Concept]

Phrase: "defined by a lack of detectable monoclonal protein"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   770   C0443737:Monoclonal protein [Amino Acid, Peptide, or Protein,Immunologic Factor]
   770   C0700271:monoclonal protein [Amino Acid, Peptide, or Protein,Immunologic Factor]
   767   C0038164:Protein A [Amino Acid, Peptide, or Protein,Immunologic Factor,Indicator, Reagent, or Diagnostic Aid]
   767 E C1317659:Protein.monoclonal [Laboratory or Test Result]
   744   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   744   C0332268:lack [Qualitative Concept]
   744   C0746619:monoclonal [Finding]
   744   C1704788:Defined [Conceptual Entity]
   744   C3539106:Defined [Intellectual Product]

Phrase: "on serum"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0229671:Serum [Body Substance]
  1000   C1546774:Serum [Intellectual Product]
  1000   C1550100:Serum [Body Substance]

Phrase: "and"

Phrase: "urine immunoelectrophoresis"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0020997:immunoelectrophoresis [Laboratory Procedure]
   805 E C0010214:Counterimmunoelectrophoresis [Laboratory Procedure]

Phrase: "and"

Phrase: "less than 5% plasma cells"
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
   806   C0032112:Plasma Cells [Cell]
   806   C0439092:Less Than [Intellectual Product]
           less
   760   C0007634:Cells [Cell]
   760   C0032105:Plasma [Body Substance]
   760   C0547044:Less [Qualitative Concept]
   760   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]
   760   C3282337:Cells [Cell]
   726 E C1269647:Cell [Cell]
   726 E C1704653:Cell [Medical Device]
   726 E C1948049:Cell [Spatial Concept]

Phrase: "within the bone marrow,"
Meta Candidates (Total=13; Excluded=5; Pruned=0; Remaining=8)
  1000   C0005953:Bone Marrow [Tissue]
   861   C0086590:Marrow [Food]
   861   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   861   C0376152:Marrow [Body Part, Organ, or Organ Component]
   861   C0391978:Bone [Tissue]
   861   C1266908:Bone [Body Part, Organ, or Organ Component]
   861   C1266909:Bone [Body System]
   861   C1546708:Marrow [Intellectual Product]
   805 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   805 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   805 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   789 E C0443157:Bony [Functional Concept]
   777 E C0330477:Marrows [Plant]

Phrase: "was"

Phrase: "28% at 1year."
Processing 00000000.tx.211: At study enrollment, twice as many patients in CR were randomized to receive an unselected transplant (16% v 8%; P=.17). 

Phrase: "At study enrollment,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1516879:Enrollment [Health Care Activity]
   861   C1696073:enrollment [Intellectual Product]

Phrase: "twice as many patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C1720725:Twice [Intellectual Product]
   770   C1948050:Twice [Quantitative Concept]

Phrase: "in CR"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0677874:Complete Remission [Finding]
   861   C0205197:Complete [Qualitative Concept]
   861   C0544452:Remission [Finding]
   861   C0687702:remission [Neoplastic Process]
   861   C0725685:COMPLEAT [Food]
   789 E C0439812:Completeness [Qualitative Concept]

Phrase: "were"

Phrase: "randomized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034656:randomized [Research Activity]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "receive"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Receive [Qualitative Concept]

Phrase: "an unselected transplant"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0040732:Transplant [Therapeutic or Preventive Procedure]
   861   C0332835:Transplant [Tissue]

Phrase: "(16% v 8%"

Phrase: "; P=.17"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.212: This ratio persisted throughout the study with CR rates two to three times as high for patients receiving an unselected product (arm B). 

Phrase: "This ratio"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0456603:Ratio [Quantitative Concept]
  1000   C1547037:Ratio [Intellectual Product]

Phrase: "persisted throughout the study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0557651:Study [Manufactured Object]
   770   C2603343:Study [Research Activity]

Phrase: "with CR rates"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   901   C0677874:Complete Remission [Finding]
   827   C0205197:Complete [Qualitative Concept]
   827   C0544452:Remission [Finding]
   827   C0687702:remission [Neoplastic Process]
   827   C0725685:COMPLEAT [Food]
   793   C0871208:Rate [Activity]
   793   C1521828:Rate [Quantitative Concept]
   755 E C0439812:Completeness [Qualitative Concept]

Phrase: "two to three times"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   819   C1948050:Two Times [Quantitative Concept]
   770   C0205448:Two [Quantitative Concept]

Phrase: "as high"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205250:High [Qualitative Concept]
  1000   C1299351:High [Qualitative Concept]
  1000   C2700149:HIGH [Intellectual Product]

Phrase: "for patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "receiving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514756:Receive [Qualitative Concept]

Phrase: "an unselected product"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1514468:product [Entity]
   861   C1704444:Product [Quantitative Concept]

Phrase: "(arm B"

Phrase: ")."
Processing 00000000.tx.213: The CR rates at day 100,6months, and 1year were 11%, 14%, and 18% for patients on arm A, versus 29%, 35%, and 38% for patients on arm B, respectively, with only the first two time points being statistically significant. 

Phrase: "The CR rates at day 100,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   778   C0677874:Complete Remission [Finding]
   748   C0205197:Complete [Qualitative Concept]
   748   C0544452:Remission [Finding]
   748   C0687702:remission [Neoplastic Process]
   748   C0725685:COMPLEAT [Food]
   714   C0871208:Rate [Activity]
   714   C1521828:Rate [Quantitative Concept]

Phrase: "6months,"

Phrase: "and"

Phrase: "1year"

Phrase: "were"

Phrase: "11%,"

Phrase: "14%,"

Phrase: "and"

Phrase: "18% for patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0030705:Patients [Patient or Disabled Group]

Phrase: "on arm A,"

Phrase: "versus"

Phrase: "29%,"

Phrase: "35%,"

Phrase: "and"

Phrase: "38% for patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0030705:Patients [Patient or Disabled Group]

Phrase: "on arm B,"

Phrase: "respectively,"

Phrase: "with only"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205171:Only [Quantitative Concept]
  1000   C1720467:Only [Intellectual Product]

Phrase: "the first two time points"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C2348792:Time Point [Temporal Concept]
   779   C1552961:Point [Quantitative Concept]
   779   C2347617:point [Quantitative Concept]

Phrase: "being"

Phrase: "statistically significant."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0237881:statistically significant [Quantitative Concept]
           significant
   928 E C1709380:Statistical Significance [Quantitative Concept]
   861   C0038215:Statistically [Occupation or Discipline]
   861   C0750502:Significant [Idea or Concept]
   861   C1546944:Significant [Qualitative Concept]
Processing 00000000.tx.214: There were 2transplant-related deaths before day 100in the unselected arm (infection on day 14and veno-occlusive disease [VOD] on day 68posttransplant) and none in the selected arm. 

Phrase: "There"

Phrase: "were"

Phrase: "2transplant-related deaths before day 100in"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0011065:deaths [Organism Function]
   753   C1306577:DEATHS [Finding]

Phrase: "the unselected arm (infection on day 14and veno-occlusive disease [VOD]"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C0009450:Infection, NOS [Disease or Syndrome]
           Infectious disease

Phrase: "on day 68posttransplant"

Phrase: ")"

Phrase: "and"

Phrase: "none in the selected arm."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   760   C0446516:Arm [Body Location or Region]
   760   C0456148:None [Quantitative Concept]
   760   C0549184:None [Quantitative Concept]
   760   C1269078:Arm [Body Part, Organ, or Organ Component]
   760   C1269612:Arm [Body Location or Region]
   726   C1707391:Select [Activity]
   704 E C0445456:Brachial [Spatial Concept]
Processing 00000000.tx.215: At 1year, 19of 66patients (29%) in the selected arm and 21of 64patients (33%) in the unselected arm had progressed or died. 

Phrase: "At 1year,"

Phrase: "19of 66patients"

Phrase: "(29%"

Phrase: ")"

Phrase: "in the selected arm"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "and"

Phrase: "21of 64patients"

Phrase: "(33%"

Phrase: ")"

Phrase: "in the unselected arm"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "had"

Phrase: "progressed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1272688:progressed [Functional Concept]
   966 E C1280477:Progress [Functional Concept]

Phrase: "or"

Phrase: "died."
Meta Candidates (Total=7; Excluded=5; Pruned=0; Remaining=2)
  1000   C0011065:Died [Organism Function]
  1000   C1546956:Died [Finding]
   928 E C0231800:Expired [Organ or Tissue Function]
   928 E C1704631:Expire [Idea or Concept]
   907 E C0184532:dying [Organism Function]
   907 E C1553404:terminated [Idea or Concept]
   907 E C2348570:Terminated [Functional Concept]
Processing 00000000.tx.216: Although these data remain immature, there is no apparent difference between the two treatment arms with respect to progression-free survival (Fig 4) and overall survival at 1year posttransplant. 

Phrase: "Although"

Phrase: "these data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "remain"

Phrase: "immature, there"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205252:Immature [Temporal Concept]

Phrase: "is"

Phrase: "no apparent difference between the two treatment arms"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1705241:*Difference [Quantitative Concept]
   744   C1705242:Difference [Qualitative Concept]

Phrase: "with respect to progression-free survival"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C0242792:Progression-Free Survival [Quantitative Concept]
   827   C0038952:Survival [Activity]
   827   C0220921:survival [Functional Concept]
   827   C0242656:progression [Pathologic Function]
   827   C0332296:free [Functional Concept]
   827   C0449258:Progression [Functional Concept]
   827   C1880497:Free [Qualitative Concept]
   827   C1996904:Free [Qualitative Concept]

Phrase: "(Fig 4"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")"

Phrase: "and"

Phrase: "overall survival at 1year"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0038952:Survival [Activity]
   770   C0220921:survival [Functional Concept]
   770   C0282416:Overall [Intellectual Product]
   770   C1561607:Overall [Qualitative Concept]

Phrase: "posttransplant."
Processing 00000000.tx.217: View larger version (21K): [in this window] [in a new window]  Fig 4. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(21K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Fig 4."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]
Processing 00000000.tx.218: Kaplan-Meier probability of progression-free survival based on data as of January 1998.

Phrase: "Kaplan-Meier probability of progression-free survival"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0033204:Probability [Quantitative Concept]

Phrase: "based on data"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   841   C0242356:data base [Intellectual Product]
   841   C0993637:Data Base [Intellectual Product]
   790   C1511726:Data [Idea or Concept]
   790   C1527178:Based [Functional Concept]
   790   C1705938:Based [Idea or Concept]
   790   C3245479:data [Medical Device]
   756 E C0002055:base [Inorganic Chemical]
   756 E C0178499:Base [Chemical Viewed Functionally]
   756 E C1880279:Base [Biomedical or Dental Material]

Phrase: "as of January 1998."
Processing 00000000.tx.219: The probabilities of the time to progression as of 1year posttransplant were the same for patients on the unselected arm and the selected arm.  

Phrase: "The probabilities of the time"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0033204:Probabilities [Quantitative Concept]

Phrase: "to progression"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0242656:progression [Pathologic Function]
  1000   C0449258:Progression [Functional Concept]

Phrase: "as of 1year"

Phrase: "posttransplant"

Phrase: "were"

Phrase: "the same for patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0445247:Same [Qualitative Concept]

Phrase: "on the unselected arm"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "and"

Phrase: "the selected arm."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]
Processing 00000000.tx.220: DISCUSSION This study represents the first controlled, randomized phase III trial comparing the use of CD34-selected versus unselected peripheral blood autografts for transplantation in patients undergoing high-dose chemotherapy. 

Phrase: "DISCUSSION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557061:Discussion [Therapeutic or Preventive Procedure]
  1000   C2584313:Discussion [Social Behavior]

Phrase: "This study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "the first"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205435:First [Quantitative Concept]
  1000   C1279901:First [Qualitative Concept]

Phrase: "controlled"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C2587213:Controlled [Functional Concept]
   966 E C0243148:control [Qualitative Concept]
   966 E C1550141:Control [Substance]
   966 E C1882979:Control [Conceptual Entity]
   966 E C3274648:Control [Qualitative Concept]

Phrase: ","

Phrase: "randomized phase III trial"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   923   C0282461:Phase III Trial [Research Activity]
   812   C0008976:Trial [Research Activity]
   812   C0205390:Phase [Temporal Concept]
   812   C0439070:III [Intellectual Product]
   812   C1705160:III [Qualitative Concept]

Phrase: "comparing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1707455:Compare [Activity]

Phrase: "the use of CD34-selected"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C1524063:Use of [Functional Concept]
   760   C0042153:use [Functional Concept]
   760   C0457083:Use [Functional Concept]
   760   C1947944:Use [Intellectual Product]

Phrase: "versus"

Phrase: "unselected peripheral blood autografts for transplantation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0040736:autografts [Therapeutic or Preventive Procedure]
   753   C0559189:Autografts [Biomedical or Dental Material]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "undergoing"

Phrase: "high-dose chemotherapy."
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C1328050:high-dose chemotherapy [Therapeutic or Preventive Procedure]
   901   C0444956:High dose [Quantitative Concept]
   827   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0013217:chemotherapy [Functional Concept]
   827   C0178602:Dose [Quantitative Concept]
   827   C0205250:High [Qualitative Concept]
   827   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0869039:Dose [Quantitative Concept]
   827   C1114758:Dose # [Clinical Attribute]
   827   C1299351:High [Qualitative Concept]
   827   C2700149:HIGH [Intellectual Product]
Processing 00000000.tx.221: Because autografts collected from patients with multiple myeloma,8,15,17,20 breast cancer35, non-Hodgkin's lymphoma,27 and other malignancies have been found to contain malignant cells, methods to remove these undesirable cells have been developed in the hope that such a step could improve patient outcome. 

Phrase: "Because"

Phrase: "autografts"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0040736:autografts [Therapeutic or Preventive Procedure]
  1000   C0559189:Autografts [Biomedical or Dental Material]

Phrase: "collected from patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C1516695:Collected [Idea or Concept]
   790   C1516698:Collected [Functional Concept]

Phrase: "with multiple myeloma,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   861   C0439064:Multiple [Quantitative Concept]
   861   C3538749:Myeloma [Intellectual Product]

Phrase: "8,"

Phrase: "15,"

Phrase: "17,"

Phrase: "20 breast cancer35,"

Phrase: "non-Hodgkin's lymphoma,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0024305:Lymphoma, Non-Hodgkin [Neoplastic Process]
  1000   C2700512:LYMPHOMA, NON-HODGKIN [Gene or Genome]
  1000   C3539720:Non-Hodgkin Lymphoma [Intellectual Product]
   901   C0019829:Hodgkin Lymphoma [Neoplastic Process]
   901   C3541281:Hodgkin Lymphoma [Intellectual Product]
   827   C0024299:Lymphoma [Neoplastic Process]
   827   C1518422:Non [Functional Concept]

Phrase: "27"

Phrase: "and"

Phrase: "other malignancies"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0006826:MALIGNANCIES [Neoplastic Process]
   966 E C1306459:Malignancy [Finding]
   916 E C0205282:Malignant [Qualitative Concept]
   916 E C0334590:MALIGNANT [Neoplastic Process]
   916 E C1533592:MALIGNANT [Neoplastic Process]

Phrase: "have"

Phrase: "been"

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "contain"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:contain [Functional Concept]
  1000   C2700400:Contain [Activity]

Phrase: "malignant cells,"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
  1000   C0334227:Malignant cells [Cell]
  1000   C2698007:Malignant Cells, NOS [Laboratory Procedure]
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "methods to"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0025663:Methods [Intellectual Product]
   861   C0025664:methods [Intellectual Product]
   861   C0449851:Methods [Functional Concept]
   827 E C0871511:METHOD [Intellectual Product]

Phrase: "remove"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0849355:remove [Qualitative Concept]
  1000   C1883720:Remove [Activity]
  1000   C3244314:remove [Functional Concept]

Phrase: "these undesirable cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "have"

Phrase: "been"

Phrase: "developed in the hope"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0392347:Hope [Mental Process]

Phrase: "that"

Phrase: "such a step"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1261552:Step [Conceptual Entity]
  1000   C1704379:Step [Functional Concept]
  1000   C1705117:Step [Quantitative Concept]
  1000   C2825408:Step [Manufactured Object]

Phrase: "could"

Phrase: "improve"

Phrase: "patient outcome."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1547647:Patient Outcome [Idea or Concept]
   861   C1274040:Outcome [Functional Concept]
Processing 00000000.tx.222: Although the contribution of these contaminating cells remains to be definitively determined, recent studies suggest that these cells may promote disease relapse. 

Phrase: "Although"

Phrase: "the contribution of these contaminating cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1880177:Contribution [Activity]

Phrase: "remains"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "definitively"

Phrase: "determined"

Phrase: ","

Phrase: "recent studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "these cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "may"

Phrase: "promote"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promote [Activity]

Phrase: "disease relapse."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0277556:DISEASE RELAPSE [Disease or Syndrome]
           Relapse
   861   C0035020:Relapse [Phenomenon or Process]
   861   C0205336:relapse [Temporal Concept]
Processing 00000000.tx.223: In one study, bone marrow autograft cells collected from patients with acute myeloid leukemia (AML) undergoing high-dose chemotherapy were marked with the neomycin resistance gene. 

Phrase: "In one study,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "bone marrow autograft cells"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   923   C0005955:Bone Marrow Cells [Cell]
   902   C0222677:Bone cells [Cell]
   886 E C0029432:Bone cell [Cell]
   812   C0007634:Cells [Cell]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]
   708   C0440800:bone autograft [Therapeutic or Preventive Procedure]
   708   C1444862:Bone autograft [Tissue]

Phrase: "collected from patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C1516695:Collected [Idea or Concept]
   790   C1516698:Collected [Functional Concept]

Phrase: "with acute myeloid leukemia (AML)"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0023467:Acute myeloid leukaemia [Neoplastic Process]
  1000   C2984331:Acute myeloid leukemia [Functional Concept]
  1000   C3541370:Acute Myeloid Leukemia [Intellectual Product]
   913   C0085669:Acute leukaemia [Neoplastic Process]
   913   C0280141:Acute Leukemia Not Otherwise Specified [Neoplastic Process]
   901   C0023470:Myeloid Leukemia [Neoplastic Process]
   827   C0023418:Leukaemia [Neoplastic Process]
   827   C0205178:acute [Temporal Concept]
   827   C0439677:Myeloid [Qualitative Concept]

Phrase: "undergoing"

Phrase: "high-dose chemotherapy"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C1328050:high-dose chemotherapy [Therapeutic or Preventive Procedure]
   901   C0444956:High dose [Quantitative Concept]
   827   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0013217:chemotherapy [Functional Concept]
   827   C0178602:Dose [Quantitative Concept]
   827   C0205250:High [Qualitative Concept]
   827   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0869039:Dose [Quantitative Concept]
   827   C1114758:Dose # [Clinical Attribute]
   827   C1299351:High [Qualitative Concept]
   827   C2700149:HIGH [Intellectual Product]

Phrase: "were"

Phrase: "marked with the neomycin resistance gene."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   833   C1366752:Neomycin resistance gene [Gene or Genome]
   790   C2945710:resistance gene [Gene or Genome]
   753   C0017337:Gene [Gene or Genome]
   753   C0027603:Neomycin [Antibiotic,Carbohydrate]
   753   C0237834:Resistance [Mental Process]
   753   C0522501:Marked [Qualitative Concept]
   753   C1514892:Resistance [Physiologic Function]
   753   C1706089:Marked [Qualitative Concept]
Processing 00000000.tx.224: Of the 12patients assessed, 4subsequently relapsed and the neomycin resistance gene was detectable within the leukemic cells in 3of these patients (neomycin gene presence was indeterminate in the fourth patient).22 Studies completed by Sharp et al23 demonstrated an increased relapse rate for those patients reinfused with morphologically appearing normal bone marrow but containing clonogenic lymphoma cells after in vitro culture.29 Finally, relapse rates for non-Hodgkin's lymphoma patients were significantly higher for those patients with autografts incompletely purged by the use of anti-B-cell antibodies and complement.24,36 Whereas the results obtained from the latter study could be explained by an inherent property of the malignancy that made tumor purging less effective or simply reflect total body tumor burden, the study of AML patients convincingly demonstrates that malignant cells within the autograft can survive and grow within a patient after reinfusion. 

Phrase: "Of the 12patients"

Phrase: "assessed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1516048:Assessed [Activity]

Phrase: ","

Phrase: "4subsequently"

Phrase: "relapsed"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0205336:relapsed [Temporal Concept]
   966 E C0035020:Relapse [Phenomenon or Process]
   966 E C0277556:Relapse [Disease or Syndrome]

Phrase: "and"

Phrase: "the neomycin resistance gene"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1366752:Neomycin resistance gene [Gene or Genome]
   901   C2945710:resistance gene [Gene or Genome]
   827   C0017337:Gene [Gene or Genome]

Phrase: "was"

Phrase: "detectable within the leukemic cells"

Phrase: "in 3of"

Phrase: "these patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "(neomycin gene presence"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0392148:Presence [Therapeutic or Preventive Procedure]
   755 E C0150312:Present [Quantitative Concept]
   755 E C0449450:Present [Idea or Concept]

Phrase: "was"

Phrase: "indeterminate in the fourth patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0205258:Indeterminate [Idea or Concept]

Phrase: ").22 Studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "completed by Sharp et al23"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0205197:COMPLETED [Qualitative Concept]
   760   C1444775:Sharp [Finding]
   760   C1539835:SHARP [Gene or Genome]

Phrase: "demonstrated"

Phrase: "an increased relapse rate for those patients"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0035020:Relapse [Phenomenon or Process]
   748   C0205336:relapse [Temporal Concept]
   748   C0277556:Relapse [Disease or Syndrome]
   748   C0871208:Rate [Activity]
   748   C1521828:Rate [Quantitative Concept]

Phrase: "reinfused with morphologically"

Phrase: "appearing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0700364:APPEAR [Qualitative Concept]

Phrase: "normal bone marrow"
Meta Candidates (Total=16; Excluded=5; Pruned=0; Remaining=11)
   901   C0005953:Bone Marrow [Tissue]
   827   C0086590:Marrow [Food]
   827   C0205307:Normal [Qualitative Concept]
   827   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   827   C0376152:Marrow [Body Part, Organ, or Organ Component]
   827   C0391978:Bone [Tissue]
   827   C0439166:% normal [Quantitative Concept]
   827   C1266908:Bone [Body Part, Organ, or Organ Component]
   827   C1266909:Bone [Body System]
   827   C1546708:Marrow [Intellectual Product]
   827   C2347086:% Normal [Quantitative Concept]
   771 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   771 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   771 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   755 E C0443157:Bony [Functional Concept]
   743 E C0330477:Marrows [Plant]

Phrase: "but"

Phrase: "containing clonogenic lymphoma cells after in vitro culture.29 Finally,"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   760   C0883208:Lymphoma cells [Cell]
   760   C2697951:Lymphoma Cells [Laboratory Procedure]
   757   C0007585:cells culture [Laboratory Procedure]
   739   C0007634:Cells [Cell]
   739   C3282337:Cells [Cell]
   706 E C1269647:Cell [Cell]
   706 E C1704653:Cell [Medical Device]
   706 E C1948049:Cell [Spatial Concept]

Phrase: "relapse rates for non-Hodgkin's lymphoma patients"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0035020:Relapse [Phenomenon or Process]
   748   C0205336:relapse [Temporal Concept]
   748   C0277556:Relapse [Disease or Syndrome]
   714   C0871208:Rate [Activity]
   714   C1521828:Rate [Quantitative Concept]

Phrase: "were"

Phrase: "significantly higher for those patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   726   C0205250:High [Qualitative Concept]
   726   C1299351:High [Qualitative Concept]
   726   C2700149:HIGH [Intellectual Product]

Phrase: "with autografts incompletely"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0040736:autografts [Therapeutic or Preventive Procedure]
   861   C0559189:Autografts [Biomedical or Dental Material]

Phrase: "purged by the use of anti-B-cell antibodies"
Meta Candidates (Total=19; Excluded=3; Pruned=0; Remaining=16)
   773   C0301850:Anti-B antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
           B cell antibody
   764   C0004561:B-cell [Cell]
   764   C0432618:Anti-B [Amino Acid, Peptide, or Protein,Immunologic Factor]
   764   C1524063:Use of [Functional Concept]
   762   C0368674:antibodies b [Amino Acid, Peptide, or Protein,Immunologic Factor]
   762   C1624602:Anti-Antibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   745 E C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   742   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   742   C0007634:Cell [Cell]
   742   C0042153:use [Functional Concept]
   742   C0457083:Use [Functional Concept]
   742   C1269647:Cell [Cell]
   742   C1548399:purged [Idea or Concept]
   742   C1704653:Cell [Medical Device]
   742   C1947944:Use [Intellectual Product]
   742   C1948049:Cell [Spatial Concept]
   708 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   708 E C0722910:Purge [Lipid,Pharmacologic Substance]

Phrase: "and"

Phrase: "complement.24,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0009498:Complement [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "36"

Phrase: "Whereas"

Phrase: "the results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "obtained from the latter study"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   760   C0557651:Study [Manufactured Object]
   760   C1301820:Obtained [Functional Concept]
   760   C2603343:Study [Research Activity]
   726 E C1706701:Obtain [Activity]

Phrase: "could"

Phrase: "be"

Phrase: "explained by an inherent property of the malignancy"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   744   C0006826:Malignancy [Neoplastic Process]
   744   C0871161:Property [Qualitative Concept]
   744   C1306459:Malignancy [Finding]
   744   C1882134:Property [Conceptual Entity]
   744   C2347695:Property [Entity]

Phrase: "that made tumor purging"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   901   C2348825:Tumor Purging [Therapeutic or Preventive Procedure]
   827   C0855227:purging [Disease or Syndrome]
   793 E C0722910:Purge [Lipid,Pharmacologic Substance]

Phrase: "less effective"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1280519:effective [Qualitative Concept]
   861   C1704419:Effective [Qualitative Concept]

Phrase: "or"

Phrase: "simply"

Phrase: "reflect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0558058:reflect [Mental Process]

Phrase: "total body tumor burden,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   875   C0005884:Body Burden [Quantitative Concept]
   861   C1449699:Tumor Burden [Diagnostic Procedure]
   812   C2828008:Burden [Idea or Concept]

Phrase: "the study of AML patients convincingly"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0557651:Study [Manufactured Object]
   744   C2603343:Study [Research Activity]

Phrase: "demonstrates"

Phrase: "that malignant cells within the autograft"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   790   C0334227:Malignant cells [Cell]
   790   C2698007:Malignant Cells, NOS [Laboratory Procedure]
   753   C0007634:Cells [Cell]
   753   C3282337:Cells [Cell]
   719 E C1269647:Cell [Cell]
   719 E C1704653:Cell [Medical Device]
   719 E C1948049:Cell [Spatial Concept]

Phrase: "can"

Phrase: "survive"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0310255:SURVIVE [Pharmacologic Substance]

Phrase: "and"

Phrase: "grow within a patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0030705:*^patient [Patient or Disabled Group]

Phrase: "after reinfusion."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0854643:Reinfusion [Therapeutic or Preventive Procedure]
Processing 00000000.tx.225: Our study of 131randomized patients with multiple myeloma demonstrated that the CEPRATE SC System effectively purged the autografts without compromising hematopoietic recovery after myeloablative therapy. 

Phrase: "Our study of 131randomized patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0557651:Study [Manufactured Object]
   760   C2603343:Study [Research Activity]

Phrase: "with multiple myeloma"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   861   C0439064:Multiple [Quantitative Concept]
   861   C3538749:Myeloma [Intellectual Product]

Phrase: "demonstrated"

Phrase: "that"

Phrase: "the CEPRATE SC System effectively"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   804   C0449913:System [Functional Concept]
   804   C1553451:System [Manufactured Object]
   804   C1704459:System [Medical Device]
   733 E C0205373:Systemic [Functional Concept]

Phrase: "purged"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1548399:purged [Idea or Concept]
   966 E C0722910:Purge [Lipid,Pharmacologic Substance]

Phrase: "the autografts without compromising hematopoietic recovery"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0040736:autografts [Therapeutic or Preventive Procedure]
   753   C0559189:Autografts [Biomedical or Dental Material]

Phrase: "after myeloablative therapy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039798:therapy [Functional Concept]
   861   C0087111:Therapy [Therapeutic or Preventive Procedure]
   861   C1363945:Therapy [Finding]
Processing 00000000.tx.226: For patients randomized to the selected arm, the median number of tumor cells in the autograft was 3.3logs lower than the median for their counterparts in the unselected arm. 

Phrase: "For patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "randomized to the selected arm,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   760   C0034656:randomized [Research Activity]
   760   C0446516:Arm [Body Location or Region]
   760   C1269078:Arm [Body Part, Organ, or Organ Component]
   760   C1269612:Arm [Body Location or Region]
   726   C1707391:Select [Activity]
   704 E C0445456:Brachial [Spatial Concept]

Phrase: "the median number of tumor cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   767   C0007584:Cell Number [Laboratory Procedure]
   753   C0237753:*Number [Quantitative Concept]
   753   C0449788:Number [Quantitative Concept]

Phrase: "in the autograft"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0040736:autograft [Therapeutic or Preventive Procedure]
   944 E C0559189:Autotransplant [Biomedical or Dental Material]

Phrase: "was"

Phrase: "3.3logs"

Phrase: "lower than the median"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0441994:Lower [Spatial Concept]
   770   C1548802:Lower [Body Location or Region]
   770   C2003888:Lower [Activity]

Phrase: "for their counterparts"

Phrase: "in the unselected arm."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]
Processing 00000000.tx.227: In addition, the true efficiency of the purging procedure is underestimated, because the CD34-selected products without detectable tumor cells were assumed to have tumor cell contamination at the lower limit of detection for the assay. 

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "the true efficiency of the purging procedure"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0013682:Efficiency [Quantitative Concept]

Phrase: "is"

Phrase: "underestimated"

Phrase: ","

Phrase: "because"

Phrase: "the CD34-selected products without detectable tumor cells"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   744   C1514468:Products [Entity]
   711 E C1704444:Product [Quantitative Concept]

Phrase: "were"

Phrase: "assumed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3242379:Assumed [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "have"

Phrase: "tumor cell contamination at the lower limit of detection"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   742   C0259846:contamination [Human-caused Phenomenon or Process]
   742   C1881659:CONTAMINATION [Event]
   742   C2349974:Contamination [Idea or Concept]

Phrase: "for the assay."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0005507:Assay [Laboratory Procedure]
  1000   C0243073:assay [Qualitative Concept]
  1000   C1510438:Assay [Laboratory Procedure]
Processing 00000000.tx.228: In fact, in the majority of patients, the autografts had no detectable tumor cells after CD34 selection (Table 4). 

Phrase: "In fact,"

Phrase: "in the majority"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0680220:majority [Social Behavior]

Phrase: "of patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "the autografts"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0040736:autografts [Therapeutic or Preventive Procedure]
  1000   C0559189:Autografts [Biomedical or Dental Material]

Phrase: "had"

Phrase: "no detectable tumor cells after CD34 selection"
Meta Candidates (Total=11; Excluded=4; Pruned=0; Remaining=7)
   778   C0431085:Tumor cells [Cell]
   774   C0882849:Cells.CD34 [Cell]
   748   C0007634:Cells [Cell]
   748   C0027651:Tumor [Neoplastic Process]
   748   C1578706:Tumor [Intellectual Product]
   748   C3273930:Tumor [Finding]
   748   C3282337:Cells [Cell]
   745 E C0597032:Tumor Cell [Cell]
   714 E C1269647:Cell [Cell]
   714 E C1704653:Cell [Medical Device]
   714 E C1948049:Cell [Spatial Concept]

Phrase: "(Table 4"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.229: The purging efficiency reported in this study is similar to results reported in the published literature of multiple myeloma patients receiving a CD34-selected autograft using the CEPRATE SC System.15,28,37-40 In the studies that quantified the level of tumor cell depletion, a greater than 2.5log depletion of tumor cells was commonly observed.15,28,40 Similar studies evaluating the results of tumor cell depletion using the CEPRATE SC System for patients with non-Hodgkin's lymphoma and breast cancer yielded comparable results.35,41-43 Whereas phase II studies evaluating tumor cell purging methods that treated the autografts with either antibody plus complement or cyclophosphamide derivatives have demonstrated equally efficient purging, these procedures appear to substantially prolong engraftment times. 

Phrase: "The purging efficiency"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0013682:Efficiency [Quantitative Concept]
   789 E C0442799:Efficient [Qualitative Concept]

Phrase: "reported in this study"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   802   C1317750:Study report [Intellectual Product]
   802   C1831145:Study report [Clinical Attribute]
   770   C0557651:Study [Manufactured Object]
   770   C0684224:Reported [Intellectual Product]
   770   C0700287:Reported [Health Care Activity]
   770   C2603343:Study [Research Activity]
   770   C3496591:Reported [Clinical Attribute]
   737 E C3273238:Report [Intellectual Product]

Phrase: "is"

Phrase: "similar to results"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C2348205:Similar [Qualitative Concept]

Phrase: "reported in the published literature of multiple myeloma patients"
Meta Candidates (Total=14; Excluded=1; Pruned=0; Remaining=13)
   764   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   745   C0747307:patients report [Intellectual Product]
   742   C0023866:Literature [Intellectual Product]
   742   C0030705:Patients [Patient or Disabled Group]
   742   C0034036:LITERATURE [Intellectual Product,Manufactured Object]
   742   C0034037:Published [Occupational Activity]
   742   C0439064:Multiple [Quantitative Concept]
   742   C0684224:Reported [Intellectual Product]
   742   C0700287:Reported [Health Care Activity]
   742   C1704324:Published [Intellectual Product]
   742   C3496591:Reported [Clinical Attribute]
   742   C3538749:Myeloma [Intellectual Product]
   708 E C3273238:Report [Intellectual Product]

Phrase: "receiving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514756:Receive [Qualitative Concept]

Phrase: "a CD34-selected autograft"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0040736:autograft [Therapeutic or Preventive Procedure]
   771 E C0559189:Autotransplant [Biomedical or Dental Material]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the CEPRATE SC System.15,"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   840   C0038250:Stem cell [Cell]
   804   C0007634:Cell [Cell]
   804   C0242767:Stem [Plant]
   804   C0449913:System [Functional Concept]
   804   C1186763:Stem [Body Part, Organ, or Organ Component]
   804   C1269647:Cell [Cell]
   804   C1553451:System [Manufactured Object]
   804   C1704459:System [Medical Device]
   804   C1704653:Cell [Medical Device]
   804   C1948049:Cell [Spatial Concept]
   733 E C0205373:Systemic [Functional Concept]

Phrase: "28,"

Phrase: "37-40 In the studies"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   760   C0439509:/40 [Temporal Concept]
   760   C0947630:studies [Laboratory Procedure]
   726 E C0557651:Study [Manufactured Object]
   726 E C2603343:Study [Research Activity]

Phrase: "that"

Phrase: "quantified"

Phrase: "the level of tumor cell depletion,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0441889:Level [Qualitative Concept]
   753   C0456079:Level [Classification]
   753   C1547707:Level [Geographic Area]
   753   C2946261:Level [Pharmacologic Substance]

Phrase: "a greater than 2.5log depletion of tumor cells"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   764   C0439093:Greater Than [Quantitative Concept]
   742   C0443228:greater [Quantitative Concept]
   742   C1704243:Greater [Quantitative Concept]
   708 E C0549177:Great [Quantitative Concept]

Phrase: "was"

Phrase: "commonly"

Phrase: "observed.15,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1441672:Observed [Functional Concept]

Phrase: "28,"

Phrase: "40 Similar studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0947630:studies [Laboratory Procedure]
   793 E C0557651:Study [Manufactured Object]
   793 E C2603343:Study [Research Activity]

Phrase: "evaluating"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0220825:Evaluate [Functional Concept]

Phrase: "the results of tumor cell depletion"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   719   C1274040:Result [Functional Concept]
   719   C1546471:Result [Idea or Concept]
   719   C2825142:Result [Finding]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the CEPRATE SC System for patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0449913:System [Functional Concept]
   748   C1553451:System [Manufactured Object]
   748   C1704459:System [Medical Device]

Phrase: "with non-Hodgkin's lymphoma"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0024305:Lymphoma, Non-Hodgkin [Neoplastic Process]
  1000   C2700512:LYMPHOMA, NON-HODGKIN [Gene or Genome]
  1000   C3539720:Non-Hodgkin Lymphoma [Intellectual Product]
   901   C0019829:Hodgkin Lymphoma [Neoplastic Process]
   901   C3541281:Hodgkin Lymphoma [Intellectual Product]
   827   C0024299:Lymphoma [Neoplastic Process]
   827   C1518422:Non [Functional Concept]

Phrase: "and"

Phrase: "breast cancer"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0006142:Breast Cancer [Neoplastic Process]
  1000   C0678222:Breast Cancer [Neoplastic Process]
   950 E C0153661:thoracic cancer [Neoplastic Process]
   861   C0006141:Breast [Body Part, Organ, or Organ Component]
   861   C0006826:Cancer [Neoplastic Process]
   861   C0998265:Cancer [Eukaryote]
   861   C1268990:Breast [Body Part, Organ, or Organ Component]
   861   C1306459:Cancer [Finding]
   805 E C0929301:Mammary [Body Part, Organ, or Organ Component]
   805 E C1521735:Pectoral [Qualitative Concept]
   777 E C0817096:Chest [Body Location or Region]
   777 E C1527391:Chest [Body Location or Region]

Phrase: "yielded"

Phrase: "comparable results.35,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   793   C1274040:Result [Functional Concept]
   793   C1546471:Result [Idea or Concept]
   793   C2825142:Result [Finding]

Phrase: "41-43"

Phrase: "Whereas"

Phrase: "phase II studies"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   988   C0282460:Phase II Study [Research Activity]
   827   C0947630:studies [Laboratory Procedure]
   793 E C0557651:Study [Manufactured Object]
   793 E C2603343:Study [Research Activity]

Phrase: "evaluating"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0220825:Evaluate [Functional Concept]

Phrase: "tumor cell purging methods"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   812   C0025663:Methods [Intellectual Product]
   812   C0025664:methods [Intellectual Product]
   812   C0449851:Methods [Functional Concept]
   779 E C0871511:METHOD [Intellectual Product]
   708   C2348825:Tumor Purging [Therapeutic or Preventive Procedure]

Phrase: "that"

Phrase: "treated"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332293:treated [Therapeutic or Preventive Procedure]
  1000   C1522326:Treated [Functional Concept]
   966 E C1292734:TREAT [Functional Concept]

Phrase: "the autografts with either antibody plus complement"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0040736:autografts [Therapeutic or Preventive Procedure]
   748   C0559189:Autografts [Biomedical or Dental Material]

Phrase: "or"

Phrase: "cyclophosphamide derivatives"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0243072:derivatives [Chemical Viewed Structurally]
   827 E C1527240:Derivative [Functional Concept]

Phrase: "have"

Phrase: "demonstrated"

Phrase: "equally efficient purging,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0855227:purging [Disease or Syndrome]
   793 E C0722910:Purge [Lipid,Pharmacologic Substance]

Phrase: "these procedures"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
  1000   C0025664:procedures [Intellectual Product]
  1000   C0184661:Procedures [Diagnostic Procedure,Therapeutic or Preventive Procedure]
  1000   C2700391:procedures [Activity]
   966 E C1948041:Procedure [Therapeutic or Preventive Procedure]
   966 E C3274430:PROCEDURE [Health Care Activity]
   966 E C3538935:Procedure [Idea or Concept]
   966 E C3539779:Procedure [Intellectual Product]

Phrase: "appear"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0700364:APPEAR [Qualitative Concept]

Phrase: "to substantially"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1883351:To [Qualitative Concept]

Phrase: "prolong"

Phrase: "engraftment times."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0040223:times [Temporal Concept]
   861   C1632851:Times [Quantitative Concept]
   827 E C3541383:Time [Temporal Concept]
   789 E C0442043:Temporal [Spatial Concept]
   789 E C2362314:Temporal [Temporal Concept]
Processing 00000000.tx.230: In contrast, CD34 selection of the autograft using the CEPRATE SC System appears safe. 

Phrase: "In contrast,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979874:Contrast [Qualitative Concept]

Phrase: "CD34 selection of the autograft"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0036576:selection [Genetic Function]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the CEPRATE SC System"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   812   C0449913:System [Functional Concept]
   812   C1553451:System [Manufactured Object]
   812   C1704459:System [Medical Device]
   741 E C0205373:Systemic [Functional Concept]

Phrase: "appears"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0700364:APPEAR [Qualitative Concept]

Phrase: "safe."
Processing 00000000.tx.231: The median time to neutrophil engraftment was 12days for patients in both arms of this study and all patients who received a transplant in the trial achieved an ANC of 500 by day 15.

Phrase: "The median time to neutrophil engraftment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0040223:Time [Temporal Concept]
   753   C3541383:Time [Temporal Concept]

Phrase: "was"

Phrase: "12days for patients"

Phrase: "in both arms"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0206655:ARMS [Neoplastic Process]
  1000   C0446516:Arm [Body Location or Region]
  1000   C1269078:Arm [Body Part, Organ, or Organ Component]
  1000   C1269612:Arm [Body Location or Region]
  1000   C2681631:ARMS [Gene or Genome]
   944 E C0445456:Brachial [Spatial Concept]

Phrase: "of this study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "and"

Phrase: "all patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "a transplant in the trial"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0040732:Transplant [Therapeutic or Preventive Procedure]
   760   C0332835:Transplant [Tissue]

Phrase: "achieved"

Phrase: "an ANC of 500"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C0948762:Absolute neutrophil count [Laboratory Procedure]
   820   C1709222:Neutrophil Count 500 [Laboratory or Test Result]
   790   C0200633:Neutrophil count [Laboratory Procedure]
   753   C0027950:Neutrophile [Cell]
   753   C0205344:Absolute [Qualitative Concept]
   753   C0750480:Count [Activity]
   753   C1705566:Count [Quantitative Concept]

Phrase: "by day 15."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0332173:/day [Temporal Concept]
   861   C0439228:day [Temporal Concept]
   861   C0439505:/day [Temporal Concept]
Processing 00000000.tx.232: These results are consistent with other large studies of autologous PBPC transplantation whereby 97% to 100% of patients achieved neutrophil engraftment after treatment with either unselected PBPCs44-46 or CD34-selected PBPCs.37,47-49 Furthermore, the median 12-day engraftment is comparable to previous studies using the CEPRATE SC System.47-50 Median times to platelet engraftment and recovery were slightly prolonged for patients receiving a CD34-selected transplant. 

Phrase: "These results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "are"

Phrase: "consistent with other large studies"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C0332290:Consistent with [Idea or Concept]
           Consistent

Phrase: "of autologous PBPC transplantation whereby 97%"
Meta Candidates (Total=31; Excluded=10; Pruned=0; Remaining=21)
   873   C0242602:peripheral blood progenitor cell transplantation [Therapeutic or Preventive Procedure]
   864   C0040736:Transplantation, Autologous [Therapeutic or Preventive Procedure]
   825   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   812   C0038250:Progenitor Cells [Cell]
   812   C0206153:cells transplantation [Therapeutic or Preventive Procedure]
   812   C0229664:peripheral blood [Body Substance]
           Blood
   795   C0189736:blood vessel transplantation [Therapeutic or Preventive Procedure]
   793   C0005767:Blood [Tissue]
   793   C0005768:blood [Body Substance]
   793   C0007634:Cells [Cell]
   793   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   793   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   793   C0040733:transplantation [Functional Concept]
   793   C0205100:Peripheral [Spatial Concept]
   793   C0439073:97 [Intellectual Product]
   793   C0439082:>97 [Quantitative Concept]
   793   C0439859:Autologous [Qualitative Concept]
   793   C0870134:Progenitor [Family Group]
   793   C3282337:Cells [Cell]
   778 E C2328697:Hemal cell [Cell]
   770 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   760 E C1269647:Cell [Cell]
   760 E C1704653:Cell [Medical Device]
   760 E C1948049:Cell [Spatial Concept]
   721 E C0333275:Bloody [Qualitative Concept]
   710 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   710 E C0392895:Bloods [Population Group]
   710 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   710 E C1511228:VESSEL, BLOOD [Tissue]

Phrase: "to 100%"

Phrase: "of patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "achieved"

Phrase: "neutrophil engraftment after treatment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1882078:Neutrophil Engraftment [Finding]
   770   C0301944:Engraftment [Physiologic Function]

Phrase: "with either unselected PBPCs44-46"

Phrase: "or"

Phrase: "CD34-selected PBPCs.37,"
Meta Candidates (Total=24; Excluded=10; Pruned=0; Remaining=14)
   877   C0882849:cd34 cells [Cell]
   835   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   818   C0038250:Progenitor Cells [Cell]
   818   C0229664:peripheral blood [Body Substance]
           Blood
   795   C0005767:Blood [Tissue]
   795   C0005768:blood [Body Substance]
   795   C0007634:Cells [Cell]
   795   C0205100:Peripheral [Spatial Concept]
   795   C0870134:Progenitor [Family Group]
   795   C3282337:Cells [Cell]
   795   C3538723:CD34 [Laboratory Procedure]
   785 E C2328697:Hemal cell [Cell]
   776 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   762 E C1269647:Cell [Cell]
   762 E C1704653:Cell [Medical Device]
   762   C1707391:Select [Activity]
   762 E C1948049:Cell [Spatial Concept]
   724 E C0333275:Bloody [Qualitative Concept]
   712 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   712 E C0392895:Bloods [Population Group]
   712 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   712 E C1511228:VESSEL, BLOOD [Tissue]

Phrase: "47-49 Furthermore,"

Phrase: "the median 12-day engraftment"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0301944:Engraftment [Physiologic Function]

Phrase: "is"

Phrase: "comparable to previous studies"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the CEPRATE SC System.47-50 Median times to platelet engraftment"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   736   C0040223:times [Temporal Concept]
   736   C1632851:Times [Quantitative Concept]
   703 E C3541383:Time [Temporal Concept]

Phrase: "and"

Phrase: "recovery"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237820:Recovery [Activity]
  1000   C1555688:recovery [Idea or Concept]
  1000   C2004454:Recovery [Organism Function]

Phrase: "were"

Phrase: "slightly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750482:Slightly [Idea or Concept]

Phrase: "prolonged for patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C0439590:Prolonged [Temporal Concept]

Phrase: "receiving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514756:Receive [Qualitative Concept]

Phrase: "a CD34-selected transplant."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0040732:Transplant [Therapeutic or Preventive Procedure]
   827   C0332835:Transplant [Tissue]
Processing 00000000.tx.233: Although this 1-to 2-day difference was statistically significant, there was no clinical impact as measured by an increased incidence of bleeding events or RBC transfusions in the patients who received a CD34-selected autograft. 

Phrase: "Although"

Phrase: "this 1-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "to 2-day difference"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C1705241:*Difference [Quantitative Concept]
   827   C1705242:Difference [Qualitative Concept]
   755 E C0443199:Differential [Qualitative Concept]

Phrase: "was"

Phrase: "statistically significant, there"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   901   C0237881:statistically significant [Quantitative Concept]
           significant
   829 E C1709380:Statistical Significance [Quantitative Concept]
   827   C0038215:Statistically [Occupation or Discipline]
   827   C0750502:Significant [Idea or Concept]
   827   C1546944:Significant [Qualitative Concept]

Phrase: "was"

Phrase: "no clinical impact"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1825598:IMPACT [Gene or Genome]

Phrase: "as"

Phrase: "measured by an increased incidence of bleeding events"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   744   C0019080:Bleeding [Pathologic Function]
   744   C0021149:Incidence [Quantitative Concept]
   744   C0205217:Increased [Quantitative Concept]
   744   C0220856:incidence [Functional Concept]
   744   C0441471:Events [Event]
   744   C0442805:Increased [Functional Concept]
   744   C0444706:Measured [Qualitative Concept]
   744   C3541888:Events [Classification]
   744   C3541902:MEASURED [Diagnostic Procedure]
   711 E C0079809:Measure [Quantitative Concept]
   711 E C0242485:Measure [Functional Concept]

Phrase: "or"

Phrase: "RBC transfusions in the patients"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   853   C0086252:Transfusions, Red Blood Cell [Therapeutic or Preventive Procedure]
   837 E C0199962:Red Blood Cell Transfusion [Therapeutic or Preventive Procedure]
   814   C0565531:blood cell transfusions [Therapeutic or Preventive Procedure]
   774   C0005841:Blood Transfusions [Therapeutic or Preventive Procedure]
           Transfusions
   757 E C0455012:Blood Transfusion [Therapeutic or Preventive Procedure]
       E   Transfusion
   748   C0199960:transfusions [Functional Concept]
   748   C1879316:Transfusions [Therapeutic or Preventive Procedure]

Phrase: "who"

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "a CD34-selected autograft."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0040736:autograft [Therapeutic or Preventive Procedure]
   771 E C0559189:Autotransplant [Biomedical or Dental Material]
Processing 00000000.tx.234: Additional analyses determined that two factors influenced the posttransplant platelet engraftment and recovery time: the platelet count at the time of randomization (immediately before leukapheresis) and the infused cell dose of CD34+ cells. 

Phrase: "Additional analyses"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0002778:Analysis [Laboratory Procedure]
   827   C0936012:Analysis [Research Activity]
   827   C1524024:analysis [Functional Concept]

Phrase: "determined"

Phrase: "that two factors"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1521761:Factor [Functional Concept]
   827   C2827422:Factor [Conceptual Entity]

Phrase: "influenced"

Phrase: "the posttransplant platelet engraftment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C1882407:Platelet Engraftment [Finding]
   827   C0301944:Engraftment [Physiologic Function]

Phrase: "and"

Phrase: "recovery time"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   861   C0040223:Time [Temporal Concept]
   861   C0237820:Recovery [Activity]
   861   C1555688:recovery [Idea or Concept]
   861   C2004454:Recovery [Organism Function]
   861   C3541383:Time [Temporal Concept]
   805 E C0442043:Temporal [Spatial Concept]
   805 E C2362314:Temporal [Temporal Concept]
   777 E C1632851:Times [Quantitative Concept]

Phrase: ":"

Phrase: "the platelet count at the time of randomization"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0032181:Platelet Count [Laboratory Procedure]
   770   C1287267:Platelet count [Laboratory or Test Result]
   744   C0005821:Platelet [Cell]
   744   C0750480:Count [Activity]
   744   C1705566:Count [Quantitative Concept]

Phrase: "(immediately"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205548:Immediately [Temporal Concept]

Phrase: "before"

Phrase: "leukapheresis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023416:Leucapheresis [Therapeutic or Preventive Procedure]

Phrase: ")"

Phrase: "and"

Phrase: "the infused cell dose of CD34+ cells."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0178602:Dose [Quantitative Concept]
   748   C0869039:Dose [Quantitative Concept]
   748   C1114758:Dose # [Clinical Attribute]
Processing 00000000.tx.235: Patients receiving a cell dose less than 2106 CD34+ cells/kg (n=11in each arm) were at increased risk for a delay in time to platelet engraftment and recovery, regardless of treatment arm. 

Phrase: "Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "receiving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514756:Receive [Qualitative Concept]

Phrase: "a cell dose less"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0178602:Dose [Quantitative Concept]
   812   C0869039:Dose [Quantitative Concept]
   812   C1114758:Dose # [Clinical Attribute]

Phrase: "than 2106 CD34+ cells/kg (n=11in"

Phrase: "each arm)"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0446516:Arm [Body Location or Region]
  1000   C1269078:Arm [Body Part, Organ, or Organ Component]
  1000   C1269612:Arm [Body Location or Region]
   944 E C0445456:Brachial [Spatial Concept]
   916 E C0206655:ARMS [Neoplastic Process]
   916 E C2681631:ARMS [Gene or Genome]

Phrase: "were at increased risk"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0035647:Risk [Qualitative Concept]
   770   C0205217:Increased [Quantitative Concept]
   770   C0442805:Increased [Functional Concept]

Phrase: "for a delay"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205421:Delay [Temporal Concept]

Phrase: "in time"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0040223:Time [Temporal Concept]
  1000   C3541383:Time [Temporal Concept]
   944 E C0442043:Temporal [Spatial Concept]
   944 E C2362314:Temporal [Temporal Concept]
   916 E C1632851:Times [Quantitative Concept]

Phrase: "to platelet engraftment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1882407:Platelet Engraftment [Finding]
   861   C0301944:Engraftment [Physiologic Function]

Phrase: "and"

Phrase: "recovery,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237820:Recovery [Activity]
  1000   C1555688:recovery [Idea or Concept]
  1000   C2004454:Recovery [Organism Function]

Phrase: "regardless of treatment arm."
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
  1000   C1522541:Treatment Arm [Research Activity]
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]
Processing 00000000.tx.236: However, there was no significant delay in the time to platelet engraftment and recovery for patients in the selected arm who received at least 2106 CD34+cells/kg (Fig 3). 

Phrase: "However,"

Phrase: "there"

Phrase: "was"

Phrase: "no significant delay in the time"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   783   C0522486:Delay time [Temporal Concept]
   753   C0205421:Delay [Temporal Concept]

Phrase: "to platelet engraftment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1882407:Platelet Engraftment [Finding]
   861   C0301944:Engraftment [Physiologic Function]

Phrase: "and"

Phrase: "recovery for patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0237820:Recovery [Activity]
   790   C1555688:recovery [Idea or Concept]
   790   C2004454:Recovery [Organism Function]

Phrase: "in the selected arm"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0446516:Arm [Body Location or Region]
   861   C1269078:Arm [Body Part, Organ, or Organ Component]
   861   C1269612:Arm [Body Location or Region]
   805 E C0445456:Brachial [Spatial Concept]
   777 E C0206655:ARMS [Neoplastic Process]
   777 E C2681631:ARMS [Gene or Genome]

Phrase: "who"

Phrase: "received at least 2106 CD34+cells/kg (Fig 3"
Meta Candidates (Total=12; Excluded=3; Pruned=0; Remaining=9)
   764   C0882849:cd34 cells [Cell]
   742   C0007634:Cells [Cell]
   742   C0022718:KG [Geographic Area]
   742   C0349966:Fig [Food]
   742   C0439209:kg [Quantitative Concept]
   742   C1337208:FIG [Food]
   742   C1514756:Received [Qualitative Concept]
   742   C3282337:Cells [Cell]
   742   C3538723:CD34 [Laboratory Procedure]
   708 E C1269647:Cell [Cell]
   708 E C1704653:Cell [Medical Device]
   708 E C1948049:Cell [Spatial Concept]

Phrase: ")."
Processing 00000000.tx.237: These results suggest that CD34+ cell dose, and not processing with the CEPRATE SC System, was the main factor influencing time to platelet engraftment. 

Phrase: "These results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that CD34+ cell dose,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0178602:Dose [Quantitative Concept]
   827   C0869039:Dose [Quantitative Concept]
   827   C1114758:Dose # [Clinical Attribute]
   734   C0882849:CD34+ cell [Cell]

Phrase: "and"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "processing with the CEPRATE SC System,"
Meta Candidates (Total=16; Excluded=3; Pruned=0; Remaining=13)
   778   C0038250:Stem cell [Cell]
   774   C0230625:cell processing [Cell Component]
   757 E C0007613:Cell Process [Cell Function]
   757   C2256362:system process [Physiologic Function]
   748   C0007634:Cell [Cell]
   748   C0242767:Stem [Plant]
   748   C0449913:System [Functional Concept]
   748   C1186763:Stem [Body Part, Organ, or Organ Component]
   748   C1269647:Cell [Cell]
   748   C1553451:System [Manufactured Object]
   748   C1704459:System [Medical Device]
   748   C1704653:Cell [Medical Device]
   748   C1709694:Processing [Activity]
   748   C1948049:Cell [Spatial Concept]
   714 E C1184743:Process [Body Part, Organ, or Organ Component]
   714 E C1522240:Process [Phenomenon or Process]

Phrase: "was"

Phrase: "the main factor influencing time to platelet engraftment."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   767   C0040225:Time Factor [Temporal Concept]
   744   C0040223:Time [Temporal Concept]
   744   C3541383:Time [Temporal Concept]
Processing 00000000.tx.238: Furthermore, these results are consistent with other studies reporting threshold doses of CD34+ cells required for rapid platelet engraftment,44-48 including the phase I/II study in multiple myeloma that established a threshold dose of 2106 CD34+ cells/kg.15 We were unable to establish a minimum CD34+ cell dose that affected neutrophil engraftment, because all transplanted patients had neutrophil engraftment by day 15postinfusion. 

Phrase: "Furthermore,"

Phrase: "these results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "are"

Phrase: "consistent with other studies"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0332290:Consistent with [Idea or Concept]
           Consistent

Phrase: "reporting"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0700287:Reporting [Health Care Activity]
   966 E C0684224:Report [Intellectual Product]
   966 E C3273238:Report [Intellectual Product]

Phrase: "threshold doses of CD34+ cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   760   C0178602:Doses [Quantitative Concept]
   760   C0449864:Threshold [Qualitative Concept]
   726 E C0869039:Dose [Quantitative Concept]
   726 E C1114758:Dose # [Clinical Attribute]
   726 E C1428722:DOS [Gene or Genome]

Phrase: "required for rapid platelet engraftment,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C1882407:Platelet Engraftment [Finding]
   760   C0005821:Platelet [Cell]
   760   C0301944:Engraftment [Physiologic Function]
   760   C0439831:Rapid [Qualitative Concept]
   760   C1514873:Required [Functional Concept]

Phrase: "44-48"

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "the phase I/II study in multiple myeloma"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   793   C0282460:Phase II Study [Research Activity]
   793   C0920321:Phase I Study [Research Activity]
   744   C0557651:Study [Manufactured Object]
   744   C2603343:Study [Research Activity]

Phrase: "that"

Phrase: "established"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0443211:Established [Qualitative Concept]
  1000   C1272684:Established [Qualitative Concept]

Phrase: "a threshold dose of 2106 CD34+ cells/kg.15"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   742   C0178602:Dose [Quantitative Concept]
   742   C0449864:Threshold [Qualitative Concept]
   742   C0869039:Dose [Quantitative Concept]
   742   C1114758:Dose # [Clinical Attribute]

Phrase: "We"

Phrase: "were"

Phrase: "unable to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1299582:Unable [Finding]

Phrase: "establish"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443211:establish [Qualitative Concept]

Phrase: "a minimum CD34+ cell dose"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0178602:Dose [Quantitative Concept]
   812   C0869039:Dose [Quantitative Concept]
   812   C1114758:Dose # [Clinical Attribute]

Phrase: "that affected neutrophil engraftment,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C1882078:Neutrophil Engraftment [Finding]
   827   C0301944:Engraftment [Physiologic Function]

Phrase: "because"

Phrase: "all transplanted patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "had"

Phrase: "neutrophil engraftment by day 15postinfusion."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C1882078:Neutrophil Engraftment [Finding]
   760   C0301944:Engraftment [Physiologic Function]
Processing 00000000.tx.239: Furthermore, there was no indication that there were significant decreases in time to neutrophil engraftment in patients receiving CD34+ cell doses greater than 2106/kg. 

Phrase: "Furthermore,"

Phrase: "there"

Phrase: "was"

Phrase: "no indication"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0392360:indication [Idea or Concept]
  1000   C3146298:Indication [Functional Concept]

Phrase: "that there"

Phrase: "were"

Phrase: "significant decreases in time"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0547047:decreases [Quantitative Concept]
   737 E C0392756:Decrease [Qualitative Concept]

Phrase: "to neutrophil engraftment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1882078:Neutrophil Engraftment [Finding]
   861   C0301944:Engraftment [Physiologic Function]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "receiving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514756:Receive [Qualitative Concept]

Phrase: "CD34+ cell doses"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0178602:Doses [Quantitative Concept]
   793 E C0869039:Dose [Quantitative Concept]
   793 E C1114758:Dose # [Clinical Attribute]
   793 E C1428722:DOS [Gene or Genome]
   734   C0882849:CD34+ cell [Cell]

Phrase: "greater than 2106/kg."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   833   C0439093:Greater Than [Quantitative Concept]
   770   C0443228:greater [Quantitative Concept]
   770   C1704243:Greater [Quantitative Concept]
   737 E C0549177:Great [Quantitative Concept]
Processing 00000000.tx.240: Recently, there has been a concern regarding a potential detrimental effect of CD34 selection on the recovery of immune function. 

Phrase: "Recently,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332185:Recently [Temporal Concept]

Phrase: "there"

Phrase: "has"

Phrase: "been"

Phrase: "a concern"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2699424:Concern [Idea or Concept]

Phrase: "regarding"

Phrase: "a potential detrimental effect of CD34 selection"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1280500:Effect [Qualitative Concept]
   748   C2348382:Effect [Qualitative Concept]

Phrase: "on the recovery"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237820:Recovery [Activity]
  1000   C1555688:recovery [Idea or Concept]
  1000   C2004454:Recovery [Organism Function]

Phrase: "of immune function."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1817756:Immune Function [Organ or Tissue Function]
   861   C0031843:function [Physiologic Function]
   861   C0439662:Immune [Functional Concept]
   861   C0542341:Function [Functional Concept]
   861   C0700205:FUNCTION [Classification]
   861   C1705273:Function [Intellectual Product]
   789 E C0205245:Functional [Functional Concept]
   789 E C2700217:Functional [Conceptual Entity]
Processing 00000000.tx.241: The clinical manifestation of delayed recovery of immune function is an increase in the incidence of infections. 

Phrase: "The clinical manifestation of delayed recovery of immune function"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   764   C1280464:Manifestation of [Qualitative Concept]
           manifestation
   742   C0205319:manifestation [Functional Concept]

Phrase: "is"

Phrase: "an increase in the incidence of infections."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0442805:Increase [Functional Concept]
Processing 00000000.tx.242: Despite the presumptive median 2.6log elimination of lymphocytes by the CEPRATE SC System, there were no significant differences in the incidence or type of infections between the patients who received a CD34-selected autograft compared with patients who received an unselected graft. 

Phrase: "Despite the presumptive median 2.6log elimination"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0221102:Elimination [Physiologic Function]

Phrase: "of lymphocytes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024264:Lymphocytes [Cell]

Phrase: "by the CEPRATE SC System,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   812   C0449913:System [Functional Concept]
   812   C1553451:System [Manufactured Object]
   812   C1704459:System [Medical Device]
   741 E C0205373:Systemic [Functional Concept]

Phrase: "there"

Phrase: "were"

Phrase: "no significant differences in the incidence"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   719   C1705241:*Difference [Quantitative Concept]
   719   C1705242:Difference [Qualitative Concept]

Phrase: "or"

Phrase: "type of infections"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   841   C0457463:infection type [Classification]
   790   C0332307:Type [Qualitative Concept]
   790   C1547052:*Type [Quantitative Concept]

Phrase: "between the patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "a CD34-selected autograft"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0040736:autograft [Therapeutic or Preventive Procedure]
   771 E C0559189:Autotransplant [Biomedical or Dental Material]

Phrase: "compared with patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C1707455:Compared [Activity]

Phrase: "who"

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "an unselected graft."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0181074:{Graft} [Biomedical or Dental Material]
   861   C0332835:Graft [Tissue]
   861   C1961139:Graft, NOS [Therapeutic or Preventive Procedure]
Processing 00000000.tx.243: Additional clinical parameters evaluated in the study supported the safety of CD34 selection with the CEPRATE SC System. 

Phrase: "Additional clinical parameters"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   827   C0449381:Parameters [Finding]
   793 E C0549193:Parameter [Spatial Concept]
   793 E C1704769:Parameter [Conceptual Entity]
   793 E C2350001:Parameter [Quantitative Concept]

Phrase: "evaluated in the study"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0220825:Evaluated [Functional Concept]
   770   C0557651:Study [Manufactured Object]
   770   C2603343:Study [Research Activity]

Phrase: "supported"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521721:Supported [Conceptual Entity]
   966 E C0183683:Support [Medical Device]

Phrase: "the safety of CD34 selection"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0036043:Safety [Human-caused Phenomenon or Process]
   760   C1705187:SAFETY [Research Activity]

Phrase: "with the CEPRATE SC System."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   812   C0449913:System [Functional Concept]
   812   C1553451:System [Manufactured Object]
   812   C1704459:System [Medical Device]
   741 E C0205373:Systemic [Functional Concept]
Processing 00000000.tx.244: These results are in contrast to a recently published report using a different CD34 selection method in which patients had delayed engraftment and immune reconstitution.51 Furthermore, patients receiving a CD34-selected graft demonstrated a significantly lower incidence of diastolic hypertension in the 24hours after transplantation that likely resulted from the reduced cell debris and quantity of DMSO contained within the selected autograft and subsequently reinfused to the patient. 

Phrase: "These results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "are in contrast to a recently published report"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   744   C0034037:Published [Occupational Activity]
   744   C0332185:Recently [Temporal Concept]
   744   C0684224:Report [Intellectual Product]
   744   C0700287:Report [Health Care Activity]
   744   C1551058:Are [Quantitative Concept]
   744   C1704324:Published [Intellectual Product]
   744   C1979874:Contrast [Qualitative Concept]
   744   C3273238:Report [Intellectual Product]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a different CD34 selection method in which patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0025663:Method [Intellectual Product]
   744   C0449851:Method [Functional Concept]
   744   C0871511:METHOD [Intellectual Product]

Phrase: "had"

Phrase: "delayed engraftment"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0301944:Engraftment [Physiologic Function]

Phrase: "and"

Phrase: "immune reconstitution.51 Furthermore,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0439662:Immune [Functional Concept]

Phrase: "patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "receiving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514756:Receive [Qualitative Concept]

Phrase: "a CD34-selected graft"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0181074:{Graft} [Biomedical or Dental Material]
   827   C0332835:Graft [Tissue]
   827   C1961139:Graft, NOS [Therapeutic or Preventive Procedure]

Phrase: "demonstrated"

Phrase: "a significantly lower incidence of diastolic hypertension"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0021149:Incidence [Quantitative Concept]
   748   C0220856:incidence [Functional Concept]

Phrase: "in the 24hours"

Phrase: "after transplantation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0029216:Transplantation [Therapeutic or Preventive Procedure]
  1000   C0040732:Transplantation [Therapeutic or Preventive Procedure]
  1000   C0040733:transplantation [Functional Concept]

Phrase: "that likely"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332148:Likely [Qualitative Concept]
  1000   C0750492:Likely [Idea or Concept]

Phrase: "resulted from the reduced cell debris"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   753   C0007634:Cell [Cell]
   753   C0392756:Reduced [Qualitative Concept]
   753   C0440266:Debris [Substance]
   753   C1269647:Cell [Cell]
   753   C1704653:Cell [Medical Device]
   753   C1948049:Cell [Spatial Concept]
   719   C1274040:Result [Functional Concept]
   719   C1546471:Result [Idea or Concept]
   719   C2825142:Result [Finding]

Phrase: "and"

Phrase: "quantity of DMSO"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C1265611:Quantity [Quantitative Concept]
   770   C1554108:Quantity [Intellectual Product]
   770   C1561573:Quantity [Intellectual Product]

Phrase: "contained within the selected autograft"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   760   C0040736:autograft [Therapeutic or Preventive Procedure]
   760   C0332256:contained [Functional Concept]
   760   C2700400:Contained [Activity]
   726   C1707391:Select [Activity]
   704 E C0559189:Autotransplant [Biomedical or Dental Material]

Phrase: "and"

Phrase: "subsequently"

Phrase: "reinfused to the patient."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0030705:*^patient [Patient or Disabled Group]
Processing 00000000.tx.245: In summary, this study showed that CD34 selection effi-ciently purged contaminating tumor cells from peripheral blood autografts in patients with multiple myeloma without adversely affecting the ability of the hematopoietic stem cells to restore hematopoiesis. 

Phrase: "In summary,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1552616:summary [Intellectual Product]
  1000   C1706244:Summary [Intellectual Product]

Phrase: "this study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that CD34 selection effi-ciently"

Phrase: "purged"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1548399:purged [Idea or Concept]
   966 E C0722910:Purge [Lipid,Pharmacologic Substance]

Phrase: "contaminating"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0205279:contaminate [Functional Concept]

Phrase: "tumor cells from peripheral blood autografts"
Meta Candidates (Total=15; Excluded=5; Pruned=0; Remaining=10)
   804   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   790   C0431085:Tumor cells [Cell]
   756 E C0597032:Tumor Cell [Cell]
   753   C0007634:Cells [Cell]
   753   C0027651:Tumor [Neoplastic Process]
   753   C1578706:Tumor [Intellectual Product]
   753   C3273930:Tumor [Finding]
   753   C3282337:Cells [Cell]
   742   C0027668:Tumor, Blood Vessel [Neoplastic Process]
   742   C0282607:Blood vessel tumor [Neoplastic Process]
   739 E C2328697:Hemal cell [Cell]
   719 E C1269647:Cell [Cell]
   719 E C1704653:Cell [Medical Device]
   719 E C1948049:Cell [Spatial Concept]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with multiple myeloma"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   861   C0439064:Multiple [Quantitative Concept]
   861   C3538749:Myeloma [Intellectual Product]

Phrase: "without adversely"

Phrase: "affecting"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0392760:Affecting [Functional Concept]
  1000   C1314939:Affecting [Functional Concept]
   966 E C0001721:Affect [Mental Process]

Phrase: "the ability of the hematopoietic stem cells to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0085732:Ability [Organism Attribute]

Phrase: "restore"

Phrase: "hematopoiesis."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0018951:Haematopoiesis [Organ or Tissue Function]
   928 E C0018957:Haematopoietic [Body System]
   928 E C0229601:Hematopoietic [Functional Concept]
Processing 00000000.tx.246: In particular, when at least 2106 CD34+ cells/kg were infused, times to neutrophil and platelet engraftment were not significantly affected by the selection procedure. 

Phrase: "In particular,"

Phrase: "when at least 2106 CD34+ cells/kg"
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
   778   C0882849:cd34 cells [Cell]
   748   C0007634:Cells [Cell]
   748   C0022718:KG [Geographic Area]
   748   C0439209:kg [Quantitative Concept]
   748   C1720477:When [Qualitative Concept]
   748   C1948054:When [Temporal Concept]
   748   C3282337:Cells [Cell]
   748   C3538723:CD34 [Laboratory Procedure]
   714 E C1269647:Cell [Cell]
   714 E C1704653:Cell [Medical Device]
   714 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "infused"

Phrase: ","

Phrase: "times to neutrophil"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   790   C0040223:times [Temporal Concept]
   790   C1632851:Times [Quantitative Concept]
   756 E C3541383:Time [Temporal Concept]
   718 E C0442043:Temporal [Spatial Concept]
   718 E C2362314:Temporal [Temporal Concept]

Phrase: "and"

Phrase: "platelet engraftment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1882407:Platelet Engraftment [Finding]
   861   C0301944:Engraftment [Physiologic Function]

Phrase: "were"

Phrase: "not significantly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "affected by the selection procedure."
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   760   C0036576:selection [Genetic Function]
   760   C0184661:Procedure [Diagnostic Procedure,Therapeutic or Preventive Procedure]
   760   C0392760:Affected [Functional Concept]
   760   C1314939:Affected [Functional Concept]
   760   C1948041:Procedure [Therapeutic or Preventive Procedure]
   760   C2700391:Procedure [Activity]
   760   C3274430:PROCEDURE [Health Care Activity]
   760   C3538935:Procedure [Idea or Concept]
   760   C3539779:Procedure [Intellectual Product]
   726 E C0001721:Affect [Mental Process]
Processing 00000000.tx.247: Patients receiving a CD34-selected autograft also had a lower incidence of toxicities associated with the autograft infusion and had no greater incidence of infections or bleeding events when compared with patients receiving an unselected autograft. 

Phrase: "Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "receiving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514756:Receive [Qualitative Concept]

Phrase: "a CD34-selected autograft also"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0040736:autograft [Therapeutic or Preventive Procedure]
   756 E C0559189:Autotransplant [Biomedical or Dental Material]

Phrase: "had"

Phrase: "a lower incidence of toxicities"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0021149:Incidence [Quantitative Concept]
   760   C0220856:incidence [Functional Concept]

Phrase: "associated with the autograft infusion"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   806   C0332281:Associated with [Qualitative Concept]
           Associated
   760   C0040736:autograft [Therapeutic or Preventive Procedure]
   760   C0574032:Infusion [Therapeutic or Preventive Procedure]
   760   C1827465:Infusion [Functional Concept]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]
   704 E C0559189:Autotransplant [Biomedical or Dental Material]

Phrase: "and"

Phrase: "had"

Phrase: "no greater incidence of infections"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0021149:Incidence [Quantitative Concept]
   760   C0220856:incidence [Functional Concept]

Phrase: "or"

Phrase: "bleeding events"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0441471:Events [Event]
   861   C3541888:Events [Classification]

Phrase: "when"

Phrase: "compared with patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C1707455:Compared [Activity]

Phrase: "receiving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514756:Receive [Qualitative Concept]

Phrase: "an unselected autograft."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0040736:autograft [Therapeutic or Preventive Procedure]
   805 E C0559189:Autotransplant [Biomedical or Dental Material]
Processing 00000000.tx.248: Further follow-up of the patients enrolled and transplanted on this trial will be required to determine whether tumor purging by CD34 selection will have a significant effect on progression-free and overall survival for multiple myeloma patients, although this study may not be sufficiently powered to detect a small but still clinically relevant difference. 

Phrase: "Further follow-up of the patients"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0589120:Follow-up [Finding]
   790   C1522577:follow-up [Health Care Activity]
   790   C1704685:FOLLOW-UP [Intellectual Product]
   790   C3274571:FOLLOW-UP [Health Care Activity]
   753   C0332283:follow [Temporal Concept]
   753   C1719822:Follow [Intellectual Product]

Phrase: "enrolled"

Phrase: "and"

Phrase: "transplanted on this trial"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0008976:Trial [Research Activity]
   770   C0040732:transplanted [Therapeutic or Preventive Procedure]
   770   C0332835:transplanted [Tissue]
   770   C0700106:Transplanted [Functional Concept]

Phrase: "will"

Phrase: "be"

Phrase: "required"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514873:Required [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "determine"

Phrase: "whether"

Phrase: "tumor purging by CD34 selection"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   806   C2348825:Tumor Purging [Therapeutic or Preventive Procedure]
   760   C0855227:purging [Disease or Syndrome]
   726 E C0722910:Purge [Lipid,Pharmacologic Substance]

Phrase: "will"

Phrase: "have"

Phrase: "a significant effect on progression-free"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "and"

Phrase: "overall survival for multiple myeloma patients,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0038952:Survival [Activity]
   753   C0220921:survival [Functional Concept]
   753   C0282416:Overall [Intellectual Product]
   753   C1561607:Overall [Qualitative Concept]

Phrase: "although"

Phrase: "this study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "may"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "be"

Phrase: "sufficiently"

Phrase: "powered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0032863:powered [Human-caused Phenomenon or Process]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "detect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0442726:detect [Finding]

Phrase: "a small"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0700321:Small [Quantitative Concept]

Phrase: "but"

Phrase: "still clinically relevant difference."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   812   C1705241:*Difference [Quantitative Concept]
   812   C1705242:Difference [Qualitative Concept]
   741 E C0443199:Differential [Qualitative Concept]
Processing 00000000.tx.249: In the absence of larger randomized phase III trials, tumor purging, as a component of a combined treatment strategy, may be a more important issue to be addressed in clinical studies. 

Phrase: "In the absence"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0332197:absence [Quantitative Concept]
  1000   C1689985:Absence [Anatomical Abnormality]
   928 E C2699517:ABSENT [Finding]

Phrase: "of larger randomized phase III trials,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   884   C0282461:Phase III Trials [Research Activity]
   804   C0205390:Phase [Temporal Concept]
   804   C0439070:III [Intellectual Product]
   804   C1705160:III [Qualitative Concept]
   771   C0008976:Trial [Research Activity]

Phrase: "tumor purging,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C2348825:Tumor Purging [Therapeutic or Preventive Procedure]
   861   C0855227:purging [Disease or Syndrome]
   827 E C0722910:Purge [Lipid,Pharmacologic Substance]

Phrase: "as"

Phrase: "a component of a combined treatment strategy,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0449432:Component [Manufactured Object]
   748   C1705248:Component [Conceptual Entity]

Phrase: "may"

Phrase: "be"

Phrase: "a more important issue to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0033213:Issue [Finding]
   812   C1706387:Issue [Intellectual Product]

Phrase: "be"

Phrase: "addressed in clinical studies."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   833   C0008972:Clinical Studies [Research Activity]
   770   C0205210:Clinical [Qualitative Concept]
   770   C0947630:studies [Laboratory Procedure]
   737   C0376649:Address [Intellectual Product]
   737 E C0557651:Study [Manufactured Object]
   737   C1442065:Address [Spatial Concept]
   737 E C2603343:Study [Research Activity]
Processing 00000000.tx.250: To that end, the CEPRATE SC System can provide efficient tumor removal without compromising hematopoietic recovery.  

Phrase: "To"

Phrase: "that end,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0444930:End [Spatial Concept]
  1000   C2746065:End [Temporal Concept]
   944 E C0205088:Terminal [Temporal Concept]
   944 E C1705314:Terminal [Manufactured Object]
   944 E C1705315:Terminal [Spatial Concept]

Phrase: "the CEPRATE SC System"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   812   C0449913:System [Functional Concept]
   812   C1553451:System [Manufactured Object]
   812   C1704459:System [Medical Device]
   741 E C0205373:Systemic [Functional Concept]

Phrase: "can"

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "efficient tumor removal without compromising hematopoietic recovery."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C0749736:tumor removal [Therapeutic or Preventive Procedure]
   748   C0015252:Removal [Therapeutic or Preventive Procedure]
   748   C0728940:Removal [Therapeutic or Preventive Procedure]
Processing 00000000.tx.251: ACKNOWLEDGMENT The authors thank Drs Mike White, Monica Krieger, and Amy Sing for their editorial contributions and Donna Speron for her assistance in the preparation of this manuscript.  

Phrase: "ACKNOWLEDGMENT"

Phrase: "The authors"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0221193:Authors [Professional or Occupational Group]

Phrase: "thank"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986676:THANK [Gene or Genome]

Phrase: "Drs Mike White,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0007457:White [Population Group]
   827   C0043157:White [Population Group]
   827   C0220938:White [Qualitative Concept]

Phrase: "Monica Krieger,"

Phrase: "and"

Phrase: "Amy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1424808:AMY [Gene or Genome]

Phrase: "Sing for their editorial contributions"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0037173:SING [Geographic Area]
   760   C0234857:sing [Individual Behavior]

Phrase: "and"

Phrase: "Donna Speron for her assistance"

Phrase: "in the preparation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0455052:Preparation [Health Care Activity]
  1000   C1521827:Preparation [Functional Concept]

Phrase: "of this manuscript."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0600659:Manuscript [Intellectual Product,Manufactured Object]
Processing 00000000.tx.252: FOOTNOTES Submitted June 11,1998; 

Phrase: "FOOTNOTES"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C2825232:Footnote [Intellectual Product]

Phrase: "Submitted"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1515023:Submitted [Functional Concept]

Phrase: "June 11,"

Phrase: "1998"

Phrase: ";"
Processing 00000000.tx.253: accepted October 30,1998. 

Phrase: "accepted October 30,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1272684:Accepted [Qualitative Concept]
   827   C1548435:Accepted [Idea or Concept]

Phrase: "1998."
Processing 00000000.tx.254: Supported in part by a grant from CellPro, Inc (Bothell, WA). 

Phrase: "Supported in part"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0449719:Part [Spatial Concept]
   790   C1521721:Supported [Conceptual Entity]
   790   C1709471:Part [Quantitative Concept]
   756 E C0183683:Support [Medical Device]

Phrase: "by a grant"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0018173:Grant [Quantitative Concept]
  1000   C1548284:Grant [Idea or Concept]

Phrase: "from CellPro,"

Phrase: "Inc (Bothell,"

Phrase: "WA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043038:WA [Geographic Area]

Phrase: ")."
Processing 00000000.tx.255: The publication costs of this article were defrayed in part by page charge payment. 

Phrase: "The publication"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0034036:Publication [Intellectual Product,Manufactured Object]
  1000   C0034037:Publication [Occupational Activity]
  1000   C1704324:Publication [Intellectual Product]

Phrase: "costs of this article"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0010186:Cost [Quantitative Concept]
   770   C0220812:Costs [Quantitative Concept]
   770   C1706852:Article [Intellectual Product]

Phrase: "were"

Phrase: "defrayed in part"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0449719:Part [Spatial Concept]
   790   C1709471:Part [Quantitative Concept]

Phrase: "by page charge payment."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0220808:payment [Quantitative Concept]
   827   C0680264:payment [Quantitative Concept]
Processing 00000000.tx.256: This article must therefore be hereby marked "advertisement" in accordance with 18U.S.C. section 1734solely to indicate this fact. 

Phrase: "This article"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1706852:Article [Intellectual Product]

Phrase: "must"

Phrase: "therefore"

Phrase: "be"

Phrase: "hereby"

Phrase: "marked"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0522501:Marked [Qualitative Concept]
  1000   C1706089:Marked [Qualitative Concept]

Phrase: """advertisement"""
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0949214:advertisement [Intellectual Product]

Phrase: "in accordance with 18U.S.C. section 1734solely to"

Phrase: "indicate"

Phrase: "this fact."
Processing 00000000.tx.257: Address reprint requests to Robert Vescio, MD, University of California, Los Angeles, 111-H West LA VAMC, 11301Wilshire Blvd, Los Angeles, CA 90073.  

Phrase: "Address reprint"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3273171:Reprint [Intellectual Product]

Phrase: "requests to Robert Vescio,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0686900:request [Functional Concept]
   770   C1272683:Request [Functional Concept]
   770   C1522634:Request [Intellectual Product]

Phrase: "MD,"

Phrase: "University of California,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0006754:California [Geographic Area]
   827   C0041740:University [Manufactured Object,Organization]
   827   C3146274:California [Plant]

Phrase: "Los Angeles,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024015:Los Angeles [Geographic Area]

Phrase: "111-H West LA VAMC,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0228335:VAmc [Body Part, Organ, or Organ Component]

Phrase: "11301Wilshire Blvd,"

Phrase: "Los Angeles,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024015:Los Angeles [Geographic Area]

Phrase: "CA 90073."
Processing 00000000.tx.258: REFERENCES TOP ABSTRACT INTRODUCTION REFERENCES 1. 

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "TOP ABSTRACT INTRODUCTION"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1293116:Introduction [Health Care Activity]
   827   C1875307:INTRODUCTION [Manufactured Object]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "1."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]
Processing 00000000.tx.259: Kyle RA: Newer approaches to the management of multiple myeloma. 

Phrase: "Kyle RA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538806:Ra [Spatial Concept]

Phrase: ":"

Phrase: "Newer approaches to the management of multiple myeloma."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0449445:Approaches [Spatial Concept]
   744   C1292724:Approaches [Functional Concept]
Processing 00000000.tx.260: Cancer 72:3489, 1993[Medline] [OrderarticleviaInfotrieve] 2. 

Phrase: "Cancer 72"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0006826:Cancer [Neoplastic Process]
   861   C0998265:Cancer [Eukaryote]
   861   C1306459:Cancer [Finding]

Phrase: ":"

Phrase: "3489,"

Phrase: "1993"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]
Processing 00000000.tx.261: Alexanian R, Dimopoulous M: The treatment of multiple myeloma. 

Phrase: "Alexanian R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Dimopoulous M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: ":"

Phrase: "The treatment of multiple myeloma."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538994:TREATMENT [Research Activity]
Processing 00000000.tx.262: N Engl J Med 330:484, 1994[Free FullText] 3. 

Phrase: "N Engl J Med 330"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   804   C0441922:N+ [Intellectual Product]
   804   C1414400:ENGL [Gene or Genome]
   804   C1553036:[n] [Quantitative Concept]

Phrase: ":"

Phrase: "484,"

Phrase: "1994"

Phrase: "[Free FullText"

Phrase: "] 3."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]
Processing 00000000.tx.263: Imamura Y, Takagi T, Yawata Y, Nishinarita S, Kosaka M, Mikuni C, Takatsuki K, Sezaki T, Mori M: Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. 

Phrase: "Imamura Y,"

Phrase: "Takagi T,"

Phrase: "Yawata Y,"

Phrase: "Nishinarita S,"

Phrase: "Kosaka M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Mikuni C,"

Phrase: "Takatsuki K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Sezaki T,"

Phrase: "Mori M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: ":"

Phrase: "Combination chemotherapy with MCNU,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C0013218:Combination Chemotherapy [Therapeutic or Preventive Procedure]
   833   C1521750:Combination Chemotherapy [Therapeutic or Preventive Procedure]
   770   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   770   C0013217:chemotherapy [Functional Concept]
   770   C0205195:Combination [Qualitative Concept]
   770   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
   770   C1947911:Combination [Physical Object]

Phrase: "vindesine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0042682:Vindesine [Organic Chemical,Pharmacologic Substance]

Phrase: "melphalan,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0025241:Melphalan [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   944 E C0591063:Alkeran [Amino Acid, Peptide, or Protein,Pharmacologic Substance]

Phrase: "and"

Phrase: "prednisolone"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0032950:prednisolone [Pharmacologic Substance,Steroid]
   944 E C0699535:Delta- Cortef [Pharmacologic Substance,Steroid]
   944 E C0699538:Sterane [Pharmacologic Substance,Steroid]
   944 E C0701477:Meticortelone [Pharmacologic Substance,Steroid]
   944 E C0702183:Hydeltra [Pharmacologic Substance,Steroid]

Phrase: "(MCNU-VMP therapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0039798:therapy [Functional Concept]
   827   C0087111:Therapy [Therapeutic or Preventive Procedure]
   827   C1363945:Therapy [Finding]

Phrase: ")"

Phrase: "in induction therapy"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0600558:Induction Therapy [Therapeutic or Preventive Procedure]
   861   C0039798:therapy [Functional Concept]
   861   C0087111:Therapy [Therapeutic or Preventive Procedure]
   861   C0205263:Induction [Functional Concept]
   861   C0857127:induction [Therapeutic or Preventive Procedure]
   861   C1363945:Therapy [Finding]

Phrase: "for multiple myeloma."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   861   C0439064:Multiple [Quantitative Concept]
   861   C3538749:Myeloma [Intellectual Product]
Processing 00000000.tx.264: Int J Hematol 59:1994 4. 

Phrase: "Int J Hematol 59"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0063789:INT [Organic Chemical]
   812   C3272375:INT [Intellectual Product]

Phrase: ":"

Phrase: "1994 4."
Processing 00000000.tx.265: Gregory WM, Richards MA, Malpas JS: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. 

Phrase: "Gregory WM,"

Phrase: "Richards MA,"

Phrase: "Malpas JS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1552154:Js [Body Part, Organ, or Organ Component]

Phrase: ":"

Phrase: "Combination chemotherapy"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0013218:Combination Chemotherapy [Therapeutic or Preventive Procedure]
  1000   C1521750:Combination Chemotherapy [Therapeutic or Preventive Procedure]
   861   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   861   C0013217:chemotherapy [Functional Concept]
   861   C0205195:Combination [Qualitative Concept]
   861   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
   861   C1947911:Combination [Physical Object]

Phrase: "versus"

Phrase: "melphalan"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0025241:Melphalan [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   944 E C0591063:Alkeran [Amino Acid, Peptide, or Protein,Pharmacologic Substance]

Phrase: "and"

Phrase: "prednisolone in the treatment of multiple myeloma"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0032950:prednisolone [Pharmacologic Substance,Steroid]

Phrase: ":"

Phrase: "An overview of published trials."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0814812:overview [Intellectual Product]
Processing 00000000.tx.266: J Clin Oncol 10:334, 1992[Abstract] 5. 

Phrase: "J Clin Oncol 10"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1315013:CLIN [Intellectual Product]

Phrase: ":"

Phrase: "334,"

Phrase: "1992"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 5."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]
Processing 00000000.tx.267: Jagannath S, Vesole DH, Tricot G, Crowley J, Salmon SE, Barlogie B: Hematopoietic stem cell transplantations for multiple myeloma. 

Phrase: "Jagannath S,"

Phrase: "Vesole DH,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1832586:DH [Disease or Syndrome]

Phrase: "Tricot G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Crowley J,"

Phrase: "Salmon SE,"

Phrase: "Barlogie B"

Phrase: ":"

Phrase: "Hematopoietic stem cell transplantations for multiple myeloma."
Meta Candidates (Total=19; Excluded=2; Pruned=0; Remaining=17)
   820   C0472699:Hematopoietic Stem Cell Transplantation [Therapeutic or Preventive Procedure]
           Hematopoietic Cell Transplantation
   814   C0018956:Haematopoietic stem cell [Cell]
   814   C1504389:Transplantations, Stem Cell [Therapeutic or Preventive Procedure]
   778   C0038250:Stem cell [Cell]
   774   C0333843:Myeloma cell [Cell]
   774   C2323499:Hematopoietic cell [Cell]
   762   C0206153:Cell Transplantation [Therapeutic or Preventive Procedure]
   748   C0007634:Cell [Cell]
   748   C0018957:Haematopoietic [Body System]
   748   C0040732:Transplantations [Therapeutic or Preventive Procedure]
   748   C0229601:Hematopoietic [Functional Concept]
   748   C0242767:Stem [Plant]
   748   C1186763:Stem [Body Part, Organ, or Organ Component]
   748   C1269647:Cell [Cell]
   748   C1704653:Cell [Medical Device]
   748   C1948049:Cell [Spatial Concept]
   714 E C0029216:Transplantation [Therapeutic or Preventive Procedure]
   714 E C0040733:transplantation [Functional Concept]
Processing 00000000.tx.268: Oncology 8:89, 1994[Medline] [OrderarticleviaInfotrieve] 6. 

Phrase: "Oncology 8"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0278627:Oncology [Biomedical Occupation or Discipline]
   789 E C0205478:Oncologic [Biomedical Occupation or Discipline]

Phrase: ":"

Phrase: "89,"

Phrase: "1994"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 6."
Processing 00000000.tx.269: Harousseau JL, Milpied N, Laporte JP, Collombat P, Facon T, Tigaud JD, Cassassus P, Gilhot F, Ifrah N, Gandhour C: Double-intensive therapy in high-risk multiple myeloma. 

Phrase: "Harousseau JL,"

Phrase: "Milpied N,"

Phrase: "Laporte JP,"

Phrase: "Collombat P,"

Phrase: "Facon T,"

Phrase: "Tigaud JD,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1549972:JD [Intellectual Product]

Phrase: "Cassassus P,"

Phrase: "Gilhot F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Ifrah N,"

Phrase: "Gandhour C"

Phrase: ":"

Phrase: "Double-intensive therapy in high-risk multiple myeloma."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   767   C0033972:Multiple therapy [Therapeutic or Preventive Procedure]
   744   C0039798:therapy [Functional Concept]
   744   C0087111:Therapy [Therapeutic or Preventive Procedure]
   744   C1363945:Therapy [Finding]
Processing 00000000.tx.270: Blood 79:2827, 1992[Abstract] 7. 

Phrase: "Blood 79"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "2827,"

Phrase: "1992"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 7."
Processing 00000000.tx.271: Bjorkstrand B, Ljungman P, Brandt TL, Brunet S, Carlson K, Cavo M, Fassas A, Ferrant A, Goldstone AH, DeLaurenzi A, Prentice HG, Remes K, Samson D, Verdonck LF, Gahrton G: Autologous stem cell transplantation (ASCT) in multiple myeloma. 

Phrase: "Bjorkstrand B,"

Phrase: "Ljungman P,"

Phrase: "Brandt TL,"

Phrase: "Brunet S,"

Phrase: "Carlson K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Cavo M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Fassas A,"

Phrase: "Ferrant A,"

Phrase: "Goldstone AH,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1836672:AH [Disease or Syndrome]

Phrase: "DeLaurenzi A,"

Phrase: "Prentice HG,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0025424:Hg [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   861   C2347108:Hg+ [Element, Ion, or Isotope]
   861   C2347109:Hg++ [Element, Ion, or Isotope]
   861   C2348272:Hg [Element, Ion, or Isotope]

Phrase: "Remes K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Samson D, Verdonck LF,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1416933:LF [Gene or Genome]
   812   C2986618:LF [Gene or Genome]

Phrase: "Gahrton G"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: ":"

Phrase: "Autologous stem cell transplantation (ASCT) in multiple myeloma."
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
   853   C1831743:Autologous Stem Cell Transplantation [Therapeutic or Preventive Procedure]
   814   C1504389:Stem Cell Transplantation [Therapeutic or Preventive Procedure]
   778   C0038250:Stem cell [Cell]
   778   C0206153:Cell Transplantation [Therapeutic or Preventive Procedure]
   774   C0040736:Transplantation, Autologous [Therapeutic or Preventive Procedure]
   774   C0333843:Myeloma cell [Cell]
   748   C0007634:Cell [Cell]
   748   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   748   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   748   C0040733:transplantation [Functional Concept]
   748   C0242767:Stem [Plant]
   748   C0439859:Autologous [Qualitative Concept]
   748   C1186763:Stem [Body Part, Organ, or Organ Component]
   748   C1269647:Cell [Cell]
   748   C1704653:Cell [Medical Device]
   748   C1948049:Cell [Spatial Concept]
Processing 00000000.tx.272: A study of the Europeon BMT registry. 

Phrase: "A study of the Europeon BMT registry."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   774   C2985664:Study Registry [Organization]
   748   C0557651:Study [Manufactured Object]
   748   C2603343:Study [Research Activity]
Processing 00000000.tx.273: Blood 84:535a, 1994 (abstr, suppl 1) 8. 

Phrase: "Blood 84"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "535a,"

Phrase: "1994"

Phrase: "(abstr,"

Phrase: "suppl 1"

Phrase: ")"

Phrase: "8."
Processing 00000000.tx.274: Fermand JP, Chevret S, Ravaud P, Divine M, Leblond V, Dreyfus F, Mariette X, Brouet JC: High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: Results of phase II trial involving 63patients. 

Phrase: "Fermand JP,"

Phrase: "Chevret S,"

Phrase: "Ravaud P,"

Phrase: "Divine M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Leblond V,"

Phrase: "Dreyfus F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Mariette X,"

Phrase: "Brouet JC"

Phrase: ":"

Phrase: "High-dose chemoradiotherapy"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0436307:Chemoradiotherapy [Therapeutic or Preventive Procedure]
   734   C0444956:High dose [Quantitative Concept]

Phrase: "and"

Phrase: "autologous blood stem cell transplantation in multiple myeloma"
Meta Candidates (Total=19; Excluded=1; Pruned=0; Remaining=18)
   822   C1831743:Autologous Stem Cell Transplantation [Therapeutic or Preventive Procedure]
   800   C1504389:Stem Cell Transplantation [Therapeutic or Preventive Procedure]
   772   C2336898:Hemal stem cell [Cell]
   770   C0038250:Stem cell [Cell]
   770   C0206153:Cell Transplantation [Therapeutic or Preventive Procedure]
   767   C0005773:Blood cell [Cell]
   767   C0040736:Transplantation, Autologous [Therapeutic or Preventive Procedure]
   767   C0333843:Myeloma cell [Cell]
   744   C0007634:Cell [Cell]
   744   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   744   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   744   C0040733:transplantation [Functional Concept]
   744   C0242767:Stem [Plant]
   744   C1186763:Stem [Body Part, Organ, or Organ Component]
   744   C1269647:Cell [Cell]
   744   C1704653:Cell [Medical Device]
   744   C1948049:Cell [Spatial Concept]
   739 E C2328697:Hemal cell [Cell]
   725   C0189736:blood vessel transplantation [Therapeutic or Preventive Procedure]

Phrase: ":"

Phrase: "Results of phase II trial"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   726   C1274040:Result [Functional Concept]
   726   C1546471:Result [Idea or Concept]
   726   C2825142:Result [Finding]

Phrase: "involving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1314939:Involving [Functional Concept]

Phrase: "63patients."
Processing 00000000.tx.275: Blood 82:2005, 1993[Abstract] 9. 

Phrase: "Blood 82"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "2005,"

Phrase: "1993"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 9."
Processing 00000000.tx.276: Attal M, Huguert F, Schlaifer D, Payen C, Laroche M, Fournie B, Mazieres B, Pris J, Laurent G: Intensive combined therapy for previously untreated aggressive myeloma. 

Phrase: "Attal M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Huguert F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Schlaifer D, Payen C,"

Phrase: "Laroche M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Fournie B,"

Phrase: "Mazieres B,"

Phrase: "Pris J,"

Phrase: "Laurent G"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: ":"

Phrase: "Intensive combined therapy for previously untreated aggressive myeloma."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   770   C0033972:Combined therapy [Therapeutic or Preventive Procedure]
   744   C0039798:therapy [Functional Concept]
   744   C0087111:Therapy [Therapeutic or Preventive Procedure]
   744   C0205195:Combined [Qualitative Concept]
   744   C1363945:Therapy [Finding]
   711 E C0336789:Combine [Manufactured Object]
Processing 00000000.tx.277: Blood 79:1130, 1992[Abstract] 10. 

Phrase: "Blood 79"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "1130,"

Phrase: "1992"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 10."
Processing 00000000.tx.278: Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Cassassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma patients. 

Phrase: "Attal M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Harousseau JL,"

Phrase: "Stoppa"

Phrase: "AM"

Phrase: ","

Phrase: "Sotto JJ,"

Phrase: "Fuzibet JG,"

Phrase: "Rossi JF,"

Phrase: "Cassassus P,"

Phrase: "Maisonneuve H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Facon T,"

Phrase: "Ifrah N,"

Phrase: "Payen C,"

Phrase: "Bataille R"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: ":"

Phrase: "A prospective, randomized trial of autologous bone marrow transplantation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0008976:Trial [Research Activity]

Phrase: "and"

Phrase: "chemotherapy in multiple myeloma patients."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   760   C0013217:chemotherapy [Functional Concept]
   760   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
Processing 00000000.tx.279: N Engl J Med 335:91, 1996[Abstract/Free FullText] 11. 

Phrase: "N Engl J Med 335"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   804   C0441922:N+ [Intellectual Product]
   804   C1414400:ENGL [Gene or Genome]
   804   C1553036:[n] [Quantitative Concept]

Phrase: ":"

Phrase: "91,"

Phrase: "1996"

Phrase: "[Abstract/Free FullText"

Phrase: "] 11."
Processing 00000000.tx.280: Marit G, Faberes C, Pico JL, Boiron JM, Bourhis JH, Brault P, Bernard P, Foures C, Cony-Makhoul, Puntous M, Vezon G, Broustet A, Girualt D, Reiffers J: Autologous peripheral-blood progenitor cell support following high-dose chemotherapy or chemoradiotherapy in patients with high-risk multiple myeloma. 

Phrase: "Marit G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Faberes C,"

Phrase: "Pico JL,"

Phrase: "Boiron JM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: "Bourhis JH,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0268060:JH [Disease or Syndrome]
   861   C1415529:JH [Gene or Genome]

Phrase: "Brault P,"

Phrase: "Bernard P,"

Phrase: "Foures C,"

Phrase: "Cony-Makhoul,"

Phrase: "Puntous M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Vezon G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Broustet A,"

Phrase: "Girualt D, Reiffers J"

Phrase: ":"

Phrase: "Autologous peripheral-blood progenitor cell support"
Meta Candidates (Total=22; Excluded=7; Pruned=0; Remaining=15)
   867   C0005773:Peripheral blood cell [Cell]
           Blood cell
   827   C0038250:Progenitor Cell [Cell]
   827   C0229664:peripheral blood [Body Substance]
           Blood
   811 E C2328697:Hemal cell [Cell]
   799   C0005767:Blood [Tissue]
   799   C0005768:blood [Body Substance]
   799   C0007634:Cell [Cell]
   799   C0183683:Support [Medical Device]
   799   C0205100:Peripheral [Spatial Concept]
   799   C0870134:Progenitor [Family Group]
   799   C1269647:Cell [Cell]
   799   C1521721:Support [Conceptual Entity]
   799   C1704653:Cell [Medical Device]
   799   C1948049:Cell [Spatial Concept]
   785 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   727 E C0333275:Bloody [Qualitative Concept]
   716 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   716 E C0392895:Bloods [Population Group]
   716 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   716 E C1511228:VESSEL, BLOOD [Tissue]

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "high-dose chemotherapy"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C1328050:high-dose chemotherapy [Therapeutic or Preventive Procedure]
   901   C0444956:High dose [Quantitative Concept]
   827   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0013217:chemotherapy [Functional Concept]
   827   C0178602:Dose [Quantitative Concept]
   827   C0205250:High [Qualitative Concept]
   827   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0869039:Dose [Quantitative Concept]
   827   C1114758:Dose # [Clinical Attribute]
   827   C1299351:High [Qualitative Concept]
   827   C2700149:HIGH [Intellectual Product]

Phrase: "or"

Phrase: "chemoradiotherapy in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0436307:Chemoradiotherapy [Therapeutic or Preventive Procedure]

Phrase: "with high-risk multiple myeloma."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   812   C0439064:Multiple [Quantitative Concept]
   812   C3538749:Myeloma [Intellectual Product]
Processing 00000000.tx.281: J Clin Oncol 14:1306, 1996[Abstract] 12. 

Phrase: "J Clin Oncol 14"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1315013:CLIN [Intellectual Product]

Phrase: ":"

Phrase: "1306,"

Phrase: "1996"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 12."
Processing 00000000.tx.282: Dimopoulous M, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, Mehra R, vanBesien K, Delasalle KB, Reading C, Deissseroth AB, Champlin RE: Thiotepa, busulfan, and cyclosphosphamide: A new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. 

Phrase: "Dimopoulous M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Alexanian R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Przepiorka D, Hester J,"

Phrase: "Andersson B,"

Phrase: "Giralt S,"

Phrase: "Mehra R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "vanBesien K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Delasalle KB,"

Phrase: "Reading"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0034754:Reading [Daily or Recreational Activity]
  1000   C1705179:Reading [Finding]

Phrase: "C,"

Phrase: "Deissseroth AB,"

Phrase: "Champlin RE"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986904:RE [Idea or Concept]

Phrase: ":"

Phrase: "Thiotepa,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039871:Thio-Tepa [Hazardous or Poisonous Substance,Organophosphorus Compound,Pharmacologic Substance]

Phrase: "busulfan,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0006463:Busulfan [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance]
   944 E C0700015:Myleran [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "cyclosphosphamide"

Phrase: ":"

Phrase: "A new preparative regimen for autologous marrow"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C1882454:Preparative Regimen [Therapeutic or Preventive Procedure]
   748   C0040808:Regimen [Therapeutic or Preventive Procedure]
   748   C2945654:regimen [Intellectual Product]

Phrase: "or"

Phrase: "blood stem cell transplantation in high-risk multiple myeloma."
Meta Candidates (Total=17; Excluded=1; Pruned=0; Remaining=16)
   790   C1504389:Stem Cell Transplantation [Therapeutic or Preventive Procedure]
   764   C0038250:Stem cell [Cell]
   764   C0206153:Cell Transplantation [Therapeutic or Preventive Procedure]
   762   C0005773:Blood cell [Cell]
   762   C0333843:Myeloma cell [Cell]
   762   C2336898:Hemal stem cell [Cell]
   742   C0007634:Cell [Cell]
   742   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   742   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   742   C0040733:transplantation [Functional Concept]
   742   C0242767:Stem [Plant]
   742   C1186763:Stem [Body Part, Organ, or Organ Component]
   742   C1269647:Cell [Cell]
   742   C1704653:Cell [Medical Device]
   742   C1948049:Cell [Spatial Concept]
   734 E C2328697:Hemal cell [Cell]
   720   C0189736:blood vessel transplantation [Therapeutic or Preventive Procedure]
Processing 00000000.tx.283: Blood 82:2324, 1993[Abstract] 13. 

Phrase: "Blood 82"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "2324,"

Phrase: "1993"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 13."
Processing 00000000.tx.284: Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B: Low-risk intensive therapy for multiple myeloma with combined autologous bone and blood stem cell support. 

Phrase: "Jagannath S,"

Phrase: "Vesole DH,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1832586:DH [Disease or Syndrome]

Phrase: "Glenn L,"

Phrase: "Crowley J,"

Phrase: "Barlogie B"

Phrase: ":"

Phrase: "Low-risk intensive therapy for multiple myeloma"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   774   C0033972:Multiple therapy [Therapeutic or Preventive Procedure]
   748   C0039798:therapy [Functional Concept]
   748   C0087111:Therapy [Therapeutic or Preventive Procedure]
   748   C1363945:Therapy [Finding]

Phrase: "with combined autologous bone"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   827   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   827   C0391978:Bone [Tissue]
   827   C1266908:Bone [Body Part, Organ, or Organ Component]
   827   C1266909:Bone [Body System]
   755 E C0443157:Bony [Functional Concept]

Phrase: "and"

Phrase: "blood stem cell support."
Meta Candidates (Total=22; Excluded=8; Pruned=0; Remaining=14)
   895   C2336898:Hemal stem cell [Cell]
   875   C0005773:Blood cell [Cell]
   861   C0038250:Stem cell [Cell]
   847 E C2328697:Hemal cell [Cell]
   812   C0005767:Blood [Tissue]
   812   C0005768:blood [Body Substance]
   812   C0007634:Cell [Cell]
   812   C0183683:Support [Medical Device]
   812   C0229664:Blood [Body Substance]
   812   C0242767:Stem [Plant]
   812   C1186763:Stem [Body Part, Organ, or Organ Component]
   812   C1269647:Cell [Cell]
   812   C1521721:Support [Conceptual Entity]
   812   C1704653:Cell [Medical Device]
   812   C1948049:Cell [Spatial Concept]
   741 E C0333275:Bloody [Qualitative Concept]
   729 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   729 E C0392895:Bloods [Population Group]
   729 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   729 E C1511228:VESSEL, BLOOD [Tissue]
   712 E C1558950:VASCULAR [Finding]
   712 E C1801960:Vascular [Qualitative Concept]
Processing 00000000.tx.285: Blood 80:1666, 1992[Abstract] 14. 

Phrase: "Blood 80"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "1666,"

Phrase: "1992"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 14."
Processing 00000000.tx.286: Schiller G, Nimer S, Vescio R, Lieb G, Lee M, Gajewski J, Territo M, Berenson J: Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma. 

Phrase: "Schiller G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Nimer S,"

Phrase: "Vescio R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Lieb G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Lee M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Gajewski J,"

Phrase: "Territo M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Berenson J"

Phrase: ":"

Phrase: "Phase I-II study of busulfan"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   820   C0282460:Phase II Study [Research Activity]
   820   C0920321:Phase I Study [Research Activity]
   753   C0557651:Study [Manufactured Object]
   753   C2603343:Study [Research Activity]

Phrase: "and"

Phrase: "cyclophosphamide conditioning for transplantation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   819   C0376450:Transplantation Conditioning [Therapeutic or Preventive Procedure]
   770   C0009647:Conditioning [Mental Process]

Phrase: "in advanced multiple myeloma."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]
Processing 00000000.tx.287: Bone Marrow Transplant 14:131, 1994[Medline] [OrderarticleviaInfotrieve] 15. 

Phrase: "Bone Marrow Transplant 14"
Meta Candidates (Total=17; Excluded=5; Pruned=0; Remaining=12)
   923   C0005961:Bone Marrow Transplant [Therapeutic or Preventive Procedure]
   875   C0005976:Bone transplant [Therapeutic or Preventive Procedure]
   861   C0005953:Bone Marrow [Tissue]
   812   C0040732:Transplant [Therapeutic or Preventive Procedure]
   812   C0086590:Marrow [Food]
   812   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   812   C0332835:Transplant [Tissue]
   812   C0376152:Marrow [Body Part, Organ, or Organ Component]
   812   C0391978:Bone [Tissue]
   812   C1266908:Bone [Body Part, Organ, or Organ Component]
   812   C1266909:Bone [Body System]
   812   C1546708:Marrow [Intellectual Product]
   756 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   756 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   756 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   741 E C0443157:Bony [Functional Concept]
   729 E C0330477:Marrows [Plant]

Phrase: ":"

Phrase: "131,"

Phrase: "1994"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 15."
Processing 00000000.tx.288: Schiller G, Vescio R, Freytes C, Spitzer G, Sahebi F, Lee M, Wu CH, Cao J, Lee JC, Hong CH, Lichtenstein A, Lill M, Hall J, Berenson R, Berenson J: Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. 

Phrase: "Schiller G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Vescio R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Freytes C,"

Phrase: "Spitzer G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Sahebi F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Lee M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Wu CH,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0558269:Ch. [Professional or Occupational Group]
   861   C1552984:[Ch] [Quantitative Concept]

Phrase: "Cao J,"

Phrase: "Lee JC,"

Phrase: "Hong CH,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0558269:Ch. [Professional or Occupational Group]
   861   C1552984:[Ch] [Quantitative Concept]

Phrase: "Lichtenstein A,"

Phrase: "Lill M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Hall J,"

Phrase: "Berenson R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Berenson J"

Phrase: ":"

Phrase: "Transplantation of CD34+ peripheral blood progenitor cells"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   863   C0242602:peripheral blood progenitor cell transplantation [Therapeutic or Preventive Procedure]
   777   C0189736:Transplantation of blood vessel [Therapeutic or Preventive Procedure]
           blood vessel transplantation
   774   C0206153:cells transplantation [Therapeutic or Preventive Procedure]
   748   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   748   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   748   C0040733:transplantation [Functional Concept]

Phrase: "after high-dose chemotherapy"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C1328050:high-dose chemotherapy [Therapeutic or Preventive Procedure]
   901   C0444956:High dose [Quantitative Concept]
   827   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0013217:chemotherapy [Functional Concept]
   827   C0178602:Dose [Quantitative Concept]
   827   C0205250:High [Qualitative Concept]
   827   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0869039:Dose [Quantitative Concept]
   827   C1114758:Dose # [Clinical Attribute]
   827   C1299351:High [Qualitative Concept]
   827   C2700149:HIGH [Intellectual Product]

Phrase: "for patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with advanced multiple myeloma."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]
Processing 00000000.tx.289: Blood 36:390, 1995[Medline] [OrderarticleviaInfotrieve] 16. 

Phrase: "Blood 36"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "390,"

Phrase: "1995"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 16."
Processing 00000000.tx.290: Korbling M, Przepiorka D, Huh YO, Engel H, vanBesien K, Giralt B, Andersson B, Kleine HD, Seong D, Deisseroth AB, Andreef M, Champlin R: Allogenic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. 

Phrase: "Korbling M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Przepiorka D, Huh YO,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1413296:Yo [Gene or Genome]

Phrase: "Engel H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "vanBesien K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Giralt B,"

Phrase: "Andersson B,"

Phrase: "Kleine HD,"

Phrase: "Seong D, Deisseroth AB,"

Phrase: "Andreef M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Champlin R"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: ":"

Phrase: "Allogenic blood stem cell transplantation for refractory leukemia"
Meta Candidates (Total=19; Excluded=1; Pruned=0; Remaining=18)
   800   C1504389:Stem Cell Transplantation [Therapeutic or Preventive Procedure]
   793   C0280141:Leukemia Stem Cell [Neoplastic Process]
   793   C1378511:LEUKEMIA STEM CELL [Neoplastic Process]
   772   C2336898:Hemal stem cell [Cell]
   770   C0038250:Stem cell [Cell]
   770   C0206153:Cell Transplantation [Therapeutic or Preventive Procedure]
   767   C0005773:Blood cell [Cell]
   744   C0007634:Cell [Cell]
   744   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   744   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   744   C0040733:transplantation [Functional Concept]
   744   C0242767:Stem [Plant]
   744   C1186763:Stem [Body Part, Organ, or Organ Component]
   744   C1269647:Cell [Cell]
   744   C1704653:Cell [Medical Device]
   744   C1948049:Cell [Spatial Concept]
   739 E C2328697:Hemal cell [Cell]
   731   C1517806:Leukemic Cell [Cell]
   725   C0189736:blood vessel transplantation [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "lymphoma"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024299:Lymphoma [Neoplastic Process]

Phrase: ":"

Phrase: "Potential advantage of blood"

Phrase: "over marrow allografts."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0040739:allografts [Therapeutic or Preventive Procedure]
   861   C0450127:Allografts [Biomedical or Dental Material]
Processing 00000000.tx.291: Blood 85:1659, 1995[Abstract/Free FullText] 17. 

Phrase: "Blood 85"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "1659,"

Phrase: "1995"

Phrase: "[Abstract/Free FullText"

Phrase: "] 17."
Processing 00000000.tx.292: Vescio R, Han EJ, Schiller GJ, Lee JC, Wu CH, Cao J, Shin J, Kim A, Lichtenstein AK, Berenson JR: Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. 

Phrase: "Vescio R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Han EJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1718783:Ej [Immunologic Factor]

Phrase: "Schiller GJ,"

Phrase: "Lee JC,"

Phrase: "Wu CH,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0558269:Ch. [Professional or Occupational Group]
   861   C1552984:[Ch] [Quantitative Concept]

Phrase: "Cao J,"

Phrase: "Shin J,"

Phrase: "Kim A,"

Phrase: "Lichtenstein AK,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0001905:AK [Geographic Area]
   861   C1412243:AK [Gene or Genome]

Phrase: "Berenson JR"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1708595:Jr [Idea or Concept]
   861   C3280986:JR [Disease or Syndrome]

Phrase: ":"

Phrase: "Quantitative comparison of multiple myeloma tumor contamination"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1707455:Comparison [Activity]

Phrase: "in bone marrow harvest"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0194015:Bone marrow harvest [Therapeutic or Preventive Procedure]
   827   C1512335:Harvest [Health Care Activity]
   734   C0005953:Bone Marrow [Tissue]

Phrase: "and"

Phrase: "leukapheresis autografts."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0040736:autografts [Therapeutic or Preventive Procedure]
   861   C0559189:Autografts [Biomedical or Dental Material]
Processing 00000000.tx.293: Bone Marrow Transplant 18:103, 1996[Medline] [OrderarticleviaInfotrieve] 18. 

Phrase: "Bone Marrow Transplant 18"
Meta Candidates (Total=17; Excluded=5; Pruned=0; Remaining=12)
   923   C0005961:Bone Marrow Transplant [Therapeutic or Preventive Procedure]
   875   C0005976:Bone transplant [Therapeutic or Preventive Procedure]
   861   C0005953:Bone Marrow [Tissue]
   812   C0040732:Transplant [Therapeutic or Preventive Procedure]
   812   C0086590:Marrow [Food]
   812   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   812   C0332835:Transplant [Tissue]
   812   C0376152:Marrow [Body Part, Organ, or Organ Component]
   812   C0391978:Bone [Tissue]
   812   C1266908:Bone [Body Part, Organ, or Organ Component]
   812   C1266909:Bone [Body System]
   812   C1546708:Marrow [Intellectual Product]
   756 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   756 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   756 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   741 E C0443157:Bony [Functional Concept]
   729 E C0330477:Marrows [Plant]

Phrase: ":"

Phrase: "103,"

Phrase: "1996"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 18."
Processing 00000000.tx.294: Gertz MA, Witzig TE, Pineda AA, Greipp P, Kyle RA, Litzow MR: Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. 

Phrase: "Gertz MA,"

Phrase: "Witzig TE,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0039462:Te [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   861   C1705540:TE [Conceptual Entity]

Phrase: "Pineda AA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1235746:Aa [Plant]
   861   C1882141:aa [Qualitative Concept]

Phrase: "Greipp P,"

Phrase: "Kyle RA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538806:Ra [Spatial Concept]

Phrase: "Litzow MR"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2347167:Mr. [Conceptual Entity]

Phrase: ":"

Phrase: "Monoclonal plasma cells in the blood stem cell harvest"
Meta Candidates (Total=14; Excluded=4; Pruned=0; Remaining=10)
   781   C0411265:cells harvest stem [Therapeutic or Preventive Procedure]
   767   C0032112:Blood plasma cell [Cell]
           Plasma Cells
   762   C0005773:Blood Cells [Cell]
   762   C0032105:Blood Plasma [Body Substance]
           Plasma
   762   C0038250:Stem cells [Cell]
   742   C0007634:Cells [Cell]
   742   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]
   742   C3282337:Cells [Cell]
   717 E C2328697:Hemal cell [Cell]
   708 E C1269647:Cell [Cell]
   708 E C1704653:Cell [Medical Device]
   708 E C1948049:Cell [Spatial Concept]

Phrase: "from patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with multiple myeloma"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   861   C0439064:Multiple [Quantitative Concept]
   861   C3538749:Myeloma [Intellectual Product]

Phrase: "are"

Phrase: "associated with shortened relapse-free survival"
Meta Candidates (Total=14; Excluded=3; Pruned=0; Remaining=11)
   790   C0332281:Associated with [Qualitative Concept]
           Associated
   753   C0035020:Relapse [Phenomenon or Process]
   753   C0038952:Survival [Activity]
   753   C0205336:relapse [Temporal Concept]
   753   C0220921:survival [Functional Concept]
   753   C0277556:Relapse [Disease or Syndrome]
   753   C0332296:free [Functional Concept]
   753   C1282927:Shortened [Qualitative Concept]
   753   C1880497:Free [Qualitative Concept]
   753   C1996904:Free [Qualitative Concept]
   719 E C0441636:shorten [Therapeutic or Preventive Procedure]
   719 E C0750490:Associate [Idea or Concept]
   719 E C1706221:Associate [Professional or Occupational Group]

Phrase: "after transplantation."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0029216:Transplantation [Therapeutic or Preventive Procedure]
  1000   C0040732:Transplantation [Therapeutic or Preventive Procedure]
  1000   C0040733:transplantation [Functional Concept]
Processing 00000000.tx.295: Bone Marrow Transplant 337:19, 1997 19. 

Phrase: "Bone Marrow Transplant 337"
Meta Candidates (Total=17; Excluded=5; Pruned=0; Remaining=12)
   923   C0005961:Bone Marrow Transplant [Therapeutic or Preventive Procedure]
   875   C0005976:Bone transplant [Therapeutic or Preventive Procedure]
   861   C0005953:Bone Marrow [Tissue]
   812   C0040732:Transplant [Therapeutic or Preventive Procedure]
   812   C0086590:Marrow [Food]
   812   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   812   C0332835:Transplant [Tissue]
   812   C0376152:Marrow [Body Part, Organ, or Organ Component]
   812   C0391978:Bone [Tissue]
   812   C1266908:Bone [Body Part, Organ, or Organ Component]
   812   C1266909:Bone [Body System]
   812   C1546708:Marrow [Intellectual Product]
   756 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   756 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   756 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   741 E C0443157:Bony [Functional Concept]
   729 E C0330477:Marrows [Plant]

Phrase: ":"

Phrase: "19,"

Phrase: "1997 19."
Processing 00000000.tx.296: Berenson J, Wong R, Kim K, Brown N, Lichtenstein A: Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. 

Phrase: "Berenson J,"

Phrase: "Wong R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Kim K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Brown N,"

Phrase: "Lichtenstein A"

Phrase: ":"

Phrase: "Evidence for peripheral blood B lymphocyte"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0332120:Evidence [Functional Concept]

Phrase: "but"

Phrase: "not T lymphocyte involvement in multiple myeloma."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1314939:Involvement [Functional Concept]
Processing 00000000.tx.297: Blood 70:1550, 1987[Abstract] 20. 

Phrase: "Blood 70"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "1550,"

Phrase: "1987"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 20."
Processing 00000000.tx.298: Billadeau D, Quam L, Thomas W, Kay N, Greipp P, Kyle R, Oken MM, VanNess B: Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. 

Phrase: "Billadeau"

Phrase: "D"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205173:Double [Functional Concept]
  1000   C1705764:Double [Activity]
  1000   C1705765:Double [Qualitative Concept]

Phrase: ","

Phrase: "Quam L,"

Phrase: "Thomas W,"

Phrase: "Kay N,"

Phrase: "Greipp P,"

Phrase: "Kyle R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Oken MM,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]

Phrase: "VanNess B"

Phrase: ":"

Phrase: "Detection"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1511790:Detection [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "quantitation of malignant cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1709793:Quantitation [Quantitative Concept]

Phrase: "in the peripheral blood"
Meta Candidates (Total=13; Excluded=8; Pruned=0; Remaining=5)
  1000   C0229664:peripheral blood [Body Substance]
           Blood
   958 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0205100:Peripheral [Spatial Concept]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: "of multiple myeloma patients."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0030705:Patients [Patient or Disabled Group]
   734   C0026764:Multiple Myeloma [Neoplastic Process]
Processing 00000000.tx.299: Blood 80:1818, 1992[Abstract] 21. 

Phrase: "Blood 80"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "1818,"

Phrase: "1992"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 21."
Processing 00000000.tx.300: Pilarski LM, Jensen GS: Monoclonal circulating B cells in multiple myeloma. 

Phrase: "Pilarski LM,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1261082:LM [Body Part, Organ, or Organ Component]
   861   C1551056:lm [Quantitative Concept]
   861   C2981682:LM [Quantitative Concept]

Phrase: "Jensen GS"

Phrase: ":"

Phrase: "Monoclonal circulating B cells in multiple myeloma."
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   778   C0004561:B-Cells [Cell]
   774   C0333843:cells myeloma [Cell]
   748   C0007634:Cells [Cell]
   748   C3282337:Cells [Cell]
   714 E C1269647:Cell [Cell]
   714 E C1704653:Cell [Medical Device]
   714 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.301: A continously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. 

Phrase: "A continously"

Phrase: "differentiating"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205615:differentiating [Qualitative Concept]

Phrase: ","

Phrase: "possibly invasive, population"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0032659:Population [Quantitative Concept]
   827   C1257890:Population [Population Group]

Phrase: "as"

Phrase: "defined by expression of CD45 isoforms"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0185117:Expression [Therapeutic or Preventive Procedure]
   753   C0597298:Isoforms [Amino Acid, Peptide, or Protein]
   753   C1704788:Defined [Conceptual Entity]
   753   C3539106:Defined [Intellectual Product]

Phrase: "and"

Phrase: "adhesion molecules."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   983   C0007578:Adhesion Molecule [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0567416:molecules [Substance]
   777 E C1521991:Molecular [Qualitative Concept]
Processing 00000000.tx.302: Hematol Oncol Clin North Am 6:297, 1992[Medline] [OrderarticleviaInfotrieve] 22. 

Phrase: "Hematol Oncol Clin North"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1709269:North [Spatial Concept]

Phrase: "Am"

Phrase: "6"

Phrase: ":"

Phrase: "297,"

Phrase: "1992"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 22."
Processing 00000000.tx.303: Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ihle JN: Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. 

Phrase: "Brenner MK,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3539059:MK [Idea or Concept]

Phrase: "Rill DR,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0031831:DR [Professional or Occupational Group]
   861   C1707664:DR [Biomedical or Dental Material]
   861   C2348314:Dr. [Conceptual Entity]
   861   C3540849:DR [Idea or Concept]

Phrase: "Moen RC,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1419366:RC [Gene or Genome]

Phrase: "Krance RA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538806:Ra [Spatial Concept]

Phrase: "Mirro J Jr,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1708595:Jr [Idea or Concept]
   827   C3280986:JR [Disease or Syndrome]

Phrase: "Anderson WF,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0043021:WF [Geographic Area]

Phrase: "Ihle JN"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1428813:JN [Gene or Genome]

Phrase: ":"

Phrase: "Gene-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017337:Gene [Gene or Genome]

Phrase: "marking to trace origin of relapse"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   753   C0035020:Relapse [Phenomenon or Process]
   753   C0079946:origin [Classification]
   753   C0205336:relapse [Temporal Concept]
   753   C0277556:Relapse [Disease or Syndrome]
   753   C0439659:Origin [Temporal Concept]
   753   C0442822:Trace [Quantitative Concept]
   753   C0522501:marking [Qualitative Concept]
   753   C1524031:Trace [Qualitative Concept]
   753   C1550512:origin [Intellectual Product]
   753   C1883002:Trace [Functional Concept]
   725   C0852910:Birth mark [Congenital Abnormality]

Phrase: "after autologous bone-marrow transplantation."
Meta Candidates (Total=24; Excluded=5; Pruned=0; Remaining=19)
  1000   C0194037:autologous bone marrow transplantation [Therapeutic or Preventive Procedure]
           Autologous Marrow Transplantation
   923   C0005961:Bone Marrow Transplantation [Therapeutic or Preventive Procedure]
           Marrow Transplantation
   923   C2986504:Autologous Bone Marrow [Body Substance]
   902   C0040736:Transplantation, Autologous [Therapeutic or Preventive Procedure]
   875   C0005976:Bone Transplantation [Therapeutic or Preventive Procedure]
   861   C0005953:Bone Marrow [Tissue]
   812   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   812   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   812   C0040733:transplantation [Functional Concept]
   812   C0086590:Marrow [Food]
   812   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   812   C0376152:Marrow [Body Part, Organ, or Organ Component]
   812   C0391978:Bone [Tissue]
   812   C0439859:Autologous [Qualitative Concept]
   812   C1266908:Bone [Body Part, Organ, or Organ Component]
   812   C1266909:Bone [Body System]
   812   C1546708:Marrow [Intellectual Product]
   756 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   756 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   756 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   741 E C0443157:Bony [Functional Concept]
   729 E C0330477:Marrows [Plant]
Processing 00000000.tx.304: Lancet 341:85, 1993[Medline] [OrderarticleviaInfotrieve] 23. 

Phrase: "Lancet 341"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0777169:Lancet [Medical Device]

Phrase: ":"

Phrase: "85,"

Phrase: "1993"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 23."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]
Processing 00000000.tx.305: Sharp JG, Kessinger A, Mann S, Crouse DA, Armitage JO, Bierman P, Weisenburger DD: Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. 

Phrase: "Sharp JG,"

Phrase: "Kessinger A,"

Phrase: "Mann S,"

Phrase: "Crouse DA,"

Phrase: "Armitage JO,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022418:JO [Geographic Area]

Phrase: "Bierman P,"

Phrase: "Weisenburger DD"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538867:DD [Gene or Genome]

Phrase: ":"

Phrase: "Outcome of high-dose therapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   844   C1518681:Outcome of Therapy [Finding]
           Therapy Outcome
   760   C1274040:Outcome [Functional Concept]

Phrase: "and"

Phrase: "autologous transplantation in non-Hodgkin's lymphoma"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0040736:Transplantation, Autologous [Therapeutic or Preventive Procedure]
   753   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   753   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   753   C0040733:transplantation [Functional Concept]

Phrase: "based on the presence of tumor"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   753   C0027651:Tumor [Neoplastic Process]
   753   C0392148:Presence [Therapeutic or Preventive Procedure]
   753   C1527178:Based [Functional Concept]
   753   C1578706:Tumor [Intellectual Product]
   753   C1705938:Based [Idea or Concept]
   753   C3273930:Tumor [Finding]
   719 E C0002055:base [Inorganic Chemical]
   719 E C0178499:Base [Chemical Viewed Functionally]
   719 E C1880279:Base [Biomedical or Dental Material]

Phrase: "in the marrow"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
  1000   C0086590:Marrow [Food]
  1000   C0376152:Marrow [Body Part, Organ, or Organ Component]
  1000   C1546708:Marrow [Intellectual Product]
   944 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   944 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   944 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   916 E C0330477:Marrows [Plant]

Phrase: "or"

Phrase: "infused hematopoietic harvest."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1512335:Harvest [Health Care Activity]
Processing 00000000.tx.306: J Clin Oncol 14:214, 1996[Abstract] 24. 

Phrase: "J Clin Oncol 14"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1315013:CLIN [Intellectual Product]

Phrase: ":"

Phrase: "214,"

Phrase: "1996"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 24."
Processing 00000000.tx.307: Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, Ritz J, Nadler LM: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. 

Phrase: "Gribben JG,"

Phrase: "Freedman AS,"

Phrase: "Neuberg D, Roy DC,"

Phrase: "Blake KW,"

Phrase: "Woo SD,"

Phrase: "Grossbard ML,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439526:/mL [Quantitative Concept]

Phrase: "Rabinowe SN,"

Phrase: "Coral F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Freeman GJ,"

Phrase: "Ritz J,"

Phrase: "Nadler LM"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1261082:LM [Body Part, Organ, or Organ Component]
   861   C1551056:lm [Quantitative Concept]
   861   C2981682:LM [Quantitative Concept]

Phrase: ":"

Phrase: "Immunologic purging of marrow"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   819   C0085079:Marrow purging [Therapeutic or Preventive Procedure]
   770   C0855227:purging [Disease or Syndrome]
   737 E C0722910:Purge [Lipid,Pharmacologic Substance]

Phrase: "assessed by PCR"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   862   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   760   C0337112:Chain [Manufactured Object]
   760   C0443286:Reaction [Functional Concept]
   760   C1114821:Reaction [Clinical Attribute]
   760   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   760   C1516048:Assessed [Activity]
   760   C1524075:Chain [Idea or Concept]

Phrase: "before autologous bone marrow transplantation"
Meta Candidates (Total=24; Excluded=5; Pruned=0; Remaining=19)
  1000   C0194037:autologous bone marrow transplantation [Therapeutic or Preventive Procedure]
           Autologous Marrow Transplantation
   923   C0005961:Bone Marrow Transplantation [Therapeutic or Preventive Procedure]
           Marrow Transplantation
   923   C2986504:Autologous Bone Marrow [Body Substance]
   902   C0040736:Transplantation, Autologous [Therapeutic or Preventive Procedure]
   875   C0005976:Bone Transplantation [Therapeutic or Preventive Procedure]
   861   C0005953:Bone Marrow [Tissue]
   812   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   812   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   812   C0040733:transplantation [Functional Concept]
   812   C0086590:Marrow [Food]
   812   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   812   C0376152:Marrow [Body Part, Organ, or Organ Component]
   812   C0391978:Bone [Tissue]
   812   C0439859:Autologous [Qualitative Concept]
   812   C1266908:Bone [Body Part, Organ, or Organ Component]
   812   C1266909:Bone [Body System]
   812   C1546708:Marrow [Intellectual Product]
   756 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   756 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   756 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   741 E C0443157:Bony [Functional Concept]
   729 E C0330477:Marrows [Plant]

Phrase: "for B-cell lymphoma."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C0079731:Lymphoma, B-Cell [Neoplastic Process]
   901   C0004561:B-cell [Cell]
   901   C0883208:cell lymphoma [Cell]
   827   C0007634:Cell [Cell]
   827   C0024299:Lymphoma [Neoplastic Process]
   827   C1269647:Cell [Cell]
   827   C1704653:Cell [Medical Device]
   827   C1948049:Cell [Spatial Concept]
Processing 00000000.tx.308: N Engl J Med 325:1525, 1991[Abstract] 25. 

Phrase: "N Engl J Med 325"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   804   C0441922:N+ [Intellectual Product]
   804   C1414400:ENGL [Gene or Genome]
   804   C1553036:[n] [Quantitative Concept]

Phrase: ":"

Phrase: "1525,"

Phrase: "1991"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 25."
Processing 00000000.tx.309: Anderson KC, Barut BA, Ritz J, Freedman AS, Takvorian T, Rabinowe SN, Soiffer R, Heflin L, Coral F, Dear K, Mauch P, Nadler LM: Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. 

Phrase: "Anderson KC,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0022575:kc [Disease or Syndrome]
   861   C1705783:KC [Gene or Genome]

Phrase: "Barut BA,"

Phrase: "Ritz J,"

Phrase: "Freedman AS,"

Phrase: "Takvorian T,"

Phrase: "Rabinowe SN,"

Phrase: "Soiffer R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Heflin L,"

Phrase: "Coral F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Dear K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Mauch P,"

Phrase: "Nadler LM"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1261082:LM [Body Part, Organ, or Organ Component]
   861   C1551056:lm [Quantitative Concept]
   861   C2981682:LM [Quantitative Concept]

Phrase: ":"

Phrase: "Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   772   C0279694:Monoclonal Antibody Therapy [Therapeutic or Preventive Procedure]
   754   C0033972:Multiple therapy [Therapeutic or Preventive Procedure]
   754   C0281176:antibody therapy [Therapeutic or Preventive Procedure]
   738   C0039798:therapy [Functional Concept]
   738   C0087111:Therapy [Therapeutic or Preventive Procedure]
   738   C1363945:Therapy [Finding]
Processing 00000000.tx.310: Blood 77:712, 1991[Abstract] 26. 

Phrase: "Blood 77"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "712,"

Phrase: "1991"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 26."
Processing 00000000.tx.311: Reece DE, Barnett MJ, Connors JM, Klingemann H, O'Reilly SE, Shepherd JD, Sutherland HJ, Phillips GL: Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using bone marrow purged with 4-hydroperoxyclophosphamide. 

Phrase: "Reece DE,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0011198:DE [Geographic Area]
   861   C0017480:DE [Geographic Area]
   861   C3541240:DE [Idea or Concept]

Phrase: "Barnett MJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439254:MJ [Medical Device]

Phrase: "Connors JM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: "Klingemann H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "O'Reilly SE,"

Phrase: "Shepherd JD,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1549972:JD [Intellectual Product]

Phrase: "Sutherland HJ,"

Phrase: "Phillips GL"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0018229:GL [Geographic Area]
   861   C1423073:GL [Gene or Genome]
   861   C1427674:GL [Gene or Genome]

Phrase: ":"

Phrase: "Treatment of multiple myeloma"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0039798:treatment [Functional Concept]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]

Phrase: "with intensive chemotherapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   861   C0013217:chemotherapy [Functional Concept]
   861   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]

Phrase: "followed by autologous BMT"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   833   C0332283:Followed by [Temporal Concept]
           followed
   770   C0005961:BMT [Therapeutic or Preventive Procedure]
   770   C0439859:Autologous [Qualitative Concept]
   737 E C1719822:Follow [Intellectual Product]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "bone marrow"
Meta Candidates (Total=13; Excluded=5; Pruned=0; Remaining=8)
  1000   C0005953:Bone Marrow [Tissue]
   861   C0086590:Marrow [Food]
   861   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   861   C0376152:Marrow [Body Part, Organ, or Organ Component]
   861   C0391978:Bone [Tissue]
   861   C1266908:Bone [Body Part, Organ, or Organ Component]
   861   C1266909:Bone [Body System]
   861   C1546708:Marrow [Intellectual Product]
   805 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   805 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   805 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   789 E C0443157:Bony [Functional Concept]
   777 E C0330477:Marrows [Plant]

Phrase: "purged with 4-hydroperoxyclophosphamide."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C1548399:purged [Idea or Concept]
   737 E C0722910:Purge [Lipid,Pharmacologic Substance]
Processing 00000000.tx.312: Bone Marrow Transplant 11:139, 1993[Medline] [OrderarticleviaInfotrieve] 27. 

Phrase: "Bone Marrow Transplant 11"
Meta Candidates (Total=17; Excluded=5; Pruned=0; Remaining=12)
   923   C0005961:Bone Marrow Transplant [Therapeutic or Preventive Procedure]
   875   C0005976:Bone transplant [Therapeutic or Preventive Procedure]
   861   C0005953:Bone Marrow [Tissue]
   812   C0040732:Transplant [Therapeutic or Preventive Procedure]
   812   C0086590:Marrow [Food]
   812   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   812   C0332835:Transplant [Tissue]
   812   C0376152:Marrow [Body Part, Organ, or Organ Component]
   812   C0391978:Bone [Tissue]
   812   C1266908:Bone [Body Part, Organ, or Organ Component]
   812   C1266909:Bone [Body System]
   812   C1546708:Marrow [Intellectual Product]
   756 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   756 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   756 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   741 E C0443157:Bony [Functional Concept]
   729 E C0330477:Marrows [Plant]

Phrase: ":"

Phrase: "139,"

Phrase: "1993"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 27."
Processing 00000000.tx.313: Vescio R, Hong C, Cao J: The hematopoietic stem cell antigen, is not expressed on the malignant cells in multiple myeloma. 

Phrase: "Vescio R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Hong C,"

Phrase: "Cao J"

Phrase: ":"

Phrase: "The hematopoietic stem cell antigen,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   812   C0003320:Antigen [Immunologic Factor]
   756   C0018956:Haematopoietic stem cell [Cell]
   712 E C2698667:ANTIGENICITY [Regulation or Law]
   708   C2323499:Hematopoietic cell [Cell]

Phrase: "is"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "expressed on the malignant cells"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   806   C0334227:Malignant cells [Cell]
   806   C2698007:Malignant Cells, NOS [Laboratory Procedure]
   760   C0007634:Cells [Cell]
   760   C0205282:Malignant [Qualitative Concept]
   760   C0334590:MALIGNANT [Neoplastic Process]
   760   C1533592:MALIGNANT [Neoplastic Process]
   760   C3282337:Cells [Cell]
   726 E C1269647:Cell [Cell]
   726 E C1704653:Cell [Medical Device]
   726 E C1948049:Cell [Spatial Concept]

Phrase: "in multiple myeloma."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   861   C0439064:Multiple [Quantitative Concept]
   861   C3538749:Myeloma [Intellectual Product]
Processing 00000000.tx.314: Blood 84:3283, 1994[Abstract/Free FullText] 28. 

Phrase: "Blood 84"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "3283,"

Phrase: "1994"

Phrase: "[Abstract/Free FullText"

Phrase: "] 28."
Processing 00000000.tx.315: Lemoli RM, Fortuna A, Motta MR, Rizzi S, Amabile M, Fogli M, Cavo M, Tura S: Transplantation of enriched CD34+ cells provides indirect purging of circulating tumor cells in multiple myeloma (MM) patients. 

Phrase: "Lemoli RM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2951520:RM [Body Location or Region]

Phrase: "Fortuna A,"

Phrase: "Motta MR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2347167:Mr. [Conceptual Entity]

Phrase: "Rizzi S,"

Phrase: "Amabile M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Fogli M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Cavo M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Tura S"

Phrase: ":"

Phrase: "Transplantation of enriched CD34+ cells"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   797   C0206153:cells transplantation [Therapeutic or Preventive Procedure]
   760   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   760   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   760   C0040733:transplantation [Functional Concept]

Phrase: "provides"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0359589:provides [Food]
  1000   C1999230:Provide [Activity]

Phrase: "indirect purging of circulating tumor cells"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   783   C2348825:Tumor Purging [Therapeutic or Preventive Procedure]
   753   C0855227:purging [Disease or Syndrome]
   719 E C0722910:Purge [Lipid,Pharmacologic Substance]

Phrase: "in multiple myeloma (MM) patients."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0030705:Patients [Patient or Disabled Group]
   734   C0026764:Multiple Myeloma [Neoplastic Process]
Processing 00000000.tx.316: Blood 84:399a, 1994 (abstr, suppl 1) 29. 

Phrase: "Blood 84"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "399a,"

Phrase: "1994"

Phrase: "(abstr,"

Phrase: "suppl 1"

Phrase: ")"

Phrase: "29."
Processing 00000000.tx.317: Shpall EJ, LeMaistre CF, Holland K, Ball E, Jones RB, Saral R, Jacobs C, Heimfeld S, Berenson R, Champlin R: A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. 

Phrase: "Shpall EJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1718783:Ej [Immunologic Factor]

Phrase: "LeMaistre CF,"

Phrase: "Holland K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Ball E,"

Phrase: "Jones RB,"

Phrase: "Saral R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Jacobs C,"

Phrase: "Heimfeld S,"

Phrase: "Berenson R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Champlin R"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: ":"

Phrase: "A prospective randomized trial of buffy coat"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0008976:Trial [Research Activity]

Phrase: "versus"

Phrase: "CD34-selected autologous bone marrow support in high-risk breast cancer patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   736   C0183683:Support [Medical Device]
   736   C1521721:Support [Conceptual Entity]

Phrase: "receiving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514756:Receive [Qualitative Concept]

Phrase: "high-dose chemotherapy."
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C1328050:high-dose chemotherapy [Therapeutic or Preventive Procedure]
   901   C0444956:High dose [Quantitative Concept]
   827   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0013217:chemotherapy [Functional Concept]
   827   C0178602:Dose [Quantitative Concept]
   827   C0205250:High [Qualitative Concept]
   827   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0869039:Dose [Quantitative Concept]
   827   C1114758:Dose # [Clinical Attribute]
   827   C1299351:High [Qualitative Concept]
   827   C2700149:HIGH [Intellectual Product]
Processing 00000000.tx.318: Blood 90:4313, 1997[Abstract/Free FullText] 30. 

Phrase: "Blood 90"
Meta Candidates (Total=12; Excluded=7; Pruned=0; Remaining=5)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   861   C0439083:>90 [Quantitative Concept]
   861   C0439087:<90 [Quantitative Concept]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "4313,"

Phrase: "1997"

Phrase: "[Abstract/Free FullText"

Phrase: "] 30."
Processing 00000000.tx.319: Durie BGM, Salmon SE: A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. 

Phrase: "Durie BGM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1825836:BGM [Gene or Genome]

Phrase: "Salmon SE"

Phrase: ":"

Phrase: "A clinical staging system for multiple myeloma"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   778   C0449394:Staging system [Intellectual Product]
   748   C0449913:System [Functional Concept]
   748   C1553451:System [Manufactured Object]
   748   C1704459:System [Medical Device]

Phrase: ":"

Phrase: "Correlation of measured myeloma cell mass"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1707520:Correlation [Qualitative Concept]

Phrase: "with presenting clinical features,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   793   C1521970:Feature [Qualitative Concept]
   793   C1706388:Feature [Conceptual Entity]
   793   C2346469:Feature [Qualitative Concept]
   793   C2348519:Feature [Qualitative Concept]

Phrase: "response to treatment,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0521982:Response to treatment [Clinical Attribute]
   790   C0871261:Response [Organism Attribute]
   790   C1704632:Response [Finding]
   790   C1706817:Response [Intellectual Product]
   790   C2911692:Response [Mental Process]

Phrase: "and"

Phrase: "survival."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0038952:Survival [Activity]
  1000   C0220921:survival [Functional Concept]
Processing 00000000.tx.320: Cancer 36:842, 1975[Medline] [OrderarticleviaInfotrieve] 31. 

Phrase: "Cancer 36"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0006826:Cancer [Neoplastic Process]
   861   C0998265:Cancer [Eukaryote]
   861   C1306459:Cancer [Finding]

Phrase: ":"

Phrase: "842,"

Phrase: "1975"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 31."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450355:31 [Intellectual Product]
Processing 00000000.tx.321: Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G: The repertoire of human germline VH sequence reveals about fifty groups of VH segments with different hypervulable loops. 

Phrase: "Tomlinson IM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3539078:IM [Idea or Concept]

Phrase: "Walter G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Marks JD,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1549972:JD [Intellectual Product]

Phrase: "Llewelyn MB,"

Phrase: "Winter G"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: ":"

Phrase: "The repertoire of human germline VH sequence"

Phrase: "reveals about fifty groups of VH"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   753   C0441833:Group [Idea or Concept]
   753   C0443289:reveal [Qualitative Concept]
   753   C0687744:group [Population Group]
   753   C1257890:Group [Population Group]
   753   C1420224:VH [Gene or Genome]
   753   C1552516:Group [Health Care Related Organization]
   753   C1552839:groups [Idea or Concept]
   753   C1705428:Group [Conceptual Entity]
   753   C1705429:Group [Population Group]

Phrase: "segments with different hypervulable loops."
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   760   C0181687:loops [Medical Device]
   760   C0441635:Segment [Spatial Concept]
   760   C1705242:Different [Qualitative Concept]
   726 E C0419518:Loop [Medical Device]
   726 E C0445022:Loop [Spatial Concept]
Processing 00000000.tx.322: J Mol Biol 227:776, 1992[Medline] [OrderarticleviaInfotrieve] 32. 

Phrase: "J Mol Biol 227"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   861   C2346604:J/mol [Quantitative Concept]
   812   C0027960:Mole [Neoplastic Process]
   812   C0324740:Mole [Mammal]
   812   C0439189:Mole [Quantitative Concept]
   812   C1456781:mole [Neoplastic Process]
   812   C1824986:mol [Gene or Genome]
   729 E C0026367:Molar [Body Part, Organ, or Organ Component]
   712 E C0027962:moles [Neoplastic Process]

Phrase: ":"

Phrase: "776,"

Phrase: "1992"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 32."
Processing 00000000.tx.323: Kabat EA, Wu TT, Reid-Miller M, Perry HM, Gottesman KS: Sequence of Proteins of Immunological Interest. 

Phrase: "Kabat EA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0014963:EA [Organic Chemical,Pharmacologic Substance]
   861   C1457900:EA [Quantitative Concept]

Phrase: "Wu TT,"

Phrase: "Reid-Miller M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]

Phrase: "Perry HM,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0262500:hm [Health Care Activity]
   861   C1512358:HM [Geographic Area]
   861   C3538713:HM [Idea or Concept]

Phrase: "Gottesman KS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3541894:ks [Quantitative Concept]

Phrase: ":"

Phrase: "Sequence of Proteins of Immunological Interest."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   767   C0002518:Protein Sequence [Amino Acid Sequence]
   753   C0004793:Sequence [Nucleotide Sequence]
   753   C0162326:Sequence [Nucleotide Sequence]
   753   C0162327:Sequence [Nucleotide Sequence]
   753   C1519249:Sequence [Functional Concept]
Processing 00000000.tx.324: Bethesda, MD, National Institutes of Health, 1987. 

Phrase: "Bethesda,"

Phrase: "MD,"

Phrase: "National Institutes of Health,"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0027468:National Institutes of Health [Health Care Related Organization]
           national institute health
   812   C0018684:Health [Idea or Concept]
   812   C0021622:Institutes [Organization]
   812   C3245503:national [Intellectual Product]
   779 E C1272753:Institute [Idea or Concept]
   712 E C0031206:healthiness [Finding]

Phrase: "1987."
Processing 00000000.tx.325: 33. 

Phrase: "33."
Processing 00000000.tx.326: Molesh DA, Hall JM: Quantitative analysis of CD34+ stem cells using RT-PCR on whole cells. 

Phrase: "Molesh DA,"

Phrase: "Hall JM"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: ":"

Phrase: "Quantitative analysis of CD34+ stem cells"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0002778:Analysis [Laboratory Procedure]
   753   C0392762:Quantitative [Quantitative Concept]
   753   C0936012:Analysis [Research Activity]
   753   C1524024:analysis [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "RT-PCR on whole cells."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   814   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   748   C0337112:Chain [Manufactured Object]
   748   C0443286:Reaction [Functional Concept]
   748   C1114821:Reaction [Clinical Attribute]
   748   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   748   C1524075:Chain [Idea or Concept]
Processing 00000000.tx.327: PCR Methods Appl 3:278, 1994[Medline] [OrderarticleviaInfotrieve] 34. 

Phrase: "PCR Methods Appl 3"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   861   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   799   C0025663:Methods [Intellectual Product]
   799   C0025664:methods [Intellectual Product]
   799   C0337112:Chain [Manufactured Object]
   799   C0443286:Reaction [Functional Concept]
   799   C0449851:Methods [Functional Concept]
   799   C1114821:Reaction [Clinical Attribute]
   799   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   799   C1524075:Chain [Idea or Concept]
   799   C1858559:APPL [Gene or Genome]
   766 E C0871511:METHOD [Intellectual Product]

Phrase: ":"

Phrase: "278,"

Phrase: "1994"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 34."
Processing 00000000.tx.328: Kaplan EL, Meier P: Nonparametric estimations from incomplete observations. 

Phrase: "Kaplan EL,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1416870:EL [Gene or Genome]
   861   C1823249:EL [Gene or Genome]

Phrase: "Meier P"

Phrase: ":"

Phrase: "Nonparametric estimations from incomplete observations."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   760   C0680844:estimations [Mental Process]
   726 E C0681916:Estimation [Quantitative Concept]
   726 E C0750572:Estimation [Quantitative Concept]
Processing 00000000.tx.329: J Am Stat Assoc 53:457, 1958 35. 

Phrase: "J"

Phrase: "Am"

Phrase: "Stat Assoc 53"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0205548:Stat [Temporal Concept]

Phrase: ":"

Phrase: "457,"

Phrase: "1958 35."
Processing 00000000.tx.330: Franklin WA, Shpall EJ, Archer P, Johnson CS, Garza-William S, Hami L, Bitter MA, Bast RC, Jones RB: Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. 

Phrase: "Franklin WA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0043038:WA [Geographic Area]

Phrase: "Shpall EJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1718783:Ej [Immunologic Factor]

Phrase: "Archer P,"

Phrase: "Johnson CS,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540510:cs [Quantitative Concept]

Phrase: "Garza-William S,"

Phrase: "Hami L,"

Phrase: "Bitter MA,"

Phrase: "Bast RC,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1419366:RC [Gene or Genome]

Phrase: "Jones RB"

Phrase: ":"

Phrase: "Immunocytochemical detection of breast cancer cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   820   C1511288:Breast Cancer Detection [Health Care Activity]
   783   C1516193:Cancer Detection [Health Care Activity]
   753   C1511790:Detection [Therapeutic or Preventive Procedure]

Phrase: "in marrow"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
  1000   C0086590:Marrow [Food]
  1000   C0376152:Marrow [Body Part, Organ, or Organ Component]
  1000   C1546708:Marrow [Intellectual Product]
   944 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   944 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   944 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   916 E C0330477:Marrows [Plant]

Phrase: "and"

Phrase: "peripheral blood of patients"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   833   C0229664:peripheral blood [Body Substance]
           Blood
   791 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   770   C0005767:Blood [Tissue]
   770   C0005768:blood [Body Substance]
   770   C0205100:Peripheral [Spatial Concept]

Phrase: "undergoing"

Phrase: "high dose chemotherapy with autologous stem cell support."
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   911   C1512429:High-Dose Chemotherapy with Stem Cell Support [Therapeutic or Preventive Procedure]
   800   C1328050:high-dose chemotherapy [Therapeutic or Preventive Procedure]
   770   C0444956:High dose [Quantitative Concept]
   744   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   744   C0013217:chemotherapy [Functional Concept]
   744   C0178602:Dose [Quantitative Concept]
   744   C0205250:High [Qualitative Concept]
   744   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
   744   C0869039:Dose [Quantitative Concept]
   744   C1114758:Dose # [Clinical Attribute]
   744   C1299351:High [Qualitative Concept]
   744   C2700149:HIGH [Intellectual Product]
Processing 00000000.tx.331: Breast Cancer Res Treat 41:1, 1996[Medline] [OrderarticleviaInfotrieve] 36. 

Phrase: "Breast Cancer Res"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C2347379:RES [Finding]
   734   C0006142:Breast Cancer [Neoplastic Process]
   734   C0678222:Breast Cancer [Neoplastic Process]

Phrase: "Treat"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1292734:TREAT [Functional Concept]
  1000   C1522326:Treat [Functional Concept]

Phrase: "41"

Phrase: ":"

Phrase: "1,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "1996"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 36."
Processing 00000000.tx.332: Gribben JG, Saporito L, Barber M, Blake KW, Edwards RM, Griffin JD, Freedman AS, Nadler LM: Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. 

Phrase: "Gribben JG,"

Phrase: "Saporito L,"

Phrase: "Barber M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Blake KW,"

Phrase: "Edwards RM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2951520:RM [Body Location or Region]

Phrase: "Griffin JD,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1549972:JD [Intellectual Product]

Phrase: "Freedman AS,"

Phrase: "Nadler LM"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1261082:LM [Body Part, Organ, or Organ Component]
   861   C1551056:lm [Quantitative Concept]
   861   C2981682:LM [Quantitative Concept]

Phrase: ":"

Phrase: "Bone marrows of non-Hodgkin's lymphoma patients"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
   762   C0005953:Bone Marrow [Tissue]
   748   C0330477:Marrows [Plant]
   738 E C1708973:Medullary Bone [Tissue]
   714 E C0086590:Marrow [Food]
   714 E C0376152:Marrow [Body Part, Organ, or Organ Component]
   714 E C1546708:Marrow [Intellectual Product]

Phrase: "with a bcl-2 translocation"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1516130:BCL-2 Translocation [Cell or Molecular Dysfunction]
   827   C0040715:Translocation [Cell or Molecular Dysfunction]
   827   C2987521:Translocation [Activity]
   734   C0376515:Bcl-2 [Gene or Genome]

Phrase: "can"

Phrase: "be"

Phrase: "purged of polymerase chain reaction-detectable lymphoma cells"
Meta Candidates (Total=16; Excluded=4; Pruned=0; Remaining=12)
   800   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   770   C0883208:Lymphoma cells [Cell]
   770   C2697951:Lymphoma Cells [Laboratory Procedure]
   744   C0007634:Cells [Cell]
   744   C0024299:Lymphoma [Neoplastic Process]
   744   C0337112:Chain [Manufactured Object]
   744   C0443286:Reaction [Functional Concept]
   744   C1114821:Reaction [Clinical Attribute]
   744   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   744   C1524075:Chain [Idea or Concept]
   744   C1548399:purged [Idea or Concept]
   744   C3282337:Cells [Cell]
   711 E C0722910:Purge [Lipid,Pharmacologic Substance]
   711 E C1269647:Cell [Cell]
   711 E C1704653:Cell [Medical Device]
   711 E C1948049:Cell [Spatial Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "monoclonal antibodies"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0003250:Monoclonal Antibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   861   C0746619:monoclonal [Finding]
   827 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "and"

Phrase: "immunomagnetic bead depletion."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0333668:Depletion [Functional Concept]
Processing 00000000.tx.333: Blood 80:1083, 1992[Abstract] 37. 

Phrase: "Blood 80"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "1083,"

Phrase: "1992"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 37."
Processing 00000000.tx.334: Owen RG, Haynes AP, Evans PA, Johnson RJ, Rawstron AC, McQuaker G, Smith GM, Galvin MC, Barnard DL, Russell NH, Child JA, Morgan GJ: Detection of clonal immunoglobulin gene rearrangements in the peripheral blood progenitor cells of patient with multiple myeloma: The potential role of purging with CD34+ positive selection. 

Phrase: "Owen RG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1412999:RG [Gene or Genome]

Phrase: "Haynes AP,"

Phrase: "Evans PA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3541314:PA [Idea or Concept]

Phrase: "Johnson RJ,"

Phrase: "Rawstron AC,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1412573:AC [Gene or Genome]
   861   C2350443:AC [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3539770:AC [Gene or Genome]

Phrase: "McQuaker G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Smith GM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0546866:GM [Antibiotic,Carbohydrate]

Phrase: "Galvin MC,"

Phrase: "Barnard DL,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3642216:/dL [Quantitative Concept]

Phrase: "Russell NH,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0268059:NH [Disease or Syndrome]

Phrase: "Child JA,"

Phrase: "Morgan GJ"

Phrase: ":"

Phrase: "Detection of clonal immunoglobulin gene rearrangements"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   820   C0202081:Detection of immunoglobulin [Laboratory Procedure]
   753   C1511790:Detection [Therapeutic or Preventive Procedure]
   704   C1516672:Clonal Immunoglobulin Gene Rearrangement [Cell or Molecular Dysfunction]

Phrase: "in the peripheral blood progenitor cells"
Meta Candidates (Total=23; Excluded=12; Pruned=0; Remaining=11)
   906   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   861   C0038250:Progenitor Cells [Cell]
   861   C0229664:peripheral blood [Body Substance]
           Blood
   830 E C2328697:Hemal cell [Cell]
   819 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   812   C0005767:Blood [Tissue]
   812   C0005768:blood [Body Substance]
   812   C0007634:Cells [Cell]
   812   C0205100:Peripheral [Spatial Concept]
   812   C0870134:Progenitor [Family Group]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]
   741 E C0333275:Bloody [Qualitative Concept]
   729 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   729 E C0392895:Bloods [Population Group]
   729 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   729 E C1511228:VESSEL, BLOOD [Tissue]
   712 E C1558950:VASCULAR [Finding]
   712 E C1801960:Vascular [Qualitative Concept]

Phrase: "of patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:*^patient [Patient or Disabled Group]

Phrase: "with multiple myeloma"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   861   C0439064:Multiple [Quantitative Concept]
   861   C3538749:Myeloma [Intellectual Product]

Phrase: ":"

Phrase: "The potential role of purging"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0035820:Role [Social Behavior]
   760   C1705810:Role [Conceptual Entity]

Phrase: "with CD34+ positive selection."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C2347644:Positive Selection [Laboratory Procedure]
   827   C0036576:selection [Genetic Function]
Processing 00000000.tx.335: J Clin Pathol 49:M112, 1996 38. 

Phrase: "J Clin Pathol 49"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1315013:CLIN [Intellectual Product]

Phrase: ":"

Phrase: "M112,"

Phrase: "1996 38."
Processing 00000000.tx.336: Johnson RJ, Owen RG, Smith GM, Child JA, Galvin M, Newton LJ, Rawstron A, Major K, Woodhead V, Robinson F, Jack A, Morgan GJ: Peripheral blood stem cell transplantation in myeloma using CD34+ selected cells. 

Phrase: "Johnson RJ,"

Phrase: "Owen RG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1412999:RG [Gene or Genome]

Phrase: "Smith GM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0546866:GM [Antibiotic,Carbohydrate]

Phrase: "Child JA,"

Phrase: "Galvin M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Newton LJ,"

Phrase: "Rawstron A,"

Phrase: "Major K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Woodhead V,"

Phrase: "Robinson F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Jack A,"

Phrase: "Morgan GJ"

Phrase: ":"

Phrase: "Peripheral blood stem cell transplantation in myeloma"
Meta Candidates (Total=28; Excluded=2; Pruned=0; Remaining=26)
   897   C0242602:Peripheral Blood Stem Cell Transplantation [Therapeutic or Preventive Procedure]
           Peripheral Stem Cell Transplantation
   853   C1518999:Peripheral blood stem cell [Cell]
           peripheral stem cell
   814   C1504389:Stem Cell Transplantation [Therapeutic or Preventive Procedure]
   804   C0005773:Peripheral blood cell [Cell]
           Blood cell
   786   C2336898:Hemal stem cell [Cell]
   778   C0038250:Stem cell [Cell]
   778   C0206153:Cell Transplantation [Therapeutic or Preventive Procedure]
   778   C0229664:peripheral blood [Body Substance]
           Blood
   774   C0333843:Myeloma cell [Cell]
   748   C0005767:Blood [Tissue]
   748   C0005768:blood [Body Substance]
   748   C0007634:Cell [Cell]
   748   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   748   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   748   C0040733:transplantation [Functional Concept]
   748   C0205100:Peripheral [Spatial Concept]
   748   C0242767:Stem [Plant]
   748   C1186763:Stem [Body Part, Organ, or Organ Component]
   748   C1269647:Cell [Cell]
   748   C1704653:Cell [Medical Device]
   748   C1948049:Cell [Spatial Concept]
   746 E C2328697:Hemal cell [Cell]
   737 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   732   C0189736:blood vessel transplantation [Therapeutic or Preventive Procedure]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "CD34+ selected cells."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   913   C0882849:cd34 cells [Cell]
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.337: Bone Marrow Transplant 17:723, 1996[Medline] [OrderarticleviaInfotrieve] 39. 

Phrase: "Bone Marrow Transplant 17"
Meta Candidates (Total=17; Excluded=5; Pruned=0; Remaining=12)
   923   C0005961:Bone Marrow Transplant [Therapeutic or Preventive Procedure]
   875   C0005976:Bone transplant [Therapeutic or Preventive Procedure]
   861   C0005953:Bone Marrow [Tissue]
   812   C0040732:Transplant [Therapeutic or Preventive Procedure]
   812   C0086590:Marrow [Food]
   812   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   812   C0332835:Transplant [Tissue]
   812   C0376152:Marrow [Body Part, Organ, or Organ Component]
   812   C0391978:Bone [Tissue]
   812   C1266908:Bone [Body Part, Organ, or Organ Component]
   812   C1266909:Bone [Body System]
   812   C1546708:Marrow [Intellectual Product]
   756 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   756 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   756 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   741 E C0443157:Bony [Functional Concept]
   729 E C0330477:Marrows [Plant]

Phrase: ":"

Phrase: "723,"

Phrase: "1996"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 39."
Processing 00000000.tx.338: Pico JL, Bourhis JH, Bennaceur AL, Beaujean F, Bayle C, Ibrahim A, Girinski T, Hayat M, Dighiero G, Tchernia G: Engraftment of CD34+ peripheral blood progenitor cells into multiple myeloma patients following total body irradiation. 

Phrase: "Pico JL,"

Phrase: "Bourhis JH,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0268060:JH [Disease or Syndrome]
   861   C1415529:JH [Gene or Genome]

Phrase: "Bennaceur AL,"

Phrase: "Beaujean F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Bayle C,"

Phrase: "Ibrahim A,"

Phrase: "Girinski T,"

Phrase: "Hayat M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Dighiero G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Tchernia G"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: ":"

Phrase: "Engraftment of CD34+ peripheral blood progenitor cells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   793   C1514470:Progenitor Cell Engraftment [Therapeutic or Preventive Procedure]
   748   C0301944:Engraftment [Physiologic Function]

Phrase: "into multiple myeloma patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0030705:Patients [Patient or Disabled Group]
   734   C0026764:Multiple Myeloma [Neoplastic Process]

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "total body irradiation."
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
  1000   C0043162:Total Body Irradiation [Therapeutic or Preventive Procedure]
   901   C0229960:Total body [Fully Formed Anatomical Structure]
   827   C0242821:body [Human]
   827   C0439175:% total [Quantitative Concept]
   827   C0439810:Total [Qualitative Concept]
   827   C0460148:Body [Anatomical Structure]
   827   C1268086:Body [Anatomical Structure]
   827   C1282930:Irradiation [Natural Phenomenon or Process]
   827   C1522449:irradiation [Therapeutic or Preventive Procedure]
   743 E C1995017:Bodies [Cell Component]
Processing 00000000.tx.339: Nouv Rev Franc Hematol 37:381, 1995 40. 

Phrase: "Nouv Rev Franc Hematol 37"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C2347961:Rev. [Professional or Occupational Group]

Phrase: ":"

Phrase: "381,"

Phrase: "1995 40."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439509:/40 [Temporal Concept]
Processing 00000000.tx.340: Rossi JF, Legouffe E, Fegueux N, Sun RX, Exbravat C, Latry P, Polge G, deVoos J, Capdevila V, Lu ZY, Klein B: Autologous transplantation (AT) of CD34+ peripheral blood progenitor cells (PBPC) after double (D) high-dose chemotherapy (HDC) in multiple myeloma (MM) is followed by severe immunodeficiency (ID) and high production of interleukin-6 (IL-6) related-C reactive protein (CRP) requiring additive immunotherapy. 

Phrase: "Rossi JF,"

Phrase: "Legouffe E,"

Phrase: "Fegueux N,"

Phrase: "Sun RX,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1425688:RX [Gene or Genome]
   861   C2709207:Rx [Therapeutic or Preventive Procedure]

Phrase: "Exbravat C,"

Phrase: "Latry P,"

Phrase: "Polge G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "deVoos J,"

Phrase: "Capdevila V,"

Phrase: "Lu ZY,"

Phrase: "Klein B"

Phrase: ":"

Phrase: "Autologous transplantation (AT) of CD34+ peripheral blood progenitor cells (PBPC)"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   839   C0242602:peripheral blood progenitor cell transplantation [Therapeutic or Preventive Procedure]
   770   C0040736:Transplantation, Autologous [Therapeutic or Preventive Procedure]
   767   C0206153:cells transplantation [Therapeutic or Preventive Procedure]
   765   C0189736:Transplantation of blood vessel [Therapeutic or Preventive Procedure]
           blood vessel transplantation
   744   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   744   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   744   C0040733:transplantation [Functional Concept]

Phrase: "after double (D) high-dose chemotherapy (HDC)"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   923   C1328050:high-dose chemotherapy [Therapeutic or Preventive Procedure]
   861   C0444956:High dose [Quantitative Concept]
   812   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   812   C0013217:chemotherapy [Functional Concept]
   812   C0178602:Dose [Quantitative Concept]
   812   C0205250:High [Qualitative Concept]
   812   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
   812   C0869039:Dose [Quantitative Concept]
   812   C1114758:Dose # [Clinical Attribute]
   812   C1299351:High [Qualitative Concept]
   812   C2700149:HIGH [Intellectual Product]

Phrase: "in multiple myeloma"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   861   C0439064:Multiple [Quantitative Concept]
   861   C3538749:Myeloma [Intellectual Product]

Phrase: "(MM"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   861   C0439064:Multiple [Quantitative Concept]
   861   C3538749:Myeloma [Intellectual Product]

Phrase: ")"

Phrase: "is"

Phrase: "followed by severe immunodeficiency (ID)"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   833   C0332283:Followed by [Temporal Concept]
           followed
   770   C0021051:IMMUNO-DEFICIENCY [Disease or Syndrome]
   770   C0205082:Severe [Qualitative Concept]
   737 E C1719822:Follow [Intellectual Product]

Phrase: "and"

Phrase: "high production of interleukin-6 (IL-6)"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   844   C1819459:interleukin-6 production [Organism Function]
   797   C3159141:interleukin production [Organism Function]
   760   C0033268:production [Occupational Activity]

Phrase: "related-"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0439849:Related [Qualitative Concept]
  1000   C0445223:Related [Finding]
   966 E C0163712:Relate [Organic Chemical]

Phrase: "C reactive protein (CRP)"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0006560:C-reactive protein [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C1879974:C-Reactive Protein [Gene or Genome]
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   827   C0205332:Reactive [Qualitative Concept]

Phrase: "requiring"

Phrase: "additive immunotherapy."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0021083:Immunotherapy [Therapeutic or Preventive Procedure]
Processing 00000000.tx.341: Blood 88:142a, 1996 (abstr, suppl 1) 41. 

Phrase: "Blood 88"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "142a,"

Phrase: "1996"

Phrase: "(abstr,"

Phrase: "suppl 1"

Phrase: ")"

Phrase: "41."
Processing 00000000.tx.342: Gorin NC, Lopez M, Laporte JP, Quittet P, Lesage S, Lemoine F, Berenson RJ, Isnard F, Grande M, Stachowiak J, Labopin M, Fouillard L, Morel P, Jouet J, Noel-Walter M, Detourmignies L, Aoudjhane M, Bauters F, Najman A, Douay L: Preparation and successful engraftment of purified CD34+ bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. 

Phrase: "Gorin NC,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0027964:NC [Geographic Area]
   861   C0028407:NC [Geographic Area]
   861   C0067895:NC [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "Lopez M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Laporte JP,"

Phrase: "Quittet P,"

Phrase: "Lesage S,"

Phrase: "Lemoine F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Berenson RJ,"

Phrase: "Isnard F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Grande M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Stachowiak J,"

Phrase: "Labopin M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Fouillard L,"

Phrase: "Morel P,"

Phrase: "Jouet J,"

Phrase: "Noel-Walter M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]

Phrase: "Detourmignies L,"

Phrase: "Aoudjhane M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Bauters F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Najman A,"

Phrase: "Douay L"

Phrase: ":"

Phrase: "Preparation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0455052:Preparation [Health Care Activity]
  1000   C1521827:Preparation [Functional Concept]

Phrase: "and"

Phrase: "successful engraftment of purified CD34+ bone marrow progenitor cells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   773   C1514470:Progenitor Cell Engraftment [Therapeutic or Preventive Procedure]
   742   C0301944:Engraftment [Physiologic Function]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with non-Hodgkin's lymphoma."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0024305:Lymphoma, Non-Hodgkin [Neoplastic Process]
  1000   C2700512:LYMPHOMA, NON-HODGKIN [Gene or Genome]
  1000   C3539720:Non-Hodgkin Lymphoma [Intellectual Product]
   901   C0019829:Hodgkin Lymphoma [Neoplastic Process]
   901   C3541281:Hodgkin Lymphoma [Intellectual Product]
   827   C0024299:Lymphoma [Neoplastic Process]
   827   C1518422:Non [Functional Concept]
Processing 00000000.tx.343: Blood 85:1647, 1995[Abstract/Free FullText] 42. 

Phrase: "Blood 85"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "1647,"

Phrase: "1995"

Phrase: "[Abstract/Free FullText"

Phrase: "] 42."
Processing 00000000.tx.344: Bachier C, Giles RE, Ellerson D, Hanania EG, Garcia-Sanchez F, Haley T, Andreef M, Cabanillas F, Champlin R, Berenson R, Heimfeld S, Deisseroth AB: Stem cell (SC) transplant and retroviral transduction of hematopoietic cells in patients with follicular non-Hodgkin's lymphoma (FNHL). 

Phrase: "Bachier C,"

Phrase: "Giles RE,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986904:RE [Idea or Concept]

Phrase: "Ellerson D, Hanania EG,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0013715:EG [Geographic Area]
   812   C1705651:EG [Idea or Concept]

Phrase: "Garcia-Sanchez F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   827   C0439133:(f) [Intellectual Product]
   827   C1553038:[f] [Quantitative Concept]

Phrase: "Haley T,"

Phrase: "Andreef M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Cabanillas F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Champlin R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Berenson R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Heimfeld S,"

Phrase: "Deisseroth AB"

Phrase: ":"

Phrase: "Stem cell (SC) transplant"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1504389:Stem cell transplant [Therapeutic or Preventive Procedure]
   901   C0206152:Transplant, Cell [Cell]
   827   C0040732:Transplant [Therapeutic or Preventive Procedure]
   827   C0332835:Transplant [Tissue]
   734   C0038250:Stem cell [Cell]

Phrase: "and"

Phrase: "retroviral transduction of hematopoietic cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1160185:transduction [Organism Function]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with follicular non-Hodgkin's lymphoma (FNHL)."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0024301:Follicular non-Hodgkin's lymphoma [Neoplastic Process]
           Lymphoma, Follicular
   923   C0024305:Lymphoma, Non-Hodgkin [Neoplastic Process]
   923   C2700512:LYMPHOMA, NON-HODGKIN [Gene or Genome]
   923   C3539720:Non-Hodgkin Lymphoma [Intellectual Product]
   861   C0019829:Hodgkin Lymphoma [Neoplastic Process]
   861   C3541281:Hodgkin Lymphoma [Intellectual Product]
   812   C0024299:Lymphoma [Neoplastic Process]
   812   C1518422:Non [Functional Concept]
Processing 00000000.tx.345: Proc Am Soc Clin Oncol 16:1997 (abstr) 43. 

Phrase: "Proc"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1418943:PROC [Gene or Genome]

Phrase: "Am"

Phrase: "Soc Clin Oncol 16"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1315013:CLIN [Intellectual Product]

Phrase: ":"

Phrase: "1997"

Phrase: "(abstr"

Phrase: ")"

Phrase: "43."
Processing 00000000.tx.346: Vogel W, Behringer D, Scheding S, Kanz L, Brugger W: Ex vivo expansion of CD34+ peripheral blood progenitor cells: Implications for the expansion of contaminating epithelial tumor cells. 

Phrase: "Vogel W,"

Phrase: "Behringer D, Scheding S,"

Phrase: "Kanz L,"

Phrase: "Brugger W"

Phrase: ":"

Phrase: "Ex vivo expansion of CD34+ peripheral blood progenitor cells"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   745   C0007595:cell expansion [Cell Function]

Phrase: ":"

Phrase: "Implications for the expansion of contaminating epithelial tumor cells."
Processing 00000000.tx.347: Blood 88:2707, 1996[Abstract/Free FullText] 44. 

Phrase: "Blood 88"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "2707,"

Phrase: "1996"

Phrase: "[Abstract/Free FullText"

Phrase: "] 44."
Processing 00000000.tx.348: Bensinger W, Applebaum F, Rowley S, Storb R, Sanders J, Lilleby K, Gooley T, Demirer T, Schiffman K, Weaver C, Clift R, Chauncey T, Klarnet J, Montgomery P, Petersdorf S, Weiden R, Witherspoon R, Buckner CD: Factors influencing collection and engraftment of autologous peripheral blood stem cells. 

Phrase: "Bensinger W,"

Phrase: "Applebaum F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Rowley S,"

Phrase: "Storb R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Sanders J,"

Phrase: "Lilleby K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Gooley T,"

Phrase: "Demirer T,"

Phrase: "Schiffman K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Weaver C,"

Phrase: "Clift R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Chauncey T,"

Phrase: "Klarnet J,"

Phrase: "Montgomery P,"

Phrase: "Petersdorf S,"

Phrase: "Weiden R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Witherspoon R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Buckner CD"

Phrase: ":"

Phrase: "Factors"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1521761:Factor [Functional Concept]
   966   C2827422:Factor [Conceptual Entity]

Phrase: "influencing"

Phrase: "collection"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1516698:Collection [Functional Concept]
  1000   C1704814:Collection [Idea or Concept]
   928 E C1516695:Collected [Idea or Concept]

Phrase: "and"

Phrase: "engraftment of autologous peripheral blood stem cells."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0301944:Engraftment [Physiologic Function]
Processing 00000000.tx.349: J Clin Oncol 13:2547, 1995[Abstract] 45. 

Phrase: "J Clin Oncol 13"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1315013:CLIN [Intellectual Product]

Phrase: ":"

Phrase: "2547,"

Phrase: "1995"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 45."
Processing 00000000.tx.350: Tricot G, Jagannath S, Vesole DH, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B: Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225patients. 

Phrase: "Tricot G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Jagannath S,"

Phrase: "Vesole DH,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1832586:DH [Disease or Syndrome]

Phrase: "Nelson J,"

Phrase: "Tindle S,"

Phrase: "Miller L,"

Phrase: "Cheson B,"

Phrase: "Crowley J,"

Phrase: "Barlogie B"

Phrase: ":"

Phrase: "Peripheral blood stem cell"
Meta Candidates (Total=26; Excluded=9; Pruned=0; Remaining=17)
  1000   C1518999:Peripheral blood stem cell [Cell]
           peripheral stem cell
   923   C0005773:Peripheral blood cell [Cell]
           Blood cell
   895   C2336898:Hemal stem cell [Cell]
   861   C0038250:Stem cell [Cell]
   861   C0229664:peripheral blood [Body Substance]
           Blood
   847 E C2328697:Hemal cell [Cell]
   819 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   812   C0005767:Blood [Tissue]
   812   C0005768:blood [Body Substance]
   812   C0007634:Cell [Cell]
   812   C0205100:Peripheral [Spatial Concept]
   812   C0242767:Stem [Plant]
   812   C1186763:Stem [Body Part, Organ, or Organ Component]
   812   C1269647:Cell [Cell]
   812   C1704653:Cell [Medical Device]
   812   C1948049:Cell [Spatial Concept]
   741 E C0333275:Bloody [Qualitative Concept]
   729 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   729 E C0392895:Bloods [Population Group]
   729 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   729 E C1511228:VESSEL, BLOOD [Tissue]
   712 E C1558950:VASCULAR [Finding]
   712 E C1801960:Vascular [Qualitative Concept]

Phrase: "transplants for multiple myeloma"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   833   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   770   C0040732:Transplant [Therapeutic or Preventive Procedure]
   770   C0332835:Transplant [Tissue]
   770   C0439064:Multiple [Quantitative Concept]
   770   C3538749:Myeloma [Intellectual Product]

Phrase: ":"

Phrase: "Identification of favorable variables"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0020792:Identification [Mental Process]
   770   C0205396:Identification [Qualitative Concept]

Phrase: "for rapid engraftment"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0301944:Engraftment [Physiologic Function]

Phrase: "in 225patients."
Processing 00000000.tx.351: Blood 85:588, 1995[Abstract/Free FullText] 46. 

Phrase: "Blood 85"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "588,"

Phrase: "1995"

Phrase: "[Abstract/Free FullText"

Phrase: "] 46."
Processing 00000000.tx.352: Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W: An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692patients after the administration of myeloabalative chemotherapy. 

Phrase: "Weaver CH,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0558269:Ch. [Professional or Occupational Group]
   861   C1552984:[Ch] [Quantitative Concept]

Phrase: "Hazelton B,"

Phrase: "Birch R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Palmer P,"

Phrase: "Allen C,"

Phrase: "Schwartzberg L,"

Phrase: "West W"

Phrase: ":"

Phrase: "An analysis of engraftment kinetics"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0002778:Analysis [Laboratory Procedure]
   760   C0936012:Analysis [Research Activity]
   760   C1524024:analysis [Functional Concept]

Phrase: "as a function"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C0031843:function [Physiologic Function]
  1000   C0542341:Function [Functional Concept]
  1000   C0700205:FUNCTION [Classification]
  1000   C1705273:Function [Intellectual Product]
   928 E C0205245:Functional [Functional Concept]
   928 E C2700217:Functional [Conceptual Entity]

Phrase: "of the CD34 content"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0423896:Content [Mental Process]
   861   C0456205:Content [Conceptual Entity]

Phrase: "of peripheral blood progenitor cell collections"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   804   C0600644:Collections [Intellectual Product]
   804   C1516698:Collection [Functional Concept]
   804   C1704814:Collection [Idea or Concept]
   722   C0005773:Peripheral blood cell [Cell]
   721 E C1516695:Collected [Idea or Concept]

Phrase: "in 692patients"

Phrase: "after the administration"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0001554:Administration [Occupational Activity]
  1000   C1533734:Administration [Therapeutic or Preventive Procedure]

Phrase: "of myeloabalative chemotherapy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   861   C0013217:chemotherapy [Functional Concept]
   861   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
Processing 00000000.tx.353: Blood 86:3961, 1995[Abstract/Free FullText] 47. 

Phrase: "Blood 86"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "3961,"

Phrase: "1995"

Phrase: "[Abstract/Free FullText"

Phrase: "] 47."
Processing 00000000.tx.354: Brugger W, Henschler R, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L: Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. 

Phrase: "Brugger W,"

Phrase: "Henschler R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Heimfeld S,"

Phrase: "Berenson RJ,"

Phrase: "Mertelsmann R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Kanz L"

Phrase: ":"

Phrase: "Positively"

Phrase: "selected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1707391:Select [Activity]

Phrase: "autologous blood CD34+ cells"
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   875   C0005773:Blood Cells [Cell]
   861   C0882849:cd34 cells [Cell]
   830 E C2328697:Hemal cell [Cell]
   812   C0007634:Cells [Cell]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]

Phrase: "and"

Phrase: "unseparated peripheral blood progenitor cells"
Meta Candidates (Total=23; Excluded=12; Pruned=0; Remaining=11)
   872   C0005773:Peripheral blood cell [Cell]
           Blood Cells
   840   C0038250:Progenitor Cells [Cell]
   840   C0229664:peripheral blood [Body Substance]
           Blood
   808 E C2328697:Hemal cell [Cell]
   804   C0005767:Blood [Tissue]
   804   C0005768:blood [Body Substance]
   804   C0007634:Cells [Cell]
   804   C0205100:Peripheral [Spatial Concept]
   804   C0870134:Progenitor [Family Group]
   804   C3282337:Cells [Cell]
   798 E C0150936:Peripheral Blood Vessel [Body Part, Organ, or Organ Component]
   771 E C1269647:Cell [Cell]
   771 E C1704653:Cell [Medical Device]
   771 E C1948049:Cell [Spatial Concept]
   733 E C0333275:Bloody [Qualitative Concept]
   721 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   721 E C0392895:Bloods [Population Group]
   721 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   721 E C1511228:VESSEL, BLOOD [Tissue]
   704 E C1558950:VASCULAR [Finding]
   704 E C1801960:Vascular [Qualitative Concept]

Phrase: "mediate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086597:Mediate [Social Behavior]

Phrase: "identical hematopoietic engraftment after high-dose VP16,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0301944:Engraftment [Physiologic Function]

Phrase: "ifosfamide,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0020823:Ifosfamide [Organophosphorus Compound,Pharmacologic Substance]

Phrase: "carboplatin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0079083:Carboplatin [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "epirubicin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0014582:Epirubicin [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.355: Blood 84:1421, 1994[Abstract/Free FullText] 48. 

Phrase: "Blood 84"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "1421,"

Phrase: "1994"

Phrase: "[Abstract/Free FullText"

Phrase: "] 48."
Processing 00000000.tx.356: Somlo G, Sniecinski I, Odom-Maryon T, Nowicki B, Chow W, Hamasaki V, Leong L, Margolin K, Morgan R Jr., Raschko J, Shibata S, Tetef M, Molina A, Berenson RJ, Forman SJ, Doroshow JH: Effects of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer. 

Phrase: "Somlo G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Sniecinski I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Odom-Maryon T,"

Phrase: "Nowicki B,"

Phrase: "Chow W,"

Phrase: "Hamasaki V,"

Phrase: "Leong L,"

Phrase: "Margolin K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Morgan R Jr.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1708595:Jr [Idea or Concept]
   827   C3280986:JR [Disease or Syndrome]

Phrase: "Raschko J,"

Phrase: "Shibata S,"

Phrase: "Tetef M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Molina A,"

Phrase: "Berenson RJ,"

Phrase: "Forman SJ,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1515101:SJ [Geographic Area]
   861   C2986905:SJ [Idea or Concept]

Phrase: "Doroshow JH"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0268060:JH [Disease or Syndrome]
   861   C1415529:JH [Gene or Genome]

Phrase: ":"

Phrase: "Effects of CD34+ selection"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C1280500:effects [Qualitative Concept]
   737 E C2348382:Effect [Qualitative Concept]

Phrase: "and"

Phrase: "various schedules of stem cell reinfusion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0086960:Schedules [Intellectual Product]
   753   C1554217:schedules [Idea or Concept]

Phrase: "and"

Phrase: "granulocyte colony-stimulating factor priming on hematopoietic recovery"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0871133:Priming [Functional Concept]

Phrase: "after high-dose chemotherapy"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
  1000   C1328050:high-dose chemotherapy [Therapeutic or Preventive Procedure]
   901   C0444956:High dose [Quantitative Concept]
   827   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0013217:chemotherapy [Functional Concept]
   827   C0178602:Dose [Quantitative Concept]
   827   C0205250:High [Qualitative Concept]
   827   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
   827   C0869039:Dose [Quantitative Concept]
   827   C1114758:Dose # [Clinical Attribute]
   827   C1299351:High [Qualitative Concept]
   827   C2700149:HIGH [Intellectual Product]

Phrase: "for breast cancer."
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0006142:Breast Cancer [Neoplastic Process]
  1000   C0678222:Breast Cancer [Neoplastic Process]
   950 E C0153661:thoracic cancer [Neoplastic Process]
   861   C0006141:Breast [Body Part, Organ, or Organ Component]
   861   C0006826:Cancer [Neoplastic Process]
   861   C0998265:Cancer [Eukaryote]
   861   C1268990:Breast [Body Part, Organ, or Organ Component]
   861   C1306459:Cancer [Finding]
   805 E C0929301:Mammary [Body Part, Organ, or Organ Component]
   805 E C1521735:Pectoral [Qualitative Concept]
   777 E C0817096:Chest [Body Location or Region]
   777 E C1527391:Chest [Body Location or Region]
Processing 00000000.tx.357: Blood 89:1521, 1997[Abstract/Free FullText] 49. 

Phrase: "Blood 89"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "1521,"

Phrase: "1997"

Phrase: "[Abstract/Free FullText"

Phrase: "] 49."
Processing 00000000.tx.358: Schiller G, Vescio R, Freytes C, Spitzer G, Lee M, Wu CH, Cao J, Lee JC, Lichtenstein A, Lill M, Berenson RJ, Berenson J: Long-term outcome of high-dose chemotherapy and autologus CD34 selected peripheral blood progenitor cell transplantation for patients with advanced multiple myeloma. 

Phrase: "Schiller G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Vescio R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Freytes C,"

Phrase: "Spitzer G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Lee M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Wu CH,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0558269:Ch. [Professional or Occupational Group]
   861   C1552984:[Ch] [Quantitative Concept]

Phrase: "Cao J,"

Phrase: "Lee JC,"

Phrase: "Lichtenstein A,"

Phrase: "Lill M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Berenson RJ,"

Phrase: "Berenson J"

Phrase: ":"

Phrase: "Long-term outcome of high-dose chemotherapy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1274040:Outcome [Functional Concept]

Phrase: "and"

Phrase: "autologus CD34"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538723:CD34 [Laboratory Procedure]

Phrase: "selected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1707391:Select [Activity]

Phrase: "peripheral blood progenitor cell transplantation for patients"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   897   C0242602:peripheral blood progenitor cell transplantation [Therapeutic or Preventive Procedure]
   778   C0206153:Cell Transplantation [Therapeutic or Preventive Procedure]
   748   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   748   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   748   C0040733:transplantation [Functional Concept]
   732   C0189736:blood vessel transplantation [Therapeutic or Preventive Procedure]

Phrase: "with advanced multiple myeloma."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0026764:Multiple Myeloma [Neoplastic Process]
           Myeloma
   827   C0439064:Multiple [Quantitative Concept]
   827   C3538749:Myeloma [Intellectual Product]
Processing 00000000.tx.359: Bone Marrow Transplant 21:141, 1998[Medline] [OrderarticleviaInfotrieve] 50. 

Phrase: "Bone Marrow Transplant 21"
Meta Candidates (Total=17; Excluded=5; Pruned=0; Remaining=12)
   923   C0005961:Bone Marrow Transplant [Therapeutic or Preventive Procedure]
   875   C0005976:Bone transplant [Therapeutic or Preventive Procedure]
   861   C0005953:Bone Marrow [Tissue]
   812   C0040732:Transplant [Therapeutic or Preventive Procedure]
   812   C0086590:Marrow [Food]
   812   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   812   C0332835:Transplant [Tissue]
   812   C0376152:Marrow [Body Part, Organ, or Organ Component]
   812   C0391978:Bone [Tissue]
   812   C1266908:Bone [Body Part, Organ, or Organ Component]
   812   C1266909:Bone [Body System]
   812   C1546708:Marrow [Intellectual Product]
   756 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   756 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   756 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   741 E C0443157:Bony [Functional Concept]
   729 E C0330477:Marrows [Plant]

Phrase: ":"

Phrase: "141,"

Phrase: "1998"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 50."
Processing 00000000.tx.360: Watts MJ, Sullivan AM, Ings SJ, Leverett D, Peniket AJ, Perry AR, Williams CD, Devereux S: Evaluation of clinical scale CD34+ cell purification: Experience of 71immunoaffinity column procedures. 

Phrase: "Watts MJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439254:MJ [Medical Device]

Phrase: "Sullivan"

Phrase: "AM"

Phrase: ","

Phrase: "Ings SJ,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1515101:SJ [Geographic Area]
   861   C2986905:SJ [Idea or Concept]

Phrase: "Leverett D, Peniket AJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0230613:AJ [Cell Component]

Phrase: "Perry AR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986463:AR+ [Finding]

Phrase: "Williams CD,"

Phrase: "Devereux S"

Phrase: ":"

Phrase: "Evaluation of clinical scale CD34+ cell purification"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   774   C1261322:Clinical evaluation [Health Care Activity]
           Evaluation
   774   C1516634:Clinical Evaluation [Research Activity]
   774   C2984640:CELL EVALUATION [Functional Concept]
   748   C0220825:Evaluation [Functional Concept]

Phrase: ":"

Phrase: "Experience of 71immunoaffinity column procedures."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0237607:experience [Mental Process]
   760   C0596545:Experience [Mental Process]
Processing 00000000.tx.361: Bone Marrow Transplant 20:157, 1997[Medline] [OrderarticleviaInfotrieve] 51. 

Phrase: "Bone Marrow Transplant 20"
Meta Candidates (Total=17; Excluded=5; Pruned=0; Remaining=12)
   923   C0005961:Bone Marrow Transplant [Therapeutic or Preventive Procedure]
   875   C0005976:Bone transplant [Therapeutic or Preventive Procedure]
   861   C0005953:Bone Marrow [Tissue]
   812   C0040732:Transplant [Therapeutic or Preventive Procedure]
   812   C0086590:Marrow [Food]
   812   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   812   C0332835:Transplant [Tissue]
   812   C0376152:Marrow [Body Part, Organ, or Organ Component]
   812   C0391978:Bone [Tissue]
   812   C1266908:Bone [Body Part, Organ, or Organ Component]
   812   C1266909:Bone [Body System]
   812   C1546708:Marrow [Intellectual Product]
   756 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   756 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   756 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   741 E C0443157:Bony [Functional Concept]
   729 E C0330477:Marrows [Plant]

Phrase: ":"

Phrase: "157,"

Phrase: "1997"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 51."
Processing 00000000.tx.362: Tricot G, Gazitt Y, Leemhuis T, Jagannath S, Desikan KR, Siegel D, Fassas A, Tindle S, Nelson J, Juttner C, Tsukamoto A, Hallagan J, Atkinson K, Reading C, Hoffman R, Barlogie B: Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. 

Phrase: "Tricot G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Gazitt Y,"

Phrase: "Leemhuis T,"

Phrase: "Jagannath S,"

Phrase: "Desikan KR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022773:KR [Geographic Area]

Phrase: "Siegel D, Fassas A,"

Phrase: "Tindle S,"

Phrase: "Nelson J,"

Phrase: "Juttner C,"

Phrase: "Tsukamoto A,"

Phrase: "Hallagan J,"

Phrase: "Atkinson K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Reading"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0034754:Reading [Daily or Recreational Activity]
  1000   C1705179:Reading [Finding]

Phrase: "C,"

Phrase: "Hoffman R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Barlogie B"

Phrase: ":"

Phrase: "Collection,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1516698:Collection [Functional Concept]
  1000   C1704814:Collection [Idea or Concept]
   928 E C1516695:Collected [Idea or Concept]

Phrase: "tumor contamination,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0259846:contamination [Human-caused Phenomenon or Process]
   861   C1881659:CONTAMINATION [Event]
   861   C2349974:Contamination [Idea or Concept]

Phrase: "and"

Phrase: "engraftment kinetics of highly"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0022702:Kinetics [Natural Phenomenon or Process]
   770   C0220865:kinetics [Functional Concept]
   770   C2825046:Kinetics [Occupation or Discipline]

Phrase: "purified"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1998793:Purified [Functional Concept]
   907 E C1947930:Cleanse [Activity]

Phrase: "hematopoietic progenitor cells to"
Meta Candidates (Total=12; Excluded=4; Pruned=0; Remaining=8)
   923   C0018956:Progenitor Cells, Hematopoietic [Cell]
   861   C0038250:Progenitor Cells [Cell]
   858   C2323499:Hematopoietic cell [Cell]
   812   C0007634:Cells [Cell]
   812   C0018957:Haematopoietic [Body System]
   812   C0229601:Hematopoietic [Functional Concept]
   812   C0870134:Progenitor [Family Group]
   812   C3282337:Cells [Cell]
   779 E C1269647:Cell [Cell]
   779 E C1704653:Cell [Medical Device]
   779 E C1948049:Cell [Spatial Concept]
   741 E C0018951:Haematopoiesis [Organ or Tissue Function]

Phrase: "support"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0183683:Support [Medical Device]
  1000   C1521721:Support [Conceptual Entity]

Phrase: "high dose therapy in multiple myeloma."
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   790   C0444956:High dose [Quantitative Concept]
   783   C0033972:Multiple therapy [Therapeutic or Preventive Procedure]
   753   C0039798:therapy [Functional Concept]
   753   C0087111:Therapy [Therapeutic or Preventive Procedure]
   753   C0178602:Dose [Quantitative Concept]
   753   C0205250:High [Qualitative Concept]
   753   C0869039:Dose [Quantitative Concept]
   753   C1114758:Dose # [Clinical Attribute]
   753   C1299351:High [Qualitative Concept]
   753   C1363945:Therapy [Finding]
   753   C2700149:HIGH [Intellectual Product]
Processing 00000000.tx.363: Blood 91:4489, 1998[Abstract/Free FullText]  1999 by The American Society of Hematology.  

Phrase: "Blood 91"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "4489,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "]  1999 by The American Society of Hematology."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   853   C1515949:American Society of Hematology [Professional Society]
   748   C0018943:Haematology NOS [Biomedical Occupation or Discipline]
   748   C0037455:society [Organization]
   748   C0200627:HEMATOLOGY [Laboratory Procedure]
   748   C0596070:American [Population Group]
Processing 00000000.tx.364: 0006-4971/99/9306-0006$3.00/0

Phrase: "0006-4971/99/9306-0006$3.00/0"

